<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Front Oncol</journal-id><journal-id journal-id-type="publisher-id">Front. Oncol.</journal-id><journal-title-group><journal-title>Frontiers in Oncology</journal-title></journal-title-group><issn pub-type="epub">2234-943X</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23226679</article-id><article-id pub-id-type="pmc">3508619</article-id><article-id pub-id-type="doi">10.3389/fonc.2012.00173</article-id><article-categories><subj-group subj-group-type="heading"><subject>Oncology</subject><subj-group><subject>Review Article</subject></subj-group></subj-group></article-categories><title-group><article-title><italic>p53</italic>, <italic>SKP2</italic>, and <italic>DKK3</italic> as MYCN Target Genes and Their Potential Therapeutic Significance</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Lindi</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tweddle</surname><given-names>Deborah A.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="author-notes" rid="fn001">*</xref></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University</institution><country>Newcastle, UK</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Arturo Sala, Brunel University/UCL Institute of Child Health, UK</p></fn><fn fn-type="edited-by"><p>Reviewed by: Paolo Salomoni, University College London Cancer Institute, UK; Giuseppe Raschell&#x000e0;, ENEA, Italy</p></fn><corresp id="fn001">*Correspondence: Deborah A. Tweddle, Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne NE2 4HH, UK. e-mail: <email xlink:type="simple">deborah.tweddle@ncl.ac.uk</email></corresp><fn fn-type="other" id="fn002"><p>This article was submitted to Frontiers in Cancer Molecular Targets and Therapeutics, a specialty of Frontiers in Oncology.</p></fn></author-notes><pub-date pub-type="epub"><day>28</day><month>11</month><year>2012</year></pub-date><pub-date pub-type="collection"><year>2012</year></pub-date><volume>2</volume><elocation-id>173</elocation-id><history><date date-type="received"><day>30</day><month>8</month><year>2012</year></date><date date-type="accepted"><day>01</day><month>11</month><year>2012</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2012 Chen and Tweddle.</copyright-statement><copyright-year>2012</copyright-year><license license-type="open-access" xlink:href="http://www.frontiersin.org/licenseagreement"><license-p>This is an open-access article distributed under the terms of the <uri xlink:type="simple" xlink:href="http://creativecommons.org/licenses/by/3.0/">Creative Commons Attribution License</uri>, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.</license-p></license></permissions><abstract><p>Neuroblastoma is the most common extra-cranial solid tumor of childhood. Despite significant advances, it currently still remains one of the most difficult childhood cancers to cure, with less than 40% of patients with high-risk disease being long-term survivors. <italic>MYCN</italic> is a proto-oncogene implicated to be directly involved in neuroblastoma development. Amplification of <italic>MYCN</italic> is associated with rapid tumor progression and poor prognosis. Novel therapeutic strategies which can improve the survival rates whilst reducing the toxicity in these patients are therefore required. Here we discuss genes regulated by MYCN in neuroblastoma, with particular reference to <italic>p53</italic>, <italic>SKP2</italic>, and <italic>DKK3</italic> and strategies that may be employed to target them.</p></abstract><kwd-group><kwd>neuroblastoma</kwd><kwd>MYCN</kwd><kwd>p53</kwd><kwd>SKP2</kwd><kwd>DKK3</kwd><kwd>MDM2-p53 antagonists</kwd></kwd-group><counts><fig-count count="4"/><table-count count="3"/><equation-count count="0"/><ref-count count="407"/><page-count count="27"/><word-count count="28475"/></counts></article-meta></front><body><sec><title>Introduction</title><p>Neuroblastoma, an embryonal malignancy of the developing neural crest, is the most common extra-cranial solid tumor of childhood. It accounts for 8&#x02013;10% of all pediatric cancers and 15% of childhood cancer mortality (Park et al., <xref ref-type="bibr" rid="B261">2010</xref>). Over 50% of patients present with high-risk metastatic disease at the time of diagnosis and most will respond to intensive multi-modal therapy despite significant acute toxicities. However relapse with chemoresistant disease is common and the overall long-term survival of high-risk patients currently remains less than 40%, with those that survive often having long-term toxicities. Thus there is a continuing need to identify novel, less toxic therapies that will ultimately improve the survival of this subset of patients. A typical feature of high-risk disease is <italic>MYCN</italic> amplification which occurs in ~25% of neuroblastoma, associating with rapid tumor progression and a poor prognosis (reviewed by Cohn and Tweddle, <xref ref-type="bibr" rid="B75">2004</xref>). <italic>MYCN</italic> is a proto-oncogene directly involved in neuroblastoma tumorigenesis, evident by the spontaneous development of neuroblastoma in a MYCN dose-dependent manner in transgenic murine models (Weiss et al., <xref ref-type="bibr" rid="B373">1997</xref>).</p><p>Direct inhibition of MYCN has not yet been clinically successful (Gustafson and Weiss, <xref ref-type="bibr" rid="B124">2010</xref>), consequently there is a focus on developing therapeutic strategies directed at destabilizing MYCN protein, and at the downstream targets or pathways which mediate the oncogenic functions of MYCN, and drive the aggressive behavior and progression of <italic>MYCN</italic> amplified tumors. This review will focus on three selected MYCN target genes <italic>p53</italic>, <italic>SKP2</italic>, and <italic>DKK3</italic>, which we have previously identified as being directly or indirectly regulated by MYCN (Bell et al., <xref ref-type="bibr" rid="B21">2007a</xref>; Chen et al., <xref ref-type="bibr" rid="B63">2010</xref>), and strategies that are now being or could be employed in the future to target them, particularly in <italic>MYCN</italic> amplified neuroblastoma.</p></sec><sec><title>MYCN</title><p>MYCN belongs to the <italic>MYC</italic> family of basic-helix-loop-helix-leucine zipper (bHLH-LZ) transcription factors which also includes c-MYC, and MYCL. Deregulated expression of <italic>Myc</italic> family members have been implicated in the genesis of several human cancers. Consistent with this, studies have shown that MYC contributes to numerous aspects of tumorigenesis including unrestricted cellular growth and proliferation, angiogenesis, inhibition of differentiation, metastasis, genomic instability, and reduced cell adhesion (reviewed by Adhikary and Eilers, <xref ref-type="bibr" rid="B3">2005</xref>).</p><p>The <italic>MYCN</italic> gene located at 2p24 encodes a 64&#x02009;kDa nuclear phosphoprotein, which contains a transcriptional activation domain at the N-terminal, and a transcriptional regulation domain with a bHLH-LZ motif at the C-terminal (Schwab, <xref ref-type="bibr" rid="B289">2000</xref>). In contrast to c-MYC, which is expressed in a wide variety of embryonic and adult tissues, MYCN expression is limited to the developing nervous system and selected other sites (Cohn and Ikegaki, <xref ref-type="bibr" rid="B74">2000</xref>).</p><sec><title>Transactivation and repression of target genes by MYCN</title><p>MYC proteins function as active heterodimers with MAX via their conserved bHLH-LZ domains to exert transcriptional activation via direct binding to E-Box motifs (CANNTG) within target gene promoters and the subsequent recruitment of multiple transcriptional coactivators. Heterodimerization with MAX is required for direct binding of MYC proteins to DNA. <italic>Myc</italic> family members have short half-lives and their expression levels are highly regulated. In contrast, MAX is stable and constitutively expressed, and normally present in stoichiometric excess to MYC, which suggests that the abundance of active heterodimers is dependent on the levels of MYC proteins (reviewed by Grandori et al., <xref ref-type="bibr" rid="B120">2000</xref>).</p><p>In contrast to transactivation mediated by MYC, transcriptional repression is independent of E-Box binding and has been shown to involve recruitment of MYC proteins to target gene promoters by Miz-1 and disruption of the interaction between transcriptional complexes. MYC mediated transcriptional repression via Miz-1 has been shown for <italic>p15<sup>INK4B</sup></italic> (Staller et al., <xref ref-type="bibr" rid="B313">2001</xref>) and <italic>p21<sup>CIP1</sup></italic> (Seoane et al., <xref ref-type="bibr" rid="B290">2002</xref>). Other candidate proteins which have been proposed to recruit MYC to core promoters include TFII-I, NF-Y, YY-1, and SP1 (reviewed by Wanzel et al., <xref ref-type="bibr" rid="B369">2003</xref>; Adhikary and Eilers, <xref ref-type="bibr" rid="B3">2005</xref>).</p></sec><sec><title>Identifying MYCN target genes</title><p>The identification of MYCN target genes enables a greater understanding of MYCN driven neuroblastoma tumorigenesis and promotes the identification of potential targets for therapeutic intervention in the treatment of neuroblastoma. A vast number of c-MYC target genes have been identified and can be found at <uri xlink:type="simple" xlink:href="http://myccancergene.org/site/mycTargetDB.asp">http://myccancergene.org/site/mycTargetDB.asp</uri> (Zeller et al., <xref ref-type="bibr" rid="B398">2003</xref>), however less is known about the target genes of MYCN. It has been estimated that MYC is bound to ~25,000 sites within the human genome (reviewed by Adhikary and Eilers, <xref ref-type="bibr" rid="B3">2005</xref>). Early studies found that several c-MYC target genes were expressed in some neuroblastoma cell lines with <italic>MYCN</italic> amplification, but not all, suggesting that other cell specific factors may be important (Ben-Yosef et al., <xref ref-type="bibr" rid="B24">1998</xref>). More recent studies have reported significant overlap between c-MYC and MYCN-regulated gene sets (Laurenti et al., <xref ref-type="bibr" rid="B194">2008</xref>; Westermann et al., <xref ref-type="bibr" rid="B376">2008</xref>).</p><p>Target genes downstream of MYCN can be classified as direct or indirect. Direct target genes of MYCN can be defined as genes which possess a MYCN binding E-Box motif located within close proximity to the transcriptional start site of the gene and/or for which MYCN has been shown to directly bind to the gene promoter to drive transcription. This involves using methods such as electrophoretic mobility shift assay (EMSA), reporter gene assays, and/or more recently Chromatin Immunoprecipitation (ChIP) analysis, a technique which allows specific protein-DNA interactions to be isolated. Indirect target genes of MYCN are genes which are altered as a consequence of other genes or pathways that are directly regulated by MYCN (Bell et al., <xref ref-type="bibr" rid="B20">2010</xref>).</p><p>There are several approaches used to identify target genes of transcription factors such as MYCN. The candidate gene approach involves selecting genes which are involved in the known biological functions of MYCN, such as cell proliferation. Furthermore due to the homology between the <italic>Myc</italic> family members, the candidate gene approach is often used to determine whether previously known c-MYC target genes are also MYCN target genes (Bell et al., <xref ref-type="bibr" rid="B20">2010</xref>). Alternatively, the inference approach is used and is based on identifying putative target genes by the presence of MYCN/MAX binding sites within their gene regulatory regions (Dang, <xref ref-type="bibr" rid="B82">1999</xref>). Moreover, target genes may also be identified based on their differential expression in conditions with varying MYCN expression levels, such as MYCN regulatable expression systems or comparing <italic>MYCN</italic> amplified versus non-amplified cell lines and/or tumors. The latter is often performed using microarray based genome-wide approaches (reviewed by Bell et al., <xref ref-type="bibr" rid="B20">2010</xref>).</p><p>More recently, with the development of ChIP and advances in technology, genome-wide <italic>in vivo</italic> approaches for identifying protein-DNA interactions have become available, including ChIP-cloning, ChIP-chip, and the latest and increasingly popular, ChIP-seq. These techniques enable the identification of direct target genes, and the specific <italic>in vivo</italic> binding sites within the genome without prior knowledge. Direct targets may be further confirmed using quantitative PCR based ChIP analysis (Wu et al., <xref ref-type="bibr" rid="B382">2006</xref>). Interestingly, a ChIP-chip array study of MYCN/c-MYC target genes in neuroblastoma demonstrated that distinct MYCN/c-MYC target gene expression was associated with overall survival, and independent of well-established markers such as <italic>MYCN</italic> amplification, disease stage, and age at diagnosis (Westermann et al., <xref ref-type="bibr" rid="B376">2008</xref>).</p></sec></sec><sec><title>p53</title><p>p53 was discovered over three decades ago as one of the first tumor suppressors (Lane and Crawford, <xref ref-type="bibr" rid="B190">1979</xref>; Linzer and Levine, <xref ref-type="bibr" rid="B204">1979</xref>) and has since been shown to be the most frequently mutated gene in human cancer. p53 is involved in the regulation of several processes that contribute to its central role in maintaining genomic stability and tumor suppression, including cell cycle arrest, apoptosis, senescence, differentiation, autophagy, DNA repair, angiogenesis, cell migration, metabolism, and the immune response. The <italic>TP53</italic> gene located at chromosome position 17p13.1 encodes a 53&#x02009;kDa nuclear phosphoprotein that consists of an N-terminal transactivation domain (TAD), a central sequence-specific DNA binding domain (DBD), a tetramerization domain, and a highly basic C-terminal regulatory domain. Nuclear export signals (NES) are located within both the N- and C-termini, and three lysine-rich nuclear localization signals (NLS) are located within the C-terminal (reviewed by Bai and Zhu, <xref ref-type="bibr" rid="B12">2006</xref>). Identified more recently, p63 and p73 are two homologs which share structural and functional similarity to p53 and belong to the p53 family (reviewed by Levrero et al., <xref ref-type="bibr" rid="B199">2000</xref>).</p><sec><title>The p53/MDM2/p14<sup>ARF</sup> pathway</title><p>Under normal cellular conditions, p53 is maintained at low levels mainly due to MDM2, an E3 ubiquitin ligase and the critical negative regulator of p53 (Honda et al., <xref ref-type="bibr" rid="B139">1997</xref>). This is supported by the observed embryonic lethality of <italic>MDM2</italic> knockout mice and their rescue by the concomitant deletion of <italic>p53</italic> (Jones et al., <xref ref-type="bibr" rid="B160">1995</xref>; Montes de Oca Luna et al., <xref ref-type="bibr" rid="B233">1995</xref>). <italic>MDM2</italic> is a direct transcriptional target of p53 and is induced in response to p53 activation thereby forming a tightly regulated negative feedback loop. MDM2 directly binds to the N-terminal TAD of p53 to inhibit p53 transcriptional activity (Momand et al., <xref ref-type="bibr" rid="B232">1992</xref>), as well as promoting nuclear export and targeting p53 for ubiquitin mediated proteasome degradation (Honda et al., <xref ref-type="bibr" rid="B139">1997</xref>; Tao and Levine, <xref ref-type="bibr" rid="B324">1999a</xref>). p14<sup>ARF</sup> is a tumor suppressor and the negative regulator of MDM2. Studies have shown that p14<sup>ARF</sup> promotes p53 stability and activity by inhibiting MDM2-mediated degradation of p53 via direct interaction with MDM2 and inhibiting its E3 ligase activity (Honda and Yasuda, <xref ref-type="bibr" rid="B140">1999</xref>), preventing MDM2 and p53 nuclear export (Tao and Levine, <xref ref-type="bibr" rid="B325">1999b</xref>), sequestering MDM2 within the nucleolus (Weber et al., <xref ref-type="bibr" rid="B370">1999</xref>), and also by promoting MDM2 degradation (Zhang et al., <xref ref-type="bibr" rid="B404">1998</xref>). Activated p53 can subsequently downregulate the expression of <italic>p14<sup>ARF</sup></italic> (Robertson and Jones, <xref ref-type="bibr" rid="B275">1998</xref>; Stott et al., <xref ref-type="bibr" rid="B317">1998</xref>). MDMX is a homolog of MDM2 and a negative regulator of p53. It has been shown to enhance MDM2-mediated ubiquitination and degradation of p53, and repress p53-mediated transcription (reviewed by Marine et al., <xref ref-type="bibr" rid="B215">2007</xref>; Kruse and Gu, <xref ref-type="bibr" rid="B184">2009</xref>). Interestingly, MDM2 can promote ubiquitination and degradation of MDMX, an effect which is stimulated by p14<sup>ARF</sup> and which correlates with the ability of p14<sup>ARF</sup> to bind MDM2 (Pan and Chen, <xref ref-type="bibr" rid="B260">2003</xref>; Figure <xref ref-type="fig" rid="F1">1</xref>).</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>MYC proteins and the p53/MDM2/p14<sup>ARF</sup> pathway</bold>. In response to cellular stresses p53 can mediate the expression of genes involved in various cellular responses such as apoptosis (e.g., BAX, NOXA, and PUMA), cell cycle arrest (e.g., p21<sup>CIP1</sup>), differentiation, DNA repair or senescence. p53, MDM2 and p14<sup>ARF</sup> form an autoregulatory feedback loop to tightly regulate p53 expression and activity. p14<sup>ARF</sup> can be activated in response to aberrant oncogenic factors such as c-MYC, and possibly MYCN (as indicated by the dashed line). p14<sup>ARF</sup> can also exhibit p53-independent tumor suppressor activity by directly binding and inhibiting the activity of c-MYC and MYCN. Both <italic>p53</italic> and <italic>MDM2</italic> are direct target genes of MYCN. MDM2 can regulate <italic>MYCN</italic> mRNA stability and translation, thereby forming a positive feedback loop.</p></caption><graphic xlink:href="fonc-02-00173-g001"/></fig></sec><sec><title>Activation and function of p53</title><p>In response to a variety of intrinsic and extrinsic cellular stresses such as DNA damage, oncogenic activation, deprivation of growth factors/signals, ribonucleotide depletion, microtubule disruption, and hypoxia, there is stabilization, nuclear accumulation, and activation of p53. This is predominantly regulated by post-translational modifications conferred on the p53 protein, such as phosphorylation, ubiquitylation, acetylation, and sumoylation (Bode and Dong, <xref ref-type="bibr" rid="B29">2004</xref>). N-terminal modifications of p53 act to inhibit the p53-MDM2 interaction thereby preventing MDM2-mediated inactivation and degradation of p53. In addition, modifications within the DBD and C-terminal of p53 have been shown to increase p53 sequence-specific DNA binding and relieve the inhibitory effect of the C-terminal regulatory domain on the core DBD of p53, respectively (reviewed by Appella and Anderson, <xref ref-type="bibr" rid="B7">2001</xref>). Once activated, p53 initiates cellular responses via transcriptional regulation of a vast repertoire of downstream target genes encoding proteins and microRNAs (miRNAs), as well as transcriptional independent functions. The type of response can be dependent on several factors that are both extrinsic and intrinsic to the cell, such as cell type, cellular environment, oncogenic lesions present in the cell, and also stress type (Jimenez et al., <xref ref-type="bibr" rid="B157">1999</xref>; Vousden and Lu, <xref ref-type="bibr" rid="B358">2002</xref>).</p><p>p53 functions as an active tetramer to directly bind to a consensus p53 DNA binding sequence consisting of two adjacent 10&#x02009;bp half-sites 5&#x02032;-RRRCWWGYYY-3&#x02032; (<italic>R</italic>&#x02009;=&#x02009;A or G, <italic>Y</italic>&#x02009;=&#x02009;C or T, <italic>W</italic>&#x02009;=&#x02009;A or T), separated by 0&#x02013;13&#x02009;bp, located within the promoters of downstream target genes (el-Deiry et al., <xref ref-type="bibr" rid="B98">1992</xref>). In contrast, most genes which are repressed by p53 tend to lack p53 DNA binding sites within their promoters (Mirza et al., <xref ref-type="bibr" rid="B226">2003</xref>). To date several mechanisms for p53-mediated transcriptional repression have been identified (reviewed by Wang et al., <xref ref-type="bibr" rid="B361">2010a</xref>; Bohlig and Rother, <xref ref-type="bibr" rid="B30">2011</xref>). The total number of p53 target genes is unknown however it has been shown that 4852 genes within the human genome contain at least one consensus p53 DNA binding site. Furthermore, the identification of non-consensus p53 binding sites also contributes to the ever expanding repertoire of p53 target genes (reviewed by Menendez et al., <xref ref-type="bibr" rid="B220">2009</xref>). p53 target genes have been previously reviewed (Mirza et al., <xref ref-type="bibr" rid="B226">2003</xref>; Harms et al., <xref ref-type="bibr" rid="B129">2004</xref>; Nakamura, <xref ref-type="bibr" rid="B241">2004</xref>; Riley et al., <xref ref-type="bibr" rid="B274">2008</xref>; Wang et al., <xref ref-type="bibr" rid="B361">2010a</xref>).</p><p>In recent years, p53 has also been shown to regulate the transcriptional expression and maturation of miRNAs, a class of endogenously expressed small (~18&#x02013;25&#x02009;nt) non-coding RNA molecules involved in post-transcriptional regulation of gene expression (Lujambio and Lowe, <xref ref-type="bibr" rid="B209">2012</xref>). p53 has been found to upregulate the expression of the <italic>miR-34</italic> cluster which is reported to mediate several tumor suppressive functions of p53 including senescence, cell cycle arrest, and apoptosis (Bommer et al., <xref ref-type="bibr" rid="B31">2007</xref>; Chang et al., <xref ref-type="bibr" rid="B59">2007</xref>; He et al., <xref ref-type="bibr" rid="B131">2007</xref>; Raver-Shapira et al., <xref ref-type="bibr" rid="B270">2007</xref>; Tarasov et al., <xref ref-type="bibr" rid="B326">2007</xref>). Consistent with this, reduced levels of <italic>miR-34</italic> have been observed in both tumors and cell lines, including neuroblastoma (Bommer et al., <xref ref-type="bibr" rid="B31">2007</xref>; Chang et al., <xref ref-type="bibr" rid="B59">2007</xref>; Tarasov et al., <xref ref-type="bibr" rid="B326">2007</xref>; Welch et al., <xref ref-type="bibr" rid="B374">2007</xref>; Feinberg-Gorenshtein et al., <xref ref-type="bibr" rid="B102">2009</xref>). Additionally, p53 has also been reported to induce the expression of <italic>miR-192</italic>, <italic>miR-215</italic>, <italic>miR-145</italic>, and <italic>miR-107</italic>, of which <italic>miR-145</italic> was shown to inhibit c-MYC expression (Braun et al., <xref ref-type="bibr" rid="B34">2008</xref>; Georges et al., <xref ref-type="bibr" rid="B113">2008</xref>; Sachdeva et al., <xref ref-type="bibr" rid="B280">2009</xref>; Yamakuchi et al., <xref ref-type="bibr" rid="B387">2010</xref>). Conversely, several miRNAs have been found to regulate the abundance and activity of p53, such as <italic>miR-380-5p</italic>, which is associated with poor outcome in <italic>MYCN</italic> amplified neuroblastoma (Swarbrick et al., <xref ref-type="bibr" rid="B322">2010</xref>).</p><p>p53 is also able to exert functions via protein-protein interactions, and several proteins involved in cell cycle control, DNA repair, gene transcription, and apoptosis have been shown to bind to p53 (Moll et al., <xref ref-type="bibr" rid="B231">2005</xref>; Braithwaite et al., <xref ref-type="bibr" rid="B33">2006</xref>; Speidel et al., <xref ref-type="bibr" rid="B310">2006</xref>). Although p53 is a nuclear protein, a fraction of p53 has been found within the cytoplasm, exhibiting non-nuclear transcriptional independent activities. Cytoplasmic p53 has been reported to directly interact with members of the BCL2 family including anti-apoptotic BCLxL and BCL2, and proapoptotic BAX and BAK which result in mitochondria membrane permeability, release of cytochrome C, and apoptosis (reviewed by Moll et al., <xref ref-type="bibr" rid="B231">2005</xref>).</p></sec><sec><title>p53 pathway inactivation and cancer</title><p>The crucial role p53 plays in tumor suppression is emphasized by observations that the p53 pathway is abrogated in around half of all cancers due to an inactivating <italic>p53</italic> mutation, and the rest have impaired upstream or downstream p53 pathways (Brown et al., <xref ref-type="bibr" rid="B39">2009</xref>). This is further supported by the severe predisposition to cancers observed in individuals with Li-Fraumeni syndrome (Evans and Lozano, <xref ref-type="bibr" rid="B100">1997</xref>). Additionally, <italic>p53</italic> null mice are reported to develop a range of spontaneous tumors, most commonly T-cell lymphomas (Donehower, <xref ref-type="bibr" rid="B93">1996</xref>).</p><p>The frequency of <italic>p53</italic> mutations varies from 10 to 70% across different cancers types, and are more common in solid tumors compared with hematological malignancies (Calin et al., <xref ref-type="bibr" rid="B41">1999</xref>; Soussi et al., <xref ref-type="bibr" rid="B309">2000</xref>). The majority are missense mutations resulting in single amino acid substitutions and map within the DBD of p53 (Brosh and Rotter, <xref ref-type="bibr" rid="B38">2009</xref>). In tumors and cell lines, mutational inactivation predominantly leads to the accumulation of high levels of mutant p53 protein. Some p53 mutants have been shown to exert a dominant negative effect on wild-type (wt) p53 owing to the requirement for p53 to function as an active tetramer (Vousden and Lu, <xref ref-type="bibr" rid="B358">2002</xref>). <italic>p53</italic> mutations identified to date can be found within publically available p53 databases such as The International Agency for Research on Cancer (IARC) <italic>TP53</italic> Mutation Database<xref ref-type="fn" rid="fn1"><sup>1</sup></xref> and The p53 Website<xref ref-type="fn" rid="fn2"><sup>2</sup></xref>. In addition to loss of tumor suppressive function and exerting dominant negative effects against wt p53, it has become increasingly evident that p53 mutants can exhibit new functions independent of wt p53 and can vary depending on the mutation. These new gain-of-function mutants have been reported to play a role in promoting tumorigenesis including increased metastasis and genomic instability, and resistance to anti-cancer therapies (reviewed by Xu, <xref ref-type="bibr" rid="B385">2008</xref>; Brosh and Rotter, <xref ref-type="bibr" rid="B38">2009</xref>; Oren and Rotter, <xref ref-type="bibr" rid="B256">2010</xref>; Hanel and Moll, <xref ref-type="bibr" rid="B127">2012</xref>). Studies using murine models have observed that mutant <italic>p53</italic> knock-in mice develop more aggressive and metastatic tumors in comparison to <italic>p53</italic> null mice, and that the different p53 mutants are associated with distinct tumor patterns (Lang et al., <xref ref-type="bibr" rid="B191">2004</xref>; Olive et al., <xref ref-type="bibr" rid="B253">2004</xref>; Lozano, <xref ref-type="bibr" rid="B208">2007</xref>; Song et al., <xref ref-type="bibr" rid="B306">2007</xref>; Oren and Rotter, <xref ref-type="bibr" rid="B256">2010</xref>).</p><p>The prognostic and predictive significance of <italic>p53</italic> somatic mutations in human cancer have been extensively evaluated over the past 15&#x02009;years however due to inconsistencies have failed to reach clinical practice to guide treatment. This has predominantly been attributed to the use of immunohistochemistry to detect p53 accumulation as a marker of <italic>p53</italic> mutational inactivation which is inaccurate as this detects both wt and mutant p53 in most cases. More recent studies which have used gene sequencing to determine <italic>p53</italic> status have obtained more consistent results. There is a general trend associating <italic>p53</italic> mutations with a poor prognosis and resistance to chemo- and radiotherapy. This has been shown for malignancies of the breast, head and neck, colorectum, and hematopoietic system (Brosh and Rotter, <xref ref-type="bibr" rid="B38">2009</xref>; Olivier and Taniere, <xref ref-type="bibr" rid="B254">2011</xref>).</p><p>In addition to <italic>p53</italic> mutations, amplification, and/or overexpression of <italic>MDM2</italic> or <italic>MDMX</italic>, as well as <italic>p14<sup>ARF</sup></italic> mutation, deletion, or methylation can also lead to abrogation of the p53 pathway (reviewed by Brown et al., <xref ref-type="bibr" rid="B39">2009</xref>). Similar to p53 null mice, mice deficient in <italic>p14<sup>ARF</sup></italic>, or overexpressing <italic>MDM2</italic> or <italic>MDMX</italic> also developed spontaneous tumors, albeit at a slower rate (Jones et al., <xref ref-type="bibr" rid="B159">1998</xref>; Kamijo et al., <xref ref-type="bibr" rid="B163">1999</xref>; Xiong et al., <xref ref-type="bibr" rid="B384">2010</xref>). Abrogation of p53 function may also occur as the result of viral inactivation such as the human papillomavirus, or impaired upstream signaling and/or downstream mediators of p53 function, such as inactivation of <italic>ATM</italic> or <italic>CHK2</italic>, or genes involved in the apoptotic response, and/or cell cycle arrest. Although it is not clear why certain mechanisms of p53 pathway inactivation are favored in some tumors but not others, it is likely to be influenced by the various selective pressures acting upon the cancer (Junttila and Evan, <xref ref-type="bibr" rid="B161">2009</xref>).</p><p>Interestingly in contrast to <italic>p53</italic>, <italic>p63</italic>, and <italic>p73</italic> are rarely mutated in human cancers and neither <italic>p63</italic> nor <italic>p73</italic> knockout mice exhibit an increased susceptibility to developing spontaneous tumors (Moll and Slade, <xref ref-type="bibr" rid="B230">2004</xref>).</p></sec><sec><title>p53 and neuroblastoma</title><sec><title>p53 accumulation and function in neuroblastoma</title><p>In contrast to many other human cancers, <italic>p53</italic> mutations in neuroblastoma are rare, occurring in ~3% of cases analyzed to date (Imamura et al., <xref ref-type="bibr" rid="B151">1993</xref>; Komuro et al., <xref ref-type="bibr" rid="B178">1993</xref>; Ohgaki et al., <xref ref-type="bibr" rid="B251">1993</xref>; Vogan et al., <xref ref-type="bibr" rid="B356">1993</xref>; Castresana et al., <xref ref-type="bibr" rid="B51">1994</xref>; Hosoi et al., <xref ref-type="bibr" rid="B141">1994</xref>; Kusafuka et al., <xref ref-type="bibr" rid="B187">1997</xref>; Manhani et al., <xref ref-type="bibr" rid="B212">1997</xref>; Omura-Minamisawa et al., <xref ref-type="bibr" rid="B255">2001</xref>; Tweddle et al., <xref ref-type="bibr" rid="B338">2001b</xref>; Carr-Wilkinson et al., <xref ref-type="bibr" rid="B50">2010</xref>). Despite this, p53 has been reported to accumulate in neuroblastoma, which has been suggested to be due to the embryonic nature of these tumors, reflecting a failure of precursor cells to mature (Sidell and Koeffler, <xref ref-type="bibr" rid="B299">1988</xref>; Davidoff et al., <xref ref-type="bibr" rid="B85">1992</xref>). This is consistent with studies which have shown a decrease in p53 expression following retinoic acid induced <italic>in vitro</italic> differentiation of neuroblastoma cell lines (Sidell and Koeffler, <xref ref-type="bibr" rid="B299">1988</xref>; Davidoff et al., <xref ref-type="bibr" rid="B85">1992</xref>; Chen et al., <xref ref-type="bibr" rid="B64">2007</xref>), and also during neuronal development/differentiation (Eizenberg et al., <xref ref-type="bibr" rid="B97">1996</xref>; Ferreira and Kosik, <xref ref-type="bibr" rid="B104">1996</xref>). In addition siRNA mediated inhibition of p53 in neuroblastoma cell lines led to morphological evidence of differentiation (Carr-Wilkinson et al., <xref ref-type="bibr" rid="B49">2011</xref>). The presence of high levels of accumulated wt p53 suggests that neuroblastoma circumvent the tumor suppressive properties of p53 by a mechanism independent of mutation. Early studies reported cytoplasmic sequestration of wt p53 as a non-mutational mechanism for p53 inactivation and accumulation in neuroblastoma (Moll et al., <xref ref-type="bibr" rid="B228">1995</xref>, <xref ref-type="bibr" rid="B229">1996</xref>). To date several mechanisms for cytoplasmic sequestration of p53 in neuroblastoma have been proposed, including masking of the p53 C-terminal nuclear localization signal (Ostermeyer et al., <xref ref-type="bibr" rid="B257">1996</xref>), hyperactive nuclear export (Stommel et al., <xref ref-type="bibr" rid="B316">1999</xref>), binding to the cytoplasmic anchor, Parc (Nikolaev and Gu, <xref ref-type="bibr" rid="B247">2003</xref>; Nikolaev et al., <xref ref-type="bibr" rid="B248">2003</xref>), aberrant hyperubiquitylation of p53 (Becker et al., <xref ref-type="bibr" rid="B19">2007</xref>), and MDMX and MDM2-mediated cytoplasmic tethering (Ohtsubo et al., <xref ref-type="bibr" rid="B252">2009</xref>). In contrast, a number of studies including our own have reported predominantly nuclear localization and/or functional p53 in neuroblastoma (Layfield et al., <xref ref-type="bibr" rid="B195">1995</xref>; Hoehner et al., <xref ref-type="bibr" rid="B137">1997</xref>; Danks et al., <xref ref-type="bibr" rid="B83">1998</xref>; Isaacs et al., <xref ref-type="bibr" rid="B153">1998</xref>; McKenzie et al., <xref ref-type="bibr" rid="B218">1999</xref>; Smart et al., <xref ref-type="bibr" rid="B304">1999</xref>; Keshelava et al., <xref ref-type="bibr" rid="B170">2000</xref>, <xref ref-type="bibr" rid="B169">2001</xref>; Tweddle et al., <xref ref-type="bibr" rid="B337">2001a</xref>,<xref ref-type="bibr" rid="B338">b</xref>; Cui et al., <xref ref-type="bibr" rid="B81">2002</xref>; Goldschneider et al., <xref ref-type="bibr" rid="B116">2004</xref>; Chen et al., <xref ref-type="bibr" rid="B64">2007</xref>, <xref ref-type="bibr" rid="B63">2010</xref>; Xue et al., <xref ref-type="bibr" rid="B386">2007</xref>; Kurata et al., <xref ref-type="bibr" rid="B185">2008</xref>; Van Maerken et al., <xref ref-type="bibr" rid="B348">2011</xref>; Gamble et al., <xref ref-type="bibr" rid="B111">2012</xref>). The conflicting results over the localization and function of p53 are likely to be due to the different p53 antibodies and the criteria used to define functional p53. Interestingly, despite functional, transcriptionally active p53, we have previously reported a failure for <italic>MYCN</italic> amplified neuroblastoma cells to G<sub>1</sub> arrest after DNA damage (Tweddle et al., <xref ref-type="bibr" rid="B338">2001b</xref>; Bell et al., <xref ref-type="bibr" rid="B23">2006</xref>) and have recently shown that the outcome of the p53-mediated response to DNA damage in neuroblastoma cell lines is determined by both morphological subtype (neuronal or substrate adherent) and MYCN expression (Carr-Wilkinson et al., <xref ref-type="bibr" rid="B49">2011</xref>).</p></sec><sec><title>Inactivation of the p53 pathway and resistance to cytotoxic therapy</title><p>Most neuroblastomas initially respond well to cytotoxic agents however the disease frequently relapses with acquired resistance to therapy thus posing a major problem in the treatment of patients with high-risk neuroblastoma. Consequently, gaining a greater understanding into the mechanisms behind resistance to cytotoxic therapies could lead to the development and use of novel therapies in progressing or relapsed disease (Tweddle et al., <xref ref-type="bibr" rid="B337">2001a</xref>). An important mechanism for chemo- and radioresistance is inactivation of the p53 pathway (reviewed by Levine, <xref ref-type="bibr" rid="B198">1997</xref>). The initial good response to chemotherapy may be partly due to the presence of functional p53 at diagnosis, and the development of resistance at relapse may be the result of acquired p53 inactivation at a later stage (reviewed by Tweddle et al., <xref ref-type="bibr" rid="B339">2003</xref>). Consistent with this, of the few <italic>p53</italic> mutations which have been identified in neuroblastoma to date, the majority were in tumors from patients with progressive or relapsed disease and/or post-chemotherapy (Imamura et al., <xref ref-type="bibr" rid="B151">1993</xref>; Komuro et al., <xref ref-type="bibr" rid="B178">1993</xref>; Ohgaki et al., <xref ref-type="bibr" rid="B251">1993</xref>; Vogan et al., <xref ref-type="bibr" rid="B356">1993</xref>; Castresana et al., <xref ref-type="bibr" rid="B51">1994</xref>; Hosoi et al., <xref ref-type="bibr" rid="B141">1994</xref>; Kusafuka et al., <xref ref-type="bibr" rid="B187">1997</xref>; Manhani et al., <xref ref-type="bibr" rid="B212">1997</xref>; Omura-Minamisawa et al., <xref ref-type="bibr" rid="B255">2001</xref>; Tweddle et al., <xref ref-type="bibr" rid="B338">2001b</xref>; Carr-Wilkinson et al., <xref ref-type="bibr" rid="B50">2010</xref>). Similarly, despite the frequency being slightly higher than those in tumors, <italic>p53</italic> mutations in neuroblastoma cell lines are also rare, and the majority were also identified in cell lines established at relapse (Tweddle et al., <xref ref-type="bibr" rid="B339">2003</xref>; Carr et al., <xref ref-type="bibr" rid="B46">2006</xref>; Table <xref ref-type="table" rid="T1">1</xref>).</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p><bold><italic>MYCN</italic> status and aberrations in the p53/MDM2/p14<sup>ARF</sup> pathway in neuroblastoma cell lines</bold>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Cell Line</th><th align="left" rowspan="1" colspan="1"><italic>MYCN</italic><break/>Status</th><th align="left" rowspan="1" colspan="1"><italic>p53</italic><break/>Mut</th><th align="left" rowspan="1" colspan="1"><italic>p53</italic> Mut<break/>Codon</th><th align="left" rowspan="1" colspan="1"><italic>MDM2</italic><break/>Amp</th><th align="left" rowspan="1" colspan="1"><italic>p14<sup>ARF</sup></italic><break/>Deln</th><th align="left" rowspan="1" colspan="1"><italic>p14<sup>ARF</sup></italic><break/>Meth</th><th align="left" rowspan="1" colspan="1">Diagnosis/<break/>Relapse<sup>&#x000a7;</sup></th><th align="left" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">ACN</td><td align="left" rowspan="1" colspan="1">nMNA</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">113</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Relapse</td><td align="left" rowspan="1" colspan="1">Forbes et al. (<xref ref-type="bibr" rid="B106">2008</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">CHLA-119</td><td align="left" rowspan="1" colspan="1">MNA<sup>1</sup></td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">342</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Relapse</td><td align="left" rowspan="1" colspan="1">Keshelava et al. (<xref ref-type="bibr" rid="B169">2001</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">CHLA-172</td><td align="left" rowspan="1" colspan="1">nMNA<sup>1</sup></td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">216</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Relapse</td><td align="left" rowspan="1" colspan="1">Keshelava et al. (<xref ref-type="bibr" rid="B169">2001</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">CHLA-90</td><td align="left" rowspan="1" colspan="1">nMNA</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">286</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Relapse</td><td align="left" rowspan="1" colspan="1">Keshelava et al. (<xref ref-type="bibr" rid="B169">2001</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">CLB-Pe</td><td align="left" rowspan="1" colspan="1">MNA</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">176</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Relapse</td><td align="left" rowspan="1" colspan="1">Mergui et al. (<xref ref-type="bibr" rid="B221">2008</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">IGRN91</td><td align="left" rowspan="1" colspan="1">MNA</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1"><sup>a</sup></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Relapse</td><td align="left" rowspan="1" colspan="1">Goldschneider et al. (<xref ref-type="bibr" rid="B116">2004</xref>, <xref ref-type="bibr" rid="B117">2006</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">IGR-NB8</td><td align="left" rowspan="1" colspan="1">MNA</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">326</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Diagnosis</td><td align="left" rowspan="1" colspan="1">Goldschneider et al. (<xref ref-type="bibr" rid="B117">2006</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">KELLY/N-206</td><td align="left" rowspan="1" colspan="1">MNA</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">177</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Unknown</td><td align="left" rowspan="1" colspan="1">Mergui et al. (<xref ref-type="bibr" rid="B221">2008</xref>), Van Maerken et al. (<xref ref-type="bibr" rid="B348">2011</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">KP-N-YS</td><td align="left" rowspan="1" colspan="1">MNA</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">135</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Diagnosis<sup>2</sup></td><td align="left" rowspan="1" colspan="1">Forbes et al. (<xref ref-type="bibr" rid="B106">2008</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">LAN-1</td><td align="left" rowspan="1" colspan="1">MNA</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">182</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Relapse</td><td align="left" rowspan="1" colspan="1">Davidoff et al. (<xref ref-type="bibr" rid="B85">1992</xref>), Van Maerken et al. (<xref ref-type="bibr" rid="B348">2011</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">LAN-2</td><td align="left" rowspan="1" colspan="1">MNA</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">337</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Diagnosis</td><td align="left" rowspan="1" colspan="1">Van Maerken et al. (<xref ref-type="bibr" rid="B348">2011</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">NB4</td><td align="left" rowspan="1" colspan="1">MNA</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">173</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Diagnosis<sup>3</sup></td><td align="left" rowspan="1" colspan="1">Teitz et al. (<xref ref-type="bibr" rid="B328">2002</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">NB6</td><td align="left" rowspan="1" colspan="1">MNA</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">282</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Relapse</td><td align="left" rowspan="1" colspan="1">Teitz et al. (<xref ref-type="bibr" rid="B328">2002</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">NB8</td><td align="left" rowspan="1" colspan="1">MNA</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1"><sup>b</sup></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Diagnosis</td><td align="left" rowspan="1" colspan="1">Teitz et al. (<xref ref-type="bibr" rid="B328">2002</xref>), Van Maerken et al. (<xref ref-type="bibr" rid="B348">2011</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">NB12</td><td align="left" rowspan="1" colspan="1">MNA</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">173</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Unknown</td><td align="left" rowspan="1" colspan="1">Teitz et al. (<xref ref-type="bibr" rid="B328">2002</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">NB13</td><td align="left" rowspan="1" colspan="1">MNA</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">173</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Unknown</td><td align="left" rowspan="1" colspan="1">Teitz et al. (<xref ref-type="bibr" rid="B328">2002</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">NB14</td><td align="left" rowspan="1" colspan="1">MNA</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1"><sup>c</sup></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Diagnosis</td><td align="left" rowspan="1" colspan="1">Teitz et al. (<xref ref-type="bibr" rid="B328">2002</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">NB15</td><td align="left" rowspan="1" colspan="1">MNA</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">248</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Unknown</td><td align="left" rowspan="1" colspan="1">Teitz et al. (<xref ref-type="bibr" rid="B328">2002</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">NB20</td><td align="left" rowspan="1" colspan="1">MNA</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">248</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Unknown</td><td align="left" rowspan="1" colspan="1">Teitz et al. (<xref ref-type="bibr" rid="B328">2002</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">NLF</td><td align="left" rowspan="1" colspan="1">MNA</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">203</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Diagnosis<sup>4</sup></td><td align="left" rowspan="1" colspan="1">Van Maerken et al. (<xref ref-type="bibr" rid="B348">2011</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">NMB</td><td align="left" rowspan="1" colspan="1">MNA</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">245</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Relapse</td><td align="left" rowspan="1" colspan="1">Goldman et al. (<xref ref-type="bibr" rid="B115">1996</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">SJNB-4</td><td align="left" rowspan="1" colspan="1">MNA</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">176</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Relapse</td><td align="left" rowspan="1" colspan="1">McPake et al. (<xref ref-type="bibr" rid="B219">1998</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">SKNAS</td><td align="left" rowspan="1" colspan="1">nMNA</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1"><sup>d</sup></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Relapse</td><td align="left" rowspan="1" colspan="1">Goldschneider et al. (<xref ref-type="bibr" rid="B117">2006</xref>), Nakamura et al. (<xref ref-type="bibr" rid="B242">2007</xref>), Van Maerken et al. (<xref ref-type="bibr" rid="B348">2011</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">SKNBE2C</td><td align="left" rowspan="1" colspan="1">MNA</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">135</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Relapse</td><td align="left" rowspan="1" colspan="1">Kaghad et al. (<xref ref-type="bibr" rid="B162">1997</xref>), Keshelava et al. (<xref ref-type="bibr" rid="B169">2001</xref>), Tweddle et al. (<xref ref-type="bibr" rid="B337">2001a</xref>,<xref ref-type="bibr" rid="B338">b</xref>) Van Maerken et al. (<xref ref-type="bibr" rid="B348">2011</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">SK-N-DZ</td><td align="left" rowspan="1" colspan="1">MNA</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">110</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Relapse<sup>5</sup></td><td align="left" rowspan="1" colspan="1">Forbes et al. (<xref ref-type="bibr" rid="B106">2008</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">SK-N-FI</td><td align="left" rowspan="1" colspan="1">nMNA</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">246</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Relapse</td><td align="left" rowspan="1" colspan="1">Van Maerken et al. (<xref ref-type="bibr" rid="B349">2006</xref>, <xref ref-type="bibr" rid="B348">2011</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">TGW</td><td align="left" rowspan="1" colspan="1">MNA</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">282</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Relapse</td><td align="left" rowspan="1" colspan="1">Sugiyama et al. (<xref ref-type="bibr" rid="B320">2003</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">NGP</td><td align="left" rowspan="1" colspan="1">MNA</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Relapse</td><td align="left" rowspan="1" colspan="1">Corvi et al. (<xref ref-type="bibr" rid="B77">1995</xref>), Tweddle et al. (<xref ref-type="bibr" rid="B338">2001b</xref>), Van Maerken et al. (<xref ref-type="bibr" rid="B348">2011</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">NB1691</td><td align="left" rowspan="1" colspan="1">MNA</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Relapse</td><td align="left" rowspan="1" colspan="1">McKenzie et al. (<xref ref-type="bibr" rid="B218">1999</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">CHLA134</td><td align="left" rowspan="1" colspan="1">MNA</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Relapse</td><td align="left" rowspan="1" colspan="1">Keshelava et al. (<xref ref-type="bibr" rid="B169">2001</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">LS</td><td align="left" rowspan="1" colspan="1">MNA</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Relapse</td><td align="left" rowspan="1" colspan="1">Corvi et al. (<xref ref-type="bibr" rid="B77">1995</xref>), Carr et al. (<xref ref-type="bibr" rid="B46">2006</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">TR-14</td><td align="left" rowspan="1" colspan="1">MNA</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Relapse</td><td align="left" rowspan="1" colspan="1">Carr et al. (<xref ref-type="bibr" rid="B46">2006</xref>), Van Maerken et al. (<xref ref-type="bibr" rid="B348">2011</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">LAN-6</td><td align="left" rowspan="1" colspan="1">nMNA</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Relapse</td><td align="left" rowspan="1" colspan="1">Keshelava et al. (<xref ref-type="bibr" rid="B169">2001</xref>), Thompson et al. (<xref ref-type="bibr" rid="B331">2001</xref>), Van Maerken et al. (<xref ref-type="bibr" rid="B348">2011</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">SHEP</td><td align="left" rowspan="1" colspan="1">nMNA</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Relapse</td><td align="left" rowspan="1" colspan="1">Tweddle et al. (<xref ref-type="bibr" rid="B338">2001b</xref>), Carr et al. (<xref ref-type="bibr" rid="B46">2006</xref>), Van Maerken et al. (<xref ref-type="bibr" rid="B348">2011</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">CHLA-101</td><td align="left" rowspan="1" colspan="1">MNA</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Yes <sup>e</sup></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Relapse</td><td align="left" rowspan="1" colspan="1">Thompson et al. (<xref ref-type="bibr" rid="B331">2001</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">CHLA-174</td><td align="left" rowspan="1" colspan="1">nMNA</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Relapse</td><td align="left" rowspan="1" colspan="1">Thompson et al. (<xref ref-type="bibr" rid="B331">2001</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">CHLA-179</td><td align="left" rowspan="1" colspan="1">MNA</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Relapse</td><td align="left" rowspan="1" colspan="1">Thompson et al. (<xref ref-type="bibr" rid="B331">2001</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">STA-NB-3</td><td align="left" rowspan="1" colspan="1">MNA</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Relapse<sup>6</sup></td><td align="left" rowspan="1" colspan="1">Van Maerken et al. (<xref ref-type="bibr" rid="B348">2011</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">GIMEN</td><td align="left" rowspan="1" colspan="1">nMNA</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Relapse</td><td align="left" rowspan="1" colspan="1">Carr et al. (<xref ref-type="bibr" rid="B46">2006</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">PER-108</td><td align="left" rowspan="1" colspan="1">MNA</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Relapse</td><td align="left" rowspan="1" colspan="1">Carr et al. (<xref ref-type="bibr" rid="B46">2006</xref>)</td></tr></tbody></table><table-wrap-foot><p><italic>Mut, mutation; Amp, amplification; Deln, deletion; Meth, methylation; MNA, <italic>MYCN</italic> amplified; nMNA, non-<italic>MYCN</italic> amplified</italic>.</p><p><italic><sup>&#x000a7;</sup>Any cell line established prior to chemo/radiotherapy was classified as established at diagnosis and any cell lines established post-treatment was classified as established at relapse</italic>.</p><p><italic><sup>1</sup>Personal communication with P. Reynolds, <sup>2</sup>Personal communication with T. Sugimoto, <sup>3</sup>Personal communication with S. Ragsdale, <sup>4</sup>Personal communication with G. Brodeur, <sup>5</sup>Personal communication with L. Helson, <sup>6</sup>Personal communication with P. Ambros</italic>.</p><p><italic><sup>a</sup>Duplication of exons 7&#x02013;9 between exons 9 and 10 resulting in an extra ~321nts, <sup>b</sup>Deletion of codons 105-125, <sup>c</sup>Deletion of codons 126&#x02013;132, <sup>d</sup>Deletion of exons 10 and 11 resulting in truncated product ~369nts, <sup>e</sup>104&#x02009;bp deletion</italic>.</p></table-wrap-foot></table-wrap><p>Using a pair of neuroblastoma cell lines derived from the same patient, before and after cytotoxic therapy, we previously demonstrated that the cell line derived after therapy, at disease relapse, had mutant non-functional p53, and was more resistant to chemotherapy compared to the cell line derived at diagnosis before therapy, which had wt functional p53 (Tweddle et al., <xref ref-type="bibr" rid="B337">2001a</xref>). Other studies have also correlated loss of p53 function with drug resistance in neuroblastoma cell lines, and found that transfection of wt p53 drug sensitive cell lines with E6 vectors led to chemoresistance (Keshelava et al., <xref ref-type="bibr" rid="B170">2000</xref>, <xref ref-type="bibr" rid="B169">2001</xref>). In line with these observations, we recently reported that the presence of a <italic>p53</italic> mutation was independently prognostic for overall survival in neuroblastoma patients (Carr-Wilkinson et al., <xref ref-type="bibr" rid="B50">2010</xref>).</p><p>In addition to <italic>p53</italic> mutations, <italic>MDM2</italic> amplification, and <italic>p14<sup>ARF</sup></italic> deletion or methylation have also been reported in neuroblastoma tumors and cell lines, most of which were from patients with progressive or relapsed disease and/or post-chemotherapy (Corvi et al., <xref ref-type="bibr" rid="B77">1995</xref>; Omura-Minamisawa et al., <xref ref-type="bibr" rid="B255">2001</xref>; Thompson et al., <xref ref-type="bibr" rid="B331">2001</xref>; Gonzalez-Gomez et al., <xref ref-type="bibr" rid="B118">2003</xref>; Su et al., <xref ref-type="bibr" rid="B318">2004</xref>; Carr et al., <xref ref-type="bibr" rid="B46">2006</xref>; Spitz et al., <xref ref-type="bibr" rid="B311">2006</xref>; Caren et al., <xref ref-type="bibr" rid="B44">2008</xref>; Carr-Wilkinson et al., <xref ref-type="bibr" rid="B50">2010</xref>; Wolf et al., <xref ref-type="bibr" rid="B378">2010</xref>). Interestingly, in our recent study of paired neuroblastoma tumors established at diagnosis and relapse which demonstrated a high frequency of p53/MDM2/p14<sup>ARF</sup> pathway abnormalities in relapsed neuroblastoma, a higher frequency of abnormalities involving <italic>MDM2</italic> amplification, and <italic>p14<sup>ARF</sup></italic> inactivation (35%) compared to <italic>p53</italic> mutations (15%) was observed. In all three cases with <italic>MDM2</italic> amplification and 8/12 cases with a <italic>p14<sup>ARF</sup></italic> alteration, the abnormality was present in both the diagnostic and relapsed specimen, whereas in 5/6 cases where a <italic>p53</italic> mutation was detected it was present in the relapsed specimen alone. This therefore suggests that for <italic>MDM2</italic> amplification and <italic>p14<sup>ARF</sup></italic> alterations their presence predisposes to relapse whereas <italic>p53</italic> mutations are acquired at relapse (Carr-Wilkinson et al., <xref ref-type="bibr" rid="B50">2010</xref>).</p><p>In recent years there has been increased interest in assessing whether polymorphisms can influence cancer risk and clinical outcome. A single-nucleotide polymorphism (SNP) in the <italic>MDM2</italic> promoter (SNP309<sub>T to G</sub>) leading to high levels of <italic>MDM2</italic> expression has been found in some tumors and is associated with a poor prognostic outcome, including neuroblastoma (Cattelani et al., <xref ref-type="bibr" rid="B53">2008</xref>; Perfumo et al., <xref ref-type="bibr" rid="B265">2008</xref>). In <italic>p53</italic>, a SNP at codon 72 which leads to an Arg&#x02009;&#x0003e;&#x02009;Pro substitution has previously been identified, and the Arg72 variant has been shown to exhibit enhanced apoptotic capability compared with the Pro72 variant (Dumont et al., <xref ref-type="bibr" rid="B94">2003</xref>). Very recently, analysis of the <italic>p53</italic> codon 72 Arg/Pro polymorphism identified the Pro/Pro phenotype as an independent marker of poor prognosis in neuroblastoma patients, and <italic>in vitro</italic> led to reduced levels of apoptosis in response to chemotherapy and irradiation (Cattelani et al., <xref ref-type="bibr" rid="B54">2012</xref>).</p></sec><sec><title>MYCN mediated upregulation of p53 as a mechanism for MYCN induced apoptosis in neuroblastoma</title><p>Members of the <italic>Myc</italic> family are known to play a paradoxical role in driving both cellular proliferation and inducing apoptosis, which is thought to provide a safeguard mechanism to prevent uncontrolled cellular proliferation and oncogenic transformation. This paradox is observed histologically by a high mitosis-karyorrhexis index, a combined index of both proliferation and apoptosis, in both human <italic>MYCN</italic> amplified neuroblastoma tumors (Shimada et al., <xref ref-type="bibr" rid="B296">1995</xref>, <xref ref-type="bibr" rid="B295">1999</xref>; Goto et al., <xref ref-type="bibr" rid="B119">2001</xref>; Altungoz et al., <xref ref-type="bibr" rid="B5">2007</xref>) and TH<italic>-MYCN</italic> transgenic mouse neuroblastoma tumors (Moore et al., <xref ref-type="bibr" rid="B234">2008</xref>).</p><p><italic>p53</italic> has long been known to be a direct target gene of c-MYC, and mediate c-MYC induced apoptosis (Reisman et al., <xref ref-type="bibr" rid="B271">1993</xref>; Hermeking and Eick, <xref ref-type="bibr" rid="B133">1994</xref>; Roy et al., <xref ref-type="bibr" rid="B278">1994</xref>; Zeller et al., <xref ref-type="bibr" rid="B398">2003</xref>). Initial studies in neuroblastoma showed that <italic>MYCN</italic> amplified tumors expressed significantly higher levels of <italic>p53</italic> mRNA in comparison with non-amplified tumors (Raschella et al., <xref ref-type="bibr" rid="B269">1991</xref>; Berwanger et al., <xref ref-type="bibr" rid="B26">2002</xref>; Westermann et al., <xref ref-type="bibr" rid="B376">2008</xref>), and higher p53 protein expression in the presence of ectopic MYCN in cell lines (Cui et al., <xref ref-type="bibr" rid="B80">2005</xref>; Bell et al., <xref ref-type="bibr" rid="B23">2006</xref>; Sugihara et al., <xref ref-type="bibr" rid="B319">2006</xref>). Using ChIP-chip arrays MYCN was reported to bind to an E-Box within the <italic>p53</italic> promoter, however this study did not include the functional upregulation of <italic>p53</italic> (Westermann et al., <xref ref-type="bibr" rid="B376">2008</xref>). Most recently, in a study of p53 expression, accumulation, and function in neuroblastoma in relation to <italic>MYCN</italic> amplification and expression, we demonstrated that p53 protein expression correlated with MYCN protein expression in both neuroblastoma tumors and cell lines (Chen et al., <xref ref-type="bibr" rid="B63">2010</xref>). Furthermore, we demonstrated that p53 was functional and exhibited greater transcriptional activity in the presence of MYCN leading to the increased expression of several p53 target genes. Finally, we showed that MYCN mediates transactivation of <italic>p53</italic> by interacting directly with the same E-Box motif (CATGTG) as previously reported for c-MYC (Reisman et al., <xref ref-type="bibr" rid="B271">1993</xref>; Figure <xref ref-type="fig" rid="F1">1</xref>), and is likely to be an important and direct mechanism by which MYCN is able to sensitize cells to p53-mediated apoptosis (Chen et al., <xref ref-type="bibr" rid="B63">2010</xref>). This is consistent with, and may help to explain why human <italic>MYCN</italic> amplified and TH<italic>-MYCN</italic> transgenic mouse neuroblastoma tumors have high levels of apoptosis, and <italic>MYCN</italic> amplified and Tet21N MYCN+ neuroblastoma cells undergo higher levels of apoptosis in response to chemotherapeutic agents (Fulda et al., <xref ref-type="bibr" rid="B109">1999</xref>, <xref ref-type="bibr" rid="B110">2000</xref>; Paffhausen et al., <xref ref-type="bibr" rid="B259">2007</xref>; Chesler et al., <xref ref-type="bibr" rid="B69">2008</xref>), irradiation (Bell et al., <xref ref-type="bibr" rid="B23">2006</xref>), and MDM2-p53 antagonists (Gamble et al., <xref ref-type="bibr" rid="B111">2012</xref>). Certainly, siRNA mediated inhibition of p53 led to reduced levels of apoptosis in <italic>MYCN</italic> amplified neuroblastoma cell lines (Chesler et al., <xref ref-type="bibr" rid="B69">2008</xref>; Chen et al., <xref ref-type="bibr" rid="B63">2010</xref>).</p><p>Further support for MYCN driven p53-dependent apoptosis being an important mechanism for tumor suppression in neuroblastoma comes from <italic>in vivo</italic> work using <italic>p53</italic> or <italic>Mdm2</italic> haploinsufficient models of neuroblastoma. MYCN driven tumor formation had higher penetrance and reduced latency in <italic>p53</italic> haploinsufficient mice, and chemotherapy induced apoptosis was shown to be p53-dependent, in which apoptosis was significantly reduced in TH-<italic>MYCN</italic>
<italic>p53</italic>&#x02009;+/-&#x02009;tumors compared with TH-<italic>MYCN</italic>
<italic>p53</italic>&#x02009;+&#x02009;/&#x02009;+&#x02009;tumors (Chesler et al., <xref ref-type="bibr" rid="B69">2008</xref>). In contrast, <italic>Mdm2</italic> deficiency suppressed MYCN driven neuroblastoma tumorigenesis, as evident by an extended tumor latency and survival and reduced tumor incidence and growth in TH-<italic>MYCN</italic>
<italic>Mdm2</italic>&#x02009;+/&#x02212;&#x02009;transgenic mice compared with TH-<italic>MYCN</italic>
<italic>Mdm2</italic>&#x02009;+&#x02009;/&#x02009;+&#x02009;mice. Additionally, TH-<italic>MYCN</italic>
<italic>Mdm2</italic>&#x02009;+/&#x02212;&#x02009;tumors commonly exhibited methylation of <italic>p19</italic><sup><italic>ARF</italic></sup>. These observations thereby demonstrate the necessity of MYCN to overcome p53-mediated tumor suppression during neuroblastoma tumorigenesis either via direct inhibition of p53 by MDM2 or suppression of the p14<sup>ARF</sup>/p53 pathway (Chen et al., <xref ref-type="bibr" rid="B66">2009</xref>).</p><p>The ability of MYCN to induce apoptosis, such as through direct upregulation of p53, may be a potential pathway for spontaneous regression. Certainly, a study analyzing MYCN/c-MYC target gene expression and outcome in neuroblastoma has previously suggested p53 as a strong candidate involved in spontaneous regression of 4s tumors (Westermann et al., <xref ref-type="bibr" rid="B376">2008</xref>).</p><p>MYCN and p53 are both expressed in the normal embryonic developing nervous system, during the phase of precursor cell expansion prior to the onset of differentiation. In the context of normal embryonic development, direct upregulation of <italic>p53</italic> by MYCN may be an important mechanism to eliminate any rapidly proliferating neuroblasts exposed to potential teratogens, to prevent deregulated proliferation and aberrations during development.</p><p>In addition to direct transcriptional upregulation of <italic>p53</italic>, c-MYC has been previously reported to sensitize cells to increased apoptosis via induction of p14<sup>ARF</sup> mediated upregulation of p53 expression, stability, and activity (Zindy et al., <xref ref-type="bibr" rid="B406">1998</xref>). Due to the homology between c-MYC and MYCN, MYCN may also be able to stabilize p53 via p14<sup>ARF</sup>, however this remains to be proven experimentally (Figures <xref ref-type="fig" rid="F1">1</xref> and <xref ref-type="fig" rid="F2">2</xref>).</p><fig id="F2" position="float"><label>Figure 2</label><caption><p><bold>Summary of the potential mechanisms by which MYCN can both positively and negatively regulate p53 activity and function</bold>.</p></caption><graphic xlink:href="fonc-02-00173-g002"/></fig></sec><sec><title>Mechanisms of p53 inactivation and evasion of p53-dependent apoptosis in <italic>MYCN</italic> amplified neuroblastoma</title><p>Several lines of evidence from published literature lend support to the notion that during the process of neuroblastoma progression there is evasion of p53-mediated tumor suppression via inactivation of the p53/MDM2/p14<sup>ARF</sup> pathway (reviewed by Van Maerken et al., <xref ref-type="bibr" rid="B347">2009b</xref>) as well as a requirement for <italic>MYCN</italic> amplified neuroblastoma to circumvent MYCN driven apoptosis (reviewed by Hogarty, <xref ref-type="bibr" rid="B138">2003</xref>). <italic>In vivo</italic> studies have demonstrated the importance of the p53 pathway in neuroblastoma (Chesler et al., <xref ref-type="bibr" rid="B69">2008</xref>; Chen et al., <xref ref-type="bibr" rid="B66">2009</xref>). Potential mechanisms whereby <italic>MYCN</italic> amplified tumors can overcome p53-mediated tumor suppression in neuroblastoma are discussed below.</p></sec><sec><title><italic>MYCN</italic> amplification and inactivation of the p53/MDM2/p14<sup>ARF</sup> pathway in neuroblastoma</title><p>There is evidence from neuroblastoma cell line studies that <italic>MYCN</italic> amplified neuroblastoma cells may circumvent MYCN driven p53-dependent apoptosis by selecting for cells with aberrations in the p53/MDM2/p14<sup>ARF</sup> pathway. Analysis of neuroblastoma cell lines reported to date with aberrations in the p53/MDM2/p14<sup>ARF</sup> pathway demonstrates that 31/40 (78%) of these cell lines are <italic>MYCN</italic> amplified and predominantly established following previous cytotoxic therapy at relapse (Table <xref ref-type="table" rid="T1">1</xref>), when abnormalities of the p53 pathway in neuroblastoma tumors have also been previously reported (reviewed by Tweddle et al., <xref ref-type="bibr" rid="B339">2003</xref>; Carr-Wilkinson et al., <xref ref-type="bibr" rid="B50">2010</xref>). In contrast, the proportion of neuroblastoma tumors with aberrations in the p53/MDM2/p14<sup>ARF</sup> pathway which are <italic>MYCN</italic> amplified are lower than in cell lines (Corvi et al., <xref ref-type="bibr" rid="B77">1995</xref>; Gonzalez-Gomez et al., <xref ref-type="bibr" rid="B118">2003</xref>; Su et al., <xref ref-type="bibr" rid="B318">2004</xref>; Spitz et al., <xref ref-type="bibr" rid="B311">2006</xref>; Caren et al., <xref ref-type="bibr" rid="B44">2008</xref>; Carr-Wilkinson et al., <xref ref-type="bibr" rid="B50">2010</xref>), therefore it is possible that these abnormalities are selected for during the <italic>in vitro</italic> establishment and/or maintenance of these cell lines. It is however important to note that <italic>MYCN</italic> amplification and/or overexpression is unlikely to be the only selection pressure for p53 inactivation as aberrations in the p53 pathway are also found in non-<italic>MYCN</italic> amplified tumors and cell lines (Table <xref ref-type="table" rid="T1">1</xref>; Carr et al., <xref ref-type="bibr" rid="B46">2006</xref>; Carr-Wilkinson et al., <xref ref-type="bibr" rid="B50">2010</xref>).</p><sec><title>MDM2-mediated MYCN driven tumorigenesis</title><p><italic>MDM2</italic> is a direct target gene of MYCN (Slack et al., <xref ref-type="bibr" rid="B302">2005</xref>; Westermann et al., <xref ref-type="bibr" rid="B376">2008</xref>) and non-syntenic co-amplification of <italic>MDM2</italic> and <italic>MYCN</italic> has been reported in neuroblastoma (Corvi et al., <xref ref-type="bibr" rid="B77">1995</xref>). Consistent with observations that <italic>Mdm2</italic> haploinsufficiency inhibits c-MYC induced lymphomagenesis (Alt et al., <xref ref-type="bibr" rid="B4">2003</xref>), MDM2 has been shown to be necessary for MYCN to overcome p53-mediated tumor suppression for MYCN directed centrosome amplification and genomic instability (Slack et al., <xref ref-type="bibr" rid="B303">2007</xref>), and also during MYCN driven neuroblastoma tumorigenesis (Chen et al., <xref ref-type="bibr" rid="B66">2009</xref>; Figure <xref ref-type="fig" rid="F2">2</xref>). The importance of MDM2 in neuroblastoma pathogenesis is further illustrated by studies which have observed that a SNP within the <italic>MDM2</italic> promoter (SNP309<sub>T to G</sub>) that can lead to higher expression of MDM2 and greater inhibition of p53, is associated with poor survival in neuroblastoma, in particular stage 4 patients with <italic>MYCN</italic> amplification (Cattelani et al., <xref ref-type="bibr" rid="B53">2008</xref>; Perfumo et al., <xref ref-type="bibr" rid="B265">2008</xref>, <xref ref-type="bibr" rid="B266">2009</xref>).</p><p>An additional mechanism whereby MYCN can overcome p53-mediated apoptosis is through reduced expression of <italic>CHD5</italic>, a tumor suppressor gene (TSG) mapping to 1p36.31, which is a region commonly deleted in neuroblastoma and frequently correlated with <italic>MYCN</italic> amplification (Figure <xref ref-type="fig" rid="F2">2</xref>). CHD5 has been shown to control proliferation, apoptosis, and senescence by inducing <italic>p19<sup>ARF</sup></italic>, the negative regulator of MDM2, and stabilizing p53 (Bagchi et al., <xref ref-type="bibr" rid="B10">2007</xref>). Low levels of <italic>CHD5</italic> expression have been found in neuroblastoma cell lines, as well as correlating with <italic>MYCN</italic> amplification and poor prognosis in neuroblastoma tumors (Thompson et al., <xref ref-type="bibr" rid="B330">2003</xref>; Fujita et al., <xref ref-type="bibr" rid="B108">2008</xref>; Koyama et al., <xref ref-type="bibr" rid="B183">2012</xref>).</p><p>Furthermore, MYCN can also suppress p53 through Aurora Kinase A (AURKA), a serine/threonine kinase which plays a key role in mitosis and is expressed at high levels in <italic>MYCN</italic> amplified neuroblastoma (Figure <xref ref-type="fig" rid="F2">2</xref>). AURKA has been shown to directly phosphorylate p53 at Ser-215 and Ser-315 which abrogates p53 DNA binding and transactivation of target genes (Liu et al., <xref ref-type="bibr" rid="B207">2004</xref>), and promotes MDM2-mediated destabilization and inhibition of p53 (Katayama et al., <xref ref-type="bibr" rid="B167">2004</xref>). There is additional evidence to suggest that AURKA can also inhibit p53 via the AKT/MDM2 axis in gastric cancer cells, however this remains to be shown in neuroblastoma (Dar et al., <xref ref-type="bibr" rid="B84">2008</xref>). Interestingly, AURKA has also been reported to stabilize MYCN, which would further promote MYCN driven tumorigenesis (Otto et al., <xref ref-type="bibr" rid="B258">2009</xref>; Figure <xref ref-type="fig" rid="F2">2</xref>).</p><p>Very recently, MDM2 was reported to play a p53-independent role by interacting directly with <italic>MYCN</italic> mRNA and regulating its stabilization and translation, thereby forming a positive feedback loop, critical for <italic>MYCN</italic> amplified neuroblastoma tumor cell growth and survival (Gu et al., <xref ref-type="bibr" rid="B122">2012</xref>; Figures <xref ref-type="fig" rid="F1">1</xref> and <xref ref-type="fig" rid="F2">2</xref>).</p></sec><sec><title>Twist-1 and BMI-1 mediated inhibition of the p53 pathway</title><p>Twist-1 which belongs to the bHLH transcription factor family, and BMI-1, a polycomb ring finger oncogene, are both overexpressed in several human cancers, and have been shown to be involved in epithelial-mesenchymal transition and cancer stemness which have clinical implications of cancer metastasis, drug resistance, and survival (Wu et al., <xref ref-type="bibr" rid="B380">2012a</xref>). <italic>Twist-1</italic> expression has been shown to be consistently overexpressed in <italic>MYCN</italic> amplified neuroblastoma tumors and cell lines, correlating with MYCN expression (Valsesia-Wittmann et al., <xref ref-type="bibr" rid="B344">2004</xref>). Studies have demonstrated the ability of Twist-1 to inhibit p53 expression and activity via both transcriptional and post-translational mechanisms (Figure <xref ref-type="fig" rid="F2">2</xref>). Twist-1 has been shown to directly interact with HOXA5, a potent transactivator of p53 (Stasinopoulos et al., <xref ref-type="bibr" rid="B314">2005</xref>). Additionally, it interferes with p53 stabilization and activity via inhibition of the p53/p14<sup>ARF</sup> pathway by reducing <italic>p14<sup>ARF</sup></italic> levels (Maestro et al., <xref ref-type="bibr" rid="B211">1999</xref>), and inhibition of Ser-20 phosphorylation in response to DNA damage (Stasinopoulos et al., <xref ref-type="bibr" rid="B314">2005</xref>). Furthermore, Twist-1 has been reported to repress p53-mediated gene transcription and stability via inhibition of p300-mediated acetylation of p53 (Hamamori et al., <xref ref-type="bibr" rid="B125">1999</xref>). Moreover, it is found to directly interact with the DBD of p53, thereby inhibiting p53-mediated transactivation of downstream target genes (Shiota et al., <xref ref-type="bibr" rid="B298">2008</xref>). Finally, very recently Twist-1 has also been reported to interact with the C-terminal regulatory domain of p53, which hinders post-translational modifications of p53 including Ser-392 phosphorylation, and promotes MDM2-mediated p53 degradation (Piccinin et al., <xref ref-type="bibr" rid="B267">2012</xref>).</p><p><italic>BMI-1</italic> is a direct transcriptional target of c-MYC and MYCN and is overexpressed in ~90% of neuroblastoma, correlating with MYCN expression (Ochiai et al., <xref ref-type="bibr" rid="B250">2010</xref>; Huang et al., <xref ref-type="bibr" rid="B147">2011b</xref>). It is reported to repress the <italic>CDKN2A</italic> (<italic>p16<sup>INK4a</sup></italic>/<italic>p14<sup>ARF</sup></italic>) locus which can lead to inactivation of the p53 pathway. In neuroblastoma, BMI-1 is shown to be essential for neuroblastoma tumorigenesis <italic>in vitro</italic> and <italic>in vivo</italic>, cooperating with MYCN via inhibition of MYCN driven apoptosis and downregulation of p53 expression (Cui et al., <xref ref-type="bibr" rid="B79">2007</xref>; Huang et al., <xref ref-type="bibr" rid="B147">2011b</xref>). Very recently, as an additional mechanism for BMI-1 mediated p53 inactivation, BMI-1 was found to directly bind to p53 in a complex with other Polycomb complex proteins in neuroblastoma cells leading to increased p53 ubiquitination and degradation (Calao et al., <xref ref-type="bibr" rid="B40">2012</xref>; Figure <xref ref-type="fig" rid="F2">2</xref>).</p></sec><sec><title>Downregulation of NDRG1 and NDRG2 mediated p53-dependent apoptosis</title><p><italic>NDRG1</italic> and <italic>NDRG2</italic> were originally identified as a genes downregulated by MYCN (Shimono et al., <xref ref-type="bibr" rid="B297">1999</xref>; Li and Kretzner, <xref ref-type="bibr" rid="B202">2003</xref>; Zhang et al., <xref ref-type="bibr" rid="B401">2006</xref>, <xref ref-type="bibr" rid="B400">2008</xref>). The promoter of <italic>NDRG1</italic> has been reported to possess a p53 binding site and leads to p53-mediated transactivation. <italic>NDRG1</italic> was shown to be upregulated by p53 after DNA damage, and inhibition of <italic>NDRG1</italic> expression by siRNA abolishes p53-dependent caspase activation and apoptosis. Furthermore, NDRG1 has been found to suppress metastatic cell growth (Stein et al., <xref ref-type="bibr" rid="B315">2004</xref>). Similar results have been reported for NDRG2 (Liu et al., <xref ref-type="bibr" rid="B205">2008a</xref>). Downregulation of <italic>NDRG1</italic> and <italic>NDRG2</italic> may therefore enable <italic>MYCN</italic> amplified and/or overexpressing neuroblastoma to evade p53 driven apoptosis (Figure <xref ref-type="fig" rid="F2">2</xref>).</p></sec><sec><title>MYCN and miRNAs</title><p>The 3&#x02032;-UTR of <italic>MYCN</italic> has been identified as a direct target of <italic>miR-34a</italic> (Wei et al., <xref ref-type="bibr" rid="B371">2008</xref>), a miRNA which is directly upregulated by p53 and mediates several tumor suppressive functions of p53 (reviewed by Hermeking, <xref ref-type="bibr" rid="B132">2007</xref>). Studies have shown that <italic>miR-34a</italic> plays a role in inhibiting cellular proliferation and inducing apoptosis in neuroblastoma cells (Welch et al., <xref ref-type="bibr" rid="B374">2007</xref>; Cole et al., <xref ref-type="bibr" rid="B76">2008</xref>). Interestingly, <italic>miR-34a</italic> is located at 1p36.23, a region showing frequent loss of heterozygosity (LOH) in neuroblastoma and which is associated with <italic>MYCN</italic> amplification and aggressive disease progression (reviewed by Wei et al., <xref ref-type="bibr" rid="B371">2008</xref>). Consistent with this, lower expression levels of <italic>miR-34a</italic> have been reported to correlate with 1p36 LOH in neuroblastoma (Welch et al., <xref ref-type="bibr" rid="B374">2007</xref>; Cole et al., <xref ref-type="bibr" rid="B76">2008</xref>; Feinberg-Gorenshtein et al., <xref ref-type="bibr" rid="B102">2009</xref>; Figure <xref ref-type="fig" rid="F2">2</xref>). More recently, <italic>miR-380-5p</italic>, a miRNA which is reported to repress p53, has been shown to be expressed at high levels in neuroblastoma correlating with poor outcome in <italic>MYCN</italic> amplified tumors. Anti-<italic>miR-380-5p</italic> treatment restored p53 function in p53 wt neuroblastoma cell lines and inhibited the growth of orthotopically transplanted TH-<italic>MYCN</italic> tumors (Swarbrick et al., <xref ref-type="bibr" rid="B322">2010</xref>).</p></sec></sec></sec><sec><title>Therapeutic strategies to overcome mechanisms of p53 inactivation in neuroblastoma</title><sec><title>MDM2-p53 antagonists</title><p>The importance of p53 in human cancer has led to vast efforts in the development of p53-based cancer therapeutics (reviewed by Lane et al., <xref ref-type="bibr" rid="B189">2010</xref>). One such approach is the development of small molecule inhibitors (SMIs) which disrupt the interaction between p53 and its negative regulator MDM2 to reactivate wt p53, as a novel class of anti-cancer agents. This class includes <italic>cis</italic>-imidazolines (e.g., Nutlins), spiro-oxindoles (MI compounds), benzodiazepinediones, isoindolinones, isoquinolinones, and thiophenes (RITA; reviewed by (Yuan et al., <xref ref-type="bibr" rid="B395">2011</xref>); (Hardcastle et al., <xref ref-type="bibr" rid="B128">2011</xref>)). All of these act by targeting the p53 binding pocket of MDM2 to inhibit the MDM2-p53 interaction, except RITA which binds directly to p53. Compounds that bind to the RING domain of MDM2 and act in part by inhibiting the interaction of MDM2 with the proteasome have also been developed and include 5-deazaflavins and tryptamines (reviewed by Yuan et al., <xref ref-type="bibr" rid="B395">2011</xref>).</p><p>Nutlins were the first potent and selective inhibitors of the MDM2-p53 interaction (Vassilev et al., <xref ref-type="bibr" rid="B351">2004</xref>), in particular Nutlin-3 has been extensively evaluated <italic>in vitro</italic> and <italic>in vivo</italic> in several types of human cancers and the <italic>cis</italic>-imidazoline RG7112 is currently in phase I clinical trials<xref ref-type="fn" rid="fn3"><sup>3</sup></xref> (NCT00559533 and NCT00623870). Overall, MDM2-p53 antagonists have been shown to activate the p53 pathway, inducing p53-dependent apoptosis and sensitizing tumor cells to cytotoxic and other molecular targeted therapies whilst inducing a reversible cell cycle arrest in normal cells (reviewed by (Van Maerken et al., <xref ref-type="bibr" rid="B346">2009a</xref>); (Vassilev, <xref ref-type="bibr" rid="B350">2004</xref>; Shangary et al., <xref ref-type="bibr" rid="B291">2008</xref>; Korotchkina et al., <xref ref-type="bibr" rid="B181">2009</xref>; Cheok et al., <xref ref-type="bibr" rid="B68">2011</xref>)). In recent years, there has been increased interest in the use of MDM2-p53 antagonists in a cyclotherapeutic setting to protect normal cells from the harmful effects of chemotherapy (reviewed by Cheok et al., <xref ref-type="bibr" rid="B68">2011</xref>; van Leeuwen, <xref ref-type="bibr" rid="B345">2012</xref>) and also in the identification of natural MDM2 inhibitors (Qin et al., <xref ref-type="bibr" rid="B268">2012</xref>). It is worth mentioning here that despite structural similarities between MDM2 and MDMX, MDM2-p53 antagonists are largely ineffective against MDMX, and in some cases overexpression of MDMX has been reported to confer resistance to MDM2 antagonists (reviewed by Wade and Wahl, <xref ref-type="bibr" rid="B359">2009</xref>).</p><p>Evaluation of Nutlin-3 and other MDM2-p53 antagonists in preclinical models of neuroblastoma have reported potent anti-tumor effects such as induction of growth arrest, senescence, differentiation and apoptosis, and inhibition of tumor cell proliferation and metastasis (Barbieri et al., <xref ref-type="bibr" rid="B13">2006</xref>; Van Maerken et al., <xref ref-type="bibr" rid="B349">2006</xref>, <xref ref-type="bibr" rid="B346">2009a</xref>, <xref ref-type="bibr" rid="B348">2011</xref>; Hardcastle et al., <xref ref-type="bibr" rid="B128">2011</xref>; Patterson et al., <xref ref-type="bibr" rid="B262">2011</xref>; Gamble et al., <xref ref-type="bibr" rid="B111">2012</xref>). In addition, Nutlin-3 has been shown to sensitize neuroblastoma cells to chemotherapy induced apoptosis (Barbieri et al., <xref ref-type="bibr" rid="B13">2006</xref>; Michaelis et al., <xref ref-type="bibr" rid="B225">2009</xref>; Peirce and Findley, <xref ref-type="bibr" rid="B263">2009a</xref>; Patterson et al., <xref ref-type="bibr" rid="B262">2011</xref>). Furthermore, in line with observations that p53 is a direct target gene of MYCN and mediates MYCN induced apoptosis, we recently reported that MYCN sensitizes neuroblastoma cells to both Nutlin-3 and MI63 (Gamble et al., <xref ref-type="bibr" rid="B111">2012</xref>). Moreover, there is also evidence that the <italic>MDM2</italic> and <italic>p14<sup>ARF</sup></italic> status of p53 wt neuroblastoma cells can affect the response to MDM2-p53 antagonists and warrants further investigation (Van Maerken et al., <xref ref-type="bibr" rid="B348">2011</xref>; Gamble et al., <xref ref-type="bibr" rid="B111">2012</xref>).</p><p>Some studies to date have reported several p53-independent functions of Nutlin-3, including disruption of the MDM2-p73 interaction, which leads to enhanced p73 activity, suppression of tumor cell growth, and induction of apoptosis in p53 deficient neuroblastoma cells (Lau et al., <xref ref-type="bibr" rid="B193">2008</xref>). Additionally, Nutlin-3 has also been shown to sensitize p53 deficient chemoresistant neuroblastoma cells to chemotherapy induced apoptosis via upregulation of TAp73 and E2F1 (Ambrosini et al., <xref ref-type="bibr" rid="B6">2007</xref>; Peirce and Findley, <xref ref-type="bibr" rid="B264">2009b</xref>), and inhibition of P-glycoprotein (Michaelis et al., <xref ref-type="bibr" rid="B225">2009</xref>).</p><p>The low incidence of <italic>p53</italic> mutations in pediatric cancers, in particular neuroblastoma, compared with adult malignancies support the use of MDM2-p53 antagonists as a novel therapeutic strategy in the treatment of neuroblastoma. This is further strengthened by reports that the <italic>MDM2</italic> SNP309<sub>T to G</sub> is associated with poor outcome, and that several mechanisms by which <italic>MYCN</italic> amplified neuroblastoma can overcome p53-mediated apoptosis are dependent on MDM2. Moreover, observations that inactivation of the p53/MDM2/p14<sup>ARF</sup> pathway in relapsed neuroblastoma is predominantly due to lesions upstream of p53 combined with the reported therapeutic efficacy of Nutlin-3 in p53 wt multi-drug-resistant preclinical models of neuroblastoma with metastatic burden (Van Maerken et al., <xref ref-type="bibr" rid="B346">2009a</xref>), highly support reactivation of p53 by inhibiting MDM2 as an attractive treatment option for metastatic relapsed neuroblastoma. MDM2-p53 antagonists are currently undergoing phase I clinical evaluation in adults and are anticipated to enter pediatric clinical trials in the near future, including neuroblastoma. There is however recent evidence in neuroblastoma cell lines suggesting that continuous exposure to Nutlin-3 can induce <italic>de novo</italic>
<italic>p53</italic> mutations, resulting in cells exhibiting Nutlin-3 and multi-drug resistance. Consequently these results suggest that patients treated with MDM2-p53 antagonists should be closely monitored for the development of <italic>p53</italic> mutations and/or that MDM2-p53 antagonists should be given in combination with other agents to try to prevent the development of p53 mutations (Michaelis et al., <xref ref-type="bibr" rid="B224">2011</xref>).</p></sec><sec><title>Aurora kinase inhibitors</title><p>The Aurora kinase family which includes Aurora A, B, and C, have attracted much attention over recent years as potential novel anti-cancer targets. In particular, AURKA has been shown to have oncogenic properties and is amplified and/or overexpressed in a range of human cancers (Maris, <xref ref-type="bibr" rid="B216">2009</xref>). In neuroblastoma AURKA has been found to be expressed at high levels in <italic>MYCN</italic> amplified tumors and required for the growth of <italic>MYCN</italic> amplified cells (Berwanger et al., <xref ref-type="bibr" rid="B26">2002</xref>; Otto et al., <xref ref-type="bibr" rid="B258">2009</xref>). Studies have shown that it suppresses p53 transcriptional activity as well as promoting increased MDM2-mediated p53 degradation (Katayama et al., <xref ref-type="bibr" rid="B167">2004</xref>; Liu et al., <xref ref-type="bibr" rid="B207">2004</xref>). Additionally, via direct interaction but in a kinase independent manner, AURKA has been reported to stabilize MYCN by preventing its ubiquitin mediated degradation (Maris, <xref ref-type="bibr" rid="B216">2009</xref>; Otto et al., <xref ref-type="bibr" rid="B258">2009</xref>). These observations support the therapeutic potential of using AURKA inhibitors to simultaneously restore p53 activity and destabilize MYCN in neuroblastoma. Consistent with this, inhibition of AURKA expression in neuroblastoma cells has been shown to lead to growth inhibition, increased p53 expression, and decreased MYCN expression (Otto et al., <xref ref-type="bibr" rid="B258">2009</xref>). Preclinical evaluations of a second generation AURKA inhibitor MLN8237 in pediatric cancers including neuroblastoma have been promising (Maris et al., <xref ref-type="bibr" rid="B217">2010</xref>; Carol et al., <xref ref-type="bibr" rid="B45">2011</xref>). Additionally, Aurora kinase inhibitor CCT137690 has also shown preclinical efficacy, downregulating MYCN, upregulating p53, and inhibiting neuroblastoma tumor growth <italic>in vitro</italic> and <italic>in vivo</italic>. Furthermore, consistent with the observation that AURKA is required for growth of <italic>MYCN</italic> amplified neuroblastoma, cells expressing high levels of MYCN were more sensitive to CCT137690 in comparison to cells expressing low or no MYCN (Faisal et al., <xref ref-type="bibr" rid="B101">2011</xref>). Several AURKA inhibitors are currently undergoing clinical evaluations for use as a single agent or in combination with existing chemotherapeutics in various phase I-II trials for different human cancers including neuroblastoma (Cheung et al., <xref ref-type="bibr" rid="B71">2011</xref>). Interestingly, the concomitant inhibition of the MDM2-p53 interaction and Aurora kinases has been shown to act synergistically to induce apoptosis in leukemia cells (Kojima et al., <xref ref-type="bibr" rid="B177">2008</xref>), and should be assessed in neuroblastoma.</p></sec><sec><title>Twist-1 and BMI-1 inhibitors</title><p>Twist-1 and BMI-1 are involved in inactivation of the p53 pathway and are overexpressed in several cancers including neuroblastoma, often correlating with aggressive disease, and poor prognosis (reviewed by Wu et al., <xref ref-type="bibr" rid="B380">2012a</xref>). Strategies which can inhibit Twist-1 and/or BMI-1 activity or expression and lead to restoration of the p53 pathway and tumor suppression are therefore therapeutically promising. In support of this, studies in neuroblastoma have observed that MYCN functionally cooperates with Twist-1 or BMI-1 to induce neuroblastoma tumorigenesis, where overexpression of Twist-1 or BMI-1 is necessary for tumor growth both <italic>in vitro</italic> and <italic>in vivo</italic> (Valsesia-Wittmann et al., <xref ref-type="bibr" rid="B344">2004</xref>; Cui et al., <xref ref-type="bibr" rid="B79">2007</xref>; Huang et al., <xref ref-type="bibr" rid="B147">2011b</xref>). To date no specific inhibitor of Twist-1 has been identified, however PTC Therapeutics Inc., has very recently announced the development of PTC596, a first in its class, potent, oral, and selective inhibitor of BMI-1 protein expression. The inhibitor acts by altering the post-translational modification of BMI-1 which results in reduced levels of the protein and subsequently the reduced action of epigenetic complexes dependent on BMI-1<xref ref-type="fn" rid="fn4"><sup>4</sup></xref>. In addition, histone deacetylase (HDAC) inhibitors and the drug artemisinin have also been shown to reduce expression levels of BMI-1 (Cao et al., <xref ref-type="bibr" rid="B43">2011</xref>). Furthermore, as Twist-1 and BMI-1 both act through negative regulation of p14<sup>ARF</sup> to inactivate the p53 pathway, this could also be overcome by the use of MDM2-p53 antagonists. A study to evaluate the therapeutic efficacy of PTC596 in neuroblastoma is warranted.</p></sec><sec><title>miRNA mimics and antagomirs</title><p>It has become increasingly evident that miRNAs play a role in tumorigenesis and thus are potential targets for cancer therapy. The widespread deregulation of miRNAs in neuroblastoma is reported to be due to <italic>MYCN</italic> amplification and chromosomal imbalances (Bray et al., <xref ref-type="bibr" rid="B35">2009</xref>). Several miRNAs have been suggested to have prognostic significance and therapeutic potential in neuroblastoma including <italic>miR-34a</italic> and <italic>miR-380-5p</italic> (reviewed by Verissimo et al., <xref ref-type="bibr" rid="B355">2011</xref>). The restoration of <italic>miR-34a</italic> and inhibition of <italic>miR-380-5p</italic> have been shown to reactivate the p53 pathway and inhibit MYCN expression, as well as inhibiting tumor growth in cell lines and orthotopic murine models of neuroblastoma (Wei et al., <xref ref-type="bibr" rid="B371">2008</xref>; Swarbrick et al., <xref ref-type="bibr" rid="B322">2010</xref>; Tivnan et al., <xref ref-type="bibr" rid="B332">2012</xref>). Advances in miRNA cancer therapy toward clinical use are being made. <italic>MiR-34</italic> mimics developed by Mirna Therapuetics Inc., are anticipated to enter clinical trials in early 2013 (Bader, <xref ref-type="bibr" rid="B9">2012</xref>). Miravirsen, a miRNA-targeted drug inhibiting <italic>miR-122</italic>, was the first of its class to enter clinical trials and is currently in phase II trials for the treatment of patients with Hepatitis C virus (Hu et al., <xref ref-type="bibr" rid="B144">2012</xref>).</p></sec><sec><title>Other strategies</title><p>Similar to <italic>miR-34a</italic>, <italic>CHD5</italic> is also located at 1p36, and is frequently deleted and/or methylated in several human cancers including neuroblastoma. 1p deletion and epigenetic silencing of <italic>CHD5</italic> have been suggested to account for the low expression observed in both neuroblastoma tumors and cell lines, as homozygous deletions or mutations were reported to be infrequent (Fujita et al., <xref ref-type="bibr" rid="B108">2008</xref>; Koyama et al., <xref ref-type="bibr" rid="B183">2012</xref>). The promising therapeutic implications of restoring <italic>CHD5</italic> expression in neuroblastoma has previously been shown by the reduced clonogenicity and xenograft tumor growth of neuroblastoma cell lines stably transfected with <italic>CHD5</italic> cDNA (Fujita et al., <xref ref-type="bibr" rid="B108">2008</xref>). Very recently, genistein has been reported to demethylate the <italic>CHD5</italic> promoter, enhance the expression of CHD5 and p53, and inhibit neuroblastoma growth <italic>in vivo</italic> (Li et al., <xref ref-type="bibr" rid="B201">2012b</xref>).</p><p>Originally identified as genes downregulated by MYCN, NDRG1, and NDRG2 have subsequently been shown to be necessary for p53-mediated apoptosis. NDRG1 has been shown to be upregulated in response to differentiation and suppress metastasis, and there is growing interest in using NDRG1 as a biomarker of disease progression (reviewed by Ellen et al., <xref ref-type="bibr" rid="B99">2008</xref>). Very recently, NDRG1 has been shown to upregulate NEDD4L, PTEN, and SMAD4 and inhibit the PI3K and Ras signaling pathways, thereby implicating its involvement in regulating key oncogenic pathways (Kovacevic et al., <xref ref-type="bibr" rid="B182">2012</xref>). The exact role of NDRG1 and family members in cancers including neuroblastoma remain to be fully elucidated, however the iron chelator Dp44mT which exhibits anti-cancer properties has been reported to upregulate the expression of NDRG1 (Chen et al., <xref ref-type="bibr" rid="B67">2012</xref>).</p></sec></sec></sec><sec><title>SKP2</title><p>S-phase kinase-associated protein 2 (SKP2) is an F-Box protein and the variable substrate recognition component of the E3 ubiquitin ligase SCF<sup>SKP2</sup> complex. The invariable core components of SCF complexes are SKP1, CUL1, and RBX1 (Skowyra et al., <xref ref-type="bibr" rid="B301">1997</xref>; Deshaies, <xref ref-type="bibr" rid="B90">1999</xref>; Nakayama and Nakayama, <xref ref-type="bibr" rid="B244">2005</xref>). SKP2 was originally discovered as a protein associated with Cyclin A-CDK2, and subsequently shown to play a key role in promoting cell cycle progression, in particular at the G<sub>1</sub>/S transition (Zhang et al., <xref ref-type="bibr" rid="B399">1995</xref>). More recently, studies have also identified the involvement of SKP2 in several processes closely linked to tumorigenesis such as cell survival, apoptosis, migration, and metastasis (reviewed by Chan et al., <xref ref-type="bibr" rid="B56">2010b</xref>).</p><p>SKP2 protein is approximately 45&#x02009;kDa, consisting of an N-terminal F-Box domain which mediates the interaction between SKP2 and SKP1, thereby tethering SKP2 to the SCF complex, and C-terminal leucine-rich repeats (LRR) which enable SKP2 to directly bind to target substrates (Bai et al., <xref ref-type="bibr" rid="B11">1996</xref>; Skowyra et al., <xref ref-type="bibr" rid="B301">1997</xref>; Schulman et al., <xref ref-type="bibr" rid="B287">2000</xref>; Zheng et al., <xref ref-type="bibr" rid="B405">2002</xref>). Since its discovery, SKP2 has been found to target numerous proteins for ubiquitination and subsequent degradation via the 26S proteasome pathway, including CDK inhibitors p21<sup>CIP1</sup> (Yu et al., <xref ref-type="bibr" rid="B394">1998</xref>; Bornstein et al., <xref ref-type="bibr" rid="B32">2003</xref>), p27<sup>KIP1</sup> (Carrano et al., <xref ref-type="bibr" rid="B47">1999</xref>; Sutterluty et al., <xref ref-type="bibr" rid="B321">1999</xref>; Tsvetkov et al., <xref ref-type="bibr" rid="B336">1999</xref>), and p57<sup>KIP2</sup> (Kamura et al., <xref ref-type="bibr" rid="B164">2003</xref>), Rb family member p130 (Tedesco et al., <xref ref-type="bibr" rid="B327">2002</xref>), apoptosis regulator FOXO1, tumor suppressors BRCA2 (Moro et al., <xref ref-type="bibr" rid="B235">2006</xref>), RASSF1A (Song et al., <xref ref-type="bibr" rid="B307">2008</xref>), and TOB1 (Hiramatsu et al., <xref ref-type="bibr" rid="B135">2006</xref>), Cyclins D (Yu et al., <xref ref-type="bibr" rid="B394">1998</xref>) and E (Yeh et al., <xref ref-type="bibr" rid="B390">2001</xref>), as well as oncogenes c-MYC (Kim et al., <xref ref-type="bibr" rid="B171">2003</xref>; von der Lehr et al., <xref ref-type="bibr" rid="B357">2003</xref>) and MYB (Charrasse et al., <xref ref-type="bibr" rid="B60">2000</xref>). The binding and recognition of the substrate by SKP2 is dependent on prior phosphorylation of the target substrate, and in some cases also requires the activity of a co-factor protein, CKS1 (Cyclin-kinase-subunit 1; Ganoth et al., <xref ref-type="bibr" rid="B112">2001</xref>; Spruck et al., <xref ref-type="bibr" rid="B312">2001</xref>; Frescas and Pagano, <xref ref-type="bibr" rid="B107">2008</xref>).</p><sec><title>Regulation of SKP2 expression, stability, and activity</title><p>Consistent with its role as a cell cycle regulator, expression levels of SKP2 oscillate during the cell cycle, and are regulated by both transcriptional and post-transcriptional mechanisms (Bashir and Pagano, <xref ref-type="bibr" rid="B17">2004</xref>). Levels of SKP2 are low in G<sub>0</sub>/G<sub>1</sub> and late M/early G<sub>1</sub>, increase during G<sub>1</sub>/S transition and reach a maximum in S phase (Wirbelauer et al., <xref ref-type="bibr" rid="B377">2000</xref>; Bashir et al., <xref ref-type="bibr" rid="B16">2004</xref>; Wei et al., <xref ref-type="bibr" rid="B372">2004</xref>). Studies to date have revealed that several transcription factors act directly via the <italic>SKP2</italic> promoter to upregulate <italic>SKP2</italic> gene expression, such as E2F1 (Zhang and Wang, <xref ref-type="bibr" rid="B403">2006</xref>), NF<sc>k</sc>B (Schneider et al., <xref ref-type="bibr" rid="B285">2006</xref>), SP1 (Appleman et al., <xref ref-type="bibr" rid="B8">2006</xref>), CBF1 (Sarmento et al., <xref ref-type="bibr" rid="B284">2005</xref>), GABP (Imaki et al., <xref ref-type="bibr" rid="B150">2003</xref>), FOXM1 (Wang et al., <xref ref-type="bibr" rid="B364">2005</xref>), c-MYC (Bretones et al., <xref ref-type="bibr" rid="B36">2011</xref>), STAT3 (Huang et al., <xref ref-type="bibr" rid="B145">2012</xref>), and NOR1 (Gizard et al., <xref ref-type="bibr" rid="B114">2011</xref>). In addition, Foxp3 (Zuo et al., <xref ref-type="bibr" rid="B407">2007</xref>), FOXO3A (Wu et al., <xref ref-type="bibr" rid="B381">2012b</xref>) and STAT1 (Wang et al., <xref ref-type="bibr" rid="B363">2010c</xref>) have been identified to transcriptionally repress <italic>SKP2</italic> expression.</p><p>The identification of <italic>SKP2</italic> as a direct target gene of E2F (Zhang and Wang, <xref ref-type="bibr" rid="B403">2006</xref>) is of particular importance as Yung et al. (<xref ref-type="bibr" rid="B397">2007</xref>) subsequently described the SKP2 autoinduction loop comprising pRB-E2F, SKP2, p27<sup>KIP1</sup>, and Cyclin E-CDK2, in which SKP2 expression initiates proteolysis of p27<sup>KIP1</sup>, activation of Cyclin E-CDK2 which feeds back to sustain pRB inactivation, E2F release, and further induction of the <italic>SKP2</italic> gene. Therefore, once activated, this autoinduction loop ensures mitogen independent cell cycle progression through the restriction point.</p><p>In addition to transcriptional regulation, SKP2 is also subject to regulation via protein stability. The E3 ubiquitin ligase APC<sup>Cdh1</sup> complex mediates the ubiquitination and subsequent degradation of SKP2, primarily in early G<sub>1</sub> (Bashir et al., <xref ref-type="bibr" rid="B16">2004</xref>; Wei et al., <xref ref-type="bibr" rid="B372">2004</xref>). The interaction between Cdh1 and SKP2 is essential for APC<sup>Cdh1</sup> complex mediated degradation of SKP2. In support of this, several kinases including CDK2, AKT, and Pim-1 have been shown to phosphorylate SKP2 at residues Ser-64 and Ser-72 and/or Thr-417, thereby inhibiting the Cdh1-SKP2 interaction and protecting SKP2 from APC<sup>Cdh1</sup> mediated ubiquitination and degradation. Furthermore, Pim-1 has also been shown to phosphorylate Cdh1, impairing its association with CDC27 and inhibiting APC<sup>Cdh1</sup> activity, thereby protecting SKP2 from degradation (reviewed by Chan et al., <xref ref-type="bibr" rid="B56">2010b</xref>). In contrast, studies have shown that pRb interacts with Cdh1 and promotes SKP2 degradation (Binne et al., <xref ref-type="bibr" rid="B27">2007</xref>), and TGF&#x003b2; signaling induces nuclear translocation of SKP2 which facilitates its ubiquitylation by APC<sup>Cdh1</sup> and subsequent degradation (Hu et al., <xref ref-type="bibr" rid="B143">2011</xref>).</p><p>Finally, the formation of the SCF<sup>SKP2</sup> complex is critical for ligase activity. Studies have demonstrated that PI3K/AKT signaling pathway and Cyclin D positively regulate SCF<sup>SKP2</sup> complex formation and ligase activity, potentially through neddylation of CUL1 (reviewed by Chan et al., <xref ref-type="bibr" rid="B56">2010b</xref>).</p></sec><sec><title>SKP2 as an oncoprotein</title><p>Numerous studies to date have provided evidence showing the oncogenic potential of SKP2, and its cross-talk with multiple signaling pathways involved in carcinogenesis such as PI3K/AKT, mTOR, ERK, NF<sc>k</sc>B, Ras/MAPK, and IGF (Wang et al., <xref ref-type="bibr" rid="B367">2012c</xref>). Overexpression of SKP2 can drive quiescent cells to enter the cell cycle (Sutterluty et al., <xref ref-type="bibr" rid="B321">1999</xref>), and promote adhesion-independent growth of cancer cells (Carrano and Pagano, <xref ref-type="bibr" rid="B48">2001</xref>; Signoretti et al., <xref ref-type="bibr" rid="B300">2002</xref>). Downregulation or inhibition of SKP2 expression leads to growth arrest and/or apoptosis, as well as reduced cell migration, invasion, and metastasis (Koga et al., <xref ref-type="bibr" rid="B176">2003</xref>; Yokoi et al., <xref ref-type="bibr" rid="B391">2003</xref>; Jiang et al., <xref ref-type="bibr" rid="B156">2005</xref>; Lee and McCormick, <xref ref-type="bibr" rid="B197">2005</xref>; Shibahara et al., <xref ref-type="bibr" rid="B293">2005</xref>; Katagiri et al., <xref ref-type="bibr" rid="B166">2006</xref>; Kitagawa et al., <xref ref-type="bibr" rid="B173">2008</xref>; Xiao et al., <xref ref-type="bibr" rid="B383">2009</xref>; Chan et al., <xref ref-type="bibr" rid="B55">2010a</xref>; Bretones et al., <xref ref-type="bibr" rid="B36">2011</xref>). In transgenic mouse models, SKP2 cooperates with N-Ras to drive lymphomagenesis (Latres et al., <xref ref-type="bibr" rid="B192">2001</xref>), and tissue targeted expression of <italic>SKP2</italic> results in hyperplasia, dysplasia, and low-grade carcinoma of the prostate gland (Shim et al., <xref ref-type="bibr" rid="B294">2003</xref>). Knockdown of <italic>SKP2</italic> significantly reduced tumor formation and metastasis of breast cancer xenografts (Chan et al., <xref ref-type="bibr" rid="B55">2010a</xref>). Furthermore, work in <italic>SKP2</italic> knockout mice demonstrated that SKP2 is necessary for tumor formation induced by <italic>PTEN</italic>, <italic>p19<sup>ARF</sup></italic>, or <italic>Rb</italic> deficiency (Lin et al., <xref ref-type="bibr" rid="B203">2010</xref>; Wang et al., <xref ref-type="bibr" rid="B362">2010b</xref>).</p><p>SKP2 overexpression at the mRNA and/or protein level have been detected in a number of human tumors and cell lines including prostate, breast, pancreatic, gastric, colorectal, ovarian, melanoma, lymphoma, and leukemia (reviewed by Nakayama and Nakayama, <xref ref-type="bibr" rid="B245">2006</xref>; Frescas and Pagano, <xref ref-type="bibr" rid="B107">2008</xref>; Hershko, <xref ref-type="bibr" rid="B134">2008</xref>). In addition, amplification of <italic>SKP2</italic> at chromosome 5p13 has been reported (Yokoi et al., <xref ref-type="bibr" rid="B392">2004</xref>; Saigusa et al., <xref ref-type="bibr" rid="B281">2005</xref>; Wang et al., <xref ref-type="bibr" rid="B368">2009</xref>; Rose et al., <xref ref-type="bibr" rid="B277">2011</xref>; Li et al., <xref ref-type="bibr" rid="B200">2012a</xref>), and tends to be observed in metastatic tumors whereas overexpression of SKP2 is reported in early cancers (Hershko, <xref ref-type="bibr" rid="B134">2008</xref>). Overall, elevated SKP2 expression has been shown to correlate with a poor prognostic outcome, tumor size, dedifferentiation, advanced grade, and metastasis (reviewed by Wang et al., <xref ref-type="bibr" rid="B367">2012c</xref>). It is worth mentioning that in some cases the latter has been correlated with cytoplasmic and not nuclear SKP2 expression. In the vast majority of cases, SKP2 overexpression inversely correlates with p27<sup>KIP1</sup> expression (Nakayama and Nakayama, <xref ref-type="bibr" rid="B245">2006</xref>; Frescas and Pagano, <xref ref-type="bibr" rid="B107">2008</xref>), which is consistent p27<sup>KIP1</sup> being a key target of SKP2 and to be rarely mutated in cancer (Chu et al., <xref ref-type="bibr" rid="B73">2008</xref>). Finally, in recent years, SKP2 overexpression has been shown to mediate resistance to TRAIL induced apoptosis (Schuler et al., <xref ref-type="bibr" rid="B286">2011</xref>), and radio- and chemoresistance of human cancer cells (Ishii et al., <xref ref-type="bibr" rid="B154">2004</xref>; Davidovich et al., <xref ref-type="bibr" rid="B86">2008</xref>; Chan et al., <xref ref-type="bibr" rid="B57">2012</xref>; Totary-Jain et al., <xref ref-type="bibr" rid="B333">2012</xref>; Wang et al., <xref ref-type="bibr" rid="B366">2012b</xref>).</p><sec><title>SKP2 mediated attenuation of p53 function</title><p>Recent key publications have identified that SKP2 and an alternatively spliced variant of <italic>SKP2</italic>, SKP2B can attenuate p53 function through independent mechanisms (Figure <xref ref-type="fig" rid="F3">3</xref>). Initially, Kitagawa et al. (<xref ref-type="bibr" rid="B173">2008</xref>) identified that SKP2 is able to suppress p53-mediated apoptosis by inhibiting the p53 transcriptional co-activator, p300. This function was shown to be independent of the F-Box motif of SKP2 and hence SCF<sup>SKP2</sup> complex function. SKP2 was found to bind to the CH1 and CH3 domain of p300, thought to be p53 binding sites, thereby antagonizing the p53-p300 interaction, suppressing p300-mediated acetylation of p53 and the transactivation ability of p53. In addition, secondary to the latter, SKP2 was also observed to promote the degradation of p300. As proof-of-concept, the study demonstrated that inhibition of SKP2 combined with DNA damaging agents or Nutlin-3, led to greater induction of apoptosis (Kitagawa et al., <xref ref-type="bibr" rid="B173">2008</xref>). More recently, SKP2B was demonstrated to attenuate p53 function via a mechanism independent of p300. SKP2B is shown to bind to and mediate the degradation of Prohibitin, a potential TSG which binds to and stimulates p53 transcriptional activity. Taken together, these observations suggest that amplification of the <italic>SKP2</italic> locus would represent a powerful mechanism to attenuate p53 function in cancer (Chander et al., <xref ref-type="bibr" rid="B58">2010</xref>; Figure <xref ref-type="fig" rid="F3">3</xref>).</p><fig id="F3" position="float"><label>Figure 3</label><caption><p><bold>MYC proteins and SKP2</bold>. SKP2 is an oncoprotein which can be upregulated by MYC proteins to drive tumorigenesis. <italic>SKP2</italic> is a direct target gene of c-MYC, and can regulate the stability of c-MYC and be a co-factor for c-MYC mediated transcriptional activation of target genes. Due to the homology between c-MYC and MYCN, it is possible that <italic>SKP2</italic> is also a direct target gene of MYCN and plays a similar role in regulating MYCN stability and transactivation of MYCN target genes (as indicated by the dashed lines). In neuroblastoma, MYCN can indirectly upregulate <italic>SKP2</italic> via CDK4. In addition to upregulation by oncogenic MYC proteins, several signaling pathways closely linked to carcinogenesis such as PI3K/AKT and mTOR have been shown to influence SKP2 expression, stability and SCF<sup>SKP2</sup> ligase activity. SKP2 is a component of the SCF<sup>SKP2</sup> complex which mediates the degradation of several substrates including CDK inhibitors p21<sup>CIP1</sup>, p27<sup>KIP1</sup>, and p57<sup>KIP2</sup>. Independently of SCF complex formation, SKP2 can bind to p300 and attenuate p53 function. Interestingly, p300 is able to reciprocally regulate SKP2 activity. SKP2B, an alternatively spliced variant of <italic>SKP2</italic>, can perturb both p53 and pRB pathways via degradation of Prohibitin. It is possible that SKP2 has other functions which may promote tumorigenesis.</p></caption><graphic xlink:href="fonc-02-00173-g003"/></fig><p>Interestingly, a very recent study has reported an additional mechanism for the SKP2-p300 interaction, whereby p300 is able to reciprocally regulate SKP2 function (Figure <xref ref-type="fig" rid="F3">3</xref>). p300-mediated acetylation of SKP2 at Lys-68 and Lys-71 within its NLS region was shown to promote SKP2 stabilization and cytoplasmic retention, thereby influencing its oncogenic potential. In part the latter was reported to be achieved through cytoplasmic SKP2 mediated increased cellular migration via ubiquitination and destruction of E-cadherin (Inuzuka et al., <xref ref-type="bibr" rid="B152">2012</xref>).</p></sec></sec><sec><title>The role of SKP2 in neuroblastoma</title><p>In line with observations that SKP2 drives cellular proliferation, cAMP induces proliferation of neuroblastoma cells by upregulating SKP2 (Cho et al., <xref ref-type="bibr" rid="B72">2007</xref>), while growth arrest and differentiation of neuroblastoma cell lines induced by retinoic acid, BMP2, and the HDAC inhibitor <italic>Helminthosporium carbonum</italic> toxin is accompanied by a decrease in SKP2 levels (Nakamura et al., <xref ref-type="bibr" rid="B238">2003a</xref>,<xref ref-type="bibr" rid="B239">b</xref>; Cuende et al., <xref ref-type="bibr" rid="B78">2008</xref>; Deubzer et al., <xref ref-type="bibr" rid="B91">2008a</xref>). This decrease has been attributed to retinoic acid induced downregulation of Rae1 which leads to increased APC<sup>Cdh1</sup> mediated degradation of SKP2, or HDAC inhibitor induced activation of the Rb pathway (Cuende et al., <xref ref-type="bibr" rid="B78">2008</xref>; Deubzer et al., <xref ref-type="bibr" rid="B92">2008b</xref>).</p><p>Several studies including our own have found higher expression of SKP2 in the presence of ectopic MYCN, and in <italic>MYCN</italic> amplified cell lines and tumors (Sugihara et al., <xref ref-type="bibr" rid="B319">2006</xref>; Bell et al., <xref ref-type="bibr" rid="B21">2007a</xref>; Westermann et al., <xref ref-type="bibr" rid="B375">2007</xref>; Chen et al., <xref ref-type="bibr" rid="B63">2010</xref>; Muth et al., <xref ref-type="bibr" rid="B237">2010</xref>; Table <xref ref-type="table" rid="T2">2</xref>), suggesting that deregulated SKP2 expression is driven by MYCN to promote neuroblastoma. The exact role of SKP2 in neuroblastoma pathogenesis is currently unclear. It is possible that high expression of SKP2 simply collaborates with MYCN to drive uncontrolled proliferation through increased degradation of CDK inhibitors. Alternatively, as <italic>Myc</italic> family members are known to drive both proliferation and apoptosis, MYCN may upregulate SKP2 to inhibit apoptosis and tip the balance in favor of proliferation. In particular, as <italic>p53</italic> has previously been shown to be a direct target gene of MYCN, and a mechanism for MYCN mediated apoptosis in neuroblastoma, it is plausible that MYCN directly upregulates SKP2 to attenuate p53-mediated apoptosis (Kitagawa et al., <xref ref-type="bibr" rid="B173">2008</xref>; Chen et al., <xref ref-type="bibr" rid="B63">2010</xref>), as has previously been reported for c-MYC (Bretones et al., <xref ref-type="bibr" rid="B36">2011</xref>; Figure <xref ref-type="fig" rid="F3">3</xref>).</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p><bold>Summary of studies which have shown increased SKP2 expression in the presence of MYCN and/or <italic>MYCN</italic> amplification in neuroblastoma</bold>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Study</th><th align="left" rowspan="1" colspan="1">Tumors</th><th align="left" rowspan="1" colspan="1">Cell Lines</th><th align="left" rowspan="1" colspan="1">Methods</th><th align="left" rowspan="1" colspan="1">Evidence</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Sugihara et al. (<xref ref-type="bibr" rid="B319">2006</xref>)</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">SHEP-MYCN<sup>1</sup></td><td align="left" rowspan="1" colspan="1">WB</td><td align="left" rowspan="1" colspan="1">E</td></tr><tr><td align="left" rowspan="1" colspan="1">Bell et al. (<xref ref-type="bibr" rid="B21">2007a</xref>)</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">IMR32, SKNBE2C, Tet21N<sup>2</sup></td><td align="left" rowspan="1" colspan="1">MYCN siRNA, microarray<sup>3</sup>, qRT-PCR</td><td align="left" rowspan="1" colspan="1">Si, E</td></tr><tr><td align="left" rowspan="1" colspan="1">Westermann et al. (<xref ref-type="bibr" rid="B375">2007</xref>)</td><td align="left" rowspan="1" colspan="1">49/117/141/19</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Microarray/qRT-PCR/IHC tissue array/WB</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">Microarray, qRT-PCR, WB, IHC</td><td align="left" rowspan="1" colspan="1">T</td></tr><tr><td align="left" rowspan="1" colspan="1">Chen et al. (<xref ref-type="bibr" rid="B63">2010</xref>)</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">Tet21N</td><td align="left" rowspan="1" colspan="1">Microarray</td><td align="left" rowspan="1" colspan="1">E</td></tr><tr><td align="left" rowspan="1" colspan="1">Muth et al. (<xref ref-type="bibr" rid="B237">2010</xref>)</td><td align="left" rowspan="1" colspan="1">251 Microarray</td><td align="left" rowspan="1" colspan="1">SHEP, SHSY5Y, SKNSH, SKNBE2C, IMR32, IMR5-75, Kelly, Tet21N, IMR5-75-shMYCN<sup>4</sup></td><td align="left" rowspan="1" colspan="1">Microarray, SKP2 promoter assay, MYCN shRNA, qRT-PCR, WB</td><td align="left" rowspan="1" colspan="1">T, R, Sh, E</td></tr></tbody></table><table-wrap-foot><p><italic><sup>1</sup>SHEP cells transfected with retroviral control vector or vector containing MYCN; <sup>2</sup>GIMEN, NB69, LAN-6, NBL-S, PER-108, SMSKCNR, NBLW, CHLA-136, and NGP were analyzed for SKP2 protein expression using WB, however no correlation between SKP2 protein expression and MYCN protein expression or <italic>MYCN</italic> amplification was observed; <sup>3</sup>Microarray analysis performed on IMR32 and SKNBE2C cells treated with scrambled or MYCN siRNA for 16 and 48&#x02009;h; <sup>4</sup>IMR5-75 cells with inducible stably transfected short hairpin RNAs against MYCN</italic>.</p><p><italic>WB, Western blotting; IHC, immunohistochemistry; R, reporter gene assays; Si, differential expression following MYCN siRNA; Sh, differential expression following MYCN shRNA; E, differential expression/correlation in ectopic MYCN expression systems; T, correlation in tumors with <italic>MYCN</italic> amplification</italic>.</p></table-wrap-foot></table-wrap><p>The precise mechanism of MYCN mediated upregulation of SKP2 remains unclear, as <italic>SKP2</italic> is a direct target gene of E2F (Zhang and Wang, <xref ref-type="bibr" rid="B403">2006</xref>), <italic>E2F</italic> is a direct target of c-MYC (Fernandez et al., <xref ref-type="bibr" rid="B103">2003</xref>) and higher E2F expression levels are observed in the presence of MYCN (Mac et al., <xref ref-type="bibr" rid="B210">2000</xref>; Woo et al., <xref ref-type="bibr" rid="B379">2008</xref>). In neuroblastoma tumors, <italic>SKP2</italic> expression has been shown to tightly correlate with <italic>E2F1</italic> expression, and both genes are expressed at significantly higher levels in <italic>MYCN</italic> amplified tumors (Westermann et al., <xref ref-type="bibr" rid="B375">2007</xref>; Muth et al., <xref ref-type="bibr" rid="B237">2010</xref>). Interestingly, although <italic>SKP2</italic> expression levels were found to be highest in <italic>MYCN</italic> amplified tumors, this did not correlate with <italic>MYCN</italic> expression in <italic>MYCN</italic> single-copy tumors (Westermann et al., <xref ref-type="bibr" rid="B375">2007</xref>). Similarly, Bell et al. (<xref ref-type="bibr" rid="B21">2007a</xref>) reported that although <italic>SKP2</italic> mRNA levels decreased after MYCN siRNA and after removal of MYCN expression in Tet21N cells, SKP2 protein levels did not correlate with MYCN protein levels or <italic>MYCN</italic> amplification in a panel of neuroblastoma cell lines. It has been suggested that deregulated MYCN expression in <italic>MYCN</italic> amplified neuroblastoma indirectly upregulates <italic>SKP2</italic> via the induction of <italic>CDK4</italic> (Figure <xref ref-type="fig" rid="F3">3</xref>), thereby reducing the abundance of repressive pRB-E2F1 complexes bound to the <italic>SKP2</italic> promoter and providing an entry point into the SKP2 autoinduction loop (Muth et al., <xref ref-type="bibr" rid="B237">2010</xref>). Whether <italic>SKP2</italic> is a direct transcriptional target of MYCN remains to be determined. However, as c-MYC and MYCN are known to share some common target genes, and c-MYC has recently been shown to directly bind to two high affinity E-Box motifs (CATGCG and CACGCG) mapping to &#x02212;756 and &#x02212;389&#x02009;bp upstream of the transcriptional start site within the <italic>SKP2</italic> promoter and drive transcription (Bretones et al., <xref ref-type="bibr" rid="B36">2011</xref>), it is therefore possible that MYCN may also directly regulate <italic>SKP2</italic> expression (Figure <xref ref-type="fig" rid="F3">3</xref>).</p><p>Whether or not <italic>SKP2</italic> is a direct target gene of MYCN, the prognostic significance of <italic>SKP2</italic> overexpression in neuroblastoma has been demonstrated in primary tumor samples. High <italic>SKP2</italic> expression was found to characterize aggressive high-risk disease independent of both <italic>MYCN</italic> status and stage. Furthermore, high SKP2 expression was observed to correlate with low p27<sup>KIP1</sup> expression levels (Westermann et al., <xref ref-type="bibr" rid="B375">2007</xref>), consistent with studies in other cancer types (reviewed by Nakayama and Nakayama, <xref ref-type="bibr" rid="B245">2006</xref>; Frescas and Pagano, <xref ref-type="bibr" rid="B107">2008</xref>; Hershko, <xref ref-type="bibr" rid="B134">2008</xref>). Interestingly, the prognostic value of low p27<sup>KIP1</sup> expression in neuroblastoma, independent of <italic>MYCN</italic> status had previously been demonstrated (Bergmann et al., <xref ref-type="bibr" rid="B25">2001</xref>).</p><p>SKP2 has previously been shown to regulate the stability of c-MYC and to be a co-factor for c-MYC mediated transcriptional activation of target genes (Kim et al., <xref ref-type="bibr" rid="B171">2003</xref>; von der Lehr et al., <xref ref-type="bibr" rid="B357">2003</xref>), however it is currently remains unclear whether it plays a similar role in regulating MYCN stability and transactivation of MYCN target genes (Figure <xref ref-type="fig" rid="F3">3</xref>).</p><p>Taken together, SKP2 has prognostic significance in neuroblastoma and could be a promising novel therapeutic target, however further studies investigating the role of SKP2 in neuroblastoma are required. Consequently, together with <italic>in vitro</italic> experiments, crossing <italic>SKP2</italic> knockout mice with murine models of neuroblastoma, such as the transgenic TH-<italic>MYCN</italic> mouse, the role of SKP2 in driving neuroblastoma could be elucidated.</p></sec><sec><title>Therapeutic strategies targeting SKP2</title><p>Over the past decade, SKP2 has emerged as a novel and attractive pharmacological target in cancer therapeutics. This is supported by the involvement of SKP2 in proliferation, apoptosis, differentiation, migration, and metastasis, as well as its cross-talk with multiple signaling pathways closely linked to carcinogenesis. In addition, the prognostic significance and overexpression of SKP2 in a variety of human cancers, combined with observations that <italic>SKP2</italic> knockout mice are both viable and fertile (Nakayama et al., <xref ref-type="bibr" rid="B243">2000</xref>), further strengthens its appeal. Furthermore, with the discovery of the role of SKP2 and SKP2B in attenuating p53-mediated apoptosis and transcriptional activity, and that <italic>SKP2</italic> deficiency triggers a potent ARF-p53-independent cellular senescence in the presence of oncogenic conditions (such as inactivation of TSGs/overexpression of proto-oncogenes), has implicated the wide applicability of targeting SKP2 as a strategy to reactivate p53 and as pro-senescence therapy (Kitagawa et al., <xref ref-type="bibr" rid="B173">2008</xref>; Chander et al., <xref ref-type="bibr" rid="B58">2010</xref>; Lin et al., <xref ref-type="bibr" rid="B203">2010</xref>). Finally, the availability of crystallographic maps of the structure of SKP2 and SCF<sup>SKP2</sup> complex components and their interaction with substrates, together with biochemical data provides the opportunity to develop novel SKP2 inhibitors (Frescas and Pagano, <xref ref-type="bibr" rid="B107">2008</xref>).</p><p>Inhibitors targeting the ubiquitin proteasome system (UPS) have been developed and used with success in preclinical and/or clinical studies thereby highlighting these inhibitors as a new class of cancer therapeutics (Kisselev et al., <xref ref-type="bibr" rid="B172">2012</xref>). Bortezomib (Velcade<sup>&#x02122;</sup>) is the first clinically approved proteasome inhibitor, and has been reported to induce p27<sup>KIP1</sup> expression through degradation of SKP2 (Uddin et al., <xref ref-type="bibr" rid="B340">2008</xref>, <xref ref-type="bibr" rid="B341">2009</xref>). Of interest, although not directly linked to SKP2, bortezomib is shown to induce apoptosis and inhibit cell growth, migration, angiogenesis, and metastasis both <italic>in vitro</italic> and in murine models of chemosensitive and chemoresistant neuroblastoma (Brignole et al., <xref ref-type="bibr" rid="B37">2006</xref>; Michaelis et al., <xref ref-type="bibr" rid="B223">2006</xref>; Hamner et al., <xref ref-type="bibr" rid="B126">2007</xref>; Valentiner et al., <xref ref-type="bibr" rid="B343">2009</xref>). Despite the overall success of bortezomib, severe side-effects have been reported in patients, and may be attributable to the broad ranging functions and targets of the UPS (Chen et al., <xref ref-type="bibr" rid="B61">2011</xref>). Therefore the development of specific inhibitors directly targeting SKP2 is likely to have enhanced efficacy and reduced toxicity.</p><p>To date, no specific inhibitor of SKP2 has been identified however three SMIs have been shown to downregulate SKP2 activity, and exhibit anti-tumor effects in preclinical studies. Using high-throughput screening, Cpd A and SMIP004 were identified (Chen et al., <xref ref-type="bibr" rid="B65">2008</xref>; Rico-Bautista et al., <xref ref-type="bibr" rid="B273">2010</xref>). CpdA, interferes with the SKP1/SKP2 interaction, thereby directly preventing SCF<sup>SKP2</sup> complex formation and ligase activity that results in the accumulation of several SCF<sup>SKP2</sup> substrates including p27<sup>KIP1</sup> and p21<sup>CIP1</sup>. It has been shown to induce cell cycle arrest and apoptosis, exhibiting preferential activity against neoplastic cells, as well as overcoming chemoresistance to dexamethasone, doxorubicin, melphalan, and bortezomib (Chen et al., <xref ref-type="bibr" rid="B65">2008</xref>). Similarly, SMIP0004 was identified and shown to inhibit cell growth and induce apoptosis, and exhibit cancer cell specificity. It was found not only to downregulate SKP2 and induce dose-dependent stabilization of p27<sup>KIP1</sup> and p21<sup>CIP1</sup>, but also to inhibit cellular CDK2 activity (Rico-Bautista et al., <xref ref-type="bibr" rid="B273">2010</xref>). Finally, MLN4924 is a compound which targets NEDD8-activating enzyme, consequently affecting CUL1 neddylation and impairing SCF<sup>SKP2</sup> complex formation and ligase activity. Preclinically, MLN4924 exhibits potent cytotoxicity against a panel of human cancer cell lines, and suppresses tumor growth in mouse xenograft models (Soucy et al., <xref ref-type="bibr" rid="B308">2009</xref>; Lin et al., <xref ref-type="bibr" rid="B203">2010</xref>). Furthermore, in contrast to bortezomib, MLN4924 did not significantly affect bulk protein turnover (Soucy et al., <xref ref-type="bibr" rid="B308">2009</xref>). MLN4924 was recently evaluated by the Pediatric Preclinical Testing Program (PPTP), exhibiting potent activity <italic>in vitro</italic> and inhibiting tumor growth against a subset of the PPTP solid tumor and ALL xenografts. Specifically in the neuroblastoma panel, MLN4924 had a median relative IC<sub>50</sub> of 278nM, and induced intermediate activity (EFS T/C values &#x0003e;2) in 1/4 xenografts (Smith et al., <xref ref-type="bibr" rid="B305">2012</xref>). In addition to the above SMIs, several natural compounds have also been shown to downregulate SKP2 activity, including retinoic acid, silibinin, curcumin, quercetin, lycopene, epigallocatechin-3-gallate (Nakamura et al., <xref ref-type="bibr" rid="B238">2003a</xref>; Roy et al., <xref ref-type="bibr" rid="B279">2007</xref>; Cuende et al., <xref ref-type="bibr" rid="B78">2008</xref>; Huang et al., <xref ref-type="bibr" rid="B146">2011a</xref>). Retinoic acid is of particular relevance to neuroblastoma, as Isotretinoin (13-<italic>cis</italic> RA) is routinely used in the treatment of high-risk disease following high-dose chemotherapy and stem cell rescue, in a setting of minimal residual disease (Wagner and Danks, <xref ref-type="bibr" rid="B360">2009</xref>).</p><p>Several signaling pathways have been shown to influence SKP2 expression, stability, and SCF<sup>SKP2</sup> ligase activity, therefore an alternative strategy would be to use inhibitors that target components of these pathways such as PI3K/AKT, mTOR, ERK, IGF, Notch, and IKK/NF<sc>k</sc>B, and some of which are currently in clinical trials. In support of this, PI3K inhibitor LY294002 and Rapamycin have been shown to decrease SKP2 expression (Motti et al., <xref ref-type="bibr" rid="B236">2005</xref>; Shapira et al., <xref ref-type="bibr" rid="B292">2006</xref>). Of interest, it is worth mentioning that LY294002 has also been shown to destabilize MYCN in neuroblastoma (Chesler et al., <xref ref-type="bibr" rid="B70">2006</xref>). Targeting the expression or stability of SKP2 is an appealing option due to the oncogenic functions of SKP2 which are independent of SCF<sup>SKP2</sup> ligase formation and activity (Ji et al., <xref ref-type="bibr" rid="B155">2006</xref>; Kitagawa et al., <xref ref-type="bibr" rid="B173">2008</xref>; Chan et al., <xref ref-type="bibr" rid="B55">2010a</xref>).</p></sec></sec><sec><title>DKK3</title><p>The Wnt signaling pathway is involved in embryogenesis, playing a key role in both early and late cell-fate decisions, and also in adult tissue homeostasis. Deregulated activation of this pathway has been implicated in several malignancies (Klaus and Birchmeier, <xref ref-type="bibr" rid="B174">2008</xref>). <italic>DKK3</italic> is a member of the <italic>Dickkopf</italic> family of secreted Wnt antagonists, which also includes <italic>DKK1</italic>, &#x02212;<italic>2</italic>, &#x02212;<italic>4</italic> and <italic>DKKL1</italic>. <italic>DKK</italic> family members encode glycoproteins which all share an N-terminal signal peptide, and with the exception of DKKL1, also share two cysteine-rich domains termed Cys1 and Cys2 that are separated by a non-conserved linker region of variable length. DKK3 has a molecular weight of 38&#x02009;kDa, and Cys1 and Cys2 are separated by a linker region of 13 amino acids (reviewed by Veeck and Dahl, <xref ref-type="bibr" rid="B353">2012</xref>).</p><p>DKK1, &#x02212;2 and &#x02212;4, are well-established antagonists of the canonical Wnt/&#x003b2;-catenin pathway through direct high affinity binding to Wnt co-receptors lipoprotein receptor-related protein 5 and 6 (LRP5/6), and also DKK receptors Kremen 1 and 2 (KRM1/2; reviewed by (Niehrs, <xref ref-type="bibr" rid="B246">2006</xref>)). The co-binding of DKK proteins to KRM1/2 receptors potentiates the ability of DKK proteins to inhibit Wnt signaling, through the formation of a ternary complex that leads to endocytosis and degradation of LRP receptors (Mao et al., <xref ref-type="bibr" rid="B214">2002</xref>; Mao and Niehrs, <xref ref-type="bibr" rid="B213">2003</xref>). In contrast, the role of DKK3 as a Wnt inhibitor is less clear. In some studies, DKK3 is not shown to bind to LRP5/6 at the cell surface membrane, and whether it binds to KRM1/2 remains controversial (Mao et al., <xref ref-type="bibr" rid="B214">2002</xref>; Nakamura and Hackam, <xref ref-type="bibr" rid="B240">2010</xref>). In contrast, others have however confirmed DKK3 as an inhibitor of the canonical pathway (Yue et al., <xref ref-type="bibr" rid="B396">2008</xref>; Lee et al., <xref ref-type="bibr" rid="B196">2009</xref>; Dellinger et al., <xref ref-type="bibr" rid="B89">2012</xref>).</p><sec><title>DKK3 as a tumor suppressor</title><p>Several lines of evidence exist to suggest that DKK3 acts as a tumor suppressor. Originally identified as a novel TSG by Tsuji et al. (<xref ref-type="bibr" rid="B334">2000</xref>) using an <italic>in vitro</italic> transformation model of normal human fibroblasts, reduced DKK3 expression was subsequently observed in cell lines and tumors of several different cancer types including liver, lung, prostate, breast, osteosarcoma, and leukemia (Tsuji et al., <xref ref-type="bibr" rid="B334">2000</xref>; Nozaki et al., <xref ref-type="bibr" rid="B249">2001</xref>; Hsieh et al., <xref ref-type="bibr" rid="B142">2004</xref>; Kurose et al., <xref ref-type="bibr" rid="B186">2004</xref>; Roman-Gomez et al., <xref ref-type="bibr" rid="B276">2004</xref>; Abarzua et al., <xref ref-type="bibr" rid="B1">2005</xref>; Tanimoto et al., <xref ref-type="bibr" rid="B323">2007</xref>; Mizobuchi et al., <xref ref-type="bibr" rid="B227">2008</xref>; Veeck et al., <xref ref-type="bibr" rid="B352">2008</xref>; Yue et al., <xref ref-type="bibr" rid="B396">2008</xref>; Yu et al., <xref ref-type="bibr" rid="B393">2009</xref>; Dellinger et al., <xref ref-type="bibr" rid="B89">2012</xref>). Studies into the mechanisms behind reduced DKK3 expression have revealed histone modification in cancers such as renal cell carcinoma (Ueno et al., <xref ref-type="bibr" rid="B342">2011</xref>), and hypermethylation of the <italic>DKK3</italic> promoter in a vast number of human cancers including lung, bladder, breast, and leukemia (reviewed by Veeck and Dahl, <xref ref-type="bibr" rid="B353">2012</xref>). Additionally, loss of heterozygousity and homozygous deletions of the <italic>DKK3</italic> gene at 11p15 have also been reported (Tsuji et al., <xref ref-type="bibr" rid="B335">2001</xref>; Bashyam et al., <xref ref-type="bibr" rid="B18">2005</xref>). In some cases, reduced DKK3 expression and/or <italic>DKK3</italic> promoter methylation has been shown to be associated with poor prognostic clinicopathologic characteristics and outcome (Roman-Gomez et al., <xref ref-type="bibr" rid="B276">2004</xref>; Yue et al., <xref ref-type="bibr" rid="B396">2008</xref>; Veeck et al., <xref ref-type="bibr" rid="B354">2009</xref>; Yu et al., <xref ref-type="bibr" rid="B393">2009</xref>; Yang et al., <xref ref-type="bibr" rid="B388">2010</xref>; Dellinger et al., <xref ref-type="bibr" rid="B89">2012</xref>; Wang et al., <xref ref-type="bibr" rid="B365">2012a</xref>).</p><p>Overexpression of DKK3 has been shown to mediate potent anti-tumor effects including reduced cell proliferation, anchorage-independent growth, and invasion and metastasis, and induced cancer cell specific apoptosis both <italic>in vitro</italic> and in murine tumor models (Tsuji et al., <xref ref-type="bibr" rid="B335">2001</xref>; Abarzua et al., <xref ref-type="bibr" rid="B1">2005</xref>; Edamura et al., <xref ref-type="bibr" rid="B96">2007</xref>; Tanimoto et al., <xref ref-type="bibr" rid="B323">2007</xref>; Koppen et al., <xref ref-type="bibr" rid="B180">2008</xref>; Mizobuchi et al., <xref ref-type="bibr" rid="B227">2008</xref>; Kawasaki et al., <xref ref-type="bibr" rid="B168">2009</xref>; Gu et al., <xref ref-type="bibr" rid="B123">2011</xref>; Than et al., <xref ref-type="bibr" rid="B329">2011</xref>; Ueno et al., <xref ref-type="bibr" rid="B342">2011</xref>; Dellinger et al., <xref ref-type="bibr" rid="B89">2012</xref>; Yang et al., <xref ref-type="bibr" rid="B389">2012</xref>). The precise mechanisms by which DKK3 inhibits tumorigenesis are not completely understood. Studies using a replication incompetent adenoviral vector incorporating the human <italic>DKK3</italic> cDNA (Ad-REIC/DKK3) have demonstrated that DKK3 induced apoptosis is mediated via ER stress triggered activation of JNK with subsequent reduction in anti-apoptotic BCL2, mitochondrial translocation of BAX, cytochrome C release, and activated caspase cleavage (Abarzua et al., <xref ref-type="bibr" rid="B1">2005</xref>, <xref ref-type="bibr" rid="B2">2007</xref>; Tanimoto et al., <xref ref-type="bibr" rid="B323">2007</xref>; Kashiwakura et al., <xref ref-type="bibr" rid="B165">2008</xref>; Kobayashi et al., <xref ref-type="bibr" rid="B175">2008</xref>; Kawasaki et al., <xref ref-type="bibr" rid="B168">2009</xref>). Ad-REIC/DKK3 has also been shown to induce an indirect host-mediated anti-tumor effect via the induction of IL-7 (Sakaguchi et al., <xref ref-type="bibr" rid="B282">2009</xref>). It is however important to mention that mechanisms which mediate resistance to DKK3 induced apoptosis have been identified, such as the overexpression of heat shock protein 70/72, an ER-residing chaperone BiP/GRP78 BiP/GRP78 and BCL2 (Veeck and Dahl, <xref ref-type="bibr" rid="B353">2012</xref>). Interestingly, despite the vast body of evidence suggesting a fundamental role for DKK3 in cancer development, <italic>DKK3</italic> knockout mice were both viable and fertile and were not observed to be more susceptible to cancer development (Barrantes Idel et al., <xref ref-type="bibr" rid="B15">2006</xref>).</p></sec><sec><title>The role of DKK3 in neuroblastoma</title><p>DKK3 is secreted in neuroblastoma cell lines, and in primary tumors is found to be expressed in the endothelium (Koppen et al., <xref ref-type="bibr" rid="B180">2008</xref>; Haug et al., <xref ref-type="bibr" rid="B130">2011</xref>). An initial study of DKK3 and neuroblastic tumors observed that <italic>DKK3</italic> expression was a marker of tumor differentiation, where the highest expression was observed in the most differentiated ganglioneuromas, and the lowest expression in the least differentiated neuroblastoma. Specifically in neuroblastoma tumors, low <italic>DKK3</italic> expression correlated significantly with poor prognosis, however this was not independent of <italic>MYCN</italic> amplification (Koppen et al., <xref ref-type="bibr" rid="B180">2008</xref>). In a more recent study of 101 neuroblastic tumors including 88 neuroblastoma tumors, both high <italic>DKK3</italic> and <italic>DKK2</italic> expression correlated with good prognosis (Revet et al., <xref ref-type="bibr" rid="B272">2010</xref>).</p><p>Several studies to date including our own have observed an inverse relationship between DKK3 expression and <italic>MYCN</italic> amplification and/or expression in both cell lines and primary tumors, thereby suggesting that downregulation of DKK3 is necessary for progression of <italic>MYCN</italic> amplified neuroblastoma (Table <xref ref-type="table" rid="T3">3</xref>; Bell et al., <xref ref-type="bibr" rid="B21">2007a</xref>; Koppen et al., <xref ref-type="bibr" rid="B180">2008</xref>; Chen et al., <xref ref-type="bibr" rid="B63">2010</xref>; Haug et al., <xref ref-type="bibr" rid="B130">2011</xref>; De Brouwer et al., <xref ref-type="bibr" rid="B87">2012</xref>; Figure <xref ref-type="fig" rid="F4">4</xref>). Consistent with this, overexpression of DKK3 inhibited the proliferation of <italic>MYCN</italic> amplified neuroblastoma cell lines <italic>in vitro</italic> (Koppen et al., <xref ref-type="bibr" rid="B180">2008</xref>).</p><table-wrap id="T3" position="float"><label>Table 3</label><caption><p><bold>Summary of studies which have observed an inverse relationship between DKK3 expression and MYCN expression and/or <italic>MYCN</italic> amplification in neuroblastoma</bold>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Study</th><th align="left" rowspan="1" colspan="1">Tumors</th><th align="left" rowspan="1" colspan="1">Cell Lines</th><th align="left" rowspan="1" colspan="1">Methods</th><th align="left" rowspan="1" colspan="1">Evidence</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Bell et al. (<xref ref-type="bibr" rid="B21">2007a</xref>)</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">IMR32, SKNBE2C and Tet21N</td><td align="left" rowspan="1" colspan="1">MYCN siRNA, Microarray<sup>1</sup>, qRT-PCR</td><td align="left" rowspan="1" colspan="1">Si, E</td></tr><tr><td align="left" rowspan="1" colspan="1">Koppen et al. (<xref ref-type="bibr" rid="B180">2008</xref>)</td><td align="left" rowspan="1" colspan="1">13 Ganglioneuroma, 14 ganglioneuroblastoma, 82 neuroblastoma</td><td align="left" rowspan="1" colspan="1">14 MNA and 8 MYCN single-copy NB cell lines<sup>2</sup>, Tet21N, SKNAS-NMYCER</td><td align="left" rowspan="1" colspan="1">Microarray<sup>3</sup>, Northern blot</td><td align="left" rowspan="1" colspan="1">T, C, E</td></tr><tr><td align="left" rowspan="1" colspan="1">Chen et al. (<xref ref-type="bibr" rid="B63">2010</xref>)</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">Tet21N</td><td align="left" rowspan="1" colspan="1">Microarray</td><td align="left" rowspan="1" colspan="1">E</td></tr><tr><td align="left" rowspan="1" colspan="1">Haug et al. (<xref ref-type="bibr" rid="B130">2011</xref>)</td><td align="left" rowspan="1" colspan="1">25 Neuroblastoma</td><td align="left" rowspan="1" colspan="1">SKNBE2C, Kelly, Tet21N</td><td align="left" rowspan="1" colspan="1">IHC, shMYCN, qRT-PCR</td><td align="left" rowspan="1" colspan="1">T, Sh, E</td></tr><tr><td align="left" rowspan="1" colspan="1">De Brouwer et al. (<xref ref-type="bibr" rid="B87">2012</xref>)</td><td align="left" rowspan="1" colspan="1">101 Neuroblastoma</td><td align="left" rowspan="1" colspan="1">7 MNA and 5 MYCN single-copy NB cell lines<sup>2</sup>, Tet21N</td><td align="left" rowspan="1" colspan="1">qRT-PCR</td><td align="left" rowspan="1" colspan="1">T, C, E</td></tr></tbody></table><table-wrap-foot><p><italic><sup>1</sup>Microarray analysis performed on IMR32 and SKNBE2C cells treated with scrambled or MYCN siRNA for 16 and 48&#x02009;h; <sup>2</sup>see publication for full list of cell lines used; <sup>3</sup>performed on 12/22 neuroblastoma cell lines</italic>.</p><p><italic>MNA; <italic>MYCN</italic> amplified; NB, neuroblastoma; IHC, immunohistochemistry; Si, differential expression following MYCN siRNA; Sh, differential expression following MYCN shRNA; E, differential expression/correlation in ectopic MYCN expression systems; T, differential expression/correlation in tumors with <italic>MYCN</italic> amplification; C, differential expression/correlation in cell lines with/without <italic>MYCN</italic> amplification</italic>.</p></table-wrap-foot></table-wrap><fig id="F4" position="float"><label>Figure 4</label><caption><p><bold>MYCN mediated downregulation of DKK proteins in neuroblastoma</bold>. DKK1 and DKK3 can inhibit the proliferation of neuroblastoma cells, therefore downregulation of DKK proteins by MYCN will favor neuroblastoma tumorigenesis. MYCN mediated downregulation of DKK3 can occur via upregulation of the oncogenic <italic>miR-17-92</italic> cluster, and due to the homology between <italic>DKK</italic> family members, this may also be a potential mechanism for MYCN mediated downregulation of DKK1 (as indicated by the dashed line). DKK1 inhibits the proliferation of neuroblastoma cells via upregulation of SYNPO2, and although the mechanism for DKK3 remains unclear, due to the homology between <italic>DKK</italic> family members this may also occur via SYNPO2 (as indicated by the dashed line).</p></caption><graphic xlink:href="fonc-02-00173-g004"/></fig><p>To determine the mechanism responsible for low DKK3 expression in <italic>MYCN</italic> amplified tumors, studies have observed that irrespective of <italic>MYCN</italic> status, reduced DKK3 expression in neuroblastoma was not due to promoter hypermethylation (Haug et al., <xref ref-type="bibr" rid="B130">2011</xref>). Through ChIP analysis, MYCN was reported to downregulate <italic>DKK3</italic> expression through a mechanism independent of direct transcriptional repression (Koppen et al., <xref ref-type="bibr" rid="B180">2008</xref>). Indeed, in support of this, two recent independent studies have shown that MYCN regulates the expression and secretion of DKK3 in neuroblastoma cells through direct upregulation of the oncogenic <italic>miR-17-92</italic> cluster (e.g., <italic>miR-92a</italic>, -<italic>92b</italic>, and -<italic>19b</italic>) which target the 3&#x02032;UTR of <italic>DKK3</italic> (Haug et al., <xref ref-type="bibr" rid="B130">2011</xref>; De Brouwer et al., <xref ref-type="bibr" rid="B87">2012</xref>; Figure <xref ref-type="fig" rid="F4">4</xref>). Analysis of primary tumors demonstrated a positive correlation between <italic>MYCN</italic> expression and <italic>miR-17-92</italic> cluster expression, consistent with previous studies (Schulte et al., <xref ref-type="bibr" rid="B288">2008</xref>), and an inverse correlation between <italic>miR-17-92</italic> cluster expression and <italic>DKK3</italic> expression (Haug et al., <xref ref-type="bibr" rid="B130">2011</xref>; De Brouwer et al., <xref ref-type="bibr" rid="B87">2012</xref>). In line with higher <italic>DKK3</italic> expression in ganglioneuroma and ganglioneuroblastoma, these tumors had lower levels of <italic>miR-92a</italic> compared with neuroblastoma (Haug et al., <xref ref-type="bibr" rid="B130">2011</xref>).</p><p>The precise mechanism by which DKK3 suppresses neuroblastoma tumorigenesis is unclear however this does not appear to be through inhibition of the canonical Wnt/&#x003b2;-catenin signaling pathway (Koppen et al., <xref ref-type="bibr" rid="B180">2008</xref>). It is possible that DKK3 may act by inhibiting non-canonical Wnt signaling pathways such as the Planar cell polarity (PCP)-pathway, or the Wnt/Ca<sup>2+</sup> pathway. Interestingly, these non-canonical Wnt pathways have previously been shown to control neural crest migration (De Calisto et al., <xref ref-type="bibr" rid="B88">2005</xref>).</p><p>Similar to DKK3, DKK1 is also reported to be secreted in neuroblastoma cell lines, and downregulated indirectly by MYCN (Koppen et al., <xref ref-type="bibr" rid="B179">2007</xref>). Lower expression was observed in the presence of ectopic MYCN and in <italic>MYCN</italic> amplified tumors (Bell et al., <xref ref-type="bibr" rid="B22">2007b</xref>; Koppen et al., <xref ref-type="bibr" rid="B179">2007</xref>; Chen et al., <xref ref-type="bibr" rid="B63">2010</xref>). Overexpression of DKK1 inhibited the proliferation of neuroblastoma cell lines through upregulation of synaptopodin-2 (SYNPO2), a protein previously reported to suppress tumor growth, and not by inhibition of canonical Wnt/&#x003b2;-catenin signaling (Koppen et al., <xref ref-type="bibr" rid="B179">2007</xref>; Figure <xref ref-type="fig" rid="F4">4</xref>).</p><p>The above findings suggest that DKK proteins may play a role in neuroblastoma pathogenesis, therefore it would be interesting to assess tumor formation in TH-<italic>MYCN</italic> transgenic mice deficient in <italic>DKK3</italic> or <italic>DKK1</italic>. Certainly, the Wnt pathway is involved in early formation of the neural crest and the subsequent development, migration, and terminal differentiation of neural crest cells (Barembaum and Bronner-Fraser, <xref ref-type="bibr" rid="B14">2005</xref>; Ille and Sommer, <xref ref-type="bibr" rid="B149">2005</xref>), and Wnt/&#x003b2;-catenin signaling has been shown to directly induce <italic>MYCN</italic> expression (Kuwahara et al., <xref ref-type="bibr" rid="B188">2010</xref>). Additionally, embryonal malignancies of childhood such as neuroblastoma have been suggested to be disorders of normal development (reviewed by Grimmer and Weiss, <xref ref-type="bibr" rid="B121">2006</xref>; Johnsen et al., <xref ref-type="bibr" rid="B158">2009</xref>), therefore it is not surprising that deregulated Wnt pathway signaling may be involved in neuroblastoma development.</p><p>To date, studies into Wnt signaling in neuroblastoma have shown that siRNA mediated inhibition of the Wnt1/&#x003b2;-catenin pathway leads to apoptosis of SHSY5Y cells (Zhang et al., <xref ref-type="bibr" rid="B402">2009</xref>), and deregulated canonical and non-canonical Wnt signaling in chemoresistant and high-risk disease (Blanc et al., <xref ref-type="bibr" rid="B28">2005</xref>; Liu et al., <xref ref-type="bibr" rid="B206">2008b</xref>; Flahaut et al., <xref ref-type="bibr" rid="B105">2009</xref>). Additionally, the expression of FZD6 is reported to predict poor survival in neuroblastoma patients, and marks rare and highly tumorigenic neuroblastoma stem cells (Cantilena et al., <xref ref-type="bibr" rid="B42">2011</xref>). Furthermore, microarray analysis of Tet21N MYCN+ and MYCN&#x02212; cells identified that in addition to <italic>DKK1</italic> and <italic>DKK3</italic>, there was deregulated expression of several components of the Wnt pathway in the presence of MYCN. These included downregulation of additional Wnt signaling antagonists <italic>SFRP1</italic> and <italic>APC</italic> together with the upregulated expression of positive regulators <italic>FRAT2</italic>, <italic>CSNK2A1</italic>, and <italic>RUVBL1</italic> (Chen, <xref ref-type="bibr" rid="B62">2009</xref>; Chen et al., <xref ref-type="bibr" rid="B63">2010</xref>). Interestingly, in an independent study, <italic>SFRP1</italic> was observed to correlate with good prognosis in neuroblastic tumors (Revet et al., <xref ref-type="bibr" rid="B272">2010</xref>). <italic>CSNK2A1</italic> and <italic>RUVBL1</italic> have been reported to play multiple roles in driving malignant transformation (Duncan and Litchfield, <xref ref-type="bibr" rid="B95">2008</xref>; Huber et al., <xref ref-type="bibr" rid="B148">2008</xref>), and <italic>RUVBL1</italic> expression was identified to be associated with poor overall survival in neuroblastoma patients (Westermann et al., <xref ref-type="bibr" rid="B376">2008</xref>). Finally, several upstream components of the Wnt pathway have been reported to be highly expressed in neuroblastic tumors and cell lines (Revet et al., <xref ref-type="bibr" rid="B272">2010</xref>). Taken together, these findings provide support to suggest that the Wnt pathway may be important in neuroblastoma pathogenesis although the precise role remains unclear and will require further investigation.</p></sec><sec><title>Therapeutic strategies to re-establish DKK3</title><p>Developmental pathways are becoming important targets for cancer therapy, and inhibitors targeting Wnt, Notch, and Hedgehog have reached clinical evaluation (see footnote 3). The low expression of DKK3 in several human cancers combined with its cancer specific apoptosis inducing effects suggest that re-establishing DKK3 holds promise as a novel targeted cancer therapy. The use of demethylating agents to re-express <italic>DKK3</italic> in cancers where promoter hypermethylation leads to gene silencing have been shown in studies using cell lines of several cancers including gastric, prostate, lung, and leukemia (reviewed by Veeck and Dahl, <xref ref-type="bibr" rid="B353">2012</xref>). Demethylating agents azacitidine and decitabine have been approved in the treatment of myelodysplastic syndromes (Cataldo et al., <xref ref-type="bibr" rid="B52">2009</xref>; Santos et al., <xref ref-type="bibr" rid="B283">2010</xref>), however this method is not gene specific and could alter the epigenetic patterns of the entire genome. In neuroblastoma, demethylating agents are unlikely to be of therapeutic use, as low DKK3 expression was not shown to be due to promoter methylation (Haug et al., <xref ref-type="bibr" rid="B130">2011</xref>). An alternative strategy involves DKK3 targeted gene therapy. The vast majority of work to date has been carried out Ad-REIC/DKK3 (Abarzua et al., <xref ref-type="bibr" rid="B1">2005</xref>), however the use of a biodegradable cationic polymer based vector has also been reported (Veeck and Dahl, <xref ref-type="bibr" rid="B353">2012</xref>). Ad-REIC/DKK3 has been used with success in preclinical studies demonstrating robust anti-tumor effects including induction of cancer cell specific apoptosis and inhibition of metastatic disease (Abarzua et al., <xref ref-type="bibr" rid="B1">2005</xref>; Edamura et al., <xref ref-type="bibr" rid="B96">2007</xref>; Kawasaki et al., <xref ref-type="bibr" rid="B168">2009</xref>; Sakaguchi et al., <xref ref-type="bibr" rid="B282">2009</xref>; Than et al., <xref ref-type="bibr" rid="B329">2011</xref>), and is currently in clinical trials for use in prostate cancer (see footnote 3; NCT01197209). In addition, DKK3 also appears to play a role in chemoresistance, and Ad-REIC/DKK3 mediated downregulation of MDR-1 expression through JNK activation sensitized previously chemoresistant tumor cells to chemotherapy, which supports the applicability of using Ad-REIC/DKK3 in combination with convention chemotherapies in the treatment of drug-resistant cancers (Kawasaki et al., <xref ref-type="bibr" rid="B168">2009</xref>; Hirata et al., <xref ref-type="bibr" rid="B136">2012</xref>). Preclinical studies to evaluate the effect of Ad-REIC/DKK3 in neuroblastoma are yet to be conducted.</p><p>Alternative strategies more specific to neuroblastoma may involve the direct targeting of the oncogenic <italic>miR-17-92</italic> cluster to re-establish <italic>DKK3</italic> expression in <italic>MYCN</italic> amplified neuroblastoma, or the use of agents which directly affect <italic>MYCN</italic> expression in neuroblastoma cells such as the BET inhibitor, JQ1 (Mertz et al., <xref ref-type="bibr" rid="B222">2011</xref>). Certainly, targeting miRNAs as a new class of therapeutics has been gaining increased interest in recent years, and Miravirsen, which inhibits <italic>miR-122</italic> is currently in phase II trials for the treatment of patients with Hepatitis C virus (Hu et al., <xref ref-type="bibr" rid="B144">2012</xref>).</p></sec></sec><sec><title>Conclusions and Perspectives</title><p>In recent years, the involvement of the p53/MDM2/p14<sup>ARF</sup> pathway in neuroblastoma has become increasingly evident and targeting this pathway through small molecule inhibitors of the MDM2-p53 interaction in neuroblastoma which remains predominantly wt even at relapse, is an attractive therapeutic option. Currently newer more potent MDM2-p53 antagonists are undergoing commercial development, which will be tested in suitable preclinical models of neuroblastoma leading to their evaluation in early phase clinical trials and hopefully eventually into standard neuroblastoma therapy.</p><p>The precise involvement of SKP2 and DKK3 in neuroblastoma will require further investigation and these targets are currently much less developed in terms of their therapeutic potential. Nevertheless their involvement in other cancers as well as neuroblastoma makes them a priority for commercial and academic drug development programs.</p><p>It is envisaged that the therapeutic strategies which have been proposed in this review are most likely to be effective in combination with existing treatment regimens or other targeted agents and not alone. The increased understanding of neuroblastoma tumorigenesis and mechanisms of therapy resistance and relapse, advances in the development of murine models which more closely resemble high-risk metastatic and/or relapsed disease, and the drive towards targeted/personalized therapies, will hopefully provide increased opportunities to test out some of the paradigms mentioned in this review. When testing therapies directed against all these targets it will be important to do so both in <italic>MYCN</italic> amplified and non-amplified settings to fully evaluate their dependence on MYCN.</p><p>This is an exciting time for neuroblastoma drug development and with many new targeted agents in the pipeline undergoing preclinical evaluation and early phase clinical trials it surely will not be long before one reaches frontline therapy and improves the outcome, whilst hopefully reducing long-term toxicity in patients with high-risk disease.</p></sec><sec><title>Conflict of Interest Statement</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></body><back><ack><p>Work carried out by Dr L. Chen in the laboratory of Professor D. A. Tweddle is currently funded by SPARKS (Sport Aiding Medical Research for Kids) and the Dubois Cancer Fund.</p></ack><fn-group><fn id="fn1"><p><sup>1</sup><uri xlink:type="simple" xlink:href="http://www-p53.iarc.fr/">http://www-p53.iarc.fr/</uri></p></fn><fn id="fn2"><p><sup>2</sup><uri xlink:type="simple" xlink:href="http://p53.free.fr/">http://p53.free.fr/</uri></p></fn><fn id="fn3"><p><sup>3</sup><uri xlink:type="simple" xlink:href="http://www.clinicaltrials.gov">http://www.clinicaltrials.gov</uri></p></fn><fn id="fn4"><p><sup>4</sup><uri xlink:type="simple" xlink:href="http://www.ptcbio.com/ptc596">http://www.ptcbio.com/ptc596</uri></p></fn></fn-group><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abarzua</surname><given-names>F.</given-names></name><name><surname>Sakaguchi</surname><given-names>M.</given-names></name><name><surname>Takaishi</surname><given-names>M.</given-names></name><name><surname>Nasu</surname><given-names>Y.</given-names></name><name><surname>Kurose</surname><given-names>K.</given-names></name><name><surname>Ebara</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Adenovirus-mediated overexpression of REIC/Dkk-3 selectively induces apoptosis in human prostate cancer cells through activation of c-Jun-NH2-kinase</article-title>. <source>Cancer Res.</source>
<volume>65</volume>, <fpage>9617</fpage>&#x02013;<lpage>9622</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-0829</pub-id><pub-id pub-id-type="pmid">16266978</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abarzua</surname><given-names>F.</given-names></name><name><surname>Sakaguchi</surname><given-names>M.</given-names></name><name><surname>Tanimoto</surname><given-names>R.</given-names></name><name><surname>Sonegawa</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>D. W.</given-names></name><name><surname>Edamura</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Heat shock proteins play a crucial role in tumor-specific apoptosis by REIC/Dkk-3</article-title>. <source>Int. J. Mol. Med.</source>
<volume>20</volume>, <fpage>37</fpage>&#x02013;<lpage>43</lpage><pub-id pub-id-type="pmid">17549386</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adhikary</surname><given-names>S.</given-names></name><name><surname>Eilers</surname><given-names>M.</given-names></name></person-group> (<year>2005</year>). <article-title>Transcriptional regulation and transformation by Myc proteins</article-title>. <source>Nat. Rev. Mol. Cell Biol.</source>
<volume>6</volume>, <fpage>635</fpage>&#x02013;<lpage>645</lpage><pub-id pub-id-type="doi">10.1038/nrm1703</pub-id><pub-id pub-id-type="pmid">16064138</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alt</surname><given-names>J. R.</given-names></name><name><surname>Greiner</surname><given-names>T. C.</given-names></name><name><surname>Cleveland</surname><given-names>J. L.</given-names></name><name><surname>Eischen</surname><given-names>C. M.</given-names></name></person-group> (<year>2003</year>). <article-title>Mdm2 haplo-insufficiency profoundly inhibits Myc-induced lymphomagenesis</article-title>. <source>EMBO J.</source>
<volume>22</volume>, <fpage>1442</fpage>&#x02013;<lpage>1450</lpage><pub-id pub-id-type="doi">10.1093/emboj/cdg133</pub-id><pub-id pub-id-type="pmid">12628936</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altungoz</surname><given-names>O.</given-names></name><name><surname>Aygun</surname><given-names>N.</given-names></name><name><surname>Tumer</surname><given-names>S.</given-names></name><name><surname>Ozer</surname><given-names>E.</given-names></name><name><surname>Olgun</surname><given-names>N.</given-names></name><name><surname>Sakizli</surname><given-names>M.</given-names></name></person-group> (<year>2007</year>). <article-title>Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma</article-title>. <source>Cancer Genet. Cytogenet.</source>
<volume>172</volume>, <fpage>113</fpage>&#x02013;<lpage>119</lpage><pub-id pub-id-type="doi">10.1016/j.cancergencyto.2006.10.005</pub-id><pub-id pub-id-type="pmid">17213019</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ambrosini</surname><given-names>G.</given-names></name><name><surname>Sambol</surname><given-names>E. B.</given-names></name><name><surname>Carvajal</surname><given-names>D.</given-names></name><name><surname>Vassilev</surname><given-names>L. T.</given-names></name><name><surname>Singer</surname><given-names>S.</given-names></name><name><surname>Schwartz</surname><given-names>G. K.</given-names></name></person-group> (<year>2007</year>). <article-title>Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1</article-title>. <source>Oncogene</source>
<volume>26</volume>, <fpage>3473</fpage>&#x02013;<lpage>3481</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1210136</pub-id><pub-id pub-id-type="pmid">17146434</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Appella</surname><given-names>E.</given-names></name><name><surname>Anderson</surname><given-names>C. W.</given-names></name></person-group> (<year>2001</year>). <article-title>Post-translational modifications and activation of p53 by genotoxic stresses</article-title>. <source>Eur. J. Biochem.</source>
<volume>268</volume>, <fpage>2764</fpage>&#x02013;<lpage>2772</lpage><pub-id pub-id-type="doi">10.1046/j.1432-1327.2001.02224.x</pub-id><pub-id pub-id-type="pmid">11358490</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Appleman</surname><given-names>L. J.</given-names></name><name><surname>Chernova</surname><given-names>I.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Boussiotis</surname><given-names>V. A.</given-names></name></person-group> (<year>2006</year>). <article-title>CD28 costimulation mediates transcription of SKP2 and CKS1, the substrate recognition components of SCFSkp2 ubiquitin ligase that leads p27kip1 to degradation</article-title>. <source>Cell Cycle</source>
<volume>5</volume>, <fpage>2123</fpage>&#x02013;<lpage>2129</lpage><pub-id pub-id-type="doi">10.4161/cc.5.18.3139</pub-id><pub-id pub-id-type="pmid">16969077</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bader</surname><given-names>A. G.</given-names></name></person-group> (<year>2012</year>). <article-title>miR-34 &#x02013; a microRNA replacement therapy is headed to the clinic</article-title>. <source>Front. Gene.</source>
<volume>3</volume>:<fpage>120</fpage><pub-id pub-id-type="doi">10.3389/fgene.2012.00120</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bagchi</surname><given-names>A.</given-names></name><name><surname>Papazoglu</surname><given-names>C.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Capurso</surname><given-names>D.</given-names></name><name><surname>Brodt</surname><given-names>M.</given-names></name><name><surname>Francis</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>CHD5 is a tumor suppressor at human 1p36</article-title>. <source>Cell</source>
<volume>128</volume>, <fpage>459</fpage>&#x02013;<lpage>475</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2006.11.052</pub-id><pub-id pub-id-type="pmid">17289567</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bai</surname><given-names>C.</given-names></name><name><surname>Sen</surname><given-names>P.</given-names></name><name><surname>Hofmann</surname><given-names>K.</given-names></name><name><surname>Ma</surname><given-names>L.</given-names></name><name><surname>Goebl</surname><given-names>M.</given-names></name><name><surname>Harper</surname><given-names>J. W.</given-names></name><etal/></person-group> (<year>1996</year>). <article-title>SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box</article-title>. <source>Cell</source>
<volume>86</volume>, <fpage>263</fpage>&#x02013;<lpage>274</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)80098-7</pub-id><pub-id pub-id-type="pmid">8706131</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bai</surname><given-names>L.</given-names></name><name><surname>Zhu</surname><given-names>W.</given-names></name></person-group> (<year>2006</year>). <article-title>p53: structure, function and therapeutic applications</article-title>. <source>J. Cancer Mol.</source>
<volume>2</volume>, <fpage>141</fpage>&#x02013;<lpage>153</lpage></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barbieri</surname><given-names>E.</given-names></name><name><surname>Mehta</surname><given-names>P.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Slack</surname><given-names>A.</given-names></name><name><surname>Berg</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death</article-title>. <source>Mol. Cancer Ther.</source>
<volume>5</volume>, <fpage>2358</fpage>&#x02013;<lpage>2365</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-06-0305</pub-id><pub-id pub-id-type="pmid">16985070</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barembaum</surname><given-names>M.</given-names></name><name><surname>Bronner-Fraser</surname><given-names>M.</given-names></name></person-group> (<year>2005</year>). <article-title>Early steps in neural crest specification</article-title>. <source>Semin. Cell Dev. Biol.</source>
<volume>16</volume>, <fpage>642</fpage>&#x02013;<lpage>646</lpage><pub-id pub-id-type="doi">10.1016/j.semcdb.2005.06.006</pub-id><pub-id pub-id-type="pmid">16039882</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrantes Idel</surname><given-names>B.</given-names></name><name><surname>Montero-Pedrazuela</surname><given-names>A.</given-names></name><name><surname>Guadano-Ferraz</surname><given-names>A.</given-names></name><name><surname>Obregon</surname><given-names>M. J.</given-names></name><name><surname>Martinez De Mena</surname><given-names>R.</given-names></name><name><surname>Gailus-Durner</surname><given-names>V.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Generation and characterization of dickkopf3 mutant mice</article-title>. <source>Mol. Cell. Biol.</source>
<volume>26</volume>, <fpage>2317</fpage>&#x02013;<lpage>2326</lpage><pub-id pub-id-type="doi">10.1128/MCB.26.6.2317-2326.2006</pub-id><pub-id pub-id-type="pmid">16508007</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bashir</surname><given-names>T.</given-names></name><name><surname>Dorrello</surname><given-names>N. V.</given-names></name><name><surname>Amador</surname><given-names>V.</given-names></name><name><surname>Guardavaccaro</surname><given-names>D.</given-names></name><name><surname>Pagano</surname><given-names>M.</given-names></name></person-group> (<year>2004</year>). <article-title>Control of the SCF(Skp2-Cks1) ubiquitin ligase by the APC/C(Cdh1) ubiquitin ligase</article-title>. <source>Nature</source>
<volume>428</volume>, <fpage>190</fpage>&#x02013;<lpage>193</lpage><pub-id pub-id-type="doi">10.1038/nature02330</pub-id><pub-id pub-id-type="pmid">15014502</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bashir</surname><given-names>T.</given-names></name><name><surname>Pagano</surname><given-names>M.</given-names></name></person-group> (<year>2004</year>). <article-title>Don&#x02019;t skip the G1 phase: how APC/CCdh1 keeps SCFSKP2 in check</article-title>. <source>Cell Cycle</source>
<volume>3</volume>, <fpage>850</fpage>&#x02013;<lpage>852</lpage><pub-id pub-id-type="doi">10.4161/cc.3.7.977</pub-id><pub-id pub-id-type="pmid">15190201</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bashyam</surname><given-names>M. D.</given-names></name><name><surname>Bair</surname><given-names>R.</given-names></name><name><surname>Kim</surname><given-names>Y. H.</given-names></name><name><surname>Wang</surname><given-names>P.</given-names></name><name><surname>Hernandez-Boussard</surname><given-names>T.</given-names></name><name><surname>Karikari</surname><given-names>C. A.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Array-based comparative genomic hybridization identifies localized DNA amplifications and homozygous deletions in pancreatic cancer</article-title>. <source>Neoplasia</source>
<volume>7</volume>, <fpage>556</fpage>&#x02013;<lpage>562</lpage><pub-id pub-id-type="doi">10.1593/neo.04586</pub-id><pub-id pub-id-type="pmid">16036106</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Becker</surname><given-names>K.</given-names></name><name><surname>Marchenko</surname><given-names>N. D.</given-names></name><name><surname>Maurice</surname><given-names>M.</given-names></name><name><surname>Moll</surname><given-names>U. M.</given-names></name></person-group> (<year>2007</year>). <article-title>Hyperubiquitylation of wild-type p53 contributes to cytoplasmic sequestration in neuroblastoma</article-title>. <source>Cell Death Differ.</source>
<volume>14</volume>, <fpage>1350</fpage>&#x02013;<lpage>1360</lpage><pub-id pub-id-type="doi">10.1038/sj.cdd.4402126</pub-id><pub-id pub-id-type="pmid">17380154</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bell</surname><given-names>E.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>T.</given-names></name><name><surname>Marshall</surname><given-names>G. M.</given-names></name><name><surname>Lunec</surname><given-names>J.</given-names></name><name><surname>Tweddle</surname><given-names>D. A.</given-names></name></person-group> (<year>2010</year>). <article-title>MYCN oncoprotein targets and their therapeutic potential</article-title>. <source>Cancer Lett.</source>
<volume>293</volume>, <fpage>144</fpage>&#x02013;<lpage>157</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2010.01.015</pub-id><pub-id pub-id-type="pmid">20153925</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bell</surname><given-names>E.</given-names></name><name><surname>Lunec</surname><given-names>J.</given-names></name><name><surname>Tweddle</surname><given-names>D. A.</given-names></name></person-group> (<year>2007a</year>). <article-title>Cell cycle regulation targets of MYCN identified by gene expression microarrays</article-title>. <source>Cell Cycle</source>
<volume>6</volume>, <fpage>1249</fpage>&#x02013;<lpage>1256</lpage><pub-id pub-id-type="doi">10.4161/cc.6.16.4614</pub-id><pub-id pub-id-type="pmid">17495526</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Bell</surname><given-names>E.</given-names></name><collab>University of Newcastle Upon Tyne. School of Clinical and Laboratory Sciences., and University of Newcastle Upon Tyne</collab></person-group> (<year>2007b</year>). <source>The Role of MYCN in p53 Activation and the Downstream Response to p53 After DNA Damage in Neuroblastoma</source>. <publisher-loc>Newcastle upon Tyne</publisher-loc>: <publisher-name>University of Newcastle upon Tyne</publisher-name></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bell</surname><given-names>E.</given-names></name><name><surname>Premkumar</surname><given-names>R.</given-names></name><name><surname>Carr</surname><given-names>J.</given-names></name><name><surname>Lu</surname><given-names>X.</given-names></name><name><surname>Lovat</surname><given-names>P. E.</given-names></name><name><surname>Kees</surname><given-names>U. R.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>The role of MYCN in the failure of MYCN amplified neuroblastoma cell lines to G1 arrest after DNA damage</article-title>. <source>Cell Cycle</source>
<volume>5</volume>, <fpage>2639</fpage>&#x02013;<lpage>2647</lpage><pub-id pub-id-type="doi">10.4161/cc.5.22.3443</pub-id><pub-id pub-id-type="pmid">17172827</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ben-Yosef</surname><given-names>T.</given-names></name><name><surname>Yanuka</surname><given-names>O.</given-names></name><name><surname>Halle</surname><given-names>D.</given-names></name><name><surname>Benvenisty</surname><given-names>N.</given-names></name></person-group> (<year>1998</year>). <article-title>Involvement of Myc targets in c-myc and N-myc induced human tumors</article-title>. <source>Oncogene</source>
<volume>17</volume>, <fpage>165</fpage>&#x02013;<lpage>171</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1201939</pub-id><pub-id pub-id-type="pmid">9674700</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bergmann</surname><given-names>E.</given-names></name><name><surname>Wanzel</surname><given-names>M.</given-names></name><name><surname>Weber</surname><given-names>A.</given-names></name><name><surname>Shin</surname><given-names>I.</given-names></name><name><surname>Christiansen</surname><given-names>H.</given-names></name><name><surname>Eilers</surname><given-names>M.</given-names></name></person-group> (<year>2001</year>). <article-title>Expression of P27(KIP1) is prognostic and independent of MYCN amplification in human neuroblastoma</article-title>. <source>Int. J. Cancer</source>
<volume>95</volume>, <fpage>176</fpage>&#x02013;<lpage>183</lpage><pub-id pub-id-type="doi">10.1002/1097-0215(20010520)95:3&#x0003c;176::AID-IJC1030&#x0003e;3.3.CO;2-Q</pub-id><pub-id pub-id-type="pmid">11307151</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berwanger</surname><given-names>B.</given-names></name><name><surname>Hartmann</surname><given-names>O.</given-names></name><name><surname>Bergmann</surname><given-names>E.</given-names></name><name><surname>Bernard</surname><given-names>S.</given-names></name><name><surname>Nielsen</surname><given-names>D.</given-names></name><name><surname>Krause</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2002</year>). <article-title>Loss of a FYN-regulated differentiation and growth arrest pathway in advanced stage neuroblastoma</article-title>. <source>Cancer Cell</source>
<volume>2</volume>, <fpage>377</fpage>&#x02013;<lpage>386</lpage><pub-id pub-id-type="doi">10.1016/S1535-6108(02)00179-4</pub-id><pub-id pub-id-type="pmid">12450793</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Binne</surname><given-names>U. K.</given-names></name><name><surname>Classon</surname><given-names>M. K.</given-names></name><name><surname>Dick</surname><given-names>F. A.</given-names></name><name><surname>Wei</surname><given-names>W.</given-names></name><name><surname>Rape</surname><given-names>M.</given-names></name><name><surname>Kaelin</surname><given-names>W. G.</given-names><suffix>Jr.</suffix></name><etal/></person-group> (<year>2007</year>). <article-title>Retinoblastoma protein and anaphase-promoting complex physically interact and functionally cooperate during cell-cycle exit</article-title>. <source>Nat. Cell Biol.</source>
<volume>9</volume>, <fpage>225</fpage>&#x02013;<lpage>232</lpage><pub-id pub-id-type="doi">10.1038/ncb1532</pub-id><pub-id pub-id-type="pmid">17187060</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blanc</surname><given-names>E.</given-names></name><name><surname>Roux</surname><given-names>G. L.</given-names></name><name><surname>Benard</surname><given-names>J.</given-names></name><name><surname>Raguenez</surname><given-names>G.</given-names></name></person-group> (<year>2005</year>). <article-title>Low expression of Wnt-5a gene is associated with high-risk neuroblastoma</article-title>. <source>Oncogene</source>
<volume>24</volume>, <fpage>1277</fpage>&#x02013;<lpage>1283</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1208255</pub-id><pub-id pub-id-type="pmid">15592517</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bode</surname><given-names>A. M.</given-names></name><name><surname>Dong</surname><given-names>Z.</given-names></name></person-group> (<year>2004</year>). <article-title>Post-translational modification of p53 in tumorigenesis</article-title>. <source>Nat. Rev. Cancer</source>
<volume>4</volume>, <fpage>793</fpage>&#x02013;<lpage>805</lpage><pub-id pub-id-type="doi">10.1038/nrc1455</pub-id><pub-id pub-id-type="pmid">15510160</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bohlig</surname><given-names>L.</given-names></name><name><surname>Rother</surname><given-names>K.</given-names></name></person-group> (<year>2011</year>). <article-title>One function &#x02013; multiple mechanisms: the manifold activities of p53 as a transcriptional repressor</article-title>. <source>J. Biomed. Biotechnol.</source>
<volume>2011</volume>, <fpage>464916</fpage><pub-id pub-id-type="doi">10.1155/2011/464916</pub-id><pub-id pub-id-type="pmid">21436991</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bommer</surname><given-names>G. T.</given-names></name><name><surname>Gerin</surname><given-names>I.</given-names></name><name><surname>Feng</surname><given-names>Y.</given-names></name><name><surname>Kaczorowski</surname><given-names>A. J.</given-names></name><name><surname>Kuick</surname><given-names>R.</given-names></name><name><surname>Love</surname><given-names>R. E.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>p53-Mediated activation of miRNA34 candidate tumor-suppressor genes</article-title>. <source>Curr. Biol.</source>
<volume>17</volume>, <fpage>1298</fpage>&#x02013;<lpage>1307</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2007.06.068</pub-id><pub-id pub-id-type="pmid">17656095</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bornstein</surname><given-names>G.</given-names></name><name><surname>Bloom</surname><given-names>J.</given-names></name><name><surname>Sitry-Shevah</surname><given-names>D.</given-names></name><name><surname>Nakayama</surname><given-names>K.</given-names></name><name><surname>Pagano</surname><given-names>M.</given-names></name><name><surname>Hershko</surname><given-names>A.</given-names></name></person-group> (<year>2003</year>). <article-title>Role of the SCFSkp2 ubiquitin ligase in the degradation of p21Cip1 in S phase</article-title>. <source>J. Biol. Chem.</source>
<volume>278</volume>, <fpage>25752</fpage>&#x02013;<lpage>25757</lpage><pub-id pub-id-type="doi">10.1074/jbc.M301774200</pub-id><pub-id pub-id-type="pmid">12730199</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braithwaite</surname><given-names>A. W.</given-names></name><name><surname>Del Sal</surname><given-names>G.</given-names></name><name><surname>Lu</surname><given-names>X.</given-names></name></person-group> (<year>2006</year>). <article-title>Some p53-binding proteins that can function as arbiters of life and death</article-title>. <source>Cell Death Differ.</source>
<volume>13</volume>, <fpage>984</fpage>&#x02013;<lpage>993</lpage><pub-id pub-id-type="doi">10.1038/sj.cdd.4401938</pub-id><pub-id pub-id-type="pmid">16575404</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braun</surname><given-names>C. J.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Savelyeva</surname><given-names>I.</given-names></name><name><surname>Wolff</surname><given-names>S.</given-names></name><name><surname>Moll</surname><given-names>U. M.</given-names></name><name><surname>Schepeler</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest</article-title>. <source>Cancer Res.</source>
<volume>68</volume>, <fpage>10094</fpage>&#x02013;<lpage>10104</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-1569</pub-id><pub-id pub-id-type="pmid">19074875</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bray</surname><given-names>I.</given-names></name><name><surname>Bryan</surname><given-names>K.</given-names></name><name><surname>Prenter</surname><given-names>S.</given-names></name><name><surname>Buckley</surname><given-names>P. G.</given-names></name><name><surname>Foley</surname><given-names>N. H.</given-names></name><name><surname>Murphy</surname><given-names>D. M.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival</article-title>. <source>PLoS ONE</source>
<volume>4</volume>, <fpage>e7850</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0007850</pub-id><pub-id pub-id-type="pmid">19924232</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bretones</surname><given-names>G.</given-names></name><name><surname>Acosta</surname><given-names>J. C.</given-names></name><name><surname>Caraballo</surname><given-names>J. M.</given-names></name><name><surname>Ferrandiz</surname><given-names>N.</given-names></name><name><surname>Gomez-Casares</surname><given-names>M. T.</given-names></name><name><surname>Albajar</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>SKP2 oncogene is a direct MYC target gene and MYC down-regulates p27(KIP1) through SKP2 in human leukemia cells</article-title>. <source>J. Biol. Chem.</source>
<volume>286</volume>, <fpage>9815</fpage>&#x02013;<lpage>9825</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.165977</pub-id><pub-id pub-id-type="pmid">21245140</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brignole</surname><given-names>C.</given-names></name><name><surname>Marimpietri</surname><given-names>D.</given-names></name><name><surname>Pastorino</surname><given-names>F.</given-names></name><name><surname>Nico</surname><given-names>B.</given-names></name><name><surname>Di Paolo</surname><given-names>D.</given-names></name><name><surname>Cioni</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis</article-title>. <source>J. Natl. Cancer Inst.</source>
<volume>98</volume>, <fpage>1142</fpage>&#x02013;<lpage>1157</lpage><pub-id pub-id-type="doi">10.1093/jnci/djj309</pub-id><pub-id pub-id-type="pmid">16912267</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brosh</surname><given-names>R.</given-names></name><name><surname>Rotter</surname><given-names>V.</given-names></name></person-group> (<year>2009</year>). <article-title>When mutants gain new powers: news from the mutant p53 field</article-title>. <source>Nat. Rev. Cancer</source>
<volume>9</volume>, <fpage>701</fpage>&#x02013;<lpage>713</lpage><pub-id pub-id-type="pmid">19693097</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>C. J.</given-names></name><name><surname>Lain</surname><given-names>S.</given-names></name><name><surname>Verma</surname><given-names>C. S.</given-names></name><name><surname>Fersht</surname><given-names>A. R.</given-names></name><name><surname>Lane</surname><given-names>D. P.</given-names></name></person-group> (<year>2009</year>). <article-title>Awakening guardian angels: drugging the p53 pathway</article-title>. <source>Nat. Rev. Cancer</source>
<volume>9</volume>, <fpage>862</fpage>&#x02013;<lpage>873</lpage><pub-id pub-id-type="doi">10.1038/nrc2763</pub-id><pub-id pub-id-type="pmid">19935675</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calao</surname><given-names>M.</given-names></name><name><surname>Sekyere</surname><given-names>E. O.</given-names></name><name><surname>Cui</surname><given-names>H. J.</given-names></name><name><surname>Cheung</surname><given-names>B. B.</given-names></name><name><surname>Thomas</surname><given-names>W. D.</given-names></name><name><surname>Keating</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Direct effects of Bmi1 on p53 protein stability inactivates oncoprotein stress responses in embryonal cancer precursor cells at tumor initiation</article-title>. <source>Oncogene</source>.<pub-id pub-id-type="doi">10.1038/onc.2012.368</pub-id><pub-id pub-id-type="pmid">22907436</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calin</surname><given-names>G.</given-names></name><name><surname>Ivan</surname><given-names>M.</given-names></name><name><surname>Stefanescu</surname><given-names>D.</given-names></name></person-group> (<year>1999</year>). <article-title>The difference between p53 mutation frequency in haematological and non-haematological malignancies: possible explanations</article-title>. <source>Med. Hypotheses</source>
<volume>53</volume>, <fpage>326</fpage>&#x02013;<lpage>328</lpage><pub-id pub-id-type="doi">10.1054/mehy.1999.0764</pub-id><pub-id pub-id-type="pmid">10608267</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cantilena</surname><given-names>S.</given-names></name><name><surname>Pastorino</surname><given-names>F.</given-names></name><name><surname>Pezzolo</surname><given-names>A.</given-names></name><name><surname>Chayka</surname><given-names>O.</given-names></name><name><surname>Pistoia</surname><given-names>V.</given-names></name><name><surname>Ponzoni</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Frizzled receptor 6 marks rare, highly tumourigenic stem-like cells in mouse and human neuroblastomas</article-title>. <source>Oncotarget</source>
<volume>2</volume>, <fpage>976</fpage>&#x02013;<lpage>983</lpage><pub-id pub-id-type="pmid">22249030</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>L.</given-names></name><name><surname>Bombard</surname><given-names>J.</given-names></name><name><surname>Cintron</surname><given-names>K.</given-names></name><name><surname>Sheedy</surname><given-names>J.</given-names></name><name><surname>Weetall</surname><given-names>M. L.</given-names></name><name><surname>Davis</surname><given-names>T. W.</given-names></name></person-group> (<year>2011</year>). <article-title>BMI1 as a novel target for drug discovery in cancer</article-title>. <source>J. Cell. Biochem.</source>
<volume>112</volume>, <fpage>2729</fpage>&#x02013;<lpage>2741</lpage><pub-id pub-id-type="doi">10.1002/jcb.23234</pub-id><pub-id pub-id-type="pmid">21678481</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caren</surname><given-names>H.</given-names></name><name><surname>Erichsen</surname><given-names>J.</given-names></name><name><surname>Olsson</surname><given-names>L.</given-names></name><name><surname>Enerback</surname><given-names>C.</given-names></name><name><surname>Sjoberg</surname><given-names>R. M.</given-names></name><name><surname>Abrahamsson</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: four cases of homozygous deletions of the CDKN2A gene</article-title>. <source>BMC Genomics</source>
<volume>9</volume>, <fpage>353</fpage><pub-id pub-id-type="doi">10.1186/1471-2164-9-353</pub-id><pub-id pub-id-type="pmid">18664255</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carol</surname><given-names>H.</given-names></name><name><surname>Boehm</surname><given-names>I.</given-names></name><name><surname>Reynolds</surname><given-names>C. P.</given-names></name><name><surname>Kang</surname><given-names>M. H.</given-names></name><name><surname>Maris</surname><given-names>J. M.</given-names></name><name><surname>Morton</surname><given-names>C. L.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Efficacy and pharmacokinetic/pharmacodynamic evaluation of the aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer</article-title>. <source>Cancer Chemother. Pharmacol.</source>
<volume>68</volume>, <fpage>1291</fpage>&#x02013;<lpage>1304</lpage><pub-id pub-id-type="doi">10.1007/s00280-011-1618-8</pub-id><pub-id pub-id-type="pmid">21448591</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carr</surname><given-names>J.</given-names></name><name><surname>Bell</surname><given-names>E.</given-names></name><name><surname>Pearson</surname><given-names>A. D.</given-names></name><name><surname>Kees</surname><given-names>U. R.</given-names></name><name><surname>Beris</surname><given-names>H.</given-names></name><name><surname>Lunec</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Increased frequency of aberrations in the p53/MDM2/p14(ARF) pathway in neuroblastoma cell lines established at relapse</article-title>. <source>Cancer Res.</source>
<volume>66</volume>, <fpage>2138</fpage>&#x02013;<lpage>2145</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-2623</pub-id><pub-id pub-id-type="pmid">16489014</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carrano</surname><given-names>A. C.</given-names></name><name><surname>Eytan</surname><given-names>E.</given-names></name><name><surname>Hershko</surname><given-names>A.</given-names></name><name><surname>Pagano</surname><given-names>M.</given-names></name></person-group> (<year>1999</year>). <article-title>SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27</article-title>. <source>Nat. Cell Biol.</source>
<volume>1</volume>, <fpage>193</fpage>&#x02013;<lpage>199</lpage><pub-id pub-id-type="doi">10.1038/70221</pub-id><pub-id pub-id-type="pmid">10559916</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carrano</surname><given-names>A. C.</given-names></name><name><surname>Pagano</surname><given-names>M.</given-names></name></person-group> (<year>2001</year>). <article-title>Role of the F-box protein Skp2 in adhesion-dependent cell cycle progression</article-title>. <source>J. Cell Biol.</source>
<volume>153</volume>, <fpage>1381</fpage>&#x02013;<lpage>1390</lpage><pub-id pub-id-type="doi">10.1083/jcb.153.7.1381</pub-id><pub-id pub-id-type="pmid">11425869</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carr-Wilkinson</surname><given-names>J.</given-names></name><name><surname>Griffiths</surname><given-names>R.</given-names></name><name><surname>Elston</surname><given-names>R.</given-names></name><name><surname>Gamble</surname><given-names>L. D.</given-names></name><name><surname>Goranov</surname><given-names>B.</given-names></name><name><surname>Redfern</surname><given-names>C. P.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Outcome of the p53-mediated DNA damage response in neuroblastoma is determined by morphological subtype and MYCN expression</article-title>. <source>Cell Cycle</source>
<volume>10</volume>, <fpage>3778</fpage>&#x02013;<lpage>3787</lpage><pub-id pub-id-type="doi">10.4161/cc.10.21.17973</pub-id><pub-id pub-id-type="pmid">22052359</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carr-Wilkinson</surname><given-names>J.</given-names></name><name><surname>O&#x02019;Toole</surname><given-names>K.</given-names></name><name><surname>Wood</surname><given-names>K. M.</given-names></name><name><surname>Challen</surname><given-names>C. C.</given-names></name><name><surname>Baker</surname><given-names>A. G.</given-names></name><name><surname>Board</surname><given-names>J. R.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>High frequency of p53/MDM2/p14ARF pathway abnormalities in relapsed neuroblastoma</article-title>. <source>Clin. Cancer Res.</source>
<volume>16</volume>, <fpage>1108</fpage>&#x02013;<lpage>1118</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-09-1865</pub-id><pub-id pub-id-type="pmid">20145180</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castresana</surname><given-names>J. S.</given-names></name><name><surname>Bello</surname><given-names>M. J.</given-names></name><name><surname>Rey</surname><given-names>J. A.</given-names></name><name><surname>Nebreda</surname><given-names>P.</given-names></name><name><surname>Queizan</surname><given-names>A.</given-names></name><name><surname>Garcia-Miguel</surname><given-names>P.</given-names></name><etal/></person-group> (<year>1994</year>). <article-title>No TP53 mutations in neuroblastomas detected by PCR-SSCP analysis</article-title>. <source>Genes Chromosomes Cancer</source>
<volume>10</volume>, <fpage>136</fpage>&#x02013;<lpage>138</lpage><pub-id pub-id-type="doi">10.1002/gcc.2870100209</pub-id><pub-id pub-id-type="pmid">7520267</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cataldo</surname><given-names>V. D.</given-names></name><name><surname>Cortes</surname><given-names>J.</given-names></name><name><surname>Quintas-Cardama</surname><given-names>A.</given-names></name></person-group> (<year>2009</year>). <article-title>Azacitidine for the treatment of myelodysplastic syndrome</article-title>. <source>Expert Rev. Anticancer Ther.</source>
<volume>9</volume>, <fpage>875</fpage>&#x02013;<lpage>884</lpage><pub-id pub-id-type="doi">10.1586/era.09.61</pub-id><pub-id pub-id-type="pmid">19589026</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cattelani</surname><given-names>S.</given-names></name><name><surname>Defferrari</surname><given-names>R.</given-names></name><name><surname>Marsilio</surname><given-names>S.</given-names></name><name><surname>Bussolari</surname><given-names>R.</given-names></name><name><surname>Candini</surname><given-names>O.</given-names></name><name><surname>Corradini</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Impact of a single nucleotide polymorphism in the MDM2 gene on neuroblastoma development and aggressiveness: results of a pilot study on 239 patients</article-title>. <source>Clin. Cancer Res.</source>
<volume>14</volume>, <fpage>3248</fpage>&#x02013;<lpage>3253</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-4725</pub-id><pub-id pub-id-type="pmid">18519749</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cattelani</surname><given-names>S.</given-names></name><name><surname>Ferrari-Amorotti</surname><given-names>G.</given-names></name><name><surname>Galavotti</surname><given-names>S.</given-names></name><name><surname>Defferrari</surname><given-names>R.</given-names></name><name><surname>Tanno</surname><given-names>B.</given-names></name><name><surname>Cialfi</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>The p53 Codon 72 Pro/Pro genotype identifies poor-prognosis neuroblastoma patients: correlation with reduced apoptosis and enhanced senescence by the p53-72P Isoform</article-title>. <source>Neoplasia</source>
<volume>14</volume>, <fpage>634</fpage>&#x02013;<lpage>643</lpage><pub-id pub-id-type="pmid">22904680</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>C. H.</given-names></name><name><surname>Lee</surname><given-names>S. W.</given-names></name><name><surname>Li</surname><given-names>C. F.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Yang</surname><given-names>W. L.</given-names></name><name><surname>Wu</surname><given-names>C. Y.</given-names></name><etal/></person-group> (<year>2010a</year>). <article-title>Deciphering the transcriptional complex critical for RhoA gene expression and cancer metastasis</article-title>. <source>Nat. Cell Biol.</source>
<volume>12</volume>, <fpage>457</fpage>&#x02013;<lpage>467</lpage><pub-id pub-id-type="doi">10.1038/ncb2047</pub-id><pub-id pub-id-type="pmid">20383141</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>C. H.</given-names></name><name><surname>Lee</surname><given-names>S. W.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Lin</surname><given-names>H. K.</given-names></name></person-group> (<year>2010b</year>). <article-title>Regulation of Skp2 expression and activity and its role in cancer progression</article-title>. <source>ScientificWorldJournal</source>
<volume>10</volume>, <fpage>1001</fpage>&#x02013;<lpage>1015</lpage><pub-id pub-id-type="doi">10.1100/tsw.2010.64</pub-id><pub-id pub-id-type="pmid">20526532</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>C. H.</given-names></name><name><surname>Li</surname><given-names>C. F.</given-names></name><name><surname>Yang</surname><given-names>W. L.</given-names></name><name><surname>Gao</surname><given-names>Y.</given-names></name><name><surname>Lee</surname><given-names>S. W.</given-names></name><name><surname>Feng</surname><given-names>Z.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis</article-title>. <source>Cell</source>
<volume>149</volume>, <fpage>1098</fpage>&#x02013;<lpage>1111</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.02.065</pub-id><pub-id pub-id-type="pmid">22632973</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chander</surname><given-names>H.</given-names></name><name><surname>Halpern</surname><given-names>M.</given-names></name><name><surname>Resnick-Silverman</surname><given-names>L.</given-names></name><name><surname>Manfredi</surname><given-names>J. J.</given-names></name><name><surname>Germain</surname><given-names>D.</given-names></name></person-group> (<year>2010</year>). <article-title>Skp2B attenuates p53 function by inhibiting prohibitin</article-title>. <source>EMBO Rep.</source>
<volume>11</volume>, <fpage>220</fpage>&#x02013;<lpage>225</lpage><pub-id pub-id-type="doi">10.1038/embor.2010.2</pub-id><pub-id pub-id-type="pmid">20134482</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>T.-C.</given-names></name><name><surname>Wentzel</surname><given-names>E. A.</given-names></name><name><surname>Kent</surname><given-names>O. A.</given-names></name><name><surname>Ramachandran</surname><given-names>K.</given-names></name><name><surname>Mullendore</surname><given-names>M.</given-names></name><name><surname>Lee Kwang</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Transactivation of miR-34a by p53 Broadly influences gene expression and promotes apoptosis</article-title>. <source>Mol. Cell</source>
<volume>26</volume>, <fpage>745</fpage>&#x02013;<lpage>752</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2007.05.010</pub-id><pub-id pub-id-type="pmid">17540599</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charrasse</surname><given-names>S.</given-names></name><name><surname>Carena</surname><given-names>I.</given-names></name><name><surname>Brondani</surname><given-names>V.</given-names></name><name><surname>Klempnauer</surname><given-names>K. H.</given-names></name><name><surname>Ferrari</surname><given-names>S.</given-names></name></person-group> (<year>2000</year>). <article-title>Degradation of B-Myb by ubiquitin-mediated proteolysis: involvement of the Cdc34-SCF(p45Skp2) pathway</article-title>. <source>Oncogene</source>
<volume>19</volume>, <fpage>2986</fpage>&#x02013;<lpage>2995</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1203618</pub-id><pub-id pub-id-type="pmid">10871850</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>D.</given-names></name><name><surname>Frezza</surname><given-names>M.</given-names></name><name><surname>Schmitt</surname><given-names>S.</given-names></name><name><surname>Kanwar</surname><given-names>J.</given-names></name><name><surname>Dou</surname><given-names>Q. P.</given-names></name></person-group> (<year>2011</year>). <article-title>Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives</article-title>. <source>Curr. Cancer Drug Targets</source>
<volume>11</volume>, <fpage>239</fpage>&#x02013;<lpage>253</lpage><pub-id pub-id-type="doi">10.2174/156800911794519752</pub-id><pub-id pub-id-type="pmid">21247388</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L.</given-names></name></person-group> (<year>2009</year>). <source>An Investigation of the Relationship Between p53 Function, Differentiation and MYCN in Neuroblastoma</source>. <publisher-loc>Newcastle upon Tyne</publisher-loc>: <publisher-name>University of Newcastle upon Tyne</publisher-name></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Iraci</surname><given-names>N.</given-names></name><name><surname>Gherardi</surname><given-names>S.</given-names></name><name><surname>Gamble</surname><given-names>L. D.</given-names></name><name><surname>Wood</surname><given-names>K. M.</given-names></name><name><surname>Perini</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>p53 Is a direct transcriptional target of MYCN in neuroblastoma</article-title>. <source>Cancer Res.</source>
<volume>70</volume>, <fpage>1377</fpage>&#x02013;<lpage>1388</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-0027</pub-id><pub-id pub-id-type="pmid">20145147</pub-id></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Malcolm</surname><given-names>A. J.</given-names></name><name><surname>Wood</surname><given-names>K. M.</given-names></name><name><surname>Cole</surname><given-names>M.</given-names></name><name><surname>Variend</surname><given-names>S.</given-names></name><name><surname>Cullinane</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>p53 is nuclear and functional in both undifferentiated and differentiated neuroblastoma</article-title>. <source>Cell Cycle</source>
<volume>6</volume>, <fpage>2685</fpage>&#x02013;<lpage>2696</lpage><pub-id pub-id-type="doi">10.4161/cc.6.21.4853</pub-id><pub-id pub-id-type="pmid">17912039</pub-id></mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Q.</given-names></name><name><surname>Xie</surname><given-names>W.</given-names></name><name><surname>Kuhn</surname><given-names>D. J.</given-names></name><name><surname>Voorhees</surname><given-names>P. M.</given-names></name><name><surname>Lopez-Girona</surname><given-names>A.</given-names></name><name><surname>Mendy</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy</article-title>. <source>Blood</source>
<volume>111</volume>, <fpage>4690</fpage>&#x02013;<lpage>4699</lpage><pub-id pub-id-type="doi">10.1182/blood-2006-12-062265</pub-id><pub-id pub-id-type="pmid">18305219</pub-id></mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Lin</surname><given-names>Y.</given-names></name><name><surname>Barbieri</surname><given-names>E.</given-names></name><name><surname>Burlingame</surname><given-names>S.</given-names></name><name><surname>Hicks</surname><given-names>J.</given-names></name><name><surname>Ludwig</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Mdm2 deficiency suppresses MYCN-driven neuroblastoma tumorigenesis in vivo</article-title>. <source>Neoplasia</source>
<volume>11</volume>, <fpage>753</fpage>&#x02013;<lpage>762</lpage><pub-id pub-id-type="pmid">19649205</pub-id></mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>D.</given-names></name><name><surname>Yue</surname><given-names>F.</given-names></name><name><surname>Zheng</surname><given-names>M.</given-names></name><name><surname>Kovacevic</surname><given-names>Z.</given-names></name><name><surname>Richardson</surname><given-names>D. R.</given-names></name></person-group> (<year>2012</year>). <article-title>The iron chelators Dp44mT and DFO inhibit TGF-beta-induced epithelial-mesenchymal transition via up-regulation of N-Myc downstream-regulated gene 1 (NDRG1)</article-title>. <source>J. Biol. Chem.</source>
<volume>287</volume>, <fpage>17016</fpage>&#x02013;<lpage>17028</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.315432</pub-id><pub-id pub-id-type="pmid">22453918</pub-id></mixed-citation></ref><ref id="B68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheok</surname><given-names>C. F.</given-names></name><name><surname>Verma</surname><given-names>C. S.</given-names></name><name><surname>Baselga</surname><given-names>J.</given-names></name><name><surname>Lane</surname><given-names>D. P.</given-names></name></person-group> (<year>2011</year>). <article-title>Translating p53 into the clinic</article-title>. <source>Nat. Rev. Clin. Oncol.</source>
<volume>8</volume>, <fpage>25</fpage>&#x02013;<lpage>37</lpage><pub-id pub-id-type="doi">10.1038/nrclinonc.2010.174</pub-id><pub-id pub-id-type="pmid">20975744</pub-id></mixed-citation></ref><ref id="B69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chesler</surname><given-names>L.</given-names></name><name><surname>Goldenberg</surname><given-names>D. D.</given-names></name><name><surname>Collins</surname><given-names>R.</given-names></name><name><surname>Grimmer</surname><given-names>M.</given-names></name><name><surname>Kim</surname><given-names>G. E.</given-names></name><name><surname>Tihan</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction</article-title>. <source>Neoplasia</source>
<volume>10</volume>, <fpage>1268</fpage>&#x02013;<lpage>1274</lpage><pub-id pub-id-type="pmid">18953436</pub-id></mixed-citation></ref><ref id="B70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chesler</surname><given-names>L.</given-names></name><name><surname>Schlieve</surname><given-names>C.</given-names></name><name><surname>Goldenberg</surname><given-names>D. D.</given-names></name><name><surname>Kenney</surname><given-names>A.</given-names></name><name><surname>Kim</surname><given-names>G.</given-names></name><name><surname>McMillan</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma</article-title>. <source>Cancer Res.</source>
<volume>66</volume>, <fpage>8139</fpage>&#x02013;<lpage>8146</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-2769</pub-id><pub-id pub-id-type="pmid">16912192</pub-id></mixed-citation></ref><ref id="B71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheung</surname><given-names>C. H.</given-names></name><name><surname>Coumar</surname><given-names>M. S.</given-names></name><name><surname>Chang</surname><given-names>J. Y.</given-names></name><name><surname>Hsieh</surname><given-names>H. P.</given-names></name></person-group> (<year>2011</year>). <article-title>Aurora kinase inhibitor patents and agents in clinical testing: an update (2009&#x02013;10)</article-title>. <source>Expert Opin. Ther. Pat.</source>
<volume>21</volume>, <fpage>857</fpage>&#x02013;<lpage>884</lpage><pub-id pub-id-type="doi">10.1517/13543776.2011.574614</pub-id><pub-id pub-id-type="pmid">21591849</pub-id></mixed-citation></ref><ref id="B72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>C. H.</given-names></name><name><surname>Seo</surname><given-names>M.</given-names></name><name><surname>Lee</surname><given-names>Y. I.</given-names></name><name><surname>Kim</surname><given-names>S. Y.</given-names></name><name><surname>Youn</surname><given-names>H. D.</given-names></name><name><surname>Juhnn</surname><given-names>Y. S.</given-names></name></person-group> (<year>2007</year>). <article-title>Dibutyryl cAMP stimulates the proliferation of SH-SY5Y human neuroblastoma cells by up-regulating Skp2 protein</article-title>. <source>J. Cancer Res. Clin. Oncol.</source>
<volume>133</volume>, <fpage>135</fpage>&#x02013;<lpage>144</lpage><pub-id pub-id-type="doi">10.1007/s00432-006-0153-1</pub-id><pub-id pub-id-type="pmid">17004068</pub-id></mixed-citation></ref><ref id="B73"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>I. M.</given-names></name><name><surname>Hengst</surname><given-names>L.</given-names></name><name><surname>Slingerland</surname><given-names>J. M.</given-names></name></person-group> (<year>2008</year>). <article-title>The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy</article-title>. <source>Nat. Rev. Cancer</source>
<volume>8</volume>, <fpage>253</fpage>&#x02013;<lpage>267</lpage><pub-id pub-id-type="doi">10.1038/nrc2347</pub-id><pub-id pub-id-type="pmid">18354415</pub-id></mixed-citation></ref><ref id="B74"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Cohn</surname><given-names>S. L.</given-names></name><name><surname>Ikegaki</surname><given-names>N.</given-names></name></person-group> (<year>2000</year>). <article-title>&#x0201c;Expression of MYCN mRNA and Protein,&#x0201d;</article-title> in <source>Neuroblastoma</source>, eds <person-group person-group-type="editor"><name><surname>Brodeur</surname><given-names>G. M.</given-names></name><name><surname>Sawada</surname><given-names>T.</given-names></name><name><surname>Tsuchida</surname><given-names>Y.</given-names></name><name><surname>Vo&#x000fb;te</surname><given-names>P. A.</given-names></name></person-group> (<publisher-loc>Amsterdam</publisher-loc>: <publisher-name>Elsevier Science B.V.</publisher-name>), <fpage>137</fpage>&#x02013;<lpage>146</lpage></mixed-citation></ref><ref id="B75"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohn</surname><given-names>S. L.</given-names></name><name><surname>Tweddle</surname><given-names>D. A.</given-names></name></person-group> (<year>2004</year>). <article-title>MYCN amplification remains prognostically strong 20 years after its &#x0201c;clinical debut.&#x0201d;</article-title>
<source>Eur. J. Cancer</source>
<volume>40</volume>, <fpage>2639</fpage>&#x02013;<lpage>2642</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2004.07.025</pub-id><pub-id pub-id-type="pmid">15571946</pub-id></mixed-citation></ref><ref id="B76"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cole</surname><given-names>K. A.</given-names></name><name><surname>Attiyeh</surname><given-names>E. F.</given-names></name><name><surname>Mosse</surname><given-names>Y. P.</given-names></name><name><surname>Laquaglia</surname><given-names>M. J.</given-names></name><name><surname>Diskin</surname><given-names>S. J.</given-names></name><name><surname>Brodeur</surname><given-names>G. M.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>A Functional Screen Identifies miR-34a as a candidate neuroblastoma tumor suppressor gene</article-title>. <source>Mol. Cancer Res.</source>
<volume>6</volume>, <fpage>735</fpage>&#x02013;<lpage>742</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-07-2102</pub-id><pub-id pub-id-type="pmid">18505919</pub-id></mixed-citation></ref><ref id="B77"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corvi</surname><given-names>R.</given-names></name><name><surname>Savelyeva</surname><given-names>L.</given-names></name><name><surname>Breit</surname><given-names>S.</given-names></name><name><surname>Wenzel</surname><given-names>A.</given-names></name><name><surname>Handgretinger</surname><given-names>R.</given-names></name><name><surname>Barak</surname><given-names>J.</given-names></name><etal/></person-group> (<year>1995</year>). <article-title>Non-syntenic amplification of MDM2 and MYCN in human neuroblastoma</article-title>. <source>Oncogene</source>
<volume>10</volume>, <fpage>1081</fpage>&#x02013;<lpage>1086</lpage><pub-id pub-id-type="pmid">7700632</pub-id></mixed-citation></ref><ref id="B78"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuende</surname><given-names>J.</given-names></name><name><surname>Moreno</surname><given-names>S.</given-names></name><name><surname>Bolanos</surname><given-names>J. P.</given-names></name><name><surname>Almeida</surname><given-names>A.</given-names></name></person-group> (<year>2008</year>). <article-title>Retinoic acid downregulates Rae1 leading to APC(Cdh1) activation and neuroblastoma SH-SY5Y differentiation</article-title>. <source>Oncogene</source>
<volume>27</volume>, <fpage>3339</fpage>&#x02013;<lpage>3344</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1210987</pub-id><pub-id pub-id-type="pmid">18212744</pub-id></mixed-citation></ref><ref id="B79"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>H.</given-names></name><name><surname>Hu</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>T.</given-names></name><name><surname>Ma</surname><given-names>J.</given-names></name><name><surname>Alam</surname><given-names>G.</given-names></name><name><surname>Gunning</surname><given-names>W. T.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Bmi-1 is essential for the tumorigenicity of neuroblastoma cells</article-title>. <source>Am. J. Pathol.</source>
<volume>170</volume>, <fpage>1370</fpage>&#x02013;<lpage>1378</lpage><pub-id pub-id-type="doi">10.2353/ajpath.2007.060754</pub-id><pub-id pub-id-type="pmid">17392175</pub-id></mixed-citation></ref><ref id="B80"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>T.</given-names></name><name><surname>Ding</surname><given-names>H. F.</given-names></name></person-group> (<year>2005</year>). <article-title>Linking of N-Myc to death receptor machinery in neuroblastoma cells</article-title>. <source>J. Biol. Chem.</source>
<volume>280</volume>, <fpage>9474</fpage>&#x02013;<lpage>9481</lpage><pub-id pub-id-type="doi">10.1074/jbc.M410450200</pub-id><pub-id pub-id-type="pmid">15632181</pub-id></mixed-citation></ref><ref id="B81"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>H.</given-names></name><name><surname>Schroering</surname><given-names>A.</given-names></name><name><surname>Ding</surname><given-names>H. F.</given-names></name></person-group> (<year>2002</year>). <article-title>p53 mediates DNA damaging drug-induced apoptosis through a caspase-9-dependent pathway in SH-SY5Y neuroblastoma cells</article-title>. <source>Mol. Cancer Ther.</source>
<volume>1</volume>, <fpage>679</fpage>&#x02013;<lpage>686</lpage><pub-id pub-id-type="pmid">12479364</pub-id></mixed-citation></ref><ref id="B82"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dang</surname><given-names>C. V.</given-names></name></person-group> (<year>1999</year>). <article-title>c-Myc target genes involved in cell growth, apoptosis, and metabolism</article-title>. <source>Mol. Cell. Biol.</source>
<volume>19</volume>, <fpage>1</fpage>&#x02013;<lpage>11</lpage><pub-id pub-id-type="pmid">9858526</pub-id></mixed-citation></ref><ref id="B83"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Danks</surname><given-names>M. K.</given-names></name><name><surname>Whipple</surname><given-names>D. O.</given-names></name><name><surname>Mcpake</surname><given-names>C. R.</given-names></name><name><surname>Lu</surname><given-names>D.</given-names></name><name><surname>Harris</surname><given-names>L. C.</given-names></name></person-group> (<year>1998</year>). <article-title>Differences in epitope accessibility of p53 monoclonal antibodies suggest at least three conformations or states of protein binding of p53 protein in human tumor cell lines</article-title>. <source>Cell Death Differ.</source>
<volume>5</volume>, <fpage>678</fpage>&#x02013;<lpage>686</lpage><pub-id pub-id-type="doi">10.1038/sj.cdd.4400408</pub-id><pub-id pub-id-type="pmid">10200523</pub-id></mixed-citation></ref><ref id="B84"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dar</surname><given-names>A. A.</given-names></name><name><surname>Zaika</surname><given-names>A.</given-names></name><name><surname>Piazuelo</surname><given-names>M. B.</given-names></name><name><surname>Correa</surname><given-names>P.</given-names></name><name><surname>Koyama</surname><given-names>T.</given-names></name><name><surname>Belkhiri</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Frequent overexpression of aurora kinase A in upper gastrointestinal adenocarcinomas correlates with potent antiapoptotic functions</article-title>. <source>Cancer</source>
<volume>112</volume>, <fpage>1688</fpage>&#x02013;<lpage>1698</lpage><pub-id pub-id-type="doi">10.1002/cncr.23371</pub-id><pub-id pub-id-type="pmid">18311783</pub-id></mixed-citation></ref><ref id="B85"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davidoff</surname><given-names>A. M.</given-names></name><name><surname>Pence</surname><given-names>J. C.</given-names></name><name><surname>Shorter</surname><given-names>N. A.</given-names></name><name><surname>Iglehart</surname><given-names>J. D.</given-names></name><name><surname>Marks</surname><given-names>J. R.</given-names></name></person-group> (<year>1992</year>). <article-title>Expression of p53 in human neuroblastoma- and neuroepithelioma-derived cell lines</article-title>. <source>Oncogene</source>
<volume>7</volume>, <fpage>127</fpage>&#x02013;<lpage>133</lpage><pub-id pub-id-type="pmid">1741160</pub-id></mixed-citation></ref><ref id="B86"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davidovich</surname><given-names>S.</given-names></name><name><surname>Ben-Izhak</surname><given-names>O.</given-names></name><name><surname>Shapira</surname><given-names>M.</given-names></name><name><surname>Futerman</surname><given-names>B.</given-names></name><name><surname>Hershko</surname><given-names>D. D.</given-names></name></person-group> (<year>2008</year>). <article-title>Over-expression of Skp2 is associated with resistance to preoperative doxorubicin-based chemotherapy in primary breast cancer</article-title>. <source>Breast Cancer Res.</source>
<volume>10</volume>, <fpage>R63</fpage><pub-id pub-id-type="doi">10.1186/bcr2061</pub-id><pub-id pub-id-type="pmid">18644126</pub-id></mixed-citation></ref><ref id="B87"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Brouwer</surname><given-names>S.</given-names></name><name><surname>Mestdagh</surname><given-names>P.</given-names></name><name><surname>Lambertz</surname><given-names>I.</given-names></name><name><surname>Pattyn</surname><given-names>F.</given-names></name><name><surname>De Paepe</surname><given-names>A.</given-names></name><name><surname>Westermann</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Dickkopf-3 is regulated by the MYCN-induced miR-17-92 cluster in neuroblastoma</article-title>. <source>Int. J. Cancer</source>
<volume>130</volume>, <fpage>2591</fpage>&#x02013;<lpage>2598</lpage><pub-id pub-id-type="doi">10.1002/ijc.26295</pub-id><pub-id pub-id-type="pmid">21796614</pub-id></mixed-citation></ref><ref id="B88"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Calisto</surname><given-names>J.</given-names></name><name><surname>Araya</surname><given-names>C.</given-names></name><name><surname>Marchant</surname><given-names>L.</given-names></name><name><surname>Riaz</surname><given-names>C. F.</given-names></name><name><surname>Mayor</surname><given-names>R.</given-names></name></person-group> (<year>2005</year>). <article-title>Essential role of non-canonical Wnt signalling in neural crest migration</article-title>. <source>Development</source>
<volume>132</volume>, <fpage>2587</fpage>&#x02013;<lpage>2597</lpage><pub-id pub-id-type="doi">10.1242/dev.01857</pub-id><pub-id pub-id-type="pmid">15857909</pub-id></mixed-citation></ref><ref id="B89"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dellinger</surname><given-names>T. H.</given-names></name><name><surname>Planutis</surname><given-names>K.</given-names></name><name><surname>Jandial</surname><given-names>D. D.</given-names></name><name><surname>Eskander</surname><given-names>R. N.</given-names></name><name><surname>Martinez</surname><given-names>M. E.</given-names></name><name><surname>Zi</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Expression of the Wnt antagonist Dickkopf-3 is associated with prognostic clinicopathologic characteristics and impairs proliferation and invasion in endometrial cancer</article-title>. <source>Gynecol. Oncol.</source>
<volume>126</volume>, <fpage>259</fpage>&#x02013;<lpage>267</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2012.04.026</pub-id><pub-id pub-id-type="pmid">22555103</pub-id></mixed-citation></ref><ref id="B90"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deshaies</surname><given-names>R. J.</given-names></name></person-group> (<year>1999</year>). <article-title>SCF and cullin/ring H2-based ubiquitin ligases</article-title>. <source>Annu. Rev. Cell Dev. Biol.</source>
<volume>15</volume>, <fpage>435</fpage>&#x02013;<lpage>467</lpage><pub-id pub-id-type="doi">10.1146/annurev.cellbio.15.1.435</pub-id><pub-id pub-id-type="pmid">10611969</pub-id></mixed-citation></ref><ref id="B91"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deubzer</surname><given-names>H. E.</given-names></name><name><surname>Ehemann</surname><given-names>V.</given-names></name><name><surname>Kulozik</surname><given-names>A. E.</given-names></name><name><surname>Westermann</surname><given-names>F.</given-names></name><name><surname>Savelyeva</surname><given-names>L.</given-names></name><name><surname>Kopp-Schneider</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2008a</year>). <article-title>Anti-neuroblastoma activity of Helminthosporium carbonum (HC)-toxin is superior to that of other differentiating compounds in vitro</article-title>. <source>Cancer Lett.</source>
<volume>264</volume>, <fpage>21</fpage>&#x02013;<lpage>28</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2008.01.002</pub-id><pub-id pub-id-type="pmid">18262346</pub-id></mixed-citation></ref><ref id="B92"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deubzer</surname><given-names>H. E.</given-names></name><name><surname>Ehemann</surname><given-names>V.</given-names></name><name><surname>Westermann</surname><given-names>F.</given-names></name><name><surname>Heinrich</surname><given-names>R.</given-names></name><name><surname>Mechtersheimer</surname><given-names>G.</given-names></name><name><surname>Kulozik</surname><given-names>A. E.</given-names></name><etal/></person-group> (<year>2008b</year>). <article-title>Histone deacetylase inhibitor helminthosporium carbonum (HC)-toxin suppresses the malignant phenotype of neuroblastoma cells</article-title>. <source>Int. J. Cancer</source>
<volume>122</volume>, <fpage>1891</fpage>&#x02013;<lpage>1900</lpage><pub-id pub-id-type="doi">10.1002/ijc.23295</pub-id><pub-id pub-id-type="pmid">18074352</pub-id></mixed-citation></ref><ref id="B93"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donehower</surname><given-names>L. A.</given-names></name></person-group> (<year>1996</year>). <article-title>The p53-deficient mouse: a model for basic and applied cancer studies</article-title>. <source>Semin. Cancer Biol.</source>
<volume>7</volume>, <fpage>269</fpage>&#x02013;<lpage>278</lpage><pub-id pub-id-type="doi">10.1006/scbi.1996.0035</pub-id><pub-id pub-id-type="pmid">9110404</pub-id></mixed-citation></ref><ref id="B94"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dumont</surname><given-names>P.</given-names></name><name><surname>Leu</surname><given-names>J. I.</given-names></name><name><surname>Della Pietra</surname><given-names>A. C.</given-names><suffix>III</suffix></name><name><surname>George</surname><given-names>D. L.</given-names></name><name><surname>Murphy</surname><given-names>M.</given-names></name></person-group> (<year>2003</year>). <article-title>The codon 72 polymorphic variants of p53 have markedly different apoptotic potential</article-title>. <source>Nat. Genet.</source>
<volume>33</volume>, <fpage>357</fpage>&#x02013;<lpage>365</lpage><pub-id pub-id-type="doi">10.1038/ng1093</pub-id><pub-id pub-id-type="pmid">12567188</pub-id></mixed-citation></ref><ref id="B95"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duncan</surname><given-names>J. S.</given-names></name><name><surname>Litchfield</surname><given-names>D. W.</given-names></name></person-group> (<year>2008</year>). <article-title>Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2</article-title>. <source>Biochim. Biophys. Acta</source>
<volume>1784</volume>, <fpage>33</fpage>&#x02013;<lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.bbapap.2007.08.017</pub-id><pub-id pub-id-type="pmid">17931986</pub-id></mixed-citation></ref><ref id="B96"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edamura</surname><given-names>K.</given-names></name><name><surname>Nasu</surname><given-names>Y.</given-names></name><name><surname>Takaishi</surname><given-names>M.</given-names></name><name><surname>Kobayashi</surname><given-names>T.</given-names></name><name><surname>Abarzua</surname><given-names>F.</given-names></name><name><surname>Sakaguchi</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Adenovirus-mediated REIC/Dkk-3 gene transfer inhibits tumor growth and metastasis in an orthotopic prostate cancer model</article-title>. <source>Cancer Gene Ther.</source>
<volume>14</volume>, <fpage>765</fpage>&#x02013;<lpage>772</lpage><pub-id pub-id-type="doi">10.1038/sj.cgt.7701071</pub-id><pub-id pub-id-type="pmid">17599093</pub-id></mixed-citation></ref><ref id="B97"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eizenberg</surname><given-names>O.</given-names></name><name><surname>Faber-Elman</surname><given-names>A.</given-names></name><name><surname>Gottlieb</surname><given-names>E.</given-names></name><name><surname>Oren</surname><given-names>M.</given-names></name><name><surname>Rotter</surname><given-names>V.</given-names></name><name><surname>Schwartz</surname><given-names>M.</given-names></name></person-group> (<year>1996</year>). <article-title>p53 plays a regulatory role in differentiation and apoptosis of central nervous system-associated cells</article-title>. <source>Mol. Cell. Biol.</source>
<volume>16</volume>, <fpage>5178</fpage>&#x02013;<lpage>5185</lpage><pub-id pub-id-type="pmid">8756675</pub-id></mixed-citation></ref><ref id="B98"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>el-Deiry</surname><given-names>W. S.</given-names></name><name><surname>Kern</surname><given-names>S. E.</given-names></name><name><surname>Pietenpol</surname><given-names>J. A.</given-names></name><name><surname>Kinzler</surname><given-names>K. W.</given-names></name><name><surname>Vogelstein</surname><given-names>B.</given-names></name></person-group> (<year>1992</year>). <article-title>Definition of a consensus binding site for p53</article-title>. <source>Nat. Genet.</source>
<volume>1</volume>, <fpage>45</fpage>&#x02013;<lpage>49</lpage><pub-id pub-id-type="doi">10.1038/ng0492-45</pub-id><pub-id pub-id-type="pmid">1301998</pub-id></mixed-citation></ref><ref id="B99"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellen</surname><given-names>T. P.</given-names></name><name><surname>Ke</surname><given-names>Q.</given-names></name><name><surname>Zhang</surname><given-names>P.</given-names></name><name><surname>Costa</surname><given-names>M.</given-names></name></person-group> (<year>2008</year>). <article-title>NDRG1, a growth and cancer related gene: regulation of gene expression and function in normal and disease states</article-title>. <source>Carcinogenesis</source>
<volume>29</volume>, <fpage>2</fpage>&#x02013;<lpage>8</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgm200</pub-id><pub-id pub-id-type="pmid">17916902</pub-id></mixed-citation></ref><ref id="B100"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>S. C.</given-names></name><name><surname>Lozano</surname><given-names>G.</given-names></name></person-group> (<year>1997</year>). <article-title>The Li-Fraumeni syndrome: an inherited susceptibility to cancer</article-title>. <source>Mol. Med. Today</source>
<volume>3</volume>, <fpage>390</fpage>&#x02013;<lpage>395</lpage><pub-id pub-id-type="doi">10.1016/S1357-4310(97)89742-0</pub-id><pub-id pub-id-type="pmid">9302689</pub-id></mixed-citation></ref><ref id="B101"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faisal</surname><given-names>A.</given-names></name><name><surname>Vaughan</surname><given-names>L.</given-names></name><name><surname>Bavetsias</surname><given-names>V.</given-names></name><name><surname>Sun</surname><given-names>C.</given-names></name><name><surname>Atrash</surname><given-names>B.</given-names></name><name><surname>Avery</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo</article-title>. <source>Mol. Cancer Ther.</source>
<volume>10</volume>, <fpage>2115</fpage>&#x02013;<lpage>2123</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-11-0333</pub-id><pub-id pub-id-type="pmid">21885865</pub-id></mixed-citation></ref><ref id="B102"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feinberg-Gorenshtein</surname><given-names>G.</given-names></name><name><surname>Avigad</surname><given-names>S.</given-names></name><name><surname>Jeison</surname><given-names>M.</given-names></name><name><surname>Halevy-Berco</surname><given-names>G.</given-names></name><name><surname>Mardoukh</surname><given-names>J.</given-names></name><name><surname>Luria</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Reduced levels of miR-34a in neuroblastoma are not caused by mutations in the TP53 binding site</article-title>. <source>Genes Chromosomes Cancer</source>
<volume>48</volume>, <fpage>539</fpage>&#x02013;<lpage>543</lpage><pub-id pub-id-type="doi">10.1002/gcc.20662</pub-id><pub-id pub-id-type="pmid">19373781</pub-id></mixed-citation></ref><ref id="B103"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandez</surname><given-names>P. C.</given-names></name><name><surname>Frank</surname><given-names>S. R.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Schroeder</surname><given-names>M.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Greene</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2003</year>). <article-title>Genomic targets of the human c-Myc protein</article-title>. <source>Genes Dev.</source>
<volume>17</volume>, <fpage>1115</fpage>&#x02013;<lpage>1129</lpage><pub-id pub-id-type="doi">10.1101/gad.1067003</pub-id><pub-id pub-id-type="pmid">12695333</pub-id></mixed-citation></ref><ref id="B104"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferreira</surname><given-names>A.</given-names></name><name><surname>Kosik</surname><given-names>K. S.</given-names></name></person-group> (<year>1996</year>). <article-title>Accelerated neuronal differentiation induced by p53 suppression</article-title>. <source>J. Cell. Sci.</source>
<volume>109</volume> (<issue>Pt 6</issue>), <fpage>1509</fpage>&#x02013;<lpage>1516</lpage><pub-id pub-id-type="pmid">8799837</pub-id></mixed-citation></ref><ref id="B105"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flahaut</surname><given-names>M.</given-names></name><name><surname>Meier</surname><given-names>R.</given-names></name><name><surname>Coulon</surname><given-names>A.</given-names></name><name><surname>Nardou</surname><given-names>K. A.</given-names></name><name><surname>Niggli</surname><given-names>F. K.</given-names></name><name><surname>Martinet</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt/beta-catenin pathway</article-title>. <source>Oncogene</source>
<volume>28</volume>, <fpage>2245</fpage>&#x02013;<lpage>2256</lpage><pub-id pub-id-type="doi">10.1038/onc.2009.80</pub-id><pub-id pub-id-type="pmid">19421142</pub-id></mixed-citation></ref><ref id="B106"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forbes</surname><given-names>S. A.</given-names></name><name><surname>Bhamra</surname><given-names>G.</given-names></name><name><surname>Bamford</surname><given-names>S.</given-names></name><name><surname>Dawson</surname><given-names>E.</given-names></name><name><surname>Kok</surname><given-names>C.</given-names></name><name><surname>Clements</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>The catalogue of somatic mutations in cancer (COSMIC)</article-title>. <source>Curr. Protoc. Hum. Genet.</source>
<volume>10</volume>, Unit 10 11.<pub-id pub-id-type="pmid">18428421</pub-id></mixed-citation></ref><ref id="B107"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frescas</surname><given-names>D.</given-names></name><name><surname>Pagano</surname><given-names>M.</given-names></name></person-group> (<year>2008</year>). <article-title>Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer</article-title>. <source>Nat. Rev. Cancer</source>
<volume>8</volume>, <fpage>438</fpage>&#x02013;<lpage>449</lpage><pub-id pub-id-type="doi">10.1038/nrc2396</pub-id><pub-id pub-id-type="pmid">18500245</pub-id></mixed-citation></ref><ref id="B108"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujita</surname><given-names>T.</given-names></name><name><surname>Igarashi</surname><given-names>J.</given-names></name><name><surname>Okawa</surname><given-names>E. R.</given-names></name><name><surname>Gotoh</surname><given-names>T.</given-names></name><name><surname>Manne</surname><given-names>J.</given-names></name><name><surname>Kolla</surname><given-names>V.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas</article-title>. <source>J. Natl. Cancer Inst.</source>
<volume>100</volume>, <fpage>940</fpage>&#x02013;<lpage>949</lpage><pub-id pub-id-type="doi">10.1093/jnci/djn176</pub-id><pub-id pub-id-type="pmid">18577749</pub-id></mixed-citation></ref><ref id="B109"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fulda</surname><given-names>S.</given-names></name><name><surname>Lutz</surname><given-names>W.</given-names></name><name><surname>Schwab</surname><given-names>M.</given-names></name><name><surname>Debatin</surname><given-names>K. M.</given-names></name></person-group> (<year>1999</year>). <article-title>MycN sensitizes neuroblastoma cells for drug-induced apoptosis</article-title>. <source>Oncogene</source>
<volume>18</volume>, <fpage>1479</fpage>&#x02013;<lpage>1486</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1202435</pub-id><pub-id pub-id-type="pmid">10050884</pub-id></mixed-citation></ref><ref id="B110"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fulda</surname><given-names>S.</given-names></name><name><surname>Lutz</surname><given-names>W.</given-names></name><name><surname>Schwab</surname><given-names>M.</given-names></name><name><surname>Debatin</surname><given-names>K. M.</given-names></name></person-group> (<year>2000</year>). <article-title>MycN sensitizes neuroblastoma cells for drug-triggered apoptosis</article-title>. <source>Med. Pediatr. Oncol.</source>
<volume>35</volume>, <fpage>582</fpage>&#x02013;<lpage>584</lpage><pub-id pub-id-type="doi">10.1002/1096-911X(20001201)35:6&#x0003c;582::AID-MPO19&#x0003e;3.0.CO;2-2</pub-id><pub-id pub-id-type="pmid">11107122</pub-id></mixed-citation></ref><ref id="B111"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gamble</surname><given-names>L. D.</given-names></name><name><surname>Kees</surname><given-names>U. R.</given-names></name><name><surname>Tweddle</surname><given-names>D. A.</given-names></name><name><surname>Lunec</surname><given-names>J.</given-names></name></person-group> (<year>2012</year>). <article-title>MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63</article-title>. <source>Oncogene</source>
<volume>31</volume>, <fpage>752</fpage>&#x02013;<lpage>763</lpage><pub-id pub-id-type="doi">10.1038/onc.2011.270</pub-id><pub-id pub-id-type="pmid">21725357</pub-id></mixed-citation></ref><ref id="B112"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ganoth</surname><given-names>D.</given-names></name><name><surname>Bornstein</surname><given-names>G.</given-names></name><name><surname>Ko</surname><given-names>T. K.</given-names></name><name><surname>Larsen</surname><given-names>B.</given-names></name><name><surname>Tyers</surname><given-names>M.</given-names></name><name><surname>Pagano</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2001</year>). <article-title>The cell-cycle regulatory protein Cks1 is required for SCF(Skp2)-mediated ubiquitinylation of p27</article-title>. <source>Nat. Cell Biol.</source>
<volume>3</volume>, <fpage>321</fpage>&#x02013;<lpage>324</lpage><pub-id pub-id-type="doi">10.1038/35060126</pub-id><pub-id pub-id-type="pmid">11231585</pub-id></mixed-citation></ref><ref id="B113"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Georges</surname><given-names>S. A.</given-names></name><name><surname>Biery</surname><given-names>M. C.</given-names></name><name><surname>Kim</surname><given-names>S. Y.</given-names></name><name><surname>Schelter</surname><given-names>J. M.</given-names></name><name><surname>Guo</surname><given-names>J.</given-names></name><name><surname>Chang</surname><given-names>A. N.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Coordinated regulation of cell cycle transcripts by p53-Inducible microRNAs, miR-192 and miR-215</article-title>. <source>Cancer Res.</source>
<volume>68</volume>, <fpage>10105</fpage>&#x02013;<lpage>10112</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-1846</pub-id><pub-id pub-id-type="pmid">19074876</pub-id></mixed-citation></ref><ref id="B114"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gizard</surname><given-names>F.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Findeisen</surname><given-names>H. M.</given-names></name><name><surname>Qing</surname><given-names>H.</given-names></name><name><surname>Cohn</surname><given-names>D.</given-names></name><name><surname>Heywood</surname><given-names>E. B.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Transcriptional regulation of S phase kinase-associated protein 2 by NR4A orphan nuclear receptor NOR1 in vascular smooth muscle cells</article-title>. <source>J. Biol. Chem.</source>
<volume>286</volume>, <fpage>35485</fpage>&#x02013;<lpage>35493</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.295840</pub-id><pub-id pub-id-type="pmid">21868379</pub-id></mixed-citation></ref><ref id="B115"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldman</surname><given-names>S. C.</given-names></name><name><surname>Chen</surname><given-names>C. Y.</given-names></name><name><surname>Lansing</surname><given-names>T. J.</given-names></name><name><surname>Gilmer</surname><given-names>T. M.</given-names></name><name><surname>Kastan</surname><given-names>M. B.</given-names></name></person-group> (<year>1996</year>). <article-title>The p53 signal transduction pathway is intact in human neuroblastoma despite cytoplasmic localization</article-title>. <source>Am. J. Pathol.</source>
<volume>148</volume>, <fpage>1381</fpage>&#x02013;<lpage>1385</lpage><pub-id pub-id-type="pmid">8623910</pub-id></mixed-citation></ref><ref id="B116"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldschneider</surname><given-names>D.</given-names></name><name><surname>Blanc</surname><given-names>E.</given-names></name><name><surname>Raguenez</surname><given-names>G.</given-names></name><name><surname>Barrois</surname><given-names>M.</given-names></name><name><surname>Legrand</surname><given-names>A.</given-names></name><name><surname>Le Roux</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Differential response of p53 target genes to p73 overexpression in SH-SY5Y neuroblastoma cell line</article-title>. <source>J. Cell. Sci.</source>
<volume>117</volume>, <fpage>293</fpage>&#x02013;<lpage>301</lpage><pub-id pub-id-type="doi">10.1242/jcs.00834</pub-id><pub-id pub-id-type="pmid">14676279</pub-id></mixed-citation></ref><ref id="B117"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldschneider</surname><given-names>D.</given-names></name><name><surname>Horvilleur</surname><given-names>E.</given-names></name><name><surname>Plassa</surname><given-names>L.-F.</given-names></name><name><surname>Guillaud-Bataille</surname><given-names>M.</given-names></name><name><surname>Million</surname><given-names>K.</given-names></name><name><surname>Wittmer-Dupret</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Expression of C-terminal deleted p53 isoforms in neuroblastoma</article-title>. <source>Nucleic Acids Res.</source>
<volume>34</volume>, <fpage>5603</fpage>&#x02013;<lpage>5612</lpage><pub-id pub-id-type="doi">10.1093/nar/gkl619</pub-id><pub-id pub-id-type="pmid">17028100</pub-id></mixed-citation></ref><ref id="B118"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez-Gomez</surname><given-names>P.</given-names></name><name><surname>Bello</surname><given-names>M. J.</given-names></name><name><surname>Lomas</surname><given-names>J.</given-names></name><name><surname>Arjona</surname><given-names>D.</given-names></name><name><surname>Alonso</surname><given-names>M. E.</given-names></name><name><surname>Aminoso</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2003</year>). <article-title>Aberrant methylation of multiple genes in neuroblastic tumours. Relationship with MYCN amplification and allelic status at 1p</article-title>. <source>Eur. J. Cancer</source>
<volume>39</volume>, <fpage>1478</fpage>&#x02013;<lpage>1485</lpage><pub-id pub-id-type="doi">10.1016/S0959-8049(03)00312-5</pub-id><pub-id pub-id-type="pmid">12826052</pub-id></mixed-citation></ref><ref id="B119"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goto</surname><given-names>S.</given-names></name><name><surname>Umehara</surname><given-names>S.</given-names></name><name><surname>Gerbing</surname><given-names>R. B.</given-names></name><name><surname>Stram</surname><given-names>D. O.</given-names></name><name><surname>Brodeur</surname><given-names>G. M.</given-names></name><name><surname>Seeger</surname><given-names>R. C.</given-names></name><etal/></person-group> (<year>2001</year>). <article-title>Histopathology (international neuroblastoma pathology classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the children&#x02019;s cancer group</article-title>. <source>Cancer</source>
<volume>92</volume>, <fpage>2699</fpage>&#x02013;<lpage>2708</lpage><pub-id pub-id-type="doi">10.1002/1097-0142(20011115)92:10&#x0003c;2699::AID-CNCR1624&#x0003e;3.0.CO;2-A</pub-id><pub-id pub-id-type="pmid">11745206</pub-id></mixed-citation></ref><ref id="B120"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grandori</surname><given-names>C.</given-names></name><name><surname>Cowley</surname><given-names>S. M.</given-names></name><name><surname>James</surname><given-names>L. P.</given-names></name><name><surname>Eisenman</surname><given-names>R. N.</given-names></name></person-group> (<year>2000</year>). <article-title>The Myc/Max/Mad network and the transcriptional control of cell behavior</article-title>. <source>Annu. Rev. Cell Dev. Biol.</source>
<volume>16</volume>, <fpage>653</fpage>&#x02013;<lpage>699</lpage><pub-id pub-id-type="doi">10.1146/annurev.cellbio.16.1.653</pub-id><pub-id pub-id-type="pmid">11031250</pub-id></mixed-citation></ref><ref id="B121"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grimmer</surname><given-names>M. R.</given-names></name><name><surname>Weiss</surname><given-names>W. A.</given-names></name></person-group> (<year>2006</year>). <article-title>Childhood tumors of the nervous system as disorders of normal development</article-title>. <source>Curr. Opin. Pediatr.</source>
<volume>18</volume>, <fpage>634</fpage>&#x02013;<lpage>638</lpage><pub-id pub-id-type="doi">10.1097/MOP.0b013e32801080fe</pub-id><pub-id pub-id-type="pmid">17099362</pub-id></mixed-citation></ref><ref id="B122"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>He</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Huang</surname><given-names>M.</given-names></name><name><surname>Zhou</surname><given-names>M.</given-names></name></person-group> (<year>2012</year>). <article-title>MDM2 regulates MYCN mRNA stabilization and translation in human neuroblastoma cells</article-title>. <source>Oncogene</source>
<volume>31</volume>, <fpage>1342</fpage>&#x02013;<lpage>1353</lpage><pub-id pub-id-type="doi">10.1038/onc.2011.343</pub-id><pub-id pub-id-type="pmid">21822304</pub-id></mixed-citation></ref><ref id="B123"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>Y. M.</given-names></name><name><surname>Ma</surname><given-names>Y. H.</given-names></name><name><surname>Zhao</surname><given-names>W. G.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name></person-group> (<year>2011</year>). <article-title>Dickkopf3 overexpression inhibits pancreatic cancer cell growth in vitro</article-title>. <source>World J. Gastroenterol.</source>
<volume>17</volume>, <fpage>3810</fpage>&#x02013;<lpage>3817</lpage><pub-id pub-id-type="doi">10.3748/wjg.v17.i34.3922</pub-id><pub-id pub-id-type="pmid">21987623</pub-id></mixed-citation></ref><ref id="B124"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gustafson</surname><given-names>W. C.</given-names></name><name><surname>Weiss</surname><given-names>W. A.</given-names></name></person-group> (<year>2010</year>). <article-title>Myc proteins as therapeutic targets</article-title>. <source>Oncogene</source>
<volume>29</volume>, <fpage>1249</fpage>&#x02013;<lpage>1259</lpage><pub-id pub-id-type="doi">10.1038/onc.2009.512</pub-id><pub-id pub-id-type="pmid">20101214</pub-id></mixed-citation></ref><ref id="B125"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamamori</surname><given-names>Y.</given-names></name><name><surname>Sartorelli</surname><given-names>V.</given-names></name><name><surname>Ogryzko</surname><given-names>V.</given-names></name><name><surname>Puri</surname><given-names>P. L.</given-names></name><name><surname>Wu</surname><given-names>H. Y.</given-names></name><name><surname>Wang</surname><given-names>J. Y.</given-names></name><etal/></person-group> (<year>1999</year>). <article-title>Regulation of histone acetyltransferases p300 and PCAF by the bHLH protein twist and adenoviral oncoprotein E1A</article-title>. <source>Cell</source>
<volume>96</volume>, <fpage>405</fpage>&#x02013;<lpage>413</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)80553-X</pub-id><pub-id pub-id-type="pmid">10025406</pub-id></mixed-citation></ref><ref id="B126"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamner</surname><given-names>J. B.</given-names></name><name><surname>Dickson</surname><given-names>P. V.</given-names></name><name><surname>Sims</surname><given-names>T. L.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>Spence</surname><given-names>Y.</given-names></name><name><surname>Ng</surname><given-names>C. Y.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Bortezomib inhibits angiogenesis and reduces tumor burden in a murine model of neuroblastoma</article-title>. <source>Surgery</source>
<volume>142</volume>, <fpage>185</fpage>&#x02013;<lpage>191</lpage><pub-id pub-id-type="doi">10.1016/j.surg.2007.04.012</pub-id><pub-id pub-id-type="pmid">17689684</pub-id></mixed-citation></ref><ref id="B127"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanel</surname><given-names>W.</given-names></name><name><surname>Moll</surname><given-names>U. M.</given-names></name></person-group> (<year>2012</year>). <article-title>Links between mutant p53 and genomic instability</article-title>. <source>J. Cell. Biochem.</source>
<volume>113</volume>, <fpage>433</fpage>&#x02013;<lpage>439</lpage><pub-id pub-id-type="doi">10.1002/jcb.23400</pub-id><pub-id pub-id-type="pmid">22006292</pub-id></mixed-citation></ref><ref id="B128"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hardcastle</surname><given-names>I. R.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Valeur</surname><given-names>E.</given-names></name><name><surname>Watson</surname><given-names>A.</given-names></name><name><surname>Ahmed</surname><given-names>S. U.</given-names></name><name><surname>Blackburn</surname><given-names>T. J.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: structure-activity studies leading to improved potency</article-title>. <source>J. Med. Chem.</source>
<volume>54</volume>, <fpage>1233</fpage>&#x02013;<lpage>1243</lpage><pub-id pub-id-type="doi">10.1021/jm1011929</pub-id><pub-id pub-id-type="pmid">21314128</pub-id></mixed-citation></ref><ref id="B129"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harms</surname><given-names>K.</given-names></name><name><surname>Nozell</surname><given-names>S.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name></person-group> (<year>2004</year>). <article-title>The common and distinct target genes of the p53 family transcription factors</article-title>. <source>Cell. Mol. Life Sci.</source>
<volume>61</volume>, <fpage>822</fpage>&#x02013;<lpage>842</lpage><pub-id pub-id-type="doi">10.1007/s00018-003-3304-4</pub-id><pub-id pub-id-type="pmid">15095006</pub-id></mixed-citation></ref><ref id="B130"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haug</surname><given-names>B. H.</given-names></name><name><surname>Henriksen</surname><given-names>J. R.</given-names></name><name><surname>Buechner</surname><given-names>J.</given-names></name><name><surname>Geerts</surname><given-names>D.</given-names></name><name><surname>Tomte</surname><given-names>E.</given-names></name><name><surname>Kogner</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>MYCN-regulated miRNA-92 inhibits secretion of the tumor suppressor DICKKOPF-3 (DKK3) in neuroblastoma</article-title>. <source>Carcinogenesis</source>
<volume>32</volume>, <fpage>1005</fpage>&#x02013;<lpage>1012</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgr073</pub-id><pub-id pub-id-type="pmid">21572098</pub-id></mixed-citation></ref><ref id="B131"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>L.</given-names></name><name><surname>He</surname><given-names>X.</given-names></name><name><surname>Lim</surname><given-names>L. P.</given-names></name><name><surname>De Stanchina</surname><given-names>E.</given-names></name><name><surname>Xuan</surname><given-names>Z.</given-names></name><name><surname>Liang</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>A microRNA component of the p53 tumour suppressor network</article-title>. <source>Nature</source>
<volume>447</volume>, <fpage>1130</fpage>&#x02013;<lpage>1134</lpage><pub-id pub-id-type="doi">10.1038/nature05939</pub-id><pub-id pub-id-type="pmid">17554337</pub-id></mixed-citation></ref><ref id="B132"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hermeking</surname><given-names>H.</given-names></name></person-group> (<year>2007</year>). <article-title>p53 enters the microRNA world</article-title>. <source>Cancer Cell</source>
<volume>12</volume>, <fpage>414</fpage>&#x02013;<lpage>418</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2007.10.028</pub-id><pub-id pub-id-type="pmid">17996645</pub-id></mixed-citation></ref><ref id="B133"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hermeking</surname><given-names>H.</given-names></name><name><surname>Eick</surname><given-names>D.</given-names></name></person-group> (<year>1994</year>). <article-title>Mediation of c-Myc-induced apoptosis by p53</article-title>. <source>Science</source>
<volume>265</volume>, <fpage>2091</fpage>&#x02013;<lpage>2093</lpage><pub-id pub-id-type="doi">10.1126/science.8091232</pub-id><pub-id pub-id-type="pmid">8091232</pub-id></mixed-citation></ref><ref id="B134"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hershko</surname><given-names>D. D.</given-names></name></person-group> (<year>2008</year>). <article-title>Oncogenic properties and prognostic implications of the ubiquitin ligase Skp2 in cancer</article-title>. <source>Cancer</source>
<volume>112</volume>, <fpage>1415</fpage>&#x02013;<lpage>1424</lpage><pub-id pub-id-type="doi">10.1002/cncr.23317</pub-id><pub-id pub-id-type="pmid">18260093</pub-id></mixed-citation></ref><ref id="B135"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hiramatsu</surname><given-names>Y.</given-names></name><name><surname>Kitagawa</surname><given-names>K.</given-names></name><name><surname>Suzuki</surname><given-names>T.</given-names></name><name><surname>Uchida</surname><given-names>C.</given-names></name><name><surname>Hattori</surname><given-names>T.</given-names></name><name><surname>Kikuchi</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Degradation of Tob1 mediated by SCFSkp2-dependent ubiquitination</article-title>. <source>Cancer Res.</source>
<volume>66</volume>, <fpage>8477</fpage>&#x02013;<lpage>8483</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-1603</pub-id><pub-id pub-id-type="pmid">16951159</pub-id></mixed-citation></ref><ref id="B136"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirata</surname><given-names>T.</given-names></name><name><surname>Watanabe</surname><given-names>M.</given-names></name><name><surname>Kaku</surname><given-names>H.</given-names></name><name><surname>Kobayashi</surname><given-names>Y.</given-names></name><name><surname>Yamada</surname><given-names>H.</given-names></name><name><surname>Sakaguchi</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>REIC/Dkk-3-encoding adenoviral vector as a potentially effective therapeutic agent for bladder cancer</article-title>. <source>Int. J. Oncol.</source>
<volume>41</volume>, <fpage>559</fpage>&#x02013;<lpage>564</lpage><pub-id pub-id-type="pmid">22665039</pub-id></mixed-citation></ref><ref id="B137"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoehner</surname><given-names>J. C.</given-names></name><name><surname>Gestblom</surname><given-names>C.</given-names></name><name><surname>Olsen</surname><given-names>L.</given-names></name><name><surname>Pahlman</surname><given-names>S.</given-names></name></person-group> (<year>1997</year>). <article-title>Spatial association of apoptosis-related gene expression and cellular death in clinical neuroblastoma</article-title>. <source>Br. J. Cancer</source>
<volume>75</volume>, <fpage>1185</fpage>&#x02013;<lpage>1194</lpage><pub-id pub-id-type="doi">10.1038/bjc.1997.203</pub-id><pub-id pub-id-type="pmid">9099968</pub-id></mixed-citation></ref><ref id="B138"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hogarty</surname><given-names>M. D.</given-names></name></person-group> (<year>2003</year>). <article-title>The requirement for evasion of programmed cell death in neuroblastomas with MYCN amplification</article-title>. <source>Cancer Lett.</source>
<volume>197</volume>, <fpage>173</fpage>&#x02013;<lpage>179</lpage><pub-id pub-id-type="doi">10.1016/S0304-3835(03)00103-4</pub-id><pub-id pub-id-type="pmid">12880978</pub-id></mixed-citation></ref><ref id="B139"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Honda</surname><given-names>R.</given-names></name><name><surname>Tanaka</surname><given-names>H.</given-names></name><name><surname>Yasuda</surname><given-names>H.</given-names></name></person-group> (<year>1997</year>). <article-title>Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53</article-title>. <source>FEBS Lett.</source>
<volume>420</volume>, <fpage>25</fpage>&#x02013;<lpage>27</lpage><pub-id pub-id-type="doi">10.1016/S0014-5793(97)01480-4</pub-id><pub-id pub-id-type="pmid">9450543</pub-id></mixed-citation></ref><ref id="B140"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Honda</surname><given-names>R.</given-names></name><name><surname>Yasuda</surname><given-names>H.</given-names></name></person-group> (<year>1999</year>). <article-title>Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53</article-title>. <source>EMBO J.</source>
<volume>18</volume>, <fpage>22</fpage>&#x02013;<lpage>27</lpage><pub-id pub-id-type="doi">10.1093/emboj/18.1.22</pub-id><pub-id pub-id-type="pmid">9878046</pub-id></mixed-citation></ref><ref id="B141"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hosoi</surname><given-names>G.</given-names></name><name><surname>Hara</surname><given-names>J.</given-names></name><name><surname>Okamura</surname><given-names>T.</given-names></name><name><surname>Osugi</surname><given-names>Y.</given-names></name><name><surname>Ishihara</surname><given-names>S.</given-names></name><name><surname>Fukuzawa</surname><given-names>M.</given-names></name><etal/></person-group> (<year>1994</year>). <article-title>Low frequency of the p53 gene mutations in neuroblastoma</article-title>. <source>Cancer</source>
<volume>73</volume>, <fpage>3087</fpage>&#x02013;<lpage>3093</lpage><pub-id pub-id-type="doi">10.1002/1097-0142(19940615)73:12&#x0003c;3087::AID-CNCR2820731230&#x0003e;3.0.CO;2-9</pub-id><pub-id pub-id-type="pmid">8200007</pub-id></mixed-citation></ref><ref id="B142"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsieh</surname><given-names>S. Y.</given-names></name><name><surname>Hsieh</surname><given-names>P. S.</given-names></name><name><surname>Chiu</surname><given-names>C. T.</given-names></name><name><surname>Chen</surname><given-names>W. Y.</given-names></name></person-group> (<year>2004</year>). <article-title>Dickkopf-3/REIC functions as a suppressor gene of tumor growth</article-title>. <source>Oncogene</source>
<volume>23</volume>, <fpage>9183</fpage>&#x02013;<lpage>9189</lpage><pub-id pub-id-type="pmid">15516983</pub-id></mixed-citation></ref><ref id="B143"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>D.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Wu</surname><given-names>G.</given-names></name><name><surname>Wan</surname><given-names>Y.</given-names></name></person-group> (<year>2011</year>). <article-title>Nuclear translocation of Skp2 facilitates its destruction in response to TGFbeta signaling</article-title>. <source>Cell Cycle</source>
<volume>10</volume>, <fpage>285</fpage>&#x02013;<lpage>292</lpage><pub-id pub-id-type="doi">10.4161/cc.10.12.16008</pub-id><pub-id pub-id-type="pmid">21212736</pub-id></mixed-citation></ref><ref id="B144"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Hao</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Meng</surname><given-names>S.</given-names></name></person-group> (<year>2012</year>). <article-title>MiR-122 in hepatic function and liver diseases</article-title>. <source>Protein Cell</source>
<volume>3</volume>, <fpage>364</fpage>&#x02013;<lpage>371</lpage><pub-id pub-id-type="doi">10.1007/s13238-012-2036-3</pub-id><pub-id pub-id-type="pmid">22610888</pub-id></mixed-citation></ref><ref id="B145"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>H.</given-names></name><name><surname>Zhao</surname><given-names>W.</given-names></name><name><surname>Yang</surname><given-names>D.</given-names></name></person-group> (<year>2012</year>). <article-title>Stat3 induces oncogenic Skp2 expression in human cervical carcinoma cells</article-title>. <source>Biochem. Biophys. Res. Commun.</source>
<volume>418</volume>, <fpage>186</fpage>&#x02013;<lpage>190</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2012.01.001</pub-id><pub-id pub-id-type="pmid">22252296</pub-id></mixed-citation></ref><ref id="B146"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>H. C.</given-names></name><name><surname>Lin</surname><given-names>C. L.</given-names></name><name><surname>Lin</surname><given-names>J. K.</given-names></name></person-group> (<year>2011a</year>). <article-title>1,2,3,4,6-penta-O-galloyl-beta-<sc>d</sc>-glucose, quercetin, curcumin and lycopene induce cell-cycle arrest in MDA-MB-231 and BT474 cells through downregulation of Skp2 protein</article-title>. <source>J. Agric. Food Chem.</source>
<volume>59</volume>, <fpage>6765</fpage>&#x02013;<lpage>6775</lpage><pub-id pub-id-type="doi">10.1021/jf103725f</pub-id><pub-id pub-id-type="pmid">21598989</pub-id></mixed-citation></ref><ref id="B147"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>R.</given-names></name><name><surname>Cheung</surname><given-names>N. K.</given-names></name><name><surname>Vider</surname><given-names>J.</given-names></name><name><surname>Cheung</surname><given-names>I. Y.</given-names></name><name><surname>Gerald</surname><given-names>W. L.</given-names></name><name><surname>Tickoo</surname><given-names>S. K.</given-names></name><etal/></person-group> (<year>2011b</year>). <article-title>MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas</article-title>. <source>FASEB J.</source>
<volume>25</volume>, <fpage>4138</fpage>&#x02013;<lpage>4149</lpage><pub-id pub-id-type="doi">10.1096/fj.11-185033</pub-id><pub-id pub-id-type="pmid">21856782</pub-id></mixed-citation></ref><ref id="B148"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huber</surname><given-names>O.</given-names></name><name><surname>Menard</surname><given-names>L.</given-names></name><name><surname>Haurie</surname><given-names>V.</given-names></name><name><surname>Nicou</surname><given-names>A.</given-names></name><name><surname>Taras</surname><given-names>D.</given-names></name><name><surname>Rosenbaum</surname><given-names>J.</given-names></name></person-group> (<year>2008</year>). <article-title>Pontin and reptin, two related ATPases with multiple roles in cancer</article-title>. <source>Cancer Res.</source>
<volume>68</volume>, <fpage>6873</fpage>&#x02013;<lpage>6876</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-0547</pub-id><pub-id pub-id-type="pmid">18757398</pub-id></mixed-citation></ref><ref id="B149"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ille</surname><given-names>F.</given-names></name><name><surname>Sommer</surname><given-names>L.</given-names></name></person-group> (<year>2005</year>). <article-title>Wnt signaling: multiple functions in neural development</article-title>. <source>Cell. Mol. Life Sci.</source>
<volume>62</volume>, <fpage>1100</fpage>&#x02013;<lpage>1108</lpage><pub-id pub-id-type="doi">10.1007/s00018-005-4552-2</pub-id><pub-id pub-id-type="pmid">15928805</pub-id></mixed-citation></ref><ref id="B150"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imaki</surname><given-names>H.</given-names></name><name><surname>Nakayama</surname><given-names>K.</given-names></name><name><surname>Delehouzee</surname><given-names>S.</given-names></name><name><surname>Handa</surname><given-names>H.</given-names></name><name><surname>Kitagawa</surname><given-names>M.</given-names></name><name><surname>Kamura</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2003</year>). <article-title>Cell cycle-dependent regulation of the Skp2 promoter by GA-binding protein</article-title>. <source>Cancer Res.</source>
<volume>63</volume>, <fpage>4607</fpage>&#x02013;<lpage>4613</lpage><pub-id pub-id-type="pmid">12907639</pub-id></mixed-citation></ref><ref id="B151"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imamura</surname><given-names>J.</given-names></name><name><surname>Bartram</surname><given-names>C. R.</given-names></name><name><surname>Berthold</surname><given-names>F.</given-names></name><name><surname>Harms</surname><given-names>D.</given-names></name><name><surname>Nakamura</surname><given-names>H.</given-names></name><name><surname>Koeffler</surname><given-names>H. P.</given-names></name></person-group> (<year>1993</year>). <article-title>Mutation of the p53 gene in neuroblastoma and its relationship with N-myc amplification</article-title>. <source>Cancer Res.</source>
<volume>53</volume>, <fpage>4053</fpage>&#x02013;<lpage>4058</lpage><pub-id pub-id-type="pmid">8358734</pub-id></mixed-citation></ref><ref id="B152"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inuzuka</surname><given-names>H.</given-names></name><name><surname>Gao</surname><given-names>D.</given-names></name><name><surname>Finley</surname><given-names>L. W.</given-names></name><name><surname>Yang</surname><given-names>W.</given-names></name><name><surname>Wan</surname><given-names>L.</given-names></name><name><surname>Fukushima</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Acetylation-dependent regulation of skp2 function</article-title>. <source>Cell</source>
<volume>150</volume>, <fpage>179</fpage>&#x02013;<lpage>193</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.05.038</pub-id><pub-id pub-id-type="pmid">22770219</pub-id></mixed-citation></ref><ref id="B153"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isaacs</surname><given-names>J. S.</given-names></name><name><surname>Hardman</surname><given-names>R.</given-names></name><name><surname>Carman</surname><given-names>T. A.</given-names></name><name><surname>Barrett</surname><given-names>J. C.</given-names></name><name><surname>Weissman</surname><given-names>B. E.</given-names></name></person-group> (<year>1998</year>). <article-title>Differential subcellular p53 localization and function in N- and S-type neuroblastoma cell lines</article-title>. <source>Cell Growth Differ.</source>
<volume>9</volume>, <fpage>545</fpage>&#x02013;<lpage>555</lpage><pub-id pub-id-type="pmid">9690622</pub-id></mixed-citation></ref><ref id="B154"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishii</surname><given-names>T.</given-names></name><name><surname>Matsuse</surname><given-names>T.</given-names></name><name><surname>Masuda</surname><given-names>M.</given-names></name><name><surname>Teramoto</surname><given-names>S.</given-names></name></person-group> (<year>2004</year>). <article-title>The effects of S-phase kinase-associated protein 2 (SKP2) on cell cycle status, viability, and chemoresistance in A549 lung adenocarcinoma cells</article-title>. <source>Exp. Lung Res.</source>
<volume>30</volume>, <fpage>687</fpage>&#x02013;<lpage>703</lpage><pub-id pub-id-type="doi">10.1080/01902140490517818</pub-id><pub-id pub-id-type="pmid">15700547</pub-id></mixed-citation></ref><ref id="B155"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>P.</given-names></name><name><surname>Goldin</surname><given-names>L.</given-names></name><name><surname>Ren</surname><given-names>H.</given-names></name><name><surname>Sun</surname><given-names>D.</given-names></name><name><surname>Guardavaccaro</surname><given-names>D.</given-names></name><name><surname>Pagano</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Skp2 contains a novel cyclin A binding domain that directly protects cyclin A from inhibition by p27Kip1</article-title>. <source>J. Biol. Chem.</source>
<volume>281</volume>, <fpage>24058</fpage>&#x02013;<lpage>24069</lpage><pub-id pub-id-type="doi">10.1074/jbc.M603105200</pub-id><pub-id pub-id-type="pmid">16774918</pub-id></mixed-citation></ref><ref id="B156"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>F.</given-names></name><name><surname>Caraway</surname><given-names>N. P.</given-names></name><name><surname>Li</surname><given-names>R.</given-names></name><name><surname>Katz</surname><given-names>R. L.</given-names></name></person-group> (<year>2005</year>). <article-title>RNA silencing of S-phase kinase-interacting protein 2 inhibits proliferation and centrosome amplification in lung cancer cells</article-title>. <source>Oncogene</source>
<volume>24</volume>, <fpage>3409</fpage>&#x02013;<lpage>3418</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1208459</pub-id><pub-id pub-id-type="pmid">15735730</pub-id></mixed-citation></ref><ref id="B157"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jimenez</surname><given-names>G. S.</given-names></name><name><surname>Khan</surname><given-names>S. H.</given-names></name><name><surname>Stommel</surname><given-names>J. M.</given-names></name><name><surname>Wahl</surname><given-names>G. M.</given-names></name></person-group> (<year>1999</year>). <article-title>p53 regulation by post-translational modification and nuclear retention in response to diverse stresses</article-title>. <source>Oncogene</source>
<volume>18</volume>, <fpage>7656</fpage>&#x02013;<lpage>7665</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1203013</pub-id><pub-id pub-id-type="pmid">10618705</pub-id></mixed-citation></ref><ref id="B158"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnsen</surname><given-names>J. I.</given-names></name><name><surname>Kogner</surname><given-names>P.</given-names></name><name><surname>Albihn</surname><given-names>A.</given-names></name><name><surname>Henriksson</surname><given-names>M. A.</given-names></name></person-group> (<year>2009</year>). <article-title>Embryonal neural tumours and cell death</article-title>. <source>Apoptosis</source>
<volume>14</volume>, <fpage>424</fpage>&#x02013;<lpage>438</lpage><pub-id pub-id-type="doi">10.1007/s10495-009-0325-y</pub-id><pub-id pub-id-type="pmid">19259824</pub-id></mixed-citation></ref><ref id="B159"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>S. N.</given-names></name><name><surname>Hancock</surname><given-names>A. R.</given-names></name><name><surname>Vogel</surname><given-names>H.</given-names></name><name><surname>Donehower</surname><given-names>L. A.</given-names></name><name><surname>Bradley</surname><given-names>A.</given-names></name></person-group> (<year>1998</year>). <article-title>Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>95</volume>, <fpage>15608</fpage>&#x02013;<lpage>15612</lpage><pub-id pub-id-type="doi">10.1073/pnas.95.26.15608</pub-id><pub-id pub-id-type="pmid">9861017</pub-id></mixed-citation></ref><ref id="B160"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>S. N.</given-names></name><name><surname>Roe</surname><given-names>A. E.</given-names></name><name><surname>Donehower</surname><given-names>L. A.</given-names></name><name><surname>Bradley</surname><given-names>A.</given-names></name></person-group> (<year>1995</year>). <article-title>Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53</article-title>. <source>Nature</source>
<volume>378</volume>, <fpage>206</fpage>&#x02013;<lpage>208</lpage><pub-id pub-id-type="doi">10.1038/378562b0</pub-id><pub-id pub-id-type="pmid">7477327</pub-id></mixed-citation></ref><ref id="B161"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Junttila</surname><given-names>M. R.</given-names></name><name><surname>Evan</surname><given-names>G. I.</given-names></name></person-group> (<year>2009</year>). <article-title>p53 &#x02013; a Jack of all trades but master of none</article-title>. <source>Nat. Rev. Cancer</source>
<volume>9</volume>, <fpage>821</fpage>&#x02013;<lpage>829</lpage><pub-id pub-id-type="doi">10.1038/nrc2728</pub-id><pub-id pub-id-type="pmid">19776747</pub-id></mixed-citation></ref><ref id="B162"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaghad</surname><given-names>M.</given-names></name><name><surname>Bonnet</surname><given-names>H.</given-names></name><name><surname>Yang</surname><given-names>A.</given-names></name><name><surname>Creancier</surname><given-names>L.</given-names></name><name><surname>Biscan</surname><given-names>J. C.</given-names></name><name><surname>Valent</surname><given-names>A.</given-names></name><etal/></person-group> (<year>1997</year>). <article-title>Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers</article-title>. <source>Cell</source>
<volume>90</volume>, <fpage>809</fpage>&#x02013;<lpage>819</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)80540-1</pub-id><pub-id pub-id-type="pmid">9288759</pub-id></mixed-citation></ref><ref id="B163"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamijo</surname><given-names>T.</given-names></name><name><surname>Bodner</surname><given-names>S.</given-names></name><name><surname>Van De Kamp</surname><given-names>E.</given-names></name><name><surname>Randle</surname><given-names>D. H.</given-names></name><name><surname>Sherr</surname><given-names>C. J.</given-names></name></person-group> (<year>1999</year>). <article-title>Tumor spectrum in ARF-deficient mice</article-title>. <source>Cancer Res.</source>
<volume>59</volume>, <fpage>2217</fpage>&#x02013;<lpage>2222</lpage><pub-id pub-id-type="pmid">10232611</pub-id></mixed-citation></ref><ref id="B164"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamura</surname><given-names>T.</given-names></name><name><surname>Hara</surname><given-names>T.</given-names></name><name><surname>Kotoshiba</surname><given-names>S.</given-names></name><name><surname>Yada</surname><given-names>M.</given-names></name><name><surname>Ishida</surname><given-names>N.</given-names></name><name><surname>Imaki</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2003</year>). <article-title>Degradation of p57Kip2 mediated by SCFSkp2-dependent ubiquitylation</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>100</volume>, <fpage>10231</fpage>&#x02013;<lpage>10236</lpage><pub-id pub-id-type="doi">10.1073/pnas.1831009100</pub-id><pub-id pub-id-type="pmid">12925736</pub-id></mixed-citation></ref><ref id="B165"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kashiwakura</surname><given-names>Y.</given-names></name><name><surname>Ochiai</surname><given-names>K.</given-names></name><name><surname>Watanabe</surname><given-names>M.</given-names></name><name><surname>Abarzua</surname><given-names>F.</given-names></name><name><surname>Sakaguchi</surname><given-names>M.</given-names></name><name><surname>Takaoka</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Down-regulation of inhibition of differentiation-1 via activation of activating transcription factor 3 and Smad regulates REIC/Dickkopf-3-induced apoptosis</article-title>. <source>Cancer Res.</source>
<volume>68</volume>, <fpage>8333</fpage>&#x02013;<lpage>8341</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-0080</pub-id><pub-id pub-id-type="pmid">18922905</pub-id></mixed-citation></ref><ref id="B166"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katagiri</surname><given-names>Y.</given-names></name><name><surname>Hozumi</surname><given-names>Y.</given-names></name><name><surname>Kondo</surname><given-names>S.</given-names></name></person-group> (<year>2006</year>). <article-title>Knockdown of Skp2 by siRNA inhibits melanoma cell growth in vitro and in vivo</article-title>. <source>J. Dermatol. Sci.</source>
<volume>42</volume>, <fpage>215</fpage>&#x02013;<lpage>224</lpage><pub-id pub-id-type="doi">10.1016/j.jdermsci.2005.12.016</pub-id><pub-id pub-id-type="pmid">16504485</pub-id></mixed-citation></ref><ref id="B167"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katayama</surname><given-names>H.</given-names></name><name><surname>Sasai</surname><given-names>K.</given-names></name><name><surname>Kawai</surname><given-names>H.</given-names></name><name><surname>Yuan</surname><given-names>Z. M.</given-names></name><name><surname>Bondaruk</surname><given-names>J.</given-names></name><name><surname>Suzuki</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53</article-title>. <source>Nat. Genet.</source>
<volume>36</volume>, <fpage>55</fpage>&#x02013;<lpage>62</lpage><pub-id pub-id-type="doi">10.1038/ng1279</pub-id><pub-id pub-id-type="pmid">14702041</pub-id></mixed-citation></ref><ref id="B168"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawasaki</surname><given-names>K.</given-names></name><name><surname>Watanabe</surname><given-names>M.</given-names></name><name><surname>Sakaguchi</surname><given-names>M.</given-names></name><name><surname>Ogasawara</surname><given-names>Y.</given-names></name><name><surname>Ochiai</surname><given-names>K.</given-names></name><name><surname>Nasu</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>REIC/Dkk-3 overexpression downregulates P-glycoprotein in multidrug-resistant MCF7/ADR cells and induces apoptosis in breast cancer</article-title>. <source>Cancer Gene Ther.</source>
<volume>16</volume>, <fpage>65</fpage>&#x02013;<lpage>72</lpage><pub-id pub-id-type="doi">10.1038/cgt.2008.58</pub-id><pub-id pub-id-type="pmid">18654608</pub-id></mixed-citation></ref><ref id="B169"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keshelava</surname><given-names>N.</given-names></name><name><surname>Zuo</surname><given-names>J. J.</given-names></name><name><surname>Chen</surname><given-names>P.</given-names></name><name><surname>Waidyaratne</surname><given-names>S. N.</given-names></name><name><surname>Luna</surname><given-names>M. C.</given-names></name><name><surname>Gomer</surname><given-names>C. J.</given-names></name><etal/></person-group> (<year>2001</year>). <article-title>Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines</article-title>. <source>Cancer Res.</source>
<volume>61</volume>, <fpage>6185</fpage>&#x02013;<lpage>6193</lpage><pub-id pub-id-type="pmid">11507071</pub-id></mixed-citation></ref><ref id="B170"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keshelava</surname><given-names>N.</given-names></name><name><surname>Zuo</surname><given-names>J. J.</given-names></name><name><surname>Waidyaratne</surname><given-names>N. S.</given-names></name><name><surname>Triche</surname><given-names>T. J.</given-names></name><name><surname>Reynolds</surname><given-names>C. P.</given-names></name></person-group> (<year>2000</year>). <article-title>p53 mutations and loss of p53 function confer multidrug resistance in neuroblastoma</article-title>. <source>Med. Pediatr. Oncol.</source>
<volume>35</volume>, <fpage>563</fpage>&#x02013;<lpage>568</lpage><pub-id pub-id-type="doi">10.1002/1096-911X(20001201)35:6&#x0003c;563::AID-MPO15&#x0003e;3.0.CO;2-J</pub-id><pub-id pub-id-type="pmid">11107118</pub-id></mixed-citation></ref><ref id="B171"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S. Y.</given-names></name><name><surname>Herbst</surname><given-names>A.</given-names></name><name><surname>Tworkowski</surname><given-names>K. A.</given-names></name><name><surname>Salghetti</surname><given-names>S. E.</given-names></name><name><surname>Tansey</surname><given-names>W. P.</given-names></name></person-group> (<year>2003</year>). <article-title>Skp2 regulates Myc protein stability and activity</article-title>. <source>Mol. Cell</source>
<volume>11</volume>, <fpage>1177</fpage>&#x02013;<lpage>1188</lpage><pub-id pub-id-type="doi">10.1016/S1097-2765(03)00114-X</pub-id><pub-id pub-id-type="pmid">12769843</pub-id></mixed-citation></ref><ref id="B172"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kisselev</surname><given-names>A. F.</given-names></name><name><surname>Van Der Linden</surname><given-names>W. A.</given-names></name><name><surname>Overkleeft</surname><given-names>H. S.</given-names></name></person-group> (<year>2012</year>). <article-title>Proteasome inhibitors: an expanding army attacking a unique target</article-title>. <source>Chem. Biol.</source>
<volume>19</volume>, <fpage>99</fpage>&#x02013;<lpage>115</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2012.01.003</pub-id><pub-id pub-id-type="pmid">22284358</pub-id></mixed-citation></ref><ref id="B173"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kitagawa</surname><given-names>M.</given-names></name><name><surname>Lee</surname><given-names>S. H.</given-names></name><name><surname>Mccormick</surname><given-names>F.</given-names></name></person-group> (<year>2008</year>). <article-title>Skp2 suppresses p53-dependent apoptosis by inhibiting p300</article-title>. <source>Mol. Cell</source>
<volume>29</volume>, <fpage>217</fpage>&#x02013;<lpage>231</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2007.11.036</pub-id><pub-id pub-id-type="pmid">18243116</pub-id></mixed-citation></ref><ref id="B174"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klaus</surname><given-names>A.</given-names></name><name><surname>Birchmeier</surname><given-names>W.</given-names></name></person-group> (<year>2008</year>). <article-title>Wnt signalling and its impact on development and cancer</article-title>. <source>Nat. Rev. Cancer</source>
<volume>8</volume>, <fpage>387</fpage>&#x02013;<lpage>398</lpage><pub-id pub-id-type="doi">10.1038/nrc2389</pub-id><pub-id pub-id-type="pmid">18432252</pub-id></mixed-citation></ref><ref id="B175"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>T.</given-names></name><name><surname>Sakaguchi</surname><given-names>M.</given-names></name><name><surname>Tanimoto</surname><given-names>R.</given-names></name><name><surname>Abarzua</surname><given-names>F.</given-names></name><name><surname>Takaishi</surname><given-names>M.</given-names></name><name><surname>Kaku</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Mechanistic analysis of resistance to REIC/Dkk-3-induced apoptosis in human bladder cancer cells</article-title>. <source>Acta Med. Okayama</source>
<volume>62</volume>, <fpage>393</fpage>&#x02013;<lpage>401</lpage><pub-id pub-id-type="pmid">19122685</pub-id></mixed-citation></ref><ref id="B176"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koga</surname><given-names>H.</given-names></name><name><surname>Harada</surname><given-names>M.</given-names></name><name><surname>Ohtsubo</surname><given-names>M.</given-names></name><name><surname>Shishido</surname><given-names>S.</given-names></name><name><surname>Kumemura</surname><given-names>H.</given-names></name><name><surname>Hanada</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2003</year>). <article-title>Troglitazone induces p27Kip1-associated cell-cycle arrest through down-regulating Skp2 in human hepatoma cells</article-title>. <source>Hepatology</source>
<volume>37</volume>, <fpage>1086</fpage>&#x02013;<lpage>1096</lpage><pub-id pub-id-type="doi">10.1053/jhep.2003.50186</pub-id><pub-id pub-id-type="pmid">12717389</pub-id></mixed-citation></ref><ref id="B177"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kojima</surname><given-names>K.</given-names></name><name><surname>Konopleva</surname><given-names>M.</given-names></name><name><surname>Tsao</surname><given-names>T.</given-names></name><name><surname>Nakakuma</surname><given-names>H.</given-names></name><name><surname>Andreeff</surname><given-names>M.</given-names></name></person-group> (<year>2008</year>). <article-title>Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia</article-title>. <source>Blood</source>
<volume>112</volume>, <fpage>2886</fpage>&#x02013;<lpage>2895</lpage><pub-id pub-id-type="doi">10.1182/blood-2008-01-128611</pub-id><pub-id pub-id-type="pmid">18633130</pub-id></mixed-citation></ref><ref id="B178"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Komuro</surname><given-names>H.</given-names></name><name><surname>Hayashi</surname><given-names>Y.</given-names></name><name><surname>Kawamura</surname><given-names>M.</given-names></name><name><surname>Hayashi</surname><given-names>K.</given-names></name><name><surname>Kaneko</surname><given-names>Y.</given-names></name><name><surname>Kamoshita</surname><given-names>S.</given-names></name><etal/></person-group> (<year>1993</year>). <article-title>Mutations of the p53 gene are involved in Ewing&#x02019;s sarcomas but not in neuroblastomas</article-title>. <source>Cancer Res.</source>
<volume>53</volume>, <fpage>5284</fpage>&#x02013;<lpage>5288</lpage><pub-id pub-id-type="pmid">8221663</pub-id></mixed-citation></ref><ref id="B179"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koppen</surname><given-names>A.</given-names></name><name><surname>Ait-Aissa</surname><given-names>R.</given-names></name><name><surname>Hopman</surname><given-names>S.</given-names></name><name><surname>Koster</surname><given-names>J.</given-names></name><name><surname>Haneveld</surname><given-names>F.</given-names></name><name><surname>Versteeg</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Dickkopf-1 is down-regulated by MYCN and inhibits neuroblastoma cell proliferation</article-title>. <source>Cancer Lett.</source>
<volume>256</volume>, <fpage>218</fpage>&#x02013;<lpage>228</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2007.06.011</pub-id><pub-id pub-id-type="pmid">17643814</pub-id></mixed-citation></ref><ref id="B180"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koppen</surname><given-names>A.</given-names></name><name><surname>Ait-Aissa</surname><given-names>R.</given-names></name><name><surname>Koster</surname><given-names>J.</given-names></name><name><surname>Ora</surname><given-names>I.</given-names></name><name><surname>Bras</surname><given-names>J.</given-names></name><name><surname>Van Sluis</surname><given-names>P. G.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Dickkopf-3 expression is a marker for neuroblastic tumor maturation and is down-regulated by MYCN</article-title>. <source>Int. J. Cancer</source>
<volume>122</volume>, <fpage>1455</fpage>&#x02013;<lpage>1464</lpage><pub-id pub-id-type="doi">10.1002/ijc.23180</pub-id><pub-id pub-id-type="pmid">18059033</pub-id></mixed-citation></ref><ref id="B181"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korotchkina</surname><given-names>L. G.</given-names></name><name><surname>Demidenko</surname><given-names>Z. N.</given-names></name><name><surname>Gudkov</surname><given-names>A. V.</given-names></name><name><surname>Blagosklonny</surname><given-names>M. V.</given-names></name></person-group> (<year>2009</year>). <article-title>Cellular quiescence caused by the Mdm2 inhibitor nutlin-3A</article-title>. <source>Cell Cycle</source>
<volume>8</volume>, <fpage>3777</fpage>&#x02013;<lpage>3781</lpage><pub-id pub-id-type="doi">10.4161/cc.8.22.10121</pub-id><pub-id pub-id-type="pmid">19855165</pub-id></mixed-citation></ref><ref id="B182"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kovacevic</surname><given-names>Z.</given-names></name><name><surname>Chikhani</surname><given-names>S.</given-names></name><name><surname>Lui</surname><given-names>G. Y.</given-names></name><name><surname>Sivagurunathan</surname><given-names>S.</given-names></name><name><surname>Richardson</surname><given-names>D. R.</given-names></name></person-group> (<year>2012</year>). <article-title>The Iron-Regulated metastasis suppressor NDRG1 targets NEDD4L, PTEN, and SMAD4 and Inhibits the PI3K and Ras signaling pathways</article-title>. <source>Antioxid Redox Signal</source>.<pub-id pub-id-type="doi">10.1089/ars.2011.4273</pub-id><pub-id pub-id-type="pmid">22462691</pub-id></mixed-citation></ref><ref id="B183"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koyama</surname><given-names>H.</given-names></name><name><surname>Zhuang</surname><given-names>T.</given-names></name><name><surname>Light</surname><given-names>J. E.</given-names></name><name><surname>Kolla</surname><given-names>V.</given-names></name><name><surname>Higashi</surname><given-names>M.</given-names></name><name><surname>McGrady</surname><given-names>P. W.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Mechanisms of CHD5 Inactivation in neuroblastomas</article-title>. <source>Clin. Cancer Res.</source>
<volume>18</volume>, <fpage>1588</fpage>&#x02013;<lpage>1597</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-11-2644</pub-id><pub-id pub-id-type="pmid">22294723</pub-id></mixed-citation></ref><ref id="B184"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kruse</surname><given-names>J. P.</given-names></name><name><surname>Gu</surname><given-names>W.</given-names></name></person-group> (<year>2009</year>). <article-title>Modes of p53 regulation</article-title>. <source>Cell</source>
<volume>137</volume>, <fpage>609</fpage>&#x02013;<lpage>622</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2009.04.050</pub-id><pub-id pub-id-type="pmid">19450511</pub-id></mixed-citation></ref><ref id="B185"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurata</surname><given-names>K.</given-names></name><name><surname>Yanagisawa</surname><given-names>R.</given-names></name><name><surname>Ohira</surname><given-names>M.</given-names></name><name><surname>Kitagawa</surname><given-names>M.</given-names></name><name><surname>Nakagawara</surname><given-names>A.</given-names></name><name><surname>Kamijo</surname><given-names>T.</given-names></name></person-group> (<year>2008</year>). <article-title>Stress via p53 pathway causes apoptosis by mitochondrial Noxa upregulation in doxorubicin-treated neuroblastoma cells</article-title>. <source>Oncogene</source>
<volume>27</volume>, <fpage>741</fpage>&#x02013;<lpage>754</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1210672</pub-id><pub-id pub-id-type="pmid">17653088</pub-id></mixed-citation></ref><ref id="B186"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurose</surname><given-names>K.</given-names></name><name><surname>Sakaguchi</surname><given-names>M.</given-names></name><name><surname>Nasu</surname><given-names>Y.</given-names></name><name><surname>Ebara</surname><given-names>S.</given-names></name><name><surname>Kaku</surname><given-names>H.</given-names></name><name><surname>Kariyama</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Decreased expression of REIC/Dkk-3 in human renal clear cell carcinoma</article-title>. <source>J. Urol.</source>
<volume>171</volume>, <fpage>1314</fpage>&#x02013;<lpage>1318</lpage><pub-id pub-id-type="doi">10.1097/01.ju.0000101047.64379.d4</pub-id><pub-id pub-id-type="pmid">14767340</pub-id></mixed-citation></ref><ref id="B187"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kusafuka</surname><given-names>T.</given-names></name><name><surname>Fukuzawa</surname><given-names>M.</given-names></name><name><surname>Oue</surname><given-names>T.</given-names></name><name><surname>Komoto</surname><given-names>Y.</given-names></name><name><surname>Yoneda</surname><given-names>A.</given-names></name><name><surname>Okada</surname><given-names>A.</given-names></name></person-group> (<year>1997</year>). <article-title>Mutation analysis of p53 gene in childhood malignant solid tumors</article-title>. <source>J. Pediatr. Surg.</source>
<volume>32</volume>, <fpage>1175</fpage>&#x02013;<lpage>1180</lpage><pub-id pub-id-type="doi">10.1016/S0022-3468(97)90398-5</pub-id><pub-id pub-id-type="pmid">9269965</pub-id></mixed-citation></ref><ref id="B188"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuwahara</surname><given-names>A.</given-names></name><name><surname>Hirabayashi</surname><given-names>Y.</given-names></name><name><surname>Knoepfler</surname><given-names>P. S.</given-names></name><name><surname>Taketo</surname><given-names>M. M.</given-names></name><name><surname>Sakai</surname><given-names>J.</given-names></name><name><surname>Kodama</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Wnt signaling and its downstream target N-myc regulate basal progenitors in the developing neocortex</article-title>. <source>Development</source>
<volume>137</volume>, <fpage>1035</fpage>&#x02013;<lpage>1044</lpage><pub-id pub-id-type="doi">10.1242/dev.046417</pub-id><pub-id pub-id-type="pmid">20215343</pub-id></mixed-citation></ref><ref id="B189"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lane</surname><given-names>D. P.</given-names></name><name><surname>Cheok</surname><given-names>C. F.</given-names></name><name><surname>Lain</surname><given-names>S.</given-names></name></person-group> (<year>2010</year>). <article-title>p53-based cancer therapy</article-title>. <source>Cold Spring Harb. Perspect. Biol.</source>
<volume>2</volume>, <fpage>a001222</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a001222</pub-id><pub-id pub-id-type="pmid">20463003</pub-id></mixed-citation></ref><ref id="B190"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lane</surname><given-names>D. P.</given-names></name><name><surname>Crawford</surname><given-names>L. V.</given-names></name></person-group> (<year>1979</year>). <article-title>T antigen is bound to a host protein in SV40-transformed cells</article-title>. <source>Nature</source>
<volume>278</volume>, <fpage>261</fpage>&#x02013;<lpage>263</lpage><pub-id pub-id-type="doi">10.1038/278261a0</pub-id><pub-id pub-id-type="pmid">218111</pub-id></mixed-citation></ref><ref id="B191"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lang</surname><given-names>G. A.</given-names></name><name><surname>Iwakuma</surname><given-names>T.</given-names></name><name><surname>Suh</surname><given-names>Y. A.</given-names></name><name><surname>Liu</surname><given-names>G.</given-names></name><name><surname>Rao</surname><given-names>V. A.</given-names></name><name><surname>Parant</surname><given-names>J. M.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome</article-title>. <source>Cell</source>
<volume>119</volume>, <fpage>861</fpage>&#x02013;<lpage>872</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2004.11.006</pub-id><pub-id pub-id-type="pmid">15607981</pub-id></mixed-citation></ref><ref id="B192"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Latres</surname><given-names>E.</given-names></name><name><surname>Chiarle</surname><given-names>R.</given-names></name><name><surname>Schulman</surname><given-names>B. A.</given-names></name><name><surname>Pavletich</surname><given-names>N. P.</given-names></name><name><surname>Pellicer</surname><given-names>A.</given-names></name><name><surname>Inghirami</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2001</year>). <article-title>Role of the F-box protein Skp2 in lymphomagenesis</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>98</volume>, <fpage>2515</fpage>&#x02013;<lpage>2520</lpage><pub-id pub-id-type="doi">10.1073/pnas.041475098</pub-id><pub-id pub-id-type="pmid">11226270</pub-id></mixed-citation></ref><ref id="B193"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lau</surname><given-names>L. M.</given-names></name><name><surname>Nugent</surname><given-names>J. K.</given-names></name><name><surname>Zhao</surname><given-names>X.</given-names></name><name><surname>Irwin</surname><given-names>M. S.</given-names></name></person-group> (<year>2008</year>). <article-title>HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function</article-title>. <source>Oncogene</source>
<volume>27</volume>, <fpage>997</fpage>&#x02013;<lpage>1003</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1210707</pub-id><pub-id pub-id-type="pmid">17700533</pub-id></mixed-citation></ref><ref id="B194"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laurenti</surname><given-names>E.</given-names></name><name><surname>Varnum-Finney</surname><given-names>B.</given-names></name><name><surname>Wilson</surname><given-names>A.</given-names></name><name><surname>Ferrero</surname><given-names>I.</given-names></name><name><surname>Blanco-Bose</surname><given-names>W. E.</given-names></name><name><surname>Ehninger</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Hematopoietic stem cell function and survival depend on c-Myc and N-Myc activity</article-title>. <source>Cell Stem Cell</source>
<volume>3</volume>, <fpage>611</fpage>&#x02013;<lpage>624</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2008.09.005</pub-id><pub-id pub-id-type="pmid">19041778</pub-id></mixed-citation></ref><ref id="B195"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Layfield</surname><given-names>L. J.</given-names></name><name><surname>Thompson</surname><given-names>J. K.</given-names></name><name><surname>Dodge</surname><given-names>R. K.</given-names></name><name><surname>Kerns</surname><given-names>B. J.</given-names></name></person-group> (<year>1995</year>). <article-title>Prognostic indicators for neuroblastoma: stage, grade, DNA ploidy, MIB-1-proliferation index, p53, HER-2/neu and EGFr &#x02013; a survival study</article-title>. <source>J. Surg. Oncol.</source>
<volume>59</volume>, <fpage>21</fpage>&#x02013;<lpage>27</lpage><pub-id pub-id-type="doi">10.1002/jso.2930590107</pub-id><pub-id pub-id-type="pmid">7745972</pub-id></mixed-citation></ref><ref id="B196"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>E. J.</given-names></name><name><surname>Jo</surname><given-names>M.</given-names></name><name><surname>Rho</surname><given-names>S. B.</given-names></name><name><surname>Park</surname><given-names>K.</given-names></name><name><surname>Yoo</surname><given-names>Y. N.</given-names></name><name><surname>Park</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Dkk3, downregulated in cervical cancer, functions as a negative regulator of beta-catenin</article-title>. <source>Int. J. Cancer</source>
<volume>124</volume>, <fpage>287</fpage>&#x02013;<lpage>297</lpage><pub-id pub-id-type="doi">10.1002/ijc.23913</pub-id><pub-id pub-id-type="pmid">19003969</pub-id></mixed-citation></ref><ref id="B197"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>S. H.</given-names></name><name><surname>McCormick</surname><given-names>F.</given-names></name></person-group> (<year>2005</year>). <article-title>Downregulation of Skp2 and p27/Kip1 synergistically induces apoptosis in T98G glioblastoma cells</article-title>. <source>J. Mol. Med.</source>
<volume>83</volume>, <fpage>296</fpage>&#x02013;<lpage>307</lpage><pub-id pub-id-type="doi">10.1007/s00109-004-0611-7</pub-id><pub-id pub-id-type="pmid">15605273</pub-id></mixed-citation></ref><ref id="B198"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levine</surname><given-names>A. J.</given-names></name></person-group> (<year>1997</year>). <article-title>p53, the cellular gatekeeper for growth and division</article-title>. <source>Cell</source>
<volume>88</volume>, <fpage>323</fpage>&#x02013;<lpage>331</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)81871-1</pub-id><pub-id pub-id-type="pmid">9039259</pub-id></mixed-citation></ref><ref id="B199"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levrero</surname><given-names>M.</given-names></name><name><surname>De Laurenzi</surname><given-names>V.</given-names></name><name><surname>Costanzo</surname><given-names>A.</given-names></name><name><surname>Gong</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>J. Y.</given-names></name><name><surname>Melino</surname><given-names>G.</given-names></name></person-group> (<year>2000</year>). <article-title>The p53/p63/p73 family of transcription factors: overlapping and distinct functions</article-title>. <source>J. Cell. Sci.</source>
<volume>113</volume>, <fpage>1661</fpage>&#x02013;<lpage>1670</lpage><pub-id pub-id-type="pmid">10769197</pub-id></mixed-citation></ref><ref id="B200"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>C. F.</given-names></name><name><surname>Wang</surname><given-names>J. M.</given-names></name><name><surname>Kang</surname><given-names>H. Y.</given-names></name><name><surname>Huang</surname><given-names>C. K.</given-names></name><name><surname>Wang</surname><given-names>J. W.</given-names></name><name><surname>Fang</surname><given-names>F. M.</given-names></name><etal/></person-group> (<year>2012a</year>). <article-title>Characterization of gene amplification-driven SKP2 overexpression in myxofibrosarcoma: potential implications in tumor progression and therapeutics</article-title>. <source>Clin. Cancer Res.</source>
<volume>18</volume>, <fpage>1598</fpage>&#x02013;<lpage>1610</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-12-1427</pub-id><pub-id pub-id-type="pmid">22322669</pub-id></mixed-citation></ref><ref id="B201"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Xu</surname><given-names>W.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Huang</surname><given-names>X.</given-names></name><name><surname>Xu</surname><given-names>L.</given-names></name><name><surname>Lv</surname><given-names>Z.</given-names></name></person-group> (<year>2012b</year>). <article-title>Genistein demethylates the promoter of CHD5 and inhibits neuroblastoma growth in vivo</article-title>. <source>Int. J. Mol. Med.</source>
<volume>30</volume>, <fpage>1081</fpage>&#x02013;<lpage>1086</lpage><pub-id pub-id-type="pmid">22960751</pub-id></mixed-citation></ref><ref id="B202"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Kretzner</surname><given-names>L.</given-names></name></person-group> (<year>2003</year>). <article-title>The growth-inhibitory Ndrg1 gene is a Myc negative target in human neuroblastomas and other cell types with overexpressed N- or c-myc</article-title>. <source>Mol. Cell. Biochem.</source>
<volume>250</volume>, <fpage>91</fpage>&#x02013;<lpage>105</lpage><pub-id pub-id-type="doi">10.1023/A:1024918328162</pub-id><pub-id pub-id-type="pmid">12962147</pub-id></mixed-citation></ref><ref id="B203"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>H. K.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>G.</given-names></name><name><surname>Nardella</surname><given-names>C.</given-names></name><name><surname>Lee</surname><given-names>S. W.</given-names></name><name><surname>Chan</surname><given-names>C. H.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence</article-title>. <source>Nature</source>
<volume>464</volume>, <fpage>374</fpage>&#x02013;<lpage>379</lpage><pub-id pub-id-type="doi">10.1038/nature08815</pub-id><pub-id pub-id-type="pmid">20237562</pub-id></mixed-citation></ref><ref id="B204"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linzer</surname><given-names>D. I.</given-names></name><name><surname>Levine</surname><given-names>A. J.</given-names></name></person-group> (<year>1979</year>). <article-title>Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells</article-title>. <source>Cell</source>
<volume>17</volume>, <fpage>43</fpage>&#x02013;<lpage>52</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(79)90293-9</pub-id><pub-id pub-id-type="pmid">222475</pub-id></mixed-citation></ref><ref id="B205"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>N.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>Q.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2008a</year>). <article-title>N-Myc downstream-regulated gene 2 is involved in p53-mediated apoptosis</article-title>. <source>Nucleic Acids Res.</source>
<volume>36</volume>, <fpage>5335</fpage>&#x02013;<lpage>5349</lpage><pub-id pub-id-type="doi">10.1093/nar/gkn109</pub-id><pub-id pub-id-type="pmid">18689861</pub-id></mixed-citation></ref><ref id="B206"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Mazanek</surname><given-names>P.</given-names></name><name><surname>Dam</surname><given-names>V.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Zhao</surname><given-names>H.</given-names></name><name><surname>Guo</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2008b</year>). <article-title>Deregulated Wnt/beta-catenin program in high-risk neuroblastomas without MYCN amplification</article-title>. <source>Oncogene</source>
<volume>27</volume>, <fpage>1478</fpage>&#x02013;<lpage>1488</lpage><pub-id pub-id-type="doi">10.1038/onc.2008.104</pub-id><pub-id pub-id-type="pmid">17724465</pub-id></mixed-citation></ref><ref id="B207"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Q.</given-names></name><name><surname>Kaneko</surname><given-names>S.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Feldman</surname><given-names>R. I.</given-names></name><name><surname>Nicosia</surname><given-names>S. V.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215</article-title>. <source>J. Biol. Chem.</source>
<volume>279</volume>, <fpage>52175</fpage>&#x02013;<lpage>52182</lpage><pub-id pub-id-type="doi">10.1074/jbc.M408062200</pub-id><pub-id pub-id-type="pmid">15469940</pub-id></mixed-citation></ref><ref id="B208"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lozano</surname><given-names>G.</given-names></name></person-group> (<year>2007</year>). <article-title>The oncogenic roles of p53 mutants in mouse models</article-title>. <source>Curr. Opin. Genet. Dev.</source>
<volume>17</volume>, <fpage>66</fpage>&#x02013;<lpage>70</lpage><pub-id pub-id-type="doi">10.1016/j.gde.2006.12.003</pub-id><pub-id pub-id-type="pmid">17208429</pub-id></mixed-citation></ref><ref id="B209"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lujambio</surname><given-names>A.</given-names></name><name><surname>Lowe</surname><given-names>S. W.</given-names></name></person-group> (<year>2012</year>). <article-title>The microcosmos of cancer</article-title>. <source>Nature</source>
<volume>482</volume>, <fpage>347</fpage>&#x02013;<lpage>355</lpage><pub-id pub-id-type="doi">10.1038/nature10888</pub-id><pub-id pub-id-type="pmid">22337054</pub-id></mixed-citation></ref><ref id="B210"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mac</surname><given-names>S. M.</given-names></name><name><surname>D&#x02019;Cunha</surname><given-names>C. A.</given-names></name><name><surname>Farnham</surname><given-names>P. J.</given-names></name></person-group> (<year>2000</year>). <article-title>Direct recruitment of N-myc to target gene promoters</article-title>. <source>Mol. Carcinog.</source>
<volume>29</volume>, <fpage>76</fpage>&#x02013;<lpage>86</lpage><pub-id pub-id-type="doi">10.1002/1098-2744(200010)29:2&#x0003c;76::AID-MC4&#x0003e;3.0.CO;2-Y</pub-id><pub-id pub-id-type="pmid">11074604</pub-id></mixed-citation></ref><ref id="B211"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maestro</surname><given-names>R.</given-names></name><name><surname>Dei Tos</surname><given-names>A. P.</given-names></name><name><surname>Hamamori</surname><given-names>Y.</given-names></name><name><surname>Krasnokutsky</surname><given-names>S.</given-names></name><name><surname>Sartorelli</surname><given-names>V.</given-names></name><name><surname>Kedes</surname><given-names>L.</given-names></name><etal/></person-group> (<year>1999</year>). <article-title>Twist is a potential oncogene that inhibits apoptosis</article-title>. <source>Genes Dev.</source>
<volume>13</volume>, <fpage>2207</fpage>&#x02013;<lpage>2217</lpage><pub-id pub-id-type="doi">10.1101/gad.13.17.2207</pub-id><pub-id pub-id-type="pmid">10485844</pub-id></mixed-citation></ref><ref id="B212"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manhani</surname><given-names>R.</given-names></name><name><surname>Cristofani</surname><given-names>L. M.</given-names></name><name><surname>Odone Filho</surname><given-names>V.</given-names></name><name><surname>Bendit</surname><given-names>I.</given-names></name></person-group> (<year>1997</year>). <article-title>Concomitant p53 mutation and MYCN amplification in neuroblastoma</article-title>. <source>Med. Pediatr. Oncol.</source>
<volume>29</volume>, <fpage>206</fpage>&#x02013;<lpage>207</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1096-911X(199709)29:3&#x0003c;206::AID-MPO7&#x0003e;3.0.CO;2-H</pub-id><pub-id pub-id-type="pmid">9212845</pub-id></mixed-citation></ref><ref id="B213"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>B.</given-names></name><name><surname>Niehrs</surname><given-names>C.</given-names></name></person-group> (<year>2003</year>). <article-title>Kremen2 modulates Dickkopf2 activity during Wnt/LRP6 signaling</article-title>. <source>Gene</source>
<volume>302</volume>, <fpage>179</fpage>&#x02013;<lpage>183</lpage><pub-id pub-id-type="doi">10.1016/S0378-1119(02)01106-X</pub-id><pub-id pub-id-type="pmid">12527209</pub-id></mixed-citation></ref><ref id="B214"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>B.</given-names></name><name><surname>Wu</surname><given-names>W.</given-names></name><name><surname>Davidson</surname><given-names>G.</given-names></name><name><surname>Marhold</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Mechler</surname><given-names>B. M.</given-names></name><etal/></person-group> (<year>2002</year>). <article-title>Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling</article-title>. <source>Nature</source>
<volume>417</volume>, <fpage>664</fpage>&#x02013;<lpage>667</lpage><pub-id pub-id-type="doi">10.1038/nature756</pub-id><pub-id pub-id-type="pmid">12050670</pub-id></mixed-citation></ref><ref id="B215"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marine</surname><given-names>J. C.</given-names></name><name><surname>Dyer</surname><given-names>M. A.</given-names></name><name><surname>Jochemsen</surname><given-names>A. G.</given-names></name></person-group> (<year>2007</year>). <article-title>MDMX: from bench to bedside</article-title>. <source>J. Cell. Sci.</source>
<volume>120</volume>, <fpage>371</fpage>&#x02013;<lpage>378</lpage><pub-id pub-id-type="doi">10.1242/jcs.03362</pub-id><pub-id pub-id-type="pmid">17251377</pub-id></mixed-citation></ref><ref id="B216"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maris</surname><given-names>J. M.</given-names></name></person-group> (<year>2009</year>). <article-title>Unholy matrimony: aurora A and N-Myc as malignant partners in neuroblastoma</article-title>. <source>Cancer Cell</source>
<volume>15</volume>, <fpage>5</fpage>&#x02013;<lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2008.12.008</pub-id><pub-id pub-id-type="pmid">19111875</pub-id></mixed-citation></ref><ref id="B217"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maris</surname><given-names>J. M.</given-names></name><name><surname>Morton</surname><given-names>C. L.</given-names></name><name><surname>Gorlick</surname><given-names>R.</given-names></name><name><surname>Kolb</surname><given-names>E. A.</given-names></name><name><surname>Lock</surname><given-names>R.</given-names></name><name><surname>Carol</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Initial testing of the aurora kinase A inhibitor MLN8237 by the pediatric preclinical testing program (PPTP)</article-title>. <source>Pediatr. Blood Cancer</source>
<volume>55</volume>, <fpage>26</fpage>&#x02013;<lpage>34</lpage><pub-id pub-id-type="pmid">20108338</pub-id></mixed-citation></ref><ref id="B218"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKenzie</surname><given-names>P. P.</given-names></name><name><surname>Guichard</surname><given-names>S. M.</given-names></name><name><surname>Middlemas</surname><given-names>D. S.</given-names></name><name><surname>Ashmun</surname><given-names>R. A.</given-names></name><name><surname>Danks</surname><given-names>M. K.</given-names></name><name><surname>Harris</surname><given-names>L. C.</given-names></name></person-group> (<year>1999</year>). <article-title>Wild-type p53 can induce p21 and apoptosis in neuroblastoma cells but the DNA damage-induced G1 checkpoint function is attenuated</article-title>. <source>Clin. Cancer Res.</source>
<volume>5</volume>, <fpage>4199</fpage>&#x02013;<lpage>4207</lpage><pub-id pub-id-type="pmid">10632361</pub-id></mixed-citation></ref><ref id="B219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McPake</surname><given-names>C. R.</given-names></name><name><surname>Tillman</surname><given-names>D. M.</given-names></name><name><surname>Poquette</surname><given-names>C. A.</given-names></name><name><surname>George</surname><given-names>E. O.</given-names></name><name><surname>Houghton</surname><given-names>J. A.</given-names></name><name><surname>Harris</surname><given-names>L. C.</given-names></name></person-group> (<year>1998</year>). <article-title>Bax is an important determinant of chemosensitivity in pediatric tumor cell lines independent of Bcl-2 expression and p53 status</article-title>. <source>Oncol. Res.</source>
<volume>10</volume>, <fpage>235</fpage>&#x02013;<lpage>244</lpage><pub-id pub-id-type="pmid">9802058</pub-id></mixed-citation></ref><ref id="B220"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menendez</surname><given-names>D.</given-names></name><name><surname>Inga</surname><given-names>A.</given-names></name><name><surname>Resnick</surname><given-names>M. A.</given-names></name></person-group> (<year>2009</year>). <article-title>The expanding universe of p53 targets</article-title>. <source>Nat. Rev. Cancer</source>
<volume>9</volume>, <fpage>724</fpage>&#x02013;<lpage>737</lpage><pub-id pub-id-type="doi">10.1038/nrc2730</pub-id><pub-id pub-id-type="pmid">19776742</pub-id></mixed-citation></ref><ref id="B221"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mergui</surname><given-names>X.</given-names></name><name><surname>Leteurtre</surname><given-names>F.</given-names></name><name><surname>Lipinski</surname><given-names>M.</given-names></name><name><surname>Benard</surname><given-names>J.</given-names></name><name><surname>Amor-Gueret</surname><given-names>M.</given-names></name></person-group> (<year>2008</year>). <article-title>Two distinctly altered cellular responses to DNA double-strand breaks in human neuroblastoma</article-title>. <source>Biochimie</source>
<volume>90</volume>, <fpage>1656</fpage>&#x02013;<lpage>1666</lpage><pub-id pub-id-type="doi">10.1016/j.biochi.2008.06.008</pub-id><pub-id pub-id-type="pmid">18627787</pub-id></mixed-citation></ref><ref id="B222"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mertz</surname><given-names>J. A.</given-names></name><name><surname>Conery</surname><given-names>A. R.</given-names></name><name><surname>Bryant</surname><given-names>B. M.</given-names></name><name><surname>Sandy</surname><given-names>P.</given-names></name><name><surname>Balasubramanian</surname><given-names>S.</given-names></name><name><surname>Mele</surname><given-names>D. A.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Targeting MYC dependence in cancer by inhibiting BET bromodomains</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>108</volume>, <fpage>16669</fpage>&#x02013;<lpage>16674</lpage><pub-id pub-id-type="doi">10.1073/pnas.1108190108</pub-id><pub-id pub-id-type="pmid">21949397</pub-id></mixed-citation></ref><ref id="B223"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michaelis</surname><given-names>M.</given-names></name><name><surname>Fichtner</surname><given-names>I.</given-names></name><name><surname>Behrens</surname><given-names>D.</given-names></name><name><surname>Haider</surname><given-names>W.</given-names></name><name><surname>Rothweiler</surname><given-names>F.</given-names></name><name><surname>Mack</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo</article-title>. <source>Int. J. Oncol.</source>
<volume>28</volume>, <fpage>439</fpage>&#x02013;<lpage>446</lpage><pub-id pub-id-type="pmid">16391799</pub-id></mixed-citation></ref><ref id="B224"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michaelis</surname><given-names>M.</given-names></name><name><surname>Rothweiler</surname><given-names>F.</given-names></name><name><surname>Barth</surname><given-names>S.</given-names></name><name><surname>Cinatl</surname><given-names>J.</given-names></name><name><surname>Van Rikxoort</surname><given-names>M.</given-names></name><name><surname>Loschmann</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells</article-title>. <source>Cell Death Dis.</source>
<volume>2</volume>, <fpage>e243</fpage><pub-id pub-id-type="doi">10.1038/cddis.2011.129</pub-id><pub-id pub-id-type="pmid">22170099</pub-id></mixed-citation></ref><ref id="B225"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michaelis</surname><given-names>M.</given-names></name><name><surname>Rothweiler</surname><given-names>F.</given-names></name><name><surname>Klassert</surname><given-names>D.</given-names></name><name><surname>Von Deimling</surname><given-names>A.</given-names></name><name><surname>Weber</surname><given-names>K.</given-names></name><name><surname>Fehse</surname><given-names>B.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3</article-title>. <source>Cancer Res.</source>
<volume>69</volume>, <fpage>416</fpage>&#x02013;<lpage>421</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-1856</pub-id><pub-id pub-id-type="pmid">19147553</pub-id></mixed-citation></ref><ref id="B226"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mirza</surname><given-names>A.</given-names></name><name><surname>Wu</surname><given-names>Q.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Mcclanahan</surname><given-names>T.</given-names></name><name><surname>Bishop</surname><given-names>W. R.</given-names></name><name><surname>Gheyas</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2003</year>). <article-title>Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progression</article-title>. <source>Oncogene</source>
<volume>22</volume>, <fpage>3645</fpage>&#x02013;<lpage>3654</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1206477</pub-id><pub-id pub-id-type="pmid">12789273</pub-id></mixed-citation></ref><ref id="B227"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mizobuchi</surname><given-names>Y.</given-names></name><name><surname>Matsuzaki</surname><given-names>K.</given-names></name><name><surname>Kuwayama</surname><given-names>K.</given-names></name><name><surname>Kitazato</surname><given-names>K.</given-names></name><name><surname>Mure</surname><given-names>H.</given-names></name><name><surname>Kageji</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>REIC/Dkk-3 induces cell death in human malignant glioma</article-title>. <source>Neuro oncol.</source>
<volume>10</volume>, <fpage>244</fpage>&#x02013;<lpage>253</lpage><pub-id pub-id-type="doi">10.1215/15228517-2008-016</pub-id><pub-id pub-id-type="pmid">18443132</pub-id></mixed-citation></ref><ref id="B228"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moll</surname><given-names>U. M.</given-names></name><name><surname>Laquaglia</surname><given-names>M.</given-names></name><name><surname>Benard</surname><given-names>J.</given-names></name><name><surname>Riou</surname><given-names>G.</given-names></name></person-group> (<year>1995</year>). <article-title>Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>92</volume>, <fpage>4407</fpage>&#x02013;<lpage>4411</lpage><pub-id pub-id-type="doi">10.1073/pnas.92.10.4407</pub-id><pub-id pub-id-type="pmid">7753819</pub-id></mixed-citation></ref><ref id="B229"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moll</surname><given-names>U. M.</given-names></name><name><surname>Ostermeyer</surname><given-names>A. G.</given-names></name><name><surname>Haladay</surname><given-names>R.</given-names></name><name><surname>Winkfield</surname><given-names>B.</given-names></name><name><surname>Frazier</surname><given-names>M.</given-names></name><name><surname>Zambetti</surname><given-names>G.</given-names></name></person-group> (<year>1996</year>). <article-title>Cytoplasmic sequestration of wild-type p53 protein impairs the G1 checkpoint after DNA damage</article-title>. <source>Mol. Cell. Biol.</source>
<volume>16</volume>, <fpage>1126</fpage>&#x02013;<lpage>1137</lpage><pub-id pub-id-type="pmid">8622657</pub-id></mixed-citation></ref><ref id="B230"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moll</surname><given-names>U. M.</given-names></name><name><surname>Slade</surname><given-names>N.</given-names></name></person-group> (<year>2004</year>). <article-title>p63 and p73: roles in development and tumor formation</article-title>. <source>Mol. Cancer Res.</source>
<volume>2</volume>, <fpage>371</fpage>&#x02013;<lpage>386</lpage><pub-id pub-id-type="pmid">15280445</pub-id></mixed-citation></ref><ref id="B231"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moll</surname><given-names>U. M.</given-names></name><name><surname>Wolff</surname><given-names>S.</given-names></name><name><surname>Speidel</surname><given-names>D.</given-names></name><name><surname>Deppert</surname><given-names>W.</given-names></name></person-group> (<year>2005</year>). <article-title>Transcription-independent pro-apoptotic functions of p53</article-title>. <source>Curr. Opin. Cell Biol.</source>
<volume>17</volume>, <fpage>631</fpage>&#x02013;<lpage>636</lpage><pub-id pub-id-type="doi">10.1016/j.ceb.2005.09.007</pub-id><pub-id pub-id-type="pmid">16226451</pub-id></mixed-citation></ref><ref id="B232"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Momand</surname><given-names>J.</given-names></name><name><surname>Zambetti</surname><given-names>G. P.</given-names></name><name><surname>Olson</surname><given-names>D. C.</given-names></name><name><surname>George</surname><given-names>D.</given-names></name><name><surname>Levine</surname><given-names>A. J.</given-names></name></person-group> (<year>1992</year>). <article-title>The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation</article-title>. <source>Cell</source>
<volume>69</volume>, <fpage>1237</fpage>&#x02013;<lpage>1245</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(92)90644-R</pub-id><pub-id pub-id-type="pmid">1535557</pub-id></mixed-citation></ref><ref id="B233"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montes de Oca Luna</surname><given-names>R.</given-names></name><name><surname>Wagner</surname><given-names>D. S.</given-names></name><name><surname>Lozano</surname><given-names>G.</given-names></name></person-group> (<year>1995</year>). <article-title>Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53</article-title>. <source>Nature</source>
<volume>378</volume>, <fpage>203</fpage>&#x02013;<lpage>206</lpage><pub-id pub-id-type="doi">10.1038/378203a0</pub-id><pub-id pub-id-type="pmid">7477326</pub-id></mixed-citation></ref><ref id="B234"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>H. C.</given-names></name><name><surname>Wood</surname><given-names>K. M.</given-names></name><name><surname>Jackson</surname><given-names>M. S.</given-names></name><name><surname>Lastowska</surname><given-names>M. A.</given-names></name><name><surname>Hall</surname><given-names>D.</given-names></name><name><surname>Imrie</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Histological profile of tumours from MYCN transgenic mice</article-title>. <source>J. Clin. Pathol.</source>
<volume>61</volume>, <fpage>1098</fpage>&#x02013;<lpage>1103</lpage><pub-id pub-id-type="doi">10.1136/jcp.2007.054627</pub-id><pub-id pub-id-type="pmid">18682419</pub-id></mixed-citation></ref><ref id="B235"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moro</surname><given-names>L.</given-names></name><name><surname>Arbini</surname><given-names>A. A.</given-names></name><name><surname>Marra</surname><given-names>E.</given-names></name><name><surname>Greco</surname><given-names>M.</given-names></name></person-group> (<year>2006</year>). <article-title>Up-regulation of Skp2 after prostate cancer cell adhesion to basement membranes results in BRCA2 degradation and cell proliferation</article-title>. <source>J. Biol. Chem.</source>
<volume>281</volume>, <fpage>22100</fpage>&#x02013;<lpage>22107</lpage><pub-id pub-id-type="doi">10.1074/jbc.M604636200</pub-id><pub-id pub-id-type="pmid">16754685</pub-id></mixed-citation></ref><ref id="B236"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motti</surname><given-names>M. L.</given-names></name><name><surname>Califano</surname><given-names>D.</given-names></name><name><surname>Troncone</surname><given-names>G.</given-names></name><name><surname>De Marco</surname><given-names>C.</given-names></name><name><surname>Migliaccio</surname><given-names>I.</given-names></name><name><surname>Palmieri</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Complex regulation of the cyclin-dependent kinase inhibitor p27kip1 in thyroid cancer cells by the PI3K/AKT pathway: regulation of p27kip1 expression and localization</article-title>. <source>Am. J. Pathol.</source>
<volume>166</volume>, <fpage>737</fpage>&#x02013;<lpage>749</lpage><pub-id pub-id-type="doi">10.1016/S0002-9440(10)62295-X</pub-id><pub-id pub-id-type="pmid">15743786</pub-id></mixed-citation></ref><ref id="B237"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muth</surname><given-names>D.</given-names></name><name><surname>Ghazaryan</surname><given-names>S.</given-names></name><name><surname>Eckerle</surname><given-names>I.</given-names></name><name><surname>Beckett</surname><given-names>E.</given-names></name><name><surname>Pohler</surname><given-names>C.</given-names></name><name><surname>Batzler</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Transcriptional repression of SKP2 is impaired in MYCN-amplified neuroblastoma</article-title>. <source>Cancer Res.</source>
<volume>70</volume>, <fpage>3791</fpage>&#x02013;<lpage>3802</lpage><pub-id pub-id-type="doi">10.1158/1538-7445.AM10-3791</pub-id><pub-id pub-id-type="pmid">20424123</pub-id></mixed-citation></ref><ref id="B238"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>M.</given-names></name><name><surname>Matsuo</surname><given-names>T.</given-names></name><name><surname>Stauffer</surname><given-names>J.</given-names></name><name><surname>Neckers</surname><given-names>L.</given-names></name><name><surname>Thiele</surname><given-names>C. J.</given-names></name></person-group> (<year>2003a</year>). <article-title>Retinoic acid decreases targeting of p27 for degradation via an N-myc-dependent decrease in p27 phosphorylation and an N-myc-independent decrease in Skp2</article-title>. <source>Cell Death Differ.</source>
<volume>10</volume>, <fpage>230</fpage>&#x02013;<lpage>239</lpage><pub-id pub-id-type="doi">10.1038/sj.cdd.4401125</pub-id><pub-id pub-id-type="pmid">12700651</pub-id></mixed-citation></ref><ref id="B239"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>Y.</given-names></name><name><surname>Ozaki</surname><given-names>T.</given-names></name><name><surname>Koseki</surname><given-names>H.</given-names></name><name><surname>Nakagawara</surname><given-names>A.</given-names></name><name><surname>Sakiyama</surname><given-names>S.</given-names></name></person-group> (<year>2003b</year>). <article-title>Accumulation of p27 KIP1 is associated with BMP2-induced growth arrest and neuronal differentiation of human neuroblastoma-derived cell lines</article-title>. <source>Biochem. Biophys. Res. Commun.</source>
<volume>307</volume>, <fpage>206</fpage>&#x02013;<lpage>213</lpage><pub-id pub-id-type="doi">10.1016/S0006-291X(03)01138-0</pub-id><pub-id pub-id-type="pmid">12850001</pub-id></mixed-citation></ref><ref id="B240"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>R. E.</given-names></name><name><surname>Hackam</surname><given-names>A. S.</given-names></name></person-group> (<year>2010</year>). <article-title>Analysis of Dickkopf3 interactions with Wnt signaling receptors</article-title>. <source>Growth Factors</source>
<volume>28</volume>, <fpage>232</fpage>&#x02013;<lpage>242</lpage><pub-id pub-id-type="doi">10.3109/08977191003738832</pub-id><pub-id pub-id-type="pmid">20370576</pub-id></mixed-citation></ref><ref id="B241"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>Y.</given-names></name></person-group> (<year>2004</year>). <article-title>Isolation of p53-target genes and their functional analysis</article-title>. <source>Cancer Sci.</source>
<volume>95</volume>, <fpage>7</fpage>&#x02013;<lpage>11</lpage><pub-id pub-id-type="doi">10.1111/j.1349-7006.2004.tb03163.x</pub-id><pub-id pub-id-type="pmid">14720320</pub-id></mixed-citation></ref><ref id="B242"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>Y.</given-names></name><name><surname>Ozaki</surname><given-names>T.</given-names></name><name><surname>Niizuma</surname><given-names>H.</given-names></name><name><surname>Ohira</surname><given-names>M.</given-names></name><name><surname>Kamijo</surname><given-names>T.</given-names></name><name><surname>Nakagawara</surname><given-names>A.</given-names></name></person-group> (<year>2007</year>). <article-title>Functional characterization of a new p53 mutant generated by homozygous deletion in a neuroblastoma cell line</article-title>. <source>Biochem. Biophys. Res. Commun.</source>
<volume>354</volume>, <fpage>892</fpage>&#x02013;<lpage>898</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2007.01.057</pub-id><pub-id pub-id-type="pmid">17276397</pub-id></mixed-citation></ref><ref id="B243"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakayama</surname><given-names>K.</given-names></name><name><surname>Nagahama</surname><given-names>H.</given-names></name><name><surname>Minamishima</surname><given-names>Y. A.</given-names></name><name><surname>Matsumoto</surname><given-names>M.</given-names></name><name><surname>Nakamichi</surname><given-names>I.</given-names></name><name><surname>Kitagawa</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2000</year>). <article-title>Targeted disruption of Skp2 results in accumulation of cyclin E and p27(Kip1), polyploidy and centrosome overduplication</article-title>. <source>EMBO J.</source>
<volume>19</volume>, <fpage>2069</fpage>&#x02013;<lpage>2081</lpage><pub-id pub-id-type="doi">10.1093/emboj/19.9.2069</pub-id><pub-id pub-id-type="pmid">10790373</pub-id></mixed-citation></ref><ref id="B244"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakayama</surname><given-names>K. I.</given-names></name><name><surname>Nakayama</surname><given-names>K.</given-names></name></person-group> (<year>2005</year>). <article-title>Regulation of the cell cycle by SCF-type ubiquitin ligases</article-title>. <source>Semin. Cell Dev. Biol.</source>
<volume>16</volume>, <fpage>323</fpage>&#x02013;<lpage>333</lpage><pub-id pub-id-type="doi">10.1016/j.semcdb.2005.02.010</pub-id><pub-id pub-id-type="pmid">15840441</pub-id></mixed-citation></ref><ref id="B245"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakayama</surname><given-names>K. I.</given-names></name><name><surname>Nakayama</surname><given-names>K.</given-names></name></person-group> (<year>2006</year>). <article-title>Ubiquitin ligases: cell-cycle control and cancer</article-title>. <source>Nat. Rev. Cancer</source>
<volume>6</volume>, <fpage>369</fpage>&#x02013;<lpage>381</lpage><pub-id pub-id-type="doi">10.1038/nrc1881</pub-id><pub-id pub-id-type="pmid">16633365</pub-id></mixed-citation></ref><ref id="B246"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niehrs</surname><given-names>C.</given-names></name></person-group> (<year>2006</year>). <article-title>Function and biological roles of the Dickkopf family of Wnt modulators</article-title>. <source>Oncogene</source>
<volume>25</volume>, <fpage>7469</fpage>&#x02013;<lpage>7481</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1210054</pub-id><pub-id pub-id-type="pmid">17143291</pub-id></mixed-citation></ref><ref id="B247"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nikolaev</surname><given-names>A. Y.</given-names></name><name><surname>Gu</surname><given-names>W.</given-names></name></person-group> (<year>2003</year>). <article-title>PARC: a potential target for cancer therapy</article-title>. <source>Cell Cycle</source>
<volume>2</volume>, <fpage>169</fpage>&#x02013;<lpage>171</lpage><pub-id pub-id-type="doi">10.4161/cc.2.3.346</pub-id><pub-id pub-id-type="pmid">12734414</pub-id></mixed-citation></ref><ref id="B248"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nikolaev</surname><given-names>A. Y.</given-names></name><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Puskas</surname><given-names>N.</given-names></name><name><surname>Qin</surname><given-names>J.</given-names></name><name><surname>Gu</surname><given-names>W.</given-names></name></person-group> (<year>2003</year>). <article-title>Parc: a cytoplasmic anchor for p53</article-title>. <source>Cell</source>
<volume>112</volume>, <fpage>29</fpage>&#x02013;<lpage>40</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(02)01255-2</pub-id><pub-id pub-id-type="pmid">12526791</pub-id></mixed-citation></ref><ref id="B249"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nozaki</surname><given-names>I.</given-names></name><name><surname>Tsuji</surname><given-names>T.</given-names></name><name><surname>Iijima</surname><given-names>O.</given-names></name><name><surname>Ohmura</surname><given-names>Y.</given-names></name><name><surname>Andou</surname><given-names>A.</given-names></name><name><surname>Miyazaki</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2001</year>). <article-title>Reduced expression of REIC/Dkk-3 gene in non-small cell lung cancer</article-title>. <source>Int. J. Oncol.</source>
<volume>19</volume>, <fpage>117</fpage>&#x02013;<lpage>121</lpage><pub-id pub-id-type="pmid">11408931</pub-id></mixed-citation></ref><ref id="B250"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ochiai</surname><given-names>H.</given-names></name><name><surname>Takenobu</surname><given-names>H.</given-names></name><name><surname>Nakagawa</surname><given-names>A.</given-names></name><name><surname>Yamaguchi</surname><given-names>Y.</given-names></name><name><surname>Kimura</surname><given-names>M.</given-names></name><name><surname>Ohira</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Bmi1 is a MYCN target gene that regulates tumorigenesis through repression of KIF1Bbeta and TSLC1 in neuroblastoma</article-title>. <source>Oncogene</source>
<volume>29</volume>, <fpage>2681</fpage>&#x02013;<lpage>2690</lpage><pub-id pub-id-type="doi">10.1038/onc.2010.22</pub-id><pub-id pub-id-type="pmid">20190806</pub-id></mixed-citation></ref><ref id="B251"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohgaki</surname><given-names>H.</given-names></name><name><surname>Eibl</surname><given-names>R. H.</given-names></name><name><surname>Schwab</surname><given-names>M.</given-names></name><name><surname>Reichel</surname><given-names>M. B.</given-names></name><name><surname>Mariani</surname><given-names>L.</given-names></name><name><surname>Gehring</surname><given-names>M.</given-names></name><etal/></person-group> (<year>1993</year>). <article-title>Mutations of the p53 tumor suppressor gene in neoplasms of the human nervous system</article-title>. <source>Mol. Carcinog.</source>
<volume>8</volume>, <fpage>74</fpage>&#x02013;<lpage>80</lpage><pub-id pub-id-type="doi">10.1002/mc.2940080203</pub-id><pub-id pub-id-type="pmid">8397797</pub-id></mixed-citation></ref><ref id="B252"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohtsubo</surname><given-names>C.</given-names></name><name><surname>Shiokawa</surname><given-names>D.</given-names></name><name><surname>Kodama</surname><given-names>M.</given-names></name><name><surname>Gaiddon</surname><given-names>C.</given-names></name><name><surname>Nakagama</surname><given-names>H.</given-names></name><name><surname>Jochemsen</surname><given-names>A. G.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Cytoplasmic tethering is involved in synergistic inhibition of p53 by Mdmx and Mdm2</article-title>. <source>Cancer Sci.</source>
<volume>100</volume>, <fpage>1291</fpage>&#x02013;<lpage>1299</lpage><pub-id pub-id-type="doi">10.1111/j.1349-7006.2009.01180.x</pub-id><pub-id pub-id-type="pmid">19432880</pub-id></mixed-citation></ref><ref id="B253"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olive</surname><given-names>K. P.</given-names></name><name><surname>Tuveson</surname><given-names>D. A.</given-names></name><name><surname>Ruhe</surname><given-names>Z. C.</given-names></name><name><surname>Yin</surname><given-names>B.</given-names></name><name><surname>Willis</surname><given-names>N. A.</given-names></name><name><surname>Bronson</surname><given-names>R. T.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome</article-title>. <source>Cell</source>
<volume>119</volume>, <fpage>847</fpage>&#x02013;<lpage>860</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2004.11.004</pub-id><pub-id pub-id-type="pmid">15607980</pub-id></mixed-citation></ref><ref id="B254"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olivier</surname><given-names>M.</given-names></name><name><surname>Taniere</surname><given-names>P.</given-names></name></person-group> (<year>2011</year>). <article-title>Somatic mutations in cancer prognosis and prediction: lessons from TP53 and EGFR genes</article-title>. <source>Curr. Opin. Oncol.</source>
<volume>23</volume>, <fpage>88</fpage>&#x02013;<lpage>92</lpage><pub-id pub-id-type="doi">10.1097/CCO.0b013e3283412dfa</pub-id><pub-id pub-id-type="pmid">21045690</pub-id></mixed-citation></ref><ref id="B255"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Omura-Minamisawa</surname><given-names>M.</given-names></name><name><surname>Diccianni</surname><given-names>M. B.</given-names></name><name><surname>Chang</surname><given-names>R. C.</given-names></name><name><surname>Batova</surname><given-names>A.</given-names></name><name><surname>Bridgeman</surname><given-names>L. J.</given-names></name><name><surname>Schiff</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2001</year>). <article-title>p16/p14(ARF) cell cycle regulatory pathways in primary neuroblastoma: p16 expression is associated with advanced stage disease</article-title>. <source>Clin. Cancer Res.</source>
<volume>7</volume>, <fpage>3481</fpage>&#x02013;<lpage>3490</lpage><pub-id pub-id-type="pmid">11705866</pub-id></mixed-citation></ref><ref id="B256"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oren</surname><given-names>M.</given-names></name><name><surname>Rotter</surname><given-names>V.</given-names></name></person-group> (<year>2010</year>). <article-title>Mutant p53 gain-of-function in cancer</article-title>. <source>Cold Spring Harb. Perspect. Biol.</source>
<volume>2</volume>, <fpage>a001107</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a001107</pub-id><pub-id pub-id-type="pmid">20182618</pub-id></mixed-citation></ref><ref id="B257"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ostermeyer</surname><given-names>A. G.</given-names></name><name><surname>Runko</surname><given-names>E.</given-names></name><name><surname>Winkfield</surname><given-names>B.</given-names></name><name><surname>Ahn</surname><given-names>B.</given-names></name><name><surname>Moll</surname><given-names>U. M.</given-names></name></person-group> (<year>1996</year>). <article-title>Cytoplasmically sequestered wild-type p53 protein in neuroblastoma is relocated to the nucleus by a C-terminal peptide</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>93</volume>, <fpage>15190</fpage>&#x02013;<lpage>15194</lpage><pub-id pub-id-type="doi">10.1073/pnas.93.26.15190</pub-id><pub-id pub-id-type="pmid">8986786</pub-id></mixed-citation></ref><ref id="B258"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Otto</surname><given-names>T.</given-names></name><name><surname>Horn</surname><given-names>S.</given-names></name><name><surname>Brockmann</surname><given-names>M.</given-names></name><name><surname>Eilers</surname><given-names>U.</given-names></name><name><surname>Schuttrumpf</surname><given-names>L.</given-names></name><name><surname>Popov</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma</article-title>. <source>Cancer Cell</source>
<volume>15</volume>, <fpage>67</fpage>&#x02013;<lpage>78</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2008.12.005</pub-id><pub-id pub-id-type="pmid">19111882</pub-id></mixed-citation></ref><ref id="B259"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paffhausen</surname><given-names>T.</given-names></name><name><surname>Schwab</surname><given-names>M.</given-names></name><name><surname>Westermann</surname><given-names>F.</given-names></name></person-group> (<year>2007</year>). <article-title>Targeted MYCN expression affects cytotoxic potential of chemotherapeutic drugs in neuroblastoma cells</article-title>. <source>Cancer Lett.</source>
<volume>250</volume>, <fpage>17</fpage>&#x02013;<lpage>24</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2006.09.010</pub-id><pub-id pub-id-type="pmid">17141950</pub-id></mixed-citation></ref><ref id="B260"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name></person-group> (<year>2003</year>). <article-title>MDM2 promotes ubiquitination and degradation of MDMX</article-title>. <source>Mol. Cell. Biol.</source>
<volume>23</volume>, <fpage>5113</fpage>&#x02013;<lpage>5121</lpage><pub-id pub-id-type="doi">10.1128/MCB.23.15.5113-5121.2003</pub-id><pub-id pub-id-type="pmid">12860999</pub-id></mixed-citation></ref><ref id="B261"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>J. R.</given-names></name><name><surname>Eggert</surname><given-names>A.</given-names></name><name><surname>Caron</surname><given-names>H.</given-names></name></person-group> (<year>2010</year>). <article-title>Neuroblastoma: biology, prognosis, and treatment</article-title>. <source>Hematol. Oncol. Clin. North Am.</source>
<volume>24</volume>, <fpage>65</fpage>&#x02013;<lpage>86</lpage><pub-id pub-id-type="doi">10.1016/j.hoc.2009.11.011</pub-id><pub-id pub-id-type="pmid">20113896</pub-id></mixed-citation></ref><ref id="B262"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patterson</surname><given-names>D. M.</given-names></name><name><surname>Gao</surname><given-names>D.</given-names></name><name><surname>Trahan</surname><given-names>D. N.</given-names></name><name><surname>Johnson</surname><given-names>B. A.</given-names></name><name><surname>Ludwig</surname><given-names>A.</given-names></name><name><surname>Barbieri</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma</article-title>. <source>Angiogenesis</source>
<volume>14</volume>, <fpage>255</fpage>&#x02013;<lpage>266</lpage><pub-id pub-id-type="doi">10.1007/s10456-011-9210-8</pub-id><pub-id pub-id-type="pmid">21484514</pub-id></mixed-citation></ref><ref id="B263"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peirce</surname><given-names>S. K.</given-names></name><name><surname>Findley</surname><given-names>H. W.</given-names></name></person-group> (<year>2009a</year>). <article-title>High level MycN expression in non-MYCN amplified neuroblastoma is induced by the combination treatment nutlin-3 and doxorubicin and enhances chemosensitivity</article-title>. <source>Oncol. Rep.</source>
<volume>22</volume>, <fpage>1443</fpage>&#x02013;<lpage>1449</lpage><pub-id pub-id-type="doi">10.3892/or_00000586</pub-id><pub-id pub-id-type="pmid">19885598</pub-id></mixed-citation></ref><ref id="B264"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peirce</surname><given-names>S. K.</given-names></name><name><surname>Findley</surname><given-names>H. W.</given-names></name></person-group> (<year>2009b</year>). <article-title>The MDM2 antagonist nutlin-3 sensitizes p53-null neuroblastoma cells to doxorubicin via E2F1 and TAp73</article-title>. <source>Int. J. Oncol.</source>
<volume>34</volume>, <fpage>1395</fpage>&#x02013;<lpage>1402</lpage><pub-id pub-id-type="pmid">19360352</pub-id></mixed-citation></ref><ref id="B265"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perfumo</surname><given-names>C.</given-names></name><name><surname>Parodi</surname><given-names>S.</given-names></name><name><surname>Mazzocco</surname><given-names>K.</given-names></name><name><surname>Defferrari</surname><given-names>R.</given-names></name><name><surname>Inga</surname><given-names>A.</given-names></name><name><surname>Haupt</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Impact of MDM2 SNP309 genotype on progression and survival of stage 4 neuroblastoma</article-title>. <source>Eur. J. Cancer</source>
<volume>44</volume>, <fpage>2634</fpage>&#x02013;<lpage>2639</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2008.08.018</pub-id><pub-id pub-id-type="pmid">18835771</pub-id></mixed-citation></ref><ref id="B266"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perfumo</surname><given-names>C.</given-names></name><name><surname>Parodi</surname><given-names>S.</given-names></name><name><surname>Mazzocco</surname><given-names>K.</given-names></name><name><surname>Defferrari</surname><given-names>R.</given-names></name><name><surname>Inga</surname><given-names>A.</given-names></name><name><surname>Scarra</surname><given-names>G. B.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>MDM2 SNP309 genotype influences survival of metastatic but not of localized neuroblastoma</article-title>. <source>Pediatr. Blood Cancer</source>
<volume>53</volume>, <fpage>576</fpage>&#x02013;<lpage>583</lpage><pub-id pub-id-type="doi">10.1002/pbc.22132</pub-id><pub-id pub-id-type="pmid">19526525</pub-id></mixed-citation></ref><ref id="B267"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piccinin</surname><given-names>S.</given-names></name><name><surname>Tonin</surname><given-names>E.</given-names></name><name><surname>Sessa</surname><given-names>S.</given-names></name><name><surname>Demontis</surname><given-names>S.</given-names></name><name><surname>Rossi</surname><given-names>S.</given-names></name><name><surname>Pecciarini</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>A &#x0201c;twist box&#x0201d; code of p53 inactivation: twist box:p53 interaction promotes p53 degradation</article-title>. <source>Cancer Cell</source>
<volume>22</volume>, <fpage>404</fpage>&#x02013;<lpage>415</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2012.08.003</pub-id><pub-id pub-id-type="pmid">22975381</pub-id></mixed-citation></ref><ref id="B268"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>J. J.</given-names></name><name><surname>Nag</surname><given-names>S.</given-names></name><name><surname>Voruganti</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>R.</given-names></name></person-group> (<year>2012</year>). <article-title>Natural Product MDM2 Inhibitors: anticancer Activity and Mechanisms of Action</article-title>. <source>Curr. Med. Chem</source>. [Epub ahead of print].<pub-id pub-id-type="pmid">22830335</pub-id></mixed-citation></ref><ref id="B269"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raschella</surname><given-names>G.</given-names></name><name><surname>Negroni</surname><given-names>A.</given-names></name><name><surname>Giubilei</surname><given-names>C.</given-names></name><name><surname>Romeo</surname><given-names>A.</given-names></name><name><surname>Ferrari</surname><given-names>S.</given-names></name><name><surname>Castello</surname><given-names>M. A.</given-names></name><etal/></person-group> (<year>1991</year>). <article-title>Transcription of N-myc and proliferation-related genes is linked in human neuroblastoma</article-title>. <source>Cancer Lett.</source>
<volume>56</volume>, <fpage>45</fpage>&#x02013;<lpage>51</lpage><pub-id pub-id-type="doi">10.1016/0304-3835(91)90192-K</pub-id><pub-id pub-id-type="pmid">2004353</pub-id></mixed-citation></ref><ref id="B270"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raver-Shapira</surname><given-names>N.</given-names></name><name><surname>Marciano</surname><given-names>E.</given-names></name><name><surname>Meiri</surname><given-names>E.</given-names></name><name><surname>Spector</surname><given-names>Y.</given-names></name><name><surname>Rosenfeld</surname><given-names>N.</given-names></name><name><surname>Moskovits</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Transcriptional activation of miR-34a contributes to p53-mediated apoptosis</article-title>. <source>Mol. Cell</source>
<volume>26</volume>, <fpage>731</fpage>&#x02013;<lpage>743</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2007.05.017</pub-id><pub-id pub-id-type="pmid">17540598</pub-id></mixed-citation></ref><ref id="B271"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reisman</surname><given-names>D.</given-names></name><name><surname>Elkind</surname><given-names>N. B.</given-names></name><name><surname>Roy</surname><given-names>B.</given-names></name><name><surname>Beamon</surname><given-names>J.</given-names></name><name><surname>Rotter</surname><given-names>V.</given-names></name></person-group> (<year>1993</year>). <article-title>c-Myc trans-activates the p53 promoter through a required downstream CACGTG motif</article-title>. <source>Cell Growth Differ.</source>
<volume>4</volume>, <fpage>57</fpage>&#x02013;<lpage>65</lpage><pub-id pub-id-type="pmid">8494784</pub-id></mixed-citation></ref><ref id="B272"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Revet</surname><given-names>I.</given-names></name><name><surname>Huizenga</surname><given-names>G.</given-names></name><name><surname>Koster</surname><given-names>J.</given-names></name><name><surname>Volckmann</surname><given-names>R.</given-names></name><name><surname>Van Sluis</surname><given-names>P.</given-names></name><name><surname>Versteeg</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>MSX1 induces the Wnt pathway antagonist genes DKK1, DKK2, DKK3, and SFRP1 in neuroblastoma cells, but does not block Wnt3 and Wnt5A signalling to DVL3</article-title>. <source>Cancer Lett.</source>
<volume>289</volume>, <fpage>195</fpage>&#x02013;<lpage>207</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2009.08.019</pub-id><pub-id pub-id-type="pmid">19815336</pub-id></mixed-citation></ref><ref id="B273"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rico-Bautista</surname><given-names>E.</given-names></name><name><surname>Yang</surname><given-names>C. C.</given-names></name><name><surname>Lu</surname><given-names>L.</given-names></name><name><surname>Roth</surname><given-names>G. P.</given-names></name><name><surname>Wolf</surname><given-names>D. A.</given-names></name></person-group> (<year>2010</year>). <article-title>Chemical genetics approach to restoring p27Kip1 reveals novel compounds with antiproliferative activity in prostate cancer cells</article-title>. <source>BMC Biol.</source>
<volume>8</volume>, <fpage>153</fpage><pub-id pub-id-type="doi">10.1186/1741-7007-8-153</pub-id><pub-id pub-id-type="pmid">21182779</pub-id></mixed-citation></ref><ref id="B274"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riley</surname><given-names>T.</given-names></name><name><surname>Sontag</surname><given-names>E.</given-names></name><name><surname>Chen</surname><given-names>P.</given-names></name><name><surname>Levine</surname><given-names>A.</given-names></name></person-group> (<year>2008</year>). <article-title>Transcriptional control of human p53-regulated genes</article-title>. <source>Nat. Rev. Mol. Cell Biol.</source>
<volume>9</volume>, <fpage>402</fpage>&#x02013;<lpage>412</lpage><pub-id pub-id-type="doi">10.1038/nrm2395</pub-id><pub-id pub-id-type="pmid">18431400</pub-id></mixed-citation></ref><ref id="B275"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robertson</surname><given-names>K. D.</given-names></name><name><surname>Jones</surname><given-names>P. A.</given-names></name></person-group> (<year>1998</year>). <article-title>The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53</article-title>. <source>Mol. Cell. Biol.</source>
<volume>18</volume>, <fpage>6457</fpage>&#x02013;<lpage>6473</lpage><pub-id pub-id-type="pmid">9774662</pub-id></mixed-citation></ref><ref id="B276"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roman-Gomez</surname><given-names>J.</given-names></name><name><surname>Jimenez-Velasco</surname><given-names>A.</given-names></name><name><surname>Agirre</surname><given-names>X.</given-names></name><name><surname>Castillejo</surname><given-names>J. A.</given-names></name><name><surname>Navarro</surname><given-names>G.</given-names></name><name><surname>Barrios</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Transcriptional silencing of the Dickkopfs-3 (Dkk-3) gene by CpG hypermethylation in acute lymphoblastic leukaemia</article-title>. <source>Br. J. Cancer</source>
<volume>91</volume>, <fpage>707</fpage>&#x02013;<lpage>713</lpage><pub-id pub-id-type="pmid">15226763</pub-id></mixed-citation></ref><ref id="B277"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rose</surname><given-names>A. E.</given-names></name><name><surname>Wang</surname><given-names>G.</given-names></name><name><surname>Hanniford</surname><given-names>D.</given-names></name><name><surname>Monni</surname><given-names>S.</given-names></name><name><surname>Tu</surname><given-names>T.</given-names></name><name><surname>Shapiro</surname><given-names>R. L.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Clinical relevance of SKP2 alterations in metastatic melanoma</article-title>. <source>Pigment Cell Melanoma Res.</source>
<volume>24</volume>, <fpage>197</fpage>&#x02013;<lpage>206</lpage><pub-id pub-id-type="doi">10.1111/j.1755-148X.2010.00784.x</pub-id><pub-id pub-id-type="pmid">20883453</pub-id></mixed-citation></ref><ref id="B278"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roy</surname><given-names>B.</given-names></name><name><surname>Beamon</surname><given-names>J.</given-names></name><name><surname>Balint</surname><given-names>E.</given-names></name><name><surname>Reisman</surname><given-names>D.</given-names></name></person-group> (<year>1994</year>). <article-title>Transactivation of the human p53 tumor suppressor gene by c-Myc/Max contributes to elevated mutant p53 expression in some tumors</article-title>. <source>Mol. Cell. Biol.</source>
<volume>14</volume>, <fpage>7805</fpage>&#x02013;<lpage>7815</lpage><pub-id pub-id-type="pmid">7969121</pub-id></mixed-citation></ref><ref id="B279"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roy</surname><given-names>S.</given-names></name><name><surname>Kaur</surname><given-names>M.</given-names></name><name><surname>Agarwal</surname><given-names>C.</given-names></name><name><surname>Tecklenburg</surname><given-names>M.</given-names></name><name><surname>Sclafani</surname><given-names>R. A.</given-names></name><name><surname>Agarwal</surname><given-names>R.</given-names></name></person-group> (<year>2007</year>). <article-title>p21 and p27 induction by silibinin is essential for its cell cycle arrest effect in prostate carcinoma cells</article-title>. <source>Mol. Cancer Ther.</source>
<volume>6</volume>, <fpage>2696</fpage>&#x02013;<lpage>2707</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-07-0104</pub-id><pub-id pub-id-type="pmid">17938263</pub-id></mixed-citation></ref><ref id="B280"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sachdeva</surname><given-names>M.</given-names></name><name><surname>Zhu</surname><given-names>S.</given-names></name><name><surname>Wu</surname><given-names>F.</given-names></name><name><surname>Wu</surname><given-names>H.</given-names></name><name><surname>Walia</surname><given-names>V.</given-names></name><name><surname>Kumar</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>p53 represses c-Myc through induction of the tumor suppressor miR-145</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>106</volume>, <fpage>3207</fpage>&#x02013;<lpage>3212</lpage><pub-id pub-id-type="doi">10.1073/pnas.0808042106</pub-id><pub-id pub-id-type="pmid">19202062</pub-id></mixed-citation></ref><ref id="B281"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saigusa</surname><given-names>K.</given-names></name><name><surname>Hashimoto</surname><given-names>N.</given-names></name><name><surname>Tsuda</surname><given-names>H.</given-names></name><name><surname>Yokoi</surname><given-names>S.</given-names></name><name><surname>Maruno</surname><given-names>M.</given-names></name><name><surname>Yoshimine</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Overexpressed Skp2 within 5p amplification detected by array-based comparative genomic hybridization is associated with poor prognosis of glioblastomas</article-title>. <source>Cancer Sci.</source>
<volume>96</volume>, <fpage>676</fpage>&#x02013;<lpage>683</lpage><pub-id pub-id-type="doi">10.1111/j.1349-7006.2005.00099.x</pub-id><pub-id pub-id-type="pmid">16232199</pub-id></mixed-citation></ref><ref id="B282"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakaguchi</surname><given-names>M.</given-names></name><name><surname>Kataoka</surname><given-names>K.</given-names></name><name><surname>Abarzua</surname><given-names>F.</given-names></name><name><surname>Tanimoto</surname><given-names>R.</given-names></name><name><surname>Watanabe</surname><given-names>M.</given-names></name><name><surname>Murata</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Overexpression of REIC/Dkk-3 in normal fibroblasts suppresses tumor growth via induction of interleukin-7</article-title>. <source>J. Biol. Chem.</source>
<volume>284</volume>, <fpage>14236</fpage>&#x02013;<lpage>14244</lpage><pub-id pub-id-type="doi">10.1074/jbc.M808002200</pub-id><pub-id pub-id-type="pmid">19279003</pub-id></mixed-citation></ref><ref id="B283"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santos</surname><given-names>F. P.</given-names></name><name><surname>Kantarjian</surname><given-names>H.</given-names></name><name><surname>Garcia-Manero</surname><given-names>G.</given-names></name><name><surname>Issa</surname><given-names>J. P.</given-names></name><name><surname>Ravandi</surname><given-names>F.</given-names></name></person-group> (<year>2010</year>). <article-title>Decitabine in the treatment of myelodysplastic syndromes</article-title>. <source>Expert Rev Anticancer Ther</source>
<volume>10</volume>, <fpage>9</fpage>&#x02013;<lpage>22</lpage><pub-id pub-id-type="doi">10.1586/era.09.164</pub-id><pub-id pub-id-type="pmid">20014881</pub-id></mixed-citation></ref><ref id="B284"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarmento</surname><given-names>L. M.</given-names></name><name><surname>Huang</surname><given-names>H.</given-names></name><name><surname>Limon</surname><given-names>A.</given-names></name><name><surname>Gordon</surname><given-names>W.</given-names></name><name><surname>Fernandes</surname><given-names>J.</given-names></name><name><surname>Tavares</surname><given-names>M. J.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Notch1 modulates timing of G1-S progression by inducing SKP2 transcription and p27 Kip1 degradation</article-title>. <source>J. Exp. Med.</source>
<volume>202</volume>, <fpage>157</fpage>&#x02013;<lpage>168</lpage><pub-id pub-id-type="doi">10.1084/jem.20050559</pub-id><pub-id pub-id-type="pmid">15998794</pub-id></mixed-citation></ref><ref id="B285"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>G.</given-names></name><name><surname>Saur</surname><given-names>D.</given-names></name><name><surname>Siveke</surname><given-names>J. T.</given-names></name><name><surname>Fritsch</surname><given-names>R.</given-names></name><name><surname>Greten</surname><given-names>F. R.</given-names></name><name><surname>Schmid</surname><given-names>R. M.</given-names></name></person-group> (<year>2006</year>). <article-title>IKKalpha controls p52/RelB at the skp2 gene promoter to regulate G1- to S-phase progression</article-title>. <source>EMBO J.</source>
<volume>25</volume>, <fpage>3801</fpage>&#x02013;<lpage>3812</lpage><pub-id pub-id-type="doi">10.1038/sj.emboj.7601259</pub-id><pub-id pub-id-type="pmid">16902410</pub-id></mixed-citation></ref><ref id="B286"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schuler</surname><given-names>S.</given-names></name><name><surname>Diersch</surname><given-names>S.</given-names></name><name><surname>Hamacher</surname><given-names>R.</given-names></name><name><surname>Schmid</surname><given-names>R. M.</given-names></name><name><surname>Saur</surname><given-names>D.</given-names></name><name><surname>Schneider</surname><given-names>G.</given-names></name></person-group> (<year>2011</year>). <article-title>SKP2 confers resistance of pancreatic cancer cells towards TRAIL-induced apoptosis</article-title>. <source>Int. J. Oncol.</source>
<volume>38</volume>, <fpage>219</fpage>&#x02013;<lpage>225</lpage><pub-id pub-id-type="pmid">21109943</pub-id></mixed-citation></ref><ref id="B287"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulman</surname><given-names>B. A.</given-names></name><name><surname>Carrano</surname><given-names>A. C.</given-names></name><name><surname>Jeffrey</surname><given-names>P. D.</given-names></name><name><surname>Bowen</surname><given-names>Z.</given-names></name><name><surname>Kinnucan</surname><given-names>E. R.</given-names></name><name><surname>Finnin</surname><given-names>M. S.</given-names></name><etal/></person-group> (<year>2000</year>). <article-title>Insights into SCF ubiquitin ligases from the structure of the Skp1-Skp2 complex</article-title>. <source>Nature</source>
<volume>408</volume>, <fpage>381</fpage>&#x02013;<lpage>386</lpage><pub-id pub-id-type="doi">10.1038/35042620</pub-id><pub-id pub-id-type="pmid">11099048</pub-id></mixed-citation></ref><ref id="B288"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulte</surname><given-names>J. H.</given-names></name><name><surname>Horn</surname><given-names>S.</given-names></name><name><surname>Otto</surname><given-names>T.</given-names></name><name><surname>Samans</surname><given-names>B.</given-names></name><name><surname>Heukamp</surname><given-names>L. C.</given-names></name><name><surname>Eilers</surname><given-names>U. C.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>MYCN regulates oncogenic MicroRNAs in neuroblastoma</article-title>. <source>Int. J. Cancer</source>
<volume>122</volume>, <fpage>699</fpage>&#x02013;<lpage>704</lpage><pub-id pub-id-type="doi">10.1002/ijc.23153</pub-id><pub-id pub-id-type="pmid">17943719</pub-id></mixed-citation></ref><ref id="B289"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Schwab</surname><given-names>M.</given-names></name></person-group> (<year>2000</year>). <article-title>&#x0201c;MYCN amplification in neuroblastoma,&#x0201d;</article-title> in <source>Neuroblastoma</source>, Eds <person-group person-group-type="editor"><name><surname>Brodeur</surname><given-names>G. M.</given-names></name><name><surname>Sawada</surname><given-names>T.</given-names></name><name><surname>Tsuchida</surname><given-names>Y.</given-names></name><name><surname>Vo&#x000fb;te</surname><given-names>P. A.</given-names></name></person-group> (<publisher-loc>Amsterdam</publisher-loc>: <publisher-name>Elsevier Science B.V.</publisher-name>), <fpage>75</fpage>&#x02013;<lpage>83</lpage></mixed-citation></ref><ref id="B290"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seoane</surname><given-names>J.</given-names></name><name><surname>Le</surname><given-names>H. V.</given-names></name><name><surname>Massague</surname><given-names>J.</given-names></name></person-group> (<year>2002</year>). <article-title>Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage</article-title>. <source>Nature</source>
<volume>419</volume>, <fpage>729</fpage>&#x02013;<lpage>734</lpage><pub-id pub-id-type="doi">10.1038/nature01119</pub-id><pub-id pub-id-type="pmid">12384701</pub-id></mixed-citation></ref><ref id="B291"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shangary</surname><given-names>S.</given-names></name><name><surname>Ding</surname><given-names>K.</given-names></name><name><surname>Qiu</surname><given-names>S.</given-names></name><name><surname>Nikolovska-Coleska</surname><given-names>Z.</given-names></name><name><surname>Bauer</surname><given-names>J. A.</given-names></name><name><surname>Liu</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer</article-title>. <source>Mol. Cancer Ther.</source>
<volume>7</volume>, <fpage>1533</fpage>&#x02013;<lpage>1542</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-08-0140</pub-id><pub-id pub-id-type="pmid">18566224</pub-id></mixed-citation></ref><ref id="B292"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shapira</surname><given-names>M.</given-names></name><name><surname>Kakiashvili</surname><given-names>E.</given-names></name><name><surname>Rosenberg</surname><given-names>T.</given-names></name><name><surname>Hershko</surname><given-names>D. D.</given-names></name></person-group> (<year>2006</year>). <article-title>The mTOR inhibitor rapamycin down-regulates the expression of the ubiquitin ligase subunit Skp2 in breast cancer cells</article-title>. <source>Breast Cancer Res.</source>
<volume>8</volume>, <fpage>R46</fpage><pub-id pub-id-type="doi">10.1186/bcr1461</pub-id><pub-id pub-id-type="pmid">16859513</pub-id></mixed-citation></ref><ref id="B293"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shibahara</surname><given-names>T.</given-names></name><name><surname>Onishi</surname><given-names>T.</given-names></name><name><surname>Franco</surname><given-names>O. E.</given-names></name><name><surname>Arima</surname><given-names>K.</given-names></name><name><surname>Sugimura</surname><given-names>Y.</given-names></name></person-group> (<year>2005</year>). <article-title>Down-regulation of Skp2 is correlated with p27-associated cell cycle arrest induced by phenylacetate in human prostate cancer cells</article-title>. <source>Anticancer Res.</source>
<volume>25</volume>, <fpage>1881</fpage>&#x02013;<lpage>1888</lpage><pub-id pub-id-type="pmid">16158921</pub-id></mixed-citation></ref><ref id="B294"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shim</surname><given-names>E. H.</given-names></name><name><surname>Johnson</surname><given-names>L.</given-names></name><name><surname>Noh</surname><given-names>H. L.</given-names></name><name><surname>Kim</surname><given-names>Y. J.</given-names></name><name><surname>Sun</surname><given-names>H.</given-names></name><name><surname>Zeiss</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2003</year>). <article-title>Expression of the F-box protein SKP2 induces hyperplasia, dysplasia, and low-grade carcinoma in the mouse prostate</article-title>. <source>Cancer Res.</source>
<volume>63</volume>, <fpage>1583</fpage>&#x02013;<lpage>1588</lpage><pub-id pub-id-type="pmid">12670908</pub-id></mixed-citation></ref><ref id="B295"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimada</surname><given-names>H.</given-names></name><name><surname>Ambros</surname><given-names>I. M.</given-names></name><name><surname>Dehner</surname><given-names>L. P.</given-names></name><name><surname>Hata</surname><given-names>J.</given-names></name><name><surname>Joshi</surname><given-names>V. V.</given-names></name><name><surname>Roald</surname><given-names>B.</given-names></name></person-group> (<year>1999</year>). <article-title>Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee</article-title>. <source>Cancer</source>
<volume>86</volume>, <fpage>349</fpage>&#x02013;<lpage>363</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-0142(19990715)86:2&#x0003c;364::AID-CNCR21&#x0003e;3.3.CO;2-Z</pub-id><pub-id pub-id-type="pmid">10421272</pub-id></mixed-citation></ref><ref id="B296"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimada</surname><given-names>H.</given-names></name><name><surname>Stram</surname><given-names>D. O.</given-names></name><name><surname>Chatten</surname><given-names>J.</given-names></name><name><surname>Joshi</surname><given-names>V. V.</given-names></name><name><surname>Hachitanda</surname><given-names>Y.</given-names></name><name><surname>Brodeur</surname><given-names>G. M.</given-names></name><etal/></person-group> (<year>1995</year>). <article-title>Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis</article-title>. <source>J. Natl. Cancer Inst.</source>
<volume>87</volume>, <fpage>1470</fpage>&#x02013;<lpage>1476</lpage><pub-id pub-id-type="doi">10.1093/jnci/87.19.1470</pub-id><pub-id pub-id-type="pmid">7674334</pub-id></mixed-citation></ref><ref id="B297"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimono</surname><given-names>A.</given-names></name><name><surname>Okuda</surname><given-names>T.</given-names></name><name><surname>Kondoh</surname><given-names>H.</given-names></name></person-group> (<year>1999</year>). <article-title>N-myc-dependent repression of ndr1, a gene identified by direct subtraction of whole mouse embryo cDNAs between wild type and N-myc mutant</article-title>. <source>Mech. Dev.</source>
<volume>83</volume>, <fpage>39</fpage>&#x02013;<lpage>52</lpage><pub-id pub-id-type="doi">10.1016/S0925-4773(99)00025-8</pub-id><pub-id pub-id-type="pmid">10381566</pub-id></mixed-citation></ref><ref id="B298"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shiota</surname><given-names>M.</given-names></name><name><surname>Izumi</surname><given-names>H.</given-names></name><name><surname>Onitsuka</surname><given-names>T.</given-names></name><name><surname>Miyamoto</surname><given-names>N.</given-names></name><name><surname>Kashiwagi</surname><given-names>E.</given-names></name><name><surname>Kidani</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Twist and p53 reciprocally regulate target genes via direct interaction</article-title>. <source>Oncogene</source>
<volume>27</volume>, <fpage>5543</fpage>&#x02013;<lpage>5553</lpage><pub-id pub-id-type="doi">10.1038/onc.2008.176</pub-id><pub-id pub-id-type="pmid">18504427</pub-id></mixed-citation></ref><ref id="B299"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sidell</surname><given-names>N.</given-names></name><name><surname>Koeffler</surname><given-names>H. P.</given-names></name></person-group> (<year>1988</year>). <article-title>Modulation of Mr 53,000 protein with induction of differentiation of human neuroblastoma cells</article-title>. <source>Cancer Res.</source>
<volume>48</volume>, <fpage>2226</fpage>&#x02013;<lpage>2230</lpage><pub-id pub-id-type="pmid">3280124</pub-id></mixed-citation></ref><ref id="B300"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Signoretti</surname><given-names>S.</given-names></name><name><surname>Di Marcotullio</surname><given-names>L.</given-names></name><name><surname>Richardson</surname><given-names>A.</given-names></name><name><surname>Ramaswamy</surname><given-names>S.</given-names></name><name><surname>Isaac</surname><given-names>B.</given-names></name><name><surname>Rue</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2002</year>). <article-title>Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer</article-title>. <source>J. Clin. Invest.</source>
<volume>110</volume>, <fpage>633</fpage>&#x02013;<lpage>641</lpage><pub-id pub-id-type="doi">10.1172/JCI15795</pub-id><pub-id pub-id-type="pmid">12208864</pub-id></mixed-citation></ref><ref id="B301"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skowyra</surname><given-names>D.</given-names></name><name><surname>Craig</surname><given-names>K. L.</given-names></name><name><surname>Tyers</surname><given-names>M.</given-names></name><name><surname>Elledge</surname><given-names>S. J.</given-names></name><name><surname>Harper</surname><given-names>J. W.</given-names></name></person-group> (<year>1997</year>). <article-title>F-box proteins are receptors that recruit phosphorylated substrates to the SCF ubiquitin-ligase complex</article-title>. <source>Cell</source>
<volume>91</volume>, <fpage>209</fpage>&#x02013;<lpage>219</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)80403-1</pub-id><pub-id pub-id-type="pmid">9346238</pub-id></mixed-citation></ref><ref id="B302"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slack</surname><given-names>A.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Tonelli</surname><given-names>R.</given-names></name><name><surname>Pule</surname><given-names>M.</given-names></name><name><surname>Hunt</surname><given-names>L.</given-names></name><name><surname>Pession</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>102</volume>, <fpage>731</fpage>&#x02013;<lpage>736</lpage><pub-id pub-id-type="doi">10.1073/pnas.0405495102</pub-id><pub-id pub-id-type="pmid">15644444</pub-id></mixed-citation></ref><ref id="B303"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slack</surname><given-names>A. D.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Ludwig</surname><given-names>A. D.</given-names></name><name><surname>Hicks</surname><given-names>J.</given-names></name><name><surname>Shohet</surname><given-names>J. M.</given-names></name></person-group> (<year>2007</year>). <article-title>MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells</article-title>. <source>Cancer Res.</source>
<volume>67</volume>, <fpage>2448</fpage>&#x02013;<lpage>2455</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-1661</pub-id><pub-id pub-id-type="pmid">17363562</pub-id></mixed-citation></ref><ref id="B304"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smart</surname><given-names>P.</given-names></name><name><surname>Lane</surname><given-names>E. B.</given-names></name><name><surname>Lane</surname><given-names>D. P.</given-names></name><name><surname>Midgley</surname><given-names>C.</given-names></name><name><surname>Vojtesek</surname><given-names>B.</given-names></name><name><surname>Lain</surname><given-names>S.</given-names></name></person-group> (<year>1999</year>). <article-title>Effects on normal fibroblasts and neuroblastoma cells of the activation of the p53 response by the nuclear export inhibitor leptomycin B</article-title>. <source>Oncogene</source>
<volume>18</volume>, <fpage>7378</fpage>&#x02013;<lpage>7386</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1203260</pub-id><pub-id pub-id-type="pmid">10602494</pub-id></mixed-citation></ref><ref id="B305"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>M. A.</given-names></name><name><surname>Maris</surname><given-names>J. M.</given-names></name><name><surname>Gorlick</surname><given-names>R.</given-names></name><name><surname>Kolb</surname><given-names>E. A.</given-names></name><name><surname>Lock</surname><given-names>R.</given-names></name><name><surname>Carol</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program</article-title>. <source>Pediatr. Blood Cancer</source>
<volume>59</volume>, <fpage>246</fpage>&#x02013;<lpage>253</lpage><pub-id pub-id-type="doi">10.1002/pbc.23319</pub-id><pub-id pub-id-type="pmid">22012946</pub-id></mixed-citation></ref><ref id="B306"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>H.</given-names></name><name><surname>Hollstein</surname><given-names>M.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name></person-group> (<year>2007</year>). <article-title>p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM</article-title>. <source>Nat. Cell Biol.</source>
<volume>9</volume>, <fpage>573</fpage>&#x02013;<lpage>580</lpage><pub-id pub-id-type="doi">10.1038/ncb0807-869</pub-id><pub-id pub-id-type="pmid">17417627</pub-id></mixed-citation></ref><ref id="B307"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>M. S.</given-names></name><name><surname>Song</surname><given-names>S. J.</given-names></name><name><surname>Kim</surname><given-names>S. J.</given-names></name><name><surname>Nakayama</surname><given-names>K.</given-names></name><name><surname>Nakayama</surname><given-names>K. I.</given-names></name><name><surname>Lim</surname><given-names>D. S.</given-names></name></person-group> (<year>2008</year>). <article-title>Skp2 regulates the antiproliferative function of the tumor suppressor RASSF1A via ubiquitin-mediated degradation at the G1-S transition</article-title>. <source>Oncogene</source>
<volume>27</volume>, <fpage>3176</fpage>&#x02013;<lpage>3185</lpage><pub-id pub-id-type="doi">10.1038/onc.2008.190</pub-id><pub-id pub-id-type="pmid">18071316</pub-id></mixed-citation></ref><ref id="B308"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soucy</surname><given-names>T. A.</given-names></name><name><surname>Smith</surname><given-names>P. G.</given-names></name><name><surname>Milhollen</surname><given-names>M. A.</given-names></name><name><surname>Berger</surname><given-names>A. J.</given-names></name><name><surname>Gavin</surname><given-names>J. M.</given-names></name><name><surname>Adhikari</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer</article-title>. <source>Nature</source>
<volume>458</volume>, <fpage>732</fpage>&#x02013;<lpage>736</lpage><pub-id pub-id-type="doi">10.1038/nature07884</pub-id><pub-id pub-id-type="pmid">19360080</pub-id></mixed-citation></ref><ref id="B309"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soussi</surname><given-names>T.</given-names></name><name><surname>Dehouche</surname><given-names>K.</given-names></name><name><surname>Beroud</surname><given-names>C.</given-names></name></person-group> (<year>2000</year>). <article-title>p53 website and analysis of p53 gene mutations in human cancer: forging a link between epidemiology and carcinogenesis</article-title>. <source>Hum. Mutat.</source>
<volume>15</volume>, <fpage>105</fpage>&#x02013;<lpage>113</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1098-1004(200001)15:1&#x0003c;105::AID-HUMU19&#x0003c;3.0.CO;2-G</pub-id><pub-id pub-id-type="pmid">10612830</pub-id></mixed-citation></ref><ref id="B310"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Speidel</surname><given-names>D.</given-names></name><name><surname>Helmbold</surname><given-names>H.</given-names></name><name><surname>Deppert</surname><given-names>W.</given-names></name></person-group> (<year>2006</year>). <article-title>Dissection of transcriptional and non-transcriptional p53 activities in the response to genotoxic stress</article-title>. <source>Oncogene</source>
<volume>25</volume>, <fpage>940</fpage>&#x02013;<lpage>953</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1209126</pub-id><pub-id pub-id-type="pmid">16247471</pub-id></mixed-citation></ref><ref id="B311"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spitz</surname><given-names>R.</given-names></name><name><surname>Oberthuer</surname><given-names>A.</given-names></name><name><surname>Zapatka</surname><given-names>M.</given-names></name><name><surname>Brors</surname><given-names>B.</given-names></name><name><surname>Hero</surname><given-names>B.</given-names></name><name><surname>Ernestus</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Oligonucleotide array-based comparative genomic hybridization (aCGH) of 90 neuroblastomas reveals aberration patterns closely associated with relapse pattern and outcome</article-title>. <source>Genes Chromosomes Cancer</source>
<volume>45</volume>, <fpage>1130</fpage>&#x02013;<lpage>1142</lpage><pub-id pub-id-type="doi">10.1002/gcc.20376</pub-id><pub-id pub-id-type="pmid">16958102</pub-id></mixed-citation></ref><ref id="B312"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spruck</surname><given-names>C.</given-names></name><name><surname>Strohmaier</surname><given-names>H.</given-names></name><name><surname>Watson</surname><given-names>M.</given-names></name><name><surname>Smith</surname><given-names>A. P.</given-names></name><name><surname>Ryan</surname><given-names>A.</given-names></name><name><surname>Krek</surname><given-names>T. W.</given-names></name><etal/></person-group> (<year>2001</year>). <article-title>A CDK-independent function of mammalian Cks1: targeting of SCF(Skp2) to the CDK inhibitor p27Kip1</article-title>. <source>Mol. Cell</source>
<volume>7</volume>, <fpage>639</fpage>&#x02013;<lpage>650</lpage><pub-id pub-id-type="doi">10.1016/S1097-2765(01)00210-6</pub-id><pub-id pub-id-type="pmid">11463388</pub-id></mixed-citation></ref><ref id="B313"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Staller</surname><given-names>P.</given-names></name><name><surname>Peukert</surname><given-names>K.</given-names></name><name><surname>Kiermaier</surname><given-names>A.</given-names></name><name><surname>Seoane</surname><given-names>J.</given-names></name><name><surname>Lukas</surname><given-names>J.</given-names></name><name><surname>Karsunky</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2001</year>). <article-title>Repression of p15INK4b expression by Myc through association with Miz-1</article-title>. <source>Nat. Cell Biol.</source>
<volume>3</volume>, <fpage>392</fpage>&#x02013;<lpage>399</lpage><pub-id pub-id-type="doi">10.1038/35070076</pub-id><pub-id pub-id-type="pmid">11283613</pub-id></mixed-citation></ref><ref id="B314"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stasinopoulos</surname><given-names>I. A.</given-names></name><name><surname>Mironchik</surname><given-names>Y.</given-names></name><name><surname>Raman</surname><given-names>A.</given-names></name><name><surname>Wildes</surname><given-names>F.</given-names></name><name><surname>Winnard</surname><given-names>P.</given-names><suffix>Jr.</suffix></name><name><surname>Raman</surname><given-names>V.</given-names></name></person-group> (<year>2005</year>). <article-title>HOXA5-twist interaction alters p53 homeostasis in breast cancer cells</article-title>. <source>J. Biol. Chem.</source>
<volume>280</volume>, <fpage>2294</fpage>&#x02013;<lpage>2299</lpage><pub-id pub-id-type="doi">10.1074/jbc.M411018200</pub-id><pub-id pub-id-type="pmid">15545268</pub-id></mixed-citation></ref><ref id="B315"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stein</surname><given-names>S.</given-names></name><name><surname>Thomas</surname><given-names>E. K.</given-names></name><name><surname>Herzog</surname><given-names>B.</given-names></name><name><surname>Westfall</surname><given-names>M. D.</given-names></name><name><surname>Rocheleau</surname><given-names>J. V.</given-names></name><name><surname>Jackson</surname><given-names>R. S.</given-names><suffix>II</suffix></name><etal/></person-group> (<year>2004</year>). <article-title>NDRG1 is necessary for p53-dependent apoptosis</article-title>. <source>J. Biol. Chem.</source>
<volume>279</volume>, <fpage>48930</fpage>&#x02013;<lpage>48940</lpage><pub-id pub-id-type="doi">10.1074/jbc.M400386200</pub-id><pub-id pub-id-type="pmid">15377670</pub-id></mixed-citation></ref><ref id="B316"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stommel</surname><given-names>J. M.</given-names></name><name><surname>Marchenko</surname><given-names>N. D.</given-names></name><name><surname>Jimenez</surname><given-names>G. S.</given-names></name><name><surname>Moll</surname><given-names>U. M.</given-names></name><name><surname>Hope</surname><given-names>T. J.</given-names></name><name><surname>Wahl</surname><given-names>G. M.</given-names></name></person-group> (<year>1999</year>). <article-title>A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking</article-title>. <source>EMBO J.</source>
<volume>18</volume>, <fpage>1660</fpage>&#x02013;<lpage>1672</lpage><pub-id pub-id-type="doi">10.1093/emboj/18.6.1660</pub-id><pub-id pub-id-type="pmid">10075936</pub-id></mixed-citation></ref><ref id="B317"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stott</surname><given-names>F. J.</given-names></name><name><surname>Bates</surname><given-names>S.</given-names></name><name><surname>James</surname><given-names>M. C.</given-names></name><name><surname>Mcconnell</surname><given-names>B. B.</given-names></name><name><surname>Starborg</surname><given-names>M.</given-names></name><name><surname>Brookes</surname><given-names>S.</given-names></name><etal/></person-group> (<year>1998</year>). <article-title>The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2</article-title>. <source>EMBO J.</source>
<volume>17</volume>, <fpage>5001</fpage>&#x02013;<lpage>5014</lpage><pub-id pub-id-type="doi">10.1093/emboj/17.17.5001</pub-id><pub-id pub-id-type="pmid">9724636</pub-id></mixed-citation></ref><ref id="B318"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>W. T.</given-names></name><name><surname>Alaminos</surname><given-names>M.</given-names></name><name><surname>Mora</surname><given-names>J.</given-names></name><name><surname>Cheung</surname><given-names>N. K.</given-names></name><name><surname>La Quaglia</surname><given-names>M. P.</given-names></name><name><surname>Gerald</surname><given-names>W. L.</given-names></name></person-group> (<year>2004</year>). <article-title>Positional gene expression analysis identifies 12q overexpression and amplification in a subset of neuroblastomas</article-title>. <source>Cancer Genet. Cytogenet.</source>
<volume>154</volume>, <fpage>131</fpage>&#x02013;<lpage>137</lpage><pub-id pub-id-type="doi">10.1016/j.cancergencyto.2004.02.009</pub-id><pub-id pub-id-type="pmid">15474148</pub-id></mixed-citation></ref><ref id="B319"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugihara</surname><given-names>E.</given-names></name><name><surname>Kanai</surname><given-names>M.</given-names></name><name><surname>Saito</surname><given-names>S.</given-names></name><name><surname>Nitta</surname><given-names>T.</given-names></name><name><surname>Toyoshima</surname><given-names>H.</given-names></name><name><surname>Nakayama</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Suppression of centrosome amplification after DNA damage depends on p27 accumulation</article-title>. <source>Cancer Res.</source>
<volume>66</volume>, <fpage>4020</fpage>&#x02013;<lpage>4029</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-3250</pub-id><pub-id pub-id-type="pmid">16618721</pub-id></mixed-citation></ref><ref id="B320"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugiyama</surname><given-names>H.</given-names></name><name><surname>Arita</surname><given-names>M.</given-names></name><name><surname>Min</surname><given-names>Z.</given-names></name><name><surname>Zhong</surname><given-names>X.</given-names></name><name><surname>Iwasaki</surname><given-names>I.</given-names></name><name><surname>Hirano</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2003</year>). <article-title>A novel dysfunctional p53 mutation in the human neuroblastoma cell line TGW</article-title>. <source>Tohoku J. Exp. Med.</source>
<volume>201</volume>, <fpage>229</fpage>&#x02013;<lpage>237</lpage><pub-id pub-id-type="doi">10.1620/tjem.201.229</pub-id><pub-id pub-id-type="pmid">14690015</pub-id></mixed-citation></ref><ref id="B321"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sutterluty</surname><given-names>H.</given-names></name><name><surname>Chatelain</surname><given-names>E.</given-names></name><name><surname>Marti</surname><given-names>A.</given-names></name><name><surname>Wirbelauer</surname><given-names>C.</given-names></name><name><surname>Senften</surname><given-names>M.</given-names></name><name><surname>Muller</surname><given-names>U.</given-names></name><etal/></person-group> (<year>1999</year>). <article-title>p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells</article-title>. <source>Nat. Cell Biol.</source>
<volume>1</volume>, <fpage>207</fpage>&#x02013;<lpage>214</lpage><pub-id pub-id-type="doi">10.1038/12027</pub-id><pub-id pub-id-type="pmid">10559918</pub-id></mixed-citation></ref><ref id="B322"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swarbrick</surname><given-names>A.</given-names></name><name><surname>Woods</surname><given-names>S. L.</given-names></name><name><surname>Shaw</surname><given-names>A.</given-names></name><name><surname>Balakrishnan</surname><given-names>A.</given-names></name><name><surname>Phua</surname><given-names>Y.</given-names></name><name><surname>Nguyen</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma</article-title>. <source>Nat. Med.</source>
<volume>16</volume>, <fpage>1134</fpage>&#x02013;<lpage>1140</lpage><pub-id pub-id-type="doi">10.1038/nm.2227</pub-id><pub-id pub-id-type="pmid">20871609</pub-id></mixed-citation></ref><ref id="B323"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanimoto</surname><given-names>R.</given-names></name><name><surname>Abarzua</surname><given-names>F.</given-names></name><name><surname>Sakaguchi</surname><given-names>M.</given-names></name><name><surname>Takaishi</surname><given-names>M.</given-names></name><name><surname>Nasu</surname><given-names>Y.</given-names></name><name><surname>Kumon</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>REIC/Dkk-3 as a potential gene therapeutic agent against human testicular cancer</article-title>. <source>Int. J. Mol. Med.</source>
<volume>19</volume>, <fpage>363</fpage>&#x02013;<lpage>368</lpage><pub-id pub-id-type="pmid">17273781</pub-id></mixed-citation></ref><ref id="B324"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tao</surname><given-names>W.</given-names></name><name><surname>Levine</surname><given-names>A. J.</given-names></name></person-group> (<year>1999a</year>). <article-title>Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>96</volume>, <fpage>3077</fpage>&#x02013;<lpage>3080</lpage><pub-id pub-id-type="doi">10.1073/pnas.96.6.3077</pub-id><pub-id pub-id-type="pmid">10077639</pub-id></mixed-citation></ref><ref id="B325"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tao</surname><given-names>W.</given-names></name><name><surname>Levine</surname><given-names>A. J.</given-names></name></person-group> (<year>1999b</year>). <article-title>P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>96</volume>, <fpage>6937</fpage>&#x02013;<lpage>6941</lpage><pub-id pub-id-type="doi">10.1073/pnas.96.6.3077</pub-id><pub-id pub-id-type="pmid">10359817</pub-id></mixed-citation></ref><ref id="B326"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tarasov</surname><given-names>V.</given-names></name><name><surname>Jung</surname><given-names>P.</given-names></name><name><surname>Verdoodt</surname><given-names>B.</given-names></name><name><surname>Lodygin</surname><given-names>D.</given-names></name><name><surname>Epanchintsev</surname><given-names>A.</given-names></name><name><surname>Menssen</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest</article-title>. <source>Cell Cycle</source>
<volume>6</volume>, <fpage>1586</fpage>&#x02013;<lpage>1593</lpage><pub-id pub-id-type="doi">10.4161/cc.6.20.4783</pub-id><pub-id pub-id-type="pmid">17554199</pub-id></mixed-citation></ref><ref id="B327"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tedesco</surname><given-names>D.</given-names></name><name><surname>Lukas</surname><given-names>J.</given-names></name><name><surname>Reed</surname><given-names>S. I.</given-names></name></person-group> (<year>2002</year>). <article-title>The pRb-related protein p130 is regulated by phosphorylation-dependent proteolysis via the protein-ubiquitin ligase SCF(Skp2)</article-title>. <source>Genes Dev.</source>
<volume>16</volume>, <fpage>2946</fpage>&#x02013;<lpage>2957</lpage><pub-id pub-id-type="doi">10.1101/gad.1011202</pub-id><pub-id pub-id-type="pmid">12435635</pub-id></mixed-citation></ref><ref id="B328"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teitz</surname><given-names>T.</given-names></name><name><surname>Wei</surname><given-names>T.</given-names></name><name><surname>Liu</surname><given-names>D.</given-names></name><name><surname>Valentine</surname><given-names>V.</given-names></name><name><surname>Valentine</surname><given-names>M.</given-names></name><name><surname>Grenet</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2002</year>). <article-title>Caspase-9 and Apaf-1 are expressed and functionally active in human neuroblastoma tumor cell lines with 1p36 LOH and amplified MYCN</article-title>. <source>Oncogene</source>
<volume>21</volume>, <fpage>1848</fpage>&#x02013;<lpage>1858</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1205180</pub-id><pub-id pub-id-type="pmid">11896617</pub-id></mixed-citation></ref><ref id="B329"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Than</surname><given-names>S. S.</given-names></name><name><surname>Kataoka</surname><given-names>K.</given-names></name><name><surname>Sakaguchi</surname><given-names>M.</given-names></name><name><surname>Murata</surname><given-names>H.</given-names></name><name><surname>Abarzua</surname><given-names>F.</given-names></name><name><surname>Taketa</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Intraperitoneal administration of an adenovirus vector carrying REIC/Dkk-3 suppresses peritoneal dissemination of scirrhous gastric carcinoma</article-title>. <source>Oncol. Rep.</source>
<volume>25</volume>, <fpage>989</fpage>&#x02013;<lpage>995</lpage><pub-id pub-id-type="pmid">21249317</pub-id></mixed-citation></ref><ref id="B330"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>P. M.</given-names></name><name><surname>Gotoh</surname><given-names>T.</given-names></name><name><surname>Kok</surname><given-names>M.</given-names></name><name><surname>White</surname><given-names>P. S.</given-names></name><name><surname>Brodeur</surname><given-names>G. M.</given-names></name></person-group> (<year>2003</year>). <article-title>CHD5, a new member of the chromodomain gene family, is preferentially expressed in the nervous system</article-title>. <source>Oncogene</source>
<volume>22</volume>, <fpage>1002</fpage>&#x02013;<lpage>1011</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1206325</pub-id><pub-id pub-id-type="pmid">12592387</pub-id></mixed-citation></ref><ref id="B331"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>P. M.</given-names></name><name><surname>Maris</surname><given-names>J. M.</given-names></name><name><surname>Hogarty</surname><given-names>M. D.</given-names></name><name><surname>Seeger</surname><given-names>R. C.</given-names></name><name><surname>Reynolds</surname><given-names>C. P.</given-names></name><name><surname>Brodeur</surname><given-names>G. M.</given-names></name><etal/></person-group> (<year>2001</year>). <article-title>Homozygous deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36 or at other tumor suppressor loci in neuroblastoma</article-title>. <source>Cancer Res.</source>
<volume>61</volume>, <fpage>679</fpage>&#x02013;<lpage>686</lpage><pub-id pub-id-type="pmid">11212268</pub-id></mixed-citation></ref><ref id="B332"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tivnan</surname><given-names>A.</given-names></name><name><surname>Orr</surname><given-names>W. S.</given-names></name><name><surname>Gubala</surname><given-names>V.</given-names></name><name><surname>Nooney</surname><given-names>R.</given-names></name><name><surname>Williams</surname><given-names>D. E.</given-names></name><name><surname>Mcdonagh</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles</article-title>. <source>PLoS ONE</source>
<volume>7</volume>, <fpage>e38129</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0038129</pub-id><pub-id pub-id-type="pmid">22662276</pub-id></mixed-citation></ref><ref id="B333"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Totary-Jain</surname><given-names>H.</given-names></name><name><surname>Sanoudou</surname><given-names>D.</given-names></name><name><surname>Dautriche</surname><given-names>C. N.</given-names></name><name><surname>Schneller</surname><given-names>H.</given-names></name><name><surname>Zambrana</surname><given-names>L.</given-names></name><name><surname>Marks</surname><given-names>A. R.</given-names></name></person-group> (<year>2012</year>). <article-title>Rapamycin resistance is linked to defective regulation of Skp2</article-title>. <source>Cancer Res.</source>
<volume>72</volume>, <fpage>1836</fpage>&#x02013;<lpage>1843</lpage><pub-id pub-id-type="doi">10.1158/1538-7445.AM2012-1836</pub-id><pub-id pub-id-type="pmid">22311674</pub-id></mixed-citation></ref><ref id="B334"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsuji</surname><given-names>T.</given-names></name><name><surname>Miyazaki</surname><given-names>M.</given-names></name><name><surname>Sakaguchi</surname><given-names>M.</given-names></name><name><surname>Inoue</surname><given-names>Y.</given-names></name><name><surname>Namba</surname><given-names>M.</given-names></name></person-group> (<year>2000</year>). <article-title>A REIC gene shows down-regulation in human immortalized cells and human tumor-derived cell lines</article-title>. <source>Biochem. Biophys. Res. Commun.</source>
<volume>268</volume>, <fpage>20</fpage>&#x02013;<lpage>24</lpage><pub-id pub-id-type="doi">10.1006/bbrc.1999.2067</pub-id><pub-id pub-id-type="pmid">10652205</pub-id></mixed-citation></ref><ref id="B335"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsuji</surname><given-names>T.</given-names></name><name><surname>Nozaki</surname><given-names>I.</given-names></name><name><surname>Miyazaki</surname><given-names>M.</given-names></name><name><surname>Sakaguchi</surname><given-names>M.</given-names></name><name><surname>Pu</surname><given-names>H.</given-names></name><name><surname>Hamazaki</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2001</year>). <article-title>Antiproliferative activity of REIC/Dkk-3 and its significant down-regulation in non-small-cell lung carcinomas</article-title>. <source>Biochem. Biophys. Res. Commun.</source>
<volume>289</volume>, <fpage>257</fpage>&#x02013;<lpage>263</lpage><pub-id pub-id-type="doi">10.1006/bbrc.2001.5972</pub-id><pub-id pub-id-type="pmid">11708809</pub-id></mixed-citation></ref><ref id="B336"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsvetkov</surname><given-names>L. M.</given-names></name><name><surname>Yeh</surname><given-names>K. H.</given-names></name><name><surname>Lee</surname><given-names>S. J.</given-names></name><name><surname>Sun</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name></person-group> (<year>1999</year>). <article-title>p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27</article-title>. <source>Curr. Biol.</source>
<volume>9</volume>, <fpage>661</fpage>&#x02013;<lpage>664</lpage><pub-id pub-id-type="doi">10.1016/S0960-9822(99)80418-7</pub-id><pub-id pub-id-type="pmid">10375532</pub-id></mixed-citation></ref><ref id="B337"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tweddle</surname><given-names>D. A.</given-names></name><name><surname>Malcolm</surname><given-names>A. J.</given-names></name><name><surname>Bown</surname><given-names>N.</given-names></name><name><surname>Pearson</surname><given-names>A. D.</given-names></name><name><surname>Lunec</surname><given-names>J.</given-names></name></person-group> (<year>2001a</year>). <article-title>Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line</article-title>. <source>Cancer Res.</source>
<volume>61</volume>, <fpage>8</fpage>&#x02013;<lpage>13</lpage><pub-id pub-id-type="pmid">11196202</pub-id></mixed-citation></ref><ref id="B338"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tweddle</surname><given-names>D. A.</given-names></name><name><surname>Malcolm</surname><given-names>A. J.</given-names></name><name><surname>Cole</surname><given-names>M.</given-names></name><name><surname>Pearson</surname><given-names>A. D.</given-names></name><name><surname>Lunec</surname><given-names>J.</given-names></name></person-group> (<year>2001b</year>). <article-title>p53 cellular localization and function in neuroblastoma: evidence for defective G(1) arrest despite WAF1 induction in MYCN-amplified cells</article-title>. <source>Am. J. Pathol.</source>
<volume>158</volume>, <fpage>2067</fpage>&#x02013;<lpage>2077</lpage><pub-id pub-id-type="doi">10.1016/S0002-9440(10)64678-0</pub-id><pub-id pub-id-type="pmid">11395384</pub-id></mixed-citation></ref><ref id="B339"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tweddle</surname><given-names>D. A.</given-names></name><name><surname>Pearson</surname><given-names>A. D.</given-names></name><name><surname>Haber</surname><given-names>M.</given-names></name><name><surname>Norris</surname><given-names>M. D.</given-names></name><name><surname>Xue</surname><given-names>C.</given-names></name><name><surname>Flemming</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2003</year>). <article-title>The p53 pathway and its inactivation in neuroblastoma</article-title>. <source>Cancer Lett.</source>
<volume>197</volume>, <fpage>93</fpage>&#x02013;<lpage>98</lpage><pub-id pub-id-type="doi">10.1016/S0304-3835(03)00088-0</pub-id><pub-id pub-id-type="pmid">12880966</pub-id></mixed-citation></ref><ref id="B340"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uddin</surname><given-names>S.</given-names></name><name><surname>Ahmed</surname><given-names>M.</given-names></name><name><surname>Bavi</surname><given-names>P.</given-names></name><name><surname>El-Sayed</surname><given-names>R.</given-names></name><name><surname>Al-Sanea</surname><given-names>N.</given-names></name><name><surname>Abduljabbar</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Bortezomib (Velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer</article-title>. <source>Cancer Res.</source>
<volume>68</volume>, <fpage>3379</fpage>&#x02013;<lpage>3388</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-6109</pub-id><pub-id pub-id-type="pmid">18451165</pub-id></mixed-citation></ref><ref id="B341"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uddin</surname><given-names>S.</given-names></name><name><surname>Ahmed</surname><given-names>M.</given-names></name><name><surname>Hussain</surname><given-names>A. R.</given-names></name><name><surname>Jehan</surname><given-names>Z.</given-names></name><name><surname>Al-Dayel</surname><given-names>F.</given-names></name><name><surname>Munkarah</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Bortezomib-mediated expression of p27Kip1 through S-phase kinase protein 2 degradation in epithelial ovarian cancer</article-title>. <source>Lab. Invest.</source>
<volume>89</volume>, <fpage>1115</fpage>&#x02013;<lpage>1127</lpage><pub-id pub-id-type="doi">10.1038/labinvest.2009.75</pub-id><pub-id pub-id-type="pmid">19636294</pub-id></mixed-citation></ref><ref id="B342"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ueno</surname><given-names>K.</given-names></name><name><surname>Hirata</surname><given-names>H.</given-names></name><name><surname>Majid</surname><given-names>S.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Zaman</surname><given-names>M. S.</given-names></name><name><surname>Tabatabai</surname><given-names>Z. L.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Wnt antagonist DICKKOPF-3 (Dkk-3) induces apoptosis in human renal cell carcinoma</article-title>. <source>Mol. Carcinog.</source>
<volume>50</volume>, <fpage>449</fpage>&#x02013;<lpage>457</lpage><pub-id pub-id-type="doi">10.1002/mc.20729</pub-id><pub-id pub-id-type="pmid">21268126</pub-id></mixed-citation></ref><ref id="B343"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valentiner</surname><given-names>U.</given-names></name><name><surname>Haane</surname><given-names>C.</given-names></name><name><surname>Nehmann</surname><given-names>N.</given-names></name><name><surname>Schumacher</surname><given-names>U.</given-names></name></person-group> (<year>2009</year>). <article-title>Effects of bortezomib on human neuroblastoma cells in vitro and in a metastatic xenograft model</article-title>. <source>Anticancer Res.</source>
<volume>29</volume>, <fpage>1219</fpage>&#x02013;<lpage>1225</lpage><pub-id pub-id-type="pmid">19414367</pub-id></mixed-citation></ref><ref id="B344"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valsesia-Wittmann</surname><given-names>S.</given-names></name><name><surname>Magdeleine</surname><given-names>M.</given-names></name><name><surname>Dupasquier</surname><given-names>S.</given-names></name><name><surname>Garin</surname><given-names>E.</given-names></name><name><surname>Jallas</surname><given-names>A. C.</given-names></name><name><surname>Combaret</surname><given-names>V.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells</article-title>. <source>Cancer Cell</source>
<volume>6</volume>, <fpage>625</fpage>&#x02013;<lpage>630</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2004.09.033</pub-id><pub-id pub-id-type="pmid">15607966</pub-id></mixed-citation></ref><ref id="B345"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Leeuwen</surname><given-names>I. M.</given-names></name></person-group> (<year>2012</year>). <article-title>Cyclotherapy: opening a therapeutic window in cancer treatment</article-title>. <source>Oncotarget</source>
<volume>3</volume>, <fpage>596</fpage>&#x02013;<lpage>600</lpage><pub-id pub-id-type="pmid">22711025</pub-id></mixed-citation></ref><ref id="B346"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Maerken</surname><given-names>T.</given-names></name><name><surname>Ferdinande</surname><given-names>L.</given-names></name><name><surname>Taildeman</surname><given-names>J.</given-names></name><name><surname>Lambertz</surname><given-names>I.</given-names></name><name><surname>Yigit</surname><given-names>N.</given-names></name><name><surname>Vercruysse</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2009a</year>). <article-title>Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53</article-title>. <source>J. Natl. Cancer Inst.</source>
<volume>101</volume>, <fpage>1562</fpage>&#x02013;<lpage>1574</lpage><pub-id pub-id-type="doi">10.1093/jnci/djp355</pub-id><pub-id pub-id-type="pmid">19903807</pub-id></mixed-citation></ref><ref id="B347"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Maerken</surname><given-names>T.</given-names></name><name><surname>Vandesompele</surname><given-names>J.</given-names></name><name><surname>Rihani</surname><given-names>A.</given-names></name><name><surname>De Paepe</surname><given-names>A.</given-names></name><name><surname>Speleman</surname><given-names>F.</given-names></name></person-group> (<year>2009b</year>). <article-title>Escape from p53-mediated tumor surveillance in neuroblastoma: switching off the p14(ARF)-MDM2-p53 axis</article-title>. <source>Cell Death Differ.</source>
<volume>16</volume>, <fpage>1563</fpage>&#x02013;<lpage>1572</lpage><pub-id pub-id-type="doi">10.1038/cdd.2009.138</pub-id><pub-id pub-id-type="pmid">19779493</pub-id></mixed-citation></ref><ref id="B348"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Maerken</surname><given-names>T.</given-names></name><name><surname>Rihani</surname><given-names>A.</given-names></name><name><surname>Dreidax</surname><given-names>D.</given-names></name><name><surname>De Clercq</surname><given-names>S.</given-names></name><name><surname>Yigit</surname><given-names>N.</given-names></name><name><surname>Marine</surname><given-names>J. C.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Functional analysis of the p53 pathway in neuroblastoma cells using the small-molecule MDM2 antagonist nutlin-3</article-title>. <source>Mol. Cancer Ther.</source>
<volume>10</volume>, <fpage>983</fpage>&#x02013;<lpage>993</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-10-1090</pub-id><pub-id pub-id-type="pmid">21460101</pub-id></mixed-citation></ref><ref id="B349"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Maerken</surname><given-names>T.</given-names></name><name><surname>Speleman</surname><given-names>F.</given-names></name><name><surname>Vermeulen</surname><given-names>J.</given-names></name><name><surname>Lambertz</surname><given-names>I.</given-names></name><name><surname>De Clercq</surname><given-names>S.</given-names></name><name><surname>De Smet</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma</article-title>. <source>Cancer Res.</source>
<volume>66</volume>, <fpage>9646</fpage>&#x02013;<lpage>9655</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-0792</pub-id><pub-id pub-id-type="pmid">17018622</pub-id></mixed-citation></ref><ref id="B350"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vassilev</surname><given-names>L. T.</given-names></name></person-group> (<year>2004</year>). <article-title>Small-molecule antagonists of p53-MDM2 binding: research tools and potential therapeutics</article-title>. <source>Cell Cycle</source>
<volume>3</volume>, <fpage>419</fpage>&#x02013;<lpage>421</lpage><pub-id pub-id-type="doi">10.4161/cc.3.4.801</pub-id><pub-id pub-id-type="pmid">15004525</pub-id></mixed-citation></ref><ref id="B351"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vassilev</surname><given-names>L. T.</given-names></name><name><surname>Vu</surname><given-names>B. T.</given-names></name><name><surname>Graves</surname><given-names>B.</given-names></name><name><surname>Carvajal</surname><given-names>D.</given-names></name><name><surname>Podlaski</surname><given-names>F.</given-names></name><name><surname>Filipovic</surname><given-names>Z.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>In vivo activation of the p53 pathway by small-molecule antagonists of MDM2</article-title>. <source>Science</source>
<volume>303</volume>, <fpage>844</fpage>&#x02013;<lpage>848</lpage><pub-id pub-id-type="doi">10.1126/science.1092472</pub-id><pub-id pub-id-type="pmid">14704432</pub-id></mixed-citation></ref><ref id="B352"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veeck</surname><given-names>J.</given-names></name><name><surname>Bektas</surname><given-names>N.</given-names></name><name><surname>Hartmann</surname><given-names>A.</given-names></name><name><surname>Kristiansen</surname><given-names>G.</given-names></name><name><surname>Heindrichs</surname><given-names>U.</given-names></name><name><surname>Knuchel</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours</article-title>. <source>Breast Cancer Res.</source>
<volume>10</volume>, <fpage>R82</fpage><pub-id pub-id-type="doi">10.1186/bcr2151</pub-id><pub-id pub-id-type="pmid">18826564</pub-id></mixed-citation></ref><ref id="B353"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veeck</surname><given-names>J.</given-names></name><name><surname>Dahl</surname><given-names>E.</given-names></name></person-group> (<year>2012</year>). <article-title>Targeting the Wnt pathway in cancer: the emerging role of Dickkopf-3</article-title>. <source>Biochim. Biophys. Acta</source>
<volume>1825</volume>, <fpage>18</fpage>&#x02013;<lpage>28</lpage><pub-id pub-id-type="pmid">21982838</pub-id></mixed-citation></ref><ref id="B354"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veeck</surname><given-names>J.</given-names></name><name><surname>Wild</surname><given-names>P. J.</given-names></name><name><surname>Fuchs</surname><given-names>T.</given-names></name><name><surname>Schuffler</surname><given-names>P. J.</given-names></name><name><surname>Hartmann</surname><given-names>A.</given-names></name><name><surname>Knuchel</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Prognostic relevance of Wnt-inhibitory factor-1 (WIF1) and Dickkopf-3 (DKK3) promoter methylation in human breast cancer</article-title>. <source>BMC Cancer</source>
<volume>9</volume>, <fpage>217</fpage><pub-id pub-id-type="doi">10.1186/1471-2407-9-217</pub-id><pub-id pub-id-type="pmid">19570204</pub-id></mixed-citation></ref><ref id="B355"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verissimo</surname><given-names>C. S.</given-names></name><name><surname>Molenaar</surname><given-names>J. J.</given-names></name><name><surname>Fitzsimons</surname><given-names>C. P.</given-names></name><name><surname>Vreugdenhil</surname><given-names>E.</given-names></name></person-group> (<year>2011</year>). <article-title>Neuroblastoma therapy: what is in the pipeline?</article-title>
<source>Endocr. Relat. Cancer</source>
<volume>18</volume>, <fpage>R213</fpage>&#x02013;<lpage>R231</lpage><pub-id pub-id-type="doi">10.1530/ERC-11-0251</pub-id><pub-id pub-id-type="pmid">21971288</pub-id></mixed-citation></ref><ref id="B356"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vogan</surname><given-names>K.</given-names></name><name><surname>Bernstein</surname><given-names>M.</given-names></name><name><surname>Leclerc</surname><given-names>J. M.</given-names></name><name><surname>Brisson</surname><given-names>L.</given-names></name><name><surname>Brossard</surname><given-names>J.</given-names></name><name><surname>Brodeur</surname><given-names>G. M.</given-names></name><etal/></person-group> (<year>1993</year>). <article-title>Absence of p53 gene mutations in primary neuroblastomas</article-title>. <source>Cancer Res.</source>
<volume>53</volume>, <fpage>5269</fpage>&#x02013;<lpage>5273</lpage><pub-id pub-id-type="pmid">8221661</pub-id></mixed-citation></ref><ref id="B357"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>von der Lehr</surname><given-names>N.</given-names></name><name><surname>Johansson</surname><given-names>S.</given-names></name><name><surname>Wu</surname><given-names>S.</given-names></name><name><surname>Bahram</surname><given-names>F.</given-names></name><name><surname>Castell</surname><given-names>A.</given-names></name><name><surname>Cetinkaya</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2003</year>). <article-title>The F-box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription</article-title>. <source>Mol. Cell</source>
<volume>11</volume>, <fpage>1189</fpage>&#x02013;<lpage>1200</lpage><pub-id pub-id-type="doi">10.1016/S1097-2765(03)00193-X</pub-id><pub-id pub-id-type="pmid">12769844</pub-id></mixed-citation></ref><ref id="B358"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vousden</surname><given-names>K. H.</given-names></name><name><surname>Lu</surname><given-names>X.</given-names></name></person-group> (<year>2002</year>). <article-title>Live or let die: the cell&#x02019;s response to p53</article-title>. <source>Nat. Rev. Cancer</source>
<volume>2</volume>, <fpage>594</fpage>&#x02013;<lpage>604</lpage><pub-id pub-id-type="doi">10.1038/nrc864</pub-id><pub-id pub-id-type="pmid">12154352</pub-id></mixed-citation></ref><ref id="B359"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wade</surname><given-names>M.</given-names></name><name><surname>Wahl</surname><given-names>G. M.</given-names></name></person-group> (<year>2009</year>). <article-title>Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?</article-title>
<source>Mol. Cancer Res.</source>
<volume>7</volume>, <fpage>1</fpage>&#x02013;<lpage>11</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-08-0423</pub-id><pub-id pub-id-type="pmid">19147532</pub-id></mixed-citation></ref><ref id="B360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>L. M.</given-names></name><name><surname>Danks</surname><given-names>M. K.</given-names></name></person-group> (<year>2009</year>). <article-title>New therapeutic targets for the treatment of high-risk neuroblastoma</article-title>. <source>J. Cell. Biochem.</source>
<volume>107</volume>, <fpage>46</fpage>&#x02013;<lpage>57</lpage><pub-id pub-id-type="doi">10.1002/jcb.22094</pub-id><pub-id pub-id-type="pmid">19277986</pub-id></mixed-citation></ref><ref id="B361"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>B.</given-names></name><name><surname>Xiao</surname><given-names>Z.</given-names></name><name><surname>Ko</surname><given-names>H. L.</given-names></name><name><surname>Ren</surname><given-names>E. C.</given-names></name></person-group> (<year>2010a</year>). <article-title>The p53 response element and transcriptional repression</article-title>. <source>Cell Cycle</source>
<volume>9</volume>, <fpage>870</fpage>&#x02013;<lpage>879</lpage><pub-id pub-id-type="doi">10.4161/cc.9.13.12120</pub-id><pub-id pub-id-type="pmid">20160511</pub-id></mixed-citation></ref><ref id="B362"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Bauzon</surname><given-names>F.</given-names></name><name><surname>Ji</surname><given-names>P.</given-names></name><name><surname>Xu</surname><given-names>X.</given-names></name><name><surname>Sun</surname><given-names>D.</given-names></name><name><surname>Locker</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2010b</year>). <article-title>Skp2 is required for survival of aberrantly proliferating Rb1-deficient cells and for tumorigenesis in Rb1&#x000b1; mice</article-title>. <source>Nat. Genet.</source>
<volume>42</volume>, <fpage>83</fpage>&#x02013;<lpage>88</lpage><pub-id pub-id-type="doi">10.1038/ng.498</pub-id><pub-id pub-id-type="pmid">19966802</pub-id></mixed-citation></ref><ref id="B363"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Raven</surname><given-names>J. F.</given-names></name><name><surname>Koromilas</surname><given-names>A. E.</given-names></name></person-group> (<year>2010c</year>). <article-title>STAT1 represses Skp2 gene transcription to promote p27Kip1 stabilization in Ras-transformed cells</article-title>. <source>Mol. Cancer Res.</source>
<volume>8</volume>, <fpage>798</fpage>&#x02013;<lpage>805</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-09-0221</pub-id><pub-id pub-id-type="pmid">20407011</pub-id></mixed-citation></ref><ref id="B364"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>I. C.</given-names></name><name><surname>Chen</surname><given-names>Y. J.</given-names></name><name><surname>Hughes</surname><given-names>D.</given-names></name><name><surname>Petrovic</surname><given-names>V.</given-names></name><name><surname>Major</surname><given-names>M. L.</given-names></name><name><surname>Park</surname><given-names>H. J.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase</article-title>. <source>Mol. Cell. Biol.</source>
<volume>25</volume>, <fpage>10875</fpage>&#x02013;<lpage>10894</lpage><pub-id pub-id-type="doi">10.1128/MCB.25.12.5022-5030.2005</pub-id><pub-id pub-id-type="pmid">16314512</pub-id></mixed-citation></ref><ref id="B365"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Zhu</surname><given-names>W.</given-names></name><name><surname>Xu</surname><given-names>X. Y.</given-names></name><name><surname>Nie</surname><given-names>X. C.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Xing</surname><given-names>Y. N.</given-names></name><etal/></person-group> (<year>2012a</year>). <article-title>The clinicopathological significance of REIC expression in colorectal carcinomas</article-title>. <source>Histol. Histopathol.</source>
<volume>27</volume>, <fpage>735</fpage>&#x02013;<lpage>743</lpage><pub-id pub-id-type="pmid">22473694</pub-id></mixed-citation></ref><ref id="B366"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X. C.</given-names></name><name><surname>Tian</surname><given-names>L. L.</given-names></name><name><surname>Tian</surname><given-names>J.</given-names></name><name><surname>Jiang</surname><given-names>X. Y.</given-names></name></person-group> (<year>2012b</year>). <article-title>Overexpression of SKP2 promotes the radiation resistance of esophageal squamous cell carcinoma</article-title>. <source>Radiat. Res.</source>
<volume>177</volume>, <fpage>52</fpage>&#x02013;<lpage>58</lpage><pub-id pub-id-type="doi">10.1667/RR2679.1</pub-id><pub-id pub-id-type="pmid">22077337</pub-id></mixed-citation></ref><ref id="B367"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Fukushima</surname><given-names>H.</given-names></name><name><surname>Inuzuka</surname><given-names>H.</given-names></name><name><surname>Wan</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>P.</given-names></name><name><surname>Gao</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2012c</year>). <article-title>Skp2 is a promising therapeutic target in breast cancer</article-title>. <source>Front. Oncol.</source>
<volume>1</volume>:<fpage>57</fpage><pub-id pub-id-type="doi">10.3389/fonc.2011.00057</pub-id></mixed-citation></ref><ref id="B368"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X. C.</given-names></name><name><surname>Wu</surname><given-names>Y. P.</given-names></name><name><surname>Ye</surname><given-names>B.</given-names></name><name><surname>Lin</surname><given-names>D. C.</given-names></name><name><surname>Feng</surname><given-names>Y. B.</given-names></name><name><surname>Zhang</surname><given-names>Z. Q.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Suppression of anoikis by SKP2 amplification and overexpression promotes metastasis of esophageal squamous cell carcinoma</article-title>. <source>Mol. Cancer Res.</source>
<volume>7</volume>, <fpage>12</fpage>&#x02013;<lpage>22</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-08-0092</pub-id><pub-id pub-id-type="pmid">19147533</pub-id></mixed-citation></ref><ref id="B369"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wanzel</surname><given-names>M.</given-names></name><name><surname>Herold</surname><given-names>S.</given-names></name><name><surname>Eilers</surname><given-names>M.</given-names></name></person-group> (<year>2003</year>). <article-title>Transcriptional repression by Myc</article-title>. <source>Trends Cell Biol.</source>
<volume>13</volume>, <fpage>146</fpage>&#x02013;<lpage>150</lpage><pub-id pub-id-type="doi">10.1016/S0962-8924(03)00003-5</pub-id><pub-id pub-id-type="pmid">12628347</pub-id></mixed-citation></ref><ref id="B370"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>J. D.</given-names></name><name><surname>Taylor</surname><given-names>L. J.</given-names></name><name><surname>Roussel</surname><given-names>M. F.</given-names></name><name><surname>Sherr</surname><given-names>C. J.</given-names></name><name><surname>Bar-Sagi</surname><given-names>D.</given-names></name></person-group> (<year>1999</year>). <article-title>Nucleolar Arf sequesters Mdm2 and activates p53</article-title>. <source>Nat. Cell Biol.</source>
<volume>1</volume>, <fpage>20</fpage>&#x02013;<lpage>26</lpage><pub-id pub-id-type="doi">10.1038/8991</pub-id><pub-id pub-id-type="pmid">10559859</pub-id></mixed-citation></ref><ref id="B371"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>J. S.</given-names></name><name><surname>Song</surname><given-names>Y. K.</given-names></name><name><surname>Durinck</surname><given-names>S.</given-names></name><name><surname>Chen</surname><given-names>Q. R.</given-names></name><name><surname>Cheuk</surname><given-names>A. T.</given-names></name><name><surname>Tsang</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>The MYCN oncogene is a direct target of miR-34a</article-title>. <source>Oncogene</source>
<volume>27</volume>, <fpage>5204</fpage>&#x02013;<lpage>5213</lpage><pub-id pub-id-type="doi">10.1038/onc.2008.154</pub-id><pub-id pub-id-type="pmid">18504438</pub-id></mixed-citation></ref><ref id="B372"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>W.</given-names></name><name><surname>Ayad</surname><given-names>N. G.</given-names></name><name><surname>Wan</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>G. J.</given-names></name><name><surname>Kirschner</surname><given-names>M. W.</given-names></name><name><surname>Kaelin</surname><given-names>W. G.</given-names><suffix>Jr.</suffix></name></person-group> (<year>2004</year>). <article-title>Degradation of the SCF component Skp2 in cell-cycle phase G1 by the anaphase-promoting complex</article-title>. <source>Nature</source>
<volume>428</volume>, <fpage>194</fpage>&#x02013;<lpage>198</lpage><pub-id pub-id-type="doi">10.1038/nature02381</pub-id><pub-id pub-id-type="pmid">15014503</pub-id></mixed-citation></ref><ref id="B373"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiss</surname><given-names>W. A.</given-names></name><name><surname>Aldape</surname><given-names>K.</given-names></name><name><surname>Mohapatra</surname><given-names>G.</given-names></name><name><surname>Feuerstein</surname><given-names>B. G.</given-names></name><name><surname>Bishop</surname><given-names>J. M.</given-names></name></person-group> (<year>1997</year>). <article-title>Targeted expression of MYCN causes neuroblastoma in transgenic mice</article-title>. <source>EMBO J.</source>
<volume>16</volume>, <fpage>2985</fpage>&#x02013;<lpage>2995</lpage><pub-id pub-id-type="doi">10.1093/emboj/16.11.2985</pub-id><pub-id pub-id-type="pmid">9214616</pub-id></mixed-citation></ref><ref id="B374"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Welch</surname><given-names>C.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Stallings</surname><given-names>R. L.</given-names></name></person-group> (<year>2007</year>). <article-title>MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells</article-title>. <source>Oncogene</source>
<volume>26</volume>, <fpage>5017</fpage>&#x02013;<lpage>5022</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1210293</pub-id><pub-id pub-id-type="pmid">17297439</pub-id></mixed-citation></ref><ref id="B375"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westermann</surname><given-names>F.</given-names></name><name><surname>Henrich</surname><given-names>K. O.</given-names></name><name><surname>Wei</surname><given-names>J. S.</given-names></name><name><surname>Lutz</surname><given-names>W.</given-names></name><name><surname>Fischer</surname><given-names>M.</given-names></name><name><surname>Konig</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>High Skp2 expression characterizes high-risk neuroblastomas independent of MYCN status</article-title>. <source>Clin. Cancer Res.</source>
<volume>13</volume>, <fpage>4695</fpage>&#x02013;<lpage>4703</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-06-2818</pub-id><pub-id pub-id-type="pmid">17652624</pub-id></mixed-citation></ref><ref id="B376"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westermann</surname><given-names>F.</given-names></name><name><surname>Muth</surname><given-names>D.</given-names></name><name><surname>Benner</surname><given-names>A.</given-names></name><name><surname>Bauer</surname><given-names>T.</given-names></name><name><surname>Henrich</surname><given-names>K. O.</given-names></name><name><surname>Oberthur</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas</article-title>. <source>Genome Biol.</source>
<volume>9</volume>, <fpage>R150</fpage><pub-id pub-id-type="doi">10.1186/gb-2008-9-10-r150</pub-id><pub-id pub-id-type="pmid">18851746</pub-id></mixed-citation></ref><ref id="B377"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wirbelauer</surname><given-names>C.</given-names></name><name><surname>Sutterluty</surname><given-names>H.</given-names></name><name><surname>Blondel</surname><given-names>M.</given-names></name><name><surname>Gstaiger</surname><given-names>M.</given-names></name><name><surname>Peter</surname><given-names>M.</given-names></name><name><surname>Reymond</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2000</year>). <article-title>The F-box protein Skp2 is a ubiquitylation target of a Cul1-based core ubiquitin ligase complex: evidence for a role of Cul1 in the suppression of Skp2 expression in quiescent fibroblasts</article-title>. <source>EMBO J.</source>
<volume>19</volume>, <fpage>5362</fpage>&#x02013;<lpage>5375</lpage><pub-id pub-id-type="doi">10.1093/emboj/19.20.5362</pub-id><pub-id pub-id-type="pmid">11032804</pub-id></mixed-citation></ref><ref id="B378"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolf</surname><given-names>M.</given-names></name><name><surname>Korja</surname><given-names>M.</given-names></name><name><surname>Karhu</surname><given-names>R.</given-names></name><name><surname>Edgren</surname><given-names>H.</given-names></name><name><surname>Kilpinen</surname><given-names>S.</given-names></name><name><surname>Ojala</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Array-based gene expression, CGH and tissue data defines a 12q24 gain in neuroblastic tumors with prognostic implication</article-title>. <source>BMC Cancer</source>
<volume>10</volume>, <fpage>181</fpage><pub-id pub-id-type="doi">10.1186/1471-2407-10-181</pub-id><pub-id pub-id-type="pmid">20444257</pub-id></mixed-citation></ref><ref id="B379"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woo</surname><given-names>C. W.</given-names></name><name><surname>Tan</surname><given-names>F.</given-names></name><name><surname>Cassano</surname><given-names>H.</given-names></name><name><surname>Lee</surname><given-names>J.</given-names></name><name><surname>Lee</surname><given-names>K. C.</given-names></name><name><surname>Thiele</surname><given-names>C. J.</given-names></name></person-group> (<year>2008</year>). <article-title>Use of RNA interference to elucidate the effect of MYCN on cell cycle in neuroblastoma</article-title>. <source>Pediatr. Blood Cancer</source>
<volume>50</volume>, <fpage>208</fpage>&#x02013;<lpage>212</lpage><pub-id pub-id-type="doi">10.1002/pbc.21195</pub-id><pub-id pub-id-type="pmid">17420990</pub-id></mixed-citation></ref><ref id="B380"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>C. Y.</given-names></name><name><surname>Hung</surname><given-names>J. J.</given-names></name><name><surname>Wu</surname><given-names>K. J.</given-names></name></person-group> (<year>2012a</year>). <article-title>Linkage between Twist1 and Bmi1: molecular mechanism of cancer metastasis/stemness and clinical implications</article-title>. <source>Clin. Exp. Pharmacol. Physiol.</source>
<volume>39</volume>, <fpage>668</fpage>&#x02013;<lpage>673</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1681.2011.05594.x</pub-id><pub-id pub-id-type="pmid">21883379</pub-id></mixed-citation></ref><ref id="B381"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Lee</surname><given-names>S. W.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Han</surname><given-names>F.</given-names></name><name><surname>Kwan</surname><given-names>S. Y.</given-names></name><name><surname>Yuan</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2012b</year>). <article-title>Foxo3a transcription factor is a negative regulator of Skp2 and Skp2 SCF complex</article-title>. <source>Oncogene</source>.<pub-id pub-id-type="doi">10.1038/onc.2012.26</pub-id></mixed-citation></ref><ref id="B382"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Smith</surname><given-names>L. T.</given-names></name><name><surname>Plass</surname><given-names>C.</given-names></name><name><surname>Huang</surname><given-names>T. H.</given-names></name></person-group> (<year>2006</year>). <article-title>ChIP-chip comes of age for genome-wide functional analysis</article-title>. <source>Cancer Res.</source>
<volume>66</volume>, <fpage>6899</fpage>&#x02013;<lpage>6902</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-3561</pub-id><pub-id pub-id-type="pmid">16849531</pub-id></mixed-citation></ref><ref id="B383"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>J.</given-names></name><name><surname>Yin</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Xie</surname><given-names>S.</given-names></name><name><surname>Nie</surname><given-names>D.</given-names></name><name><surname>Ma</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>SKP2 siRNA inhibits the degradation of P27kip1 and down-regulates the expression of MRP in HL-60/A cells</article-title>. <source>Acta Biochim. Biophys. Sin. (Shanghai)</source>
<volume>41</volume>, <fpage>699</fpage>&#x02013;<lpage>708</lpage><pub-id pub-id-type="doi">10.1093/abbs/gmp058</pub-id><pub-id pub-id-type="pmid">19657571</pub-id></mixed-citation></ref><ref id="B384"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname><given-names>S.</given-names></name><name><surname>Pant</surname><given-names>V.</given-names></name><name><surname>Suh</surname><given-names>Y. A.</given-names></name><name><surname>Van Pelt</surname><given-names>C. S.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Valentin-Vega</surname><given-names>Y. A.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Spontaneous tumorigenesis in mice overexpressing the p53-negative regulator Mdm4</article-title>. <source>Cancer Res.</source>
<volume>70</volume>, <fpage>7148</fpage>&#x02013;<lpage>7154</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-1457</pub-id><pub-id pub-id-type="pmid">20736370</pub-id></mixed-citation></ref><ref id="B385"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y.</given-names></name></person-group> (<year>2008</year>). <article-title>Induction of genetic instability by gain-of-function p53 cancer mutants</article-title>. <source>Oncogene</source>
<volume>27</volume>, <fpage>3501</fpage>&#x02013;<lpage>3507</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1211023</pub-id><pub-id pub-id-type="pmid">18223686</pub-id></mixed-citation></ref><ref id="B386"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname><given-names>C.</given-names></name><name><surname>Haber</surname><given-names>M.</given-names></name><name><surname>Flemming</surname><given-names>C.</given-names></name><name><surname>Marshall</surname><given-names>G. M.</given-names></name><name><surname>Lock</surname><given-names>R. B.</given-names></name><name><surname>Mackenzie</surname><given-names>K. L.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>p53 determines multidrug sensitivity of childhood neuroblastoma</article-title>. <source>Cancer Res.</source>
<volume>67</volume>, <fpage>10351</fpage>&#x02013;<lpage>10360</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-3200</pub-id><pub-id pub-id-type="pmid">17974978</pub-id></mixed-citation></ref><ref id="B387"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamakuchi</surname><given-names>M.</given-names></name><name><surname>Lotterman</surname><given-names>C. D.</given-names></name><name><surname>Bao</surname><given-names>C.</given-names></name><name><surname>Hruban</surname><given-names>R. H.</given-names></name><name><surname>Karim</surname><given-names>B.</given-names></name><name><surname>Mendell</surname><given-names>J. T.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>P53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesis</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>107</volume>, <fpage>6334</fpage>&#x02013;<lpage>6339</lpage><pub-id pub-id-type="doi">10.1073/pnas.0911082107</pub-id><pub-id pub-id-type="pmid">20308559</pub-id></mixed-citation></ref><ref id="B388"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>B.</given-names></name><name><surname>Du</surname><given-names>Z.</given-names></name><name><surname>Gao</surname><given-names>Y. T.</given-names></name><name><surname>Lou</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>S. G.</given-names></name><name><surname>Bai</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Methylation of Dickkopf-3 as a prognostic factor in cirrhosis-related hepatocellular carcinoma</article-title>. <source>World J. Gastroenterol.</source>
<volume>16</volume>, <fpage>755</fpage>&#x02013;<lpage>763</lpage><pub-id pub-id-type="doi">10.3748/wjg.v16.i6.755</pub-id><pub-id pub-id-type="pmid">20135726</pub-id></mixed-citation></ref><ref id="B389"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Z. R.</given-names></name><name><surname>Dong</surname><given-names>W. G.</given-names></name><name><surname>Lei</surname><given-names>X. F.</given-names></name><name><surname>Liu</surname><given-names>M.</given-names></name><name><surname>Liu</surname><given-names>Q. S.</given-names></name></person-group> (<year>2012</year>). <article-title>Overexpression of Dickkopf-3 induces apoptosis through mitochondrial pathway in human colon cancer</article-title>. <source>World J. Gastroenterol.</source>
<volume>18</volume>, <fpage>1590</fpage>&#x02013;<lpage>1601</lpage><pub-id pub-id-type="doi">10.3748/wjg.v18.i43.6345</pub-id><pub-id pub-id-type="pmid">22529687</pub-id></mixed-citation></ref><ref id="B390"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeh</surname><given-names>K. H.</given-names></name><name><surname>Kondo</surname><given-names>T.</given-names></name><name><surname>Zheng</surname><given-names>J.</given-names></name><name><surname>Tsvetkov</surname><given-names>L. M.</given-names></name><name><surname>Blair</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name></person-group> (<year>2001</year>). <article-title>The F-box protein SKP2 binds to the phosphorylated threonine 380 in cyclin E and regulates ubiquitin-dependent degradation of cyclin E</article-title>. <source>Biochem. Biophys. Res. Commun.</source>
<volume>281</volume>, <fpage>884</fpage>&#x02013;<lpage>890</lpage><pub-id pub-id-type="doi">10.1006/bbrc.2001.4442</pub-id><pub-id pub-id-type="pmid">11237742</pub-id></mixed-citation></ref><ref id="B391"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yokoi</surname><given-names>S.</given-names></name><name><surname>Yasui</surname><given-names>K.</given-names></name><name><surname>Iizasa</surname><given-names>T.</given-names></name><name><surname>Takahashi</surname><given-names>T.</given-names></name><name><surname>Fujisawa</surname><given-names>T.</given-names></name><name><surname>Inazawa</surname><given-names>J.</given-names></name></person-group> (<year>2003</year>). <article-title>Down-regulation of SKP2 induces apoptosis in lung-cancer cells</article-title>. <source>Cancer Sci.</source>
<volume>94</volume>, <fpage>344</fpage>&#x02013;<lpage>349</lpage><pub-id pub-id-type="doi">10.1111/j.1349-7006.2003.tb01444.x</pub-id><pub-id pub-id-type="pmid">12824902</pub-id></mixed-citation></ref><ref id="B392"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yokoi</surname><given-names>S.</given-names></name><name><surname>Yasui</surname><given-names>K.</given-names></name><name><surname>Mori</surname><given-names>M.</given-names></name><name><surname>Iizasa</surname><given-names>T.</given-names></name><name><surname>Fujisawa</surname><given-names>T.</given-names></name><name><surname>Inazawa</surname><given-names>J.</given-names></name></person-group> (<year>2004</year>). <article-title>Amplification and overexpression of SKP2 are associated with metastasis of non-small-cell lung cancers to lymph nodes</article-title>. <source>Am. J. Pathol.</source>
<volume>165</volume>, <fpage>175</fpage>&#x02013;<lpage>180</lpage><pub-id pub-id-type="doi">10.1016/S0002-9440(10)63286-5</pub-id><pub-id pub-id-type="pmid">15215173</pub-id></mixed-citation></ref><ref id="B393"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>J.</given-names></name><name><surname>Tao</surname><given-names>Q.</given-names></name><name><surname>Cheng</surname><given-names>Y. Y.</given-names></name><name><surname>Lee</surname><given-names>K. Y.</given-names></name><name><surname>Ng</surname><given-names>S. S.</given-names></name><name><surname>Cheung</surname><given-names>K. F.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Promoter methylation of the Wnt/beta-catenin signaling antagonist Dkk-3 is associated with poor survival in gastric cancer</article-title>. <source>Cancer</source>
<volume>115</volume>, <fpage>49</fpage>&#x02013;<lpage>60</lpage><pub-id pub-id-type="doi">10.1002/cncr.23989</pub-id><pub-id pub-id-type="pmid">19051296</pub-id></mixed-citation></ref><ref id="B394"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>Z. K.</given-names></name><name><surname>Gervais</surname><given-names>J. L.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name></person-group> (<year>1998</year>). <article-title>Human CUL-1 associates with the SKP1/SKP2 complex and regulates p21(CIP1/WAF1) and cyclin D proteins</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>95</volume>, <fpage>11324</fpage>&#x02013;<lpage>11329</lpage><pub-id pub-id-type="doi">10.1073/pnas.95.18.10632</pub-id><pub-id pub-id-type="pmid">9736735</pub-id></mixed-citation></ref><ref id="B395"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>Y.</given-names></name><name><surname>Liao</surname><given-names>Y. M.</given-names></name><name><surname>Hsueh</surname><given-names>C. T.</given-names></name><name><surname>Mirshahidi</surname><given-names>H. R.</given-names></name></person-group> (<year>2011</year>). <article-title>Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP</article-title>. <source>J. Hematol. Oncol.</source>
<volume>4</volume>, <fpage>16</fpage><pub-id pub-id-type="doi">10.1186/1756-8722-4-16</pub-id><pub-id pub-id-type="pmid">21504625</pub-id></mixed-citation></ref><ref id="B396"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yue</surname><given-names>W.</given-names></name><name><surname>Sun</surname><given-names>Q.</given-names></name><name><surname>Dacic</surname><given-names>S.</given-names></name><name><surname>Landreneau</surname><given-names>R. J.</given-names></name><name><surname>Siegfried</surname><given-names>J. M.</given-names></name><name><surname>Yu</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Downregulation of Dkk3 activates beta-catenin/TCF-4 signaling in lung cancer</article-title>. <source>Carcinogenesis</source>
<volume>29</volume>, <fpage>84</fpage>&#x02013;<lpage>92</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgm267</pub-id><pub-id pub-id-type="pmid">18048388</pub-id></mixed-citation></ref><ref id="B397"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yung</surname><given-names>Y.</given-names></name><name><surname>Walker</surname><given-names>J. L.</given-names></name><name><surname>Roberts</surname><given-names>J. M.</given-names></name><name><surname>Assoian</surname><given-names>R. K.</given-names></name></person-group> (<year>2007</year>). <article-title>A Skp2 autoinduction loop and restriction point control</article-title>. <source>J. Cell Biol.</source>
<volume>178</volume>, <fpage>741</fpage>&#x02013;<lpage>747</lpage><pub-id pub-id-type="doi">10.1083/jcb.200703034</pub-id><pub-id pub-id-type="pmid">17724117</pub-id></mixed-citation></ref><ref id="B398"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeller</surname><given-names>K. I.</given-names></name><name><surname>Jegga</surname><given-names>A. G.</given-names></name><name><surname>Aronow</surname><given-names>B. J.</given-names></name><name><surname>O&#x02019;Donnell</surname><given-names>K. A.</given-names></name><name><surname>Dang</surname><given-names>C. V.</given-names></name></person-group> (<year>2003</year>). <article-title>An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets</article-title>. <source>Genome Biol.</source>
<volume>4</volume>, <fpage>R69</fpage><pub-id pub-id-type="doi">10.1186/gb-2003-4-10-r69</pub-id><pub-id pub-id-type="pmid">14519204</pub-id></mixed-citation></ref><ref id="B399"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Kobayashi</surname><given-names>R.</given-names></name><name><surname>Galaktionov</surname><given-names>K.</given-names></name><name><surname>Beach</surname><given-names>D.</given-names></name></person-group> (<year>1995</year>). <article-title>p19Skp1 and p45Skp2 are essential elements of the cyclin A-CDK2 S phase kinase</article-title>. <source>Cell</source>
<volume>82</volume>, <fpage>915</fpage>&#x02013;<lpage>925</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(95)90271-6</pub-id><pub-id pub-id-type="pmid">7553852</pub-id></mixed-citation></ref><ref id="B400"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Shi</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Human differentiation-related gene NDRG1 is a Myc downstream-regulated gene that is repressed by Myc on the core promoter region</article-title>. <source>Gene</source>
<volume>417</volume>, <fpage>5</fpage>&#x02013;<lpage>12</lpage><pub-id pub-id-type="doi">10.1016/j.gene.2008.03.002</pub-id><pub-id pub-id-type="pmid">18455888</pub-id></mixed-citation></ref><ref id="B401"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>F.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Shen</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Su</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>The repression of human differentiation-related gene NDRG2 expression by Myc via Miz-1-dependent interaction with the NDRG2 core promoter</article-title>. <source>J. Biol. Chem.</source>
<volume>281</volume>, <fpage>39159</fpage>&#x02013;<lpage>39168</lpage><pub-id pub-id-type="doi">10.1074/jbc.M601384200</pub-id><pub-id pub-id-type="pmid">17050536</pub-id></mixed-citation></ref><ref id="B402"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>K.</given-names></name><name><surname>Lv</surname><given-names>Z.</given-names></name><name><surname>Xiao</surname><given-names>X.</given-names></name><name><surname>Zheng</surname><given-names>J.</given-names></name></person-group> (<year>2009</year>). <article-title>The effect on cell growth by Wnt1 RNAi in human neuroblastoma SH-SY5Y cell line</article-title>. <source>Pediatr. Surg. Int.</source>
<volume>25</volume>, <fpage>1065</fpage>&#x02013;<lpage>1071</lpage><pub-id pub-id-type="doi">10.1007/s00383-009-2481-0</pub-id><pub-id pub-id-type="pmid">19756656</pub-id></mixed-citation></ref><ref id="B403"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name></person-group> (<year>2006</year>). <article-title>F-box protein Skp2: a novel transcriptional target of E2F</article-title>. <source>Oncogene</source>
<volume>25</volume>, <fpage>2615</fpage>&#x02013;<lpage>2627</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1209530</pub-id><pub-id pub-id-type="pmid">16331253</pub-id></mixed-citation></ref><ref id="B404"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Xiong</surname><given-names>Y.</given-names></name><name><surname>Yarbrough</surname><given-names>W. G.</given-names></name></person-group> (<year>1998</year>). <article-title>ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways</article-title>. <source>Cell</source>
<volume>92</volume>, <fpage>725</fpage>&#x02013;<lpage>734</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)81401-4</pub-id><pub-id pub-id-type="pmid">9529249</pub-id></mixed-citation></ref><ref id="B405"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>N.</given-names></name><name><surname>Schulman</surname><given-names>B. A.</given-names></name><name><surname>Song</surname><given-names>L.</given-names></name><name><surname>Miller</surname><given-names>J. J.</given-names></name><name><surname>Jeffrey</surname><given-names>P. D.</given-names></name><name><surname>Wang</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2002</year>). <article-title>Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex</article-title>. <source>Nature</source>
<volume>416</volume>, <fpage>703</fpage>&#x02013;<lpage>709</lpage><pub-id pub-id-type="doi">10.1038/416703a</pub-id><pub-id pub-id-type="pmid">11961546</pub-id></mixed-citation></ref><ref id="B406"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zindy</surname><given-names>F.</given-names></name><name><surname>Eischen</surname><given-names>C. M.</given-names></name><name><surname>Randle</surname><given-names>D. H.</given-names></name><name><surname>Kamijo</surname><given-names>T.</given-names></name><name><surname>Cleveland</surname><given-names>J. L.</given-names></name><name><surname>Sherr</surname><given-names>C. J.</given-names></name><etal/></person-group> (<year>1998</year>). <article-title>Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization</article-title>. <source>Genes Dev.</source>
<volume>12</volume>, <fpage>2424</fpage>&#x02013;<lpage>2433</lpage><pub-id pub-id-type="doi">10.1101/gad.12.15.2424</pub-id><pub-id pub-id-type="pmid">9694806</pub-id></mixed-citation></ref><ref id="B407"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuo</surname><given-names>T.</given-names></name><name><surname>Liu</surname><given-names>R.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Chang</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>FOXP3 is a novel transcriptional repressor for the breast cancer oncogene SKP2</article-title>. <source>J. Clin. Invest.</source>
<volume>117</volume>, <fpage>3765</fpage>&#x02013;<lpage>3773</lpage><pub-id pub-id-type="pmid">18008005</pub-id></mixed-citation></ref></ref-list></back></article>